

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2009238550 B2**

- (54) Title
Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
- (51) International Patent Classification(s)
A61K 38/48 (2006.01) **C12N 9/64** (2006.01)
A61P 3/06 (2006.01)
- (21) Application No: **2009238550** (22) Date of Filing: **2009.02.20**
- (87) WIPO No: **WO09/131740**
- (30) Priority Data
- (31) Number (32) Date (33) Country
61/125,304 **2008.04.23** **US**
- (43) Publication Date: **2009.10.29**
(44) Accepted Journal Date: **2014.11.27**
- (71) Applicant(s)
Amgen Inc.
- (72) Inventor(s)
Piper, Derek Evan; Jackson, Simon Mark
- (74) Agent / Attorney
Shelston IP, L 21 60 Margaret St, Sydney, NSW, 2000
- (56) Related Art
BENJANNET S. et al, The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A, The Journal of Biological Chemistry, 2006, Vol. 281(41), pg. 30561-30572

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 October 2009 (29.10.2009)

PCT

(10) International Publication Number
WO 2009/131740 A3

(51) International Patent Classification:

A61K 38/48 (2006.01) A61P 3/06 (2006.01)
C12N 9/64 (2006.01)

(21) International Application Number:

PCT/US2009/034775

(22) International Filing Date:

20 February 2009 (20.02.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/125,304 23 April 2008 (23.04.2008) US

(71) Applicant (for all designated States except US): **AM-GEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JACKSON, Simon, Mark** [GB/US]; 2071 Birch Avenue, San Carlos, CA 94070 (US). **PIPER, Derek, Evan** [US/US]; 675 Gianni Drive, Santa Clara, CA 95051 (US).

(74) Agent: **HART, Daniel**; Knobbe Martens Olson & Bear, LLP, 2040 Main Street, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

7 January 2010

(54) Title: NEUTRALIZING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) VARIANTS AND USES THEREOF




FIG. 5

(57) Abstract: Neutralizing PCSK9 variants that interact with low density lipoprotein receptor (LDLR) are described. Methods and compositions for treating disorders by administering a pharmaceutically effective amount of a neutralizing PCSK9 variant are described.



WO 2009/131740 A3

NEUTRALIZING PROPROTEIN CONVERTASE SUBTILISINKEXIN TYPE 9 (PCSK9) VARIANTS AND USES THEREOF

RELATED APPLICATIONS

[0001] The present application claims priority to U.S. Provisional Application 61/125,304, filed April 23, 2008, the entirety of which is hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to variants of proprotein convertase subtilisin kexin type 9 (and molecules related thereto) and methods of using the variants (and molecules related thereto) for treating various disorders.

BACKGROUND OF VARIOUS EMBODIMENTS

[0002a] Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

[0003] Proprotein convertase subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the levels of the low density lipoprotein receptor (LDLR) protein (Horton *et al.*, 2007; Seidah and Prat, 2007). *In vitro* experiments have shown that adding PCSK9 to HepG2 cells lowers the levels of cell surface LDLR (Benjannet *et al.*, 2004; Lagace *et al.*, 2006; Maxwell *et al.*, 2005; Park *et al.*, 2004). Experiments with mice have shown that increasing PCSK9 protein levels decreases levels of LDLR protein in the liver (Benjannet *et al.*, 2004; Lagace *et al.*, 2006; Maxwell *et al.*, 2005; Park *et al.*, 2004), while PCSK9 knockout mice have increased levels of LDLR in the liver (Rashid *et al.*, 2005). Additionally, various human PCSK9 mutations that result in either increased or decreased levels of plasma LDL have been identified (Kotowski *et al.*, 2006; Zhao *et al.*, 2006). PCSK9 has been shown to directly interact with the LDLR protein, be endocytosed along with the LDLR, and co-immunofluoresce with the LDLR throughout the endosomal pathway (Lagace *et al.*, 2006). Degradation of the LDLR by PCSK9 has not been observed and the mechanism through which it lowers extracellular LDLR protein levels is uncertain.

[0004] PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah *et al.*, 2003). Humans have nine prohormone-proprotein convertases that can be divided between the S8A and S8B subfamilies (Rawlings *et al.*, 2006). Furin,

PC1/PC3, PC2, PACE4, PC4, PC5/PC6 and PC7/PC8/LPC/SPC7 are classified in subfamily S8B. Crystal and NMR structures of different domains from mouse furin and PC1 reveal subtilisin-like pro- and catalytic domains, and a P domain directly C-terminal to the catalytic domain (Henrich *et al.*, 2003; Tangrea *et al.*, 2002). Based on the amino acid sequence similarity within this subfamily, all seven members are predicted to have similar structures (Henrich *et al.*, 2005). SKI-1/S1P and PCSK9 are classified in subfamily S8A. Sequence comparisons with these proteins also suggest the presence of subtilisin-like pro- and catalytic domains (Sakai *et al.*, 1998; Seidah *et al.*, 2003; Seidah *et al.*, 1999). In these proteins the amino acid sequence C-terminal to the catalytic domain is more variable and does not suggest the presence of a P domain.

[0005] Prohormone-proprotein convertases are expressed as zymogens and they mature through a multi step process. The function of the pro-domain in this process is two-fold. The pro-domain first acts as a chaperone and is required for proper folding of the catalytic domain (Ikemura *et al.*, 1987). Once the catalytic domain is folded, autocatalysis occurs between the pro-domain and catalytic domain. Following this initial cleavage reaction, the pro-domain remains bound to the catalytic domain where it then acts as an inhibitor of catalytic activity (Fu *et al.*, 2000). When conditions are correct, maturation proceeds with a second autocatalytic event at a site within the pro-domain (Anderson *et al.*, 1997). After this second cleavage event occurs the pro-domain and catalytic domain dissociate, giving rise to an active protease.

[0006] Autocatalysis of the PCSK9 zymogen occurs between Gln152 and Ser153 (VFAQ|SIP) (Naureckiene *et al.*, 2003), and has been shown to be required for its secretion from cells (Seidah *et al.*, 2003). A second autocatalytic event at a site within PCSK9's pro-domain has not been observed. Purified PCSK9 is made up of two species that can be separated by non-reducing SDS-PAGE; the pro-domain at 17 Kd, and the catalytic plus C-terminal domains at 65 Kd. PCSK9 has not been isolated without its inhibitory pro-domain, and measurements of PCSK9's catalytic activity have been variable (Naureckiene *et al.*, 2003; Seidah *et al.*, 2003).

SUMMARY OF VARIOUS EMBODIMENTS

[0006a] According to a first aspect, the present invention relates to an isolated neutralizing PCSK9 variant comprising:

- (a) a Pro/Cat domain, or fragment thereof; and
- (b) an inactive V domain,

wherein the Pro/Cat domain or the fragment thereof

- i) lacks amino acids 1-60 of SEQ ID NO: 3; or
- ii) lacks amino acids 1-30 of SEQ ID NO: 3; and

wherein the neutralizing PCSK9 variant lacks at least 14 C-terminal amino acids of SEQ ID NO: 3, preferably the PCSK9 variant lacks the protein sequence defined from amino acids 453 to 692 of SEQ ID NO: 3.

[0006b] According to a second aspect, the present invention relates to an isolated nucleic acid molecule encoding the neutralizing PCSK9 variant according to the first aspect, preferably operably linked to a control sequence.

[0006c] According to a third aspect, the present invention relates to a vector comprising a nucleic acid molecule according to the second aspect.

[0006d] According to a fourth aspect, the present invention relates to a host cell comprising the nucleic acid molecule according to the second aspect or the vector according to the third aspect.

[0006e] According to a fifth aspect, the present invention relates to a pharmaceutical composition comprising at least one neutralizing PCSK9 variant according to the first aspect, and a pharmaceutically acceptable excipient, optionally further comprising an additional active agent, preferably selected from the group consisting of a radioisotope, radionuclide, a toxin, or a therapeutic and a chemotherapeutic group.

[0006f] According to a sixth aspect, the present invention relates to a method for treating or preventing a condition associated with elevated serum cholesterol in a patient, comprising administering to a patient in thereof an effective amount of at least one neutralizing PCSK9 variant according to the first aspect, wherein the condition preferably is hypercholesterolemia.

[0006g] According to a seventh aspect, the present invention relates to a method of inhibiting binding of PCSK9 to LDLR in a patient comprising administering an effective amount of a neutralizing PCSK9 variant according to the first aspect.

[0006d] According to an eighth aspect, the present invention relates to method for treating or preventing a condition associated with elevated serum cholesterol in a subject, said method comprising administering to a subject in need thereof an effective amount of at least one neutralizing PCSK9 variant according to the first aspect simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein,

wherein the agent that elevates the availability of LDLR protein optionally comprises a statin, preferably selected from the group consisting of atorvastatin, cerivastatin, fluvastatin,

lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

[0006h] According to a ninth aspect, the present invention relates to a method of lowering serum cholesterol in a subject, said method comprising administering to a subject an effective amount of at least one isolated neutralizing PCSK9 variant according to the first aspect, preferably simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.

[0006i] According to a tenth aspect, the present invention relates to use of a neutralizing PCSK9 variant of the first aspect in the manufacture of a medicament for the treatment of hypercholesterolemia.

[0006j] According to an eleventh aspect, the present invention relates to use of a neutralizing PCSK9 variant of the first aspect in the manufacture of a medicament for inhibiting binding of PCSK9 to LDLR.

[0006k] According to a twelfth aspect, the present invention relates to use of a neutralizing PCSK9 variant of the first aspect in the manufacture of a medicament for treating a condition associated with elevated serum cholesterol in a subject, wherein said medicament is adapted for simultaneous or sequential administration with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein,

wherein the agent that elevates the availability of LDLR protein optionally comprises a statin, preferably selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

[0006l] According to a thirteenth aspect, the present invention relates to use of a neutralizing PCSK9 variant of the first aspect in the manufacture of a medicament for lowering serum cholesterol in a subject, wherein said medicament is adapted for simultaneous or sequential administration with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.

[0006m] According to a fourteenth aspect, the present invention relates to a pharmaceutical composition comprising at least one neutralizing PCSK9 variant according to the first aspect, wherein the neutralizing PCSK9 variant is present in an amount effective for the treatment of a cholesterol related disorder.

[0006n] According to a fifteenth aspect, the present invention relates to a pharmaceutical composition comprising:

- (a) a Pro/Cat domain, or fragment thereof;
- (b) an inactive V domain; and
- (c) a pharmaceutically acceptable carrier or diluent,

wherein the Pro/Cat domain, or the fragment thereof

- (i) lacks amino acids 1-60 of SEQ ID NO: 3; or
- (ii) lacks amino acids 1-30 of SEQ ID NO: 3; and

wherein the neutralizing PCSK9 variant lacks at least 14 C-terminal amino acids of SEQ ID NO: 3, preferably the PCSK9 variant lacks the protein sequence defined from amino acids 453 to 692 of SEQ ID NO: 3.

[0006o] According to a sixteenth aspect, the present invention relates to a pharmaceutical composition comprising a Pro/Cat domain, or fragment thereof, and an inactive V domain, wherein the Pro/Cat domain is present in an amount sufficient for the treatment of a cholesterol related disorder,

wherein the Pro/Cat domain:

- (i) comprises the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (ii) consists of the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (iii) consists essentially of the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (iv) comprises the Cat domain of at least one of the amino acids sequences of SEQ ID NOs: 9, 11, 13, 15 or 3.

[0006p] Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

[0007] In some embodiments, the invention comprises a PCSK9 variant and/or a use thereof.

[0008] In some embodiments, the PCSK9 variant can be a neutralizing PCSK9 variant that can include a Pro/Cat domain, or fragment thereof, that binds to low density lipoprotein receptor (LDLR) and an inactive V domain to LDLR activity. The inactive V domain does not result in the degradation of LDLR.

[0009] In some embodiments, the invention comprises a nucleic acid molecule that encodes for a PCSK9 variant (or neutralizing variant).

[0010] In some embodiments, the invention comprises a host cell that comprises a herein disclosed nucleic acid molecule that encodes for a PCSK9 variant.

[0011] In some embodiments, the invention comprises a vector that comprises a herein disclosed nucleic acid molecule that encodes for a PCSK9 variant.

[0012] In some embodiments, the invention comprises a pharmaceutical composition comprising at least one neutralizing PCSK9 variant (or a nucleic acid sequence encoding for a neutralizing PCSK9 variant) and a pharmaceutically acceptable carrier and/or excipient.

[0013] In some embodiments, the invention comprises a method of treating or preventing a condition associated with elevated serum cholesterol in a patient. In some embodiments, the method can comprise administering to a patient in need thereof an effective amount of at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant).

[0014] In some embodiments, the invention comprises a method of inhibiting the binding of endogenous PCSK9 to LDLR in a patient. In some embodiments, the method comprises administering an effective amount of at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) to a subject in need thereof.

[0015] In some embodiments, the invention comprises a method of treating or preventing a condition associated with elevated serum cholesterol in a subject. In some embodiments, the method can comprise administering to a subject in need thereof an effective amount at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.

[0016] In some embodiments, the invention comprises a method of lowering serum cholesterol in a subject. In some embodiments, the method can comprise administering to a subject an effective amount of at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant).

[0017] In some embodiments, the invention comprises a method of lowering serum cholesterol in a subject. In some embodiments, the method can comprise administering to a subject an effective amount of at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.

[0018] In some embodiments, the invention comprises the use of at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) in the manufacture of a medicament for the treatment of hypercholesterolemia.

[0019] In some embodiments, the invention comprises at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) for use as a medicament.

[0020] In some embodiments, the invention comprises at least one of the herein disclosed compounds (including, for example, a neutralizing PCSK9 variant and/or a nucleic acid sequence encoding a neutralizing PCSK9 variant) for use in treating hypercholesterolemia.

[0021] In some embodiments, the invention comprises a pharmaceutical composition comprising a Pro/Cat domain, or fragment thereof, that binds to low density lipoprotein receptor (LDLR), and an inactive V domain to LDLR activity. The inactive V domain does not result in the degradation of LDLR. The pharmaceutical composition further comprises a pharmaceutically acceptable carrier or diluent.

[0022] In some embodiments, the invention comprises a pharmaceutical composition comprising a Pro/Cat domain, or fragment thereof, that binds to low density lipoprotein receptor (LDLR) and an inactive V domain to LDLR activity. The inactive V domain does not result in the degradation of LDLR. The pro/cat domain is present in an amount sufficient for the treatment of a cholesterol related disorder.

BRIEF DESCRIPTION OF THE FIGURES

[0023] FIG. 1A depicts an amino acid sequence of the mature form of the PCSK9 with the pro-domain underlined.

[0024] FIGs. 1B₁-1B₄ depict amino acid and nucleic acid sequences of PCSK9 with the pro-domain underlined and the signal sequence in bold.

[0025] FIG. 1C is a comparison on the sequences of PCSK9 from various organisms. (Any "O" in FIGs. 1C-1E are actually "Q")

[0026] FIG. 1D is a continuation of FIG. 1C.

[0027] FIG. 1E is a continuation of FIG. 1D.

[0028] FIG. 1F is an alignment of the Cat domain of the PCSK9 protein of SEQ ID NO: 3 with another Cat domain of another PCSK9 protein.

[0029] FIG. 1G is an alignment of the Cat domain of the PCSK9 protein of SEQ ID NO: 3 with another Cat domain of another PCSK9 protein.

[0030] FIG. 1H is an alignment of the Cat domain of the PCSK9 protein of SEQ ID NO: 3 with another Cat domain of another PCSK9 protein.

[0031] FIG. 1I is an alignment and consensus sequence for the amino acid sequence of LDLR.

[0032] FIG. 1J is a continuation of the alignment and consensus sequence for the amino acid sequence of LDLR presented in FIG. 1I.

[0033] FIG. 1K is an alignment and consensus sequence for the amino acid sequence of LDLR.

[0034] FIG. 1L is a continuation of the alignment and consensus sequence for the amino acid sequence of LDLR presented in FIG. 1K.

[0035] FIGs. 1M₁ and 1M₂ depict an embodiment of a PCSK9 protein.

[0036] FIGs. 1N₁ and 1N₂ depict an embodiment of a PCSK9 protein.

[0037] FIGs. 1O₁ and 1O₂ depict an embodiment of a PCSK9 protein.

[0038] FIGs. 1P₁ and 1P₂ depict an embodiment of a PCSK9 protein.

[0039] FIGs. 1Q₁ and 1Q₂ depict an embodiment of a PCSK9 protein.

[0040] FIGs. 1R₁ and 1R₂ depict an embodiment of a consensus sequence for a PCSK9 protein.

[0041] FIGs. 1S₁ and 1S₂ depict an embodiment of a human PCSK9 protein.

[0042] FIG. 2 is a graph depicting the results of a binding assay between LDLR and biotin-labeled full length PCSK9, competed with either a) unlabeled full length PCSK9, b) unlabeled residues 31-447 of PCSK9, or c) the unlabeled V domain of PCSK9 (residues 450-692).

[0043] FIG. 3A is a graph depicting the results of the activity of residues 31-447 of PCSK9 on LDL uptake.

[0044] FIG. 3B is a graph depicting the results of the activity of residues 31-447 of PCSK9 on LDL uptake.

[0045] FIG. 4 is a depiction of a Western blot comparing the effect of full length PCSK9 vs. residues 31-447 of PCSK9 (a Pro/Cat fragment) on LDLR protein levels and PCSK9 uptake. As can be seen in the left-hand side of the gel, full length PCSK9 (FL PC9) results in a decrease in LDLR, while residues 31-447 of PCSK9 (a Pro/Cat fragment that functions as a neutralizing PCSK9 variant) does not result in a decrease in LDLR.

[0046] FIG. 5 is a depiction of the structure of PCSK9 and the EGFA section of LDLR.

[0047] FIG. 6 is a depiction of a structural model of PCSK9 and LDLR.

[0048] FIG. 7 is a depiction of the structural model of PCSK9 and LDLR from an alternative perspective.

[0049] FIG. 8 is a graph depicting the results of the activity of the D374Y variant of residues 31-447 of PCSK9 (an example of another variant of the Pro/Cat domain) on LDL uptake.

[0050] FIG. 9 is a graph depicting the results of a competition assay which included the D374Y variant of residues 31-447 of PCSK9.

DETAILED DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS

[0051] Proprotein convertase subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the levels of the low density lipoprotein receptor (LDLR) protein. It is believed that native PCSK9 binds to LDLR *in vivo* and is involved in the degradation of LDLR. This can be problematic because the reduction in available LDLR results in less binding between

LDLR and LDL, which in turn results in more LDL in the serum of the subject, resulting in an increase in serum cholesterol.

[0052] The full length PCSK9 protein includes a signal sequence (generally amino acids 1-30), a N-terminal prodomain ("Pro" domain, generally amino acids 31-152), a subtilisin-like catalytic domain ("Cat" domain, generally amino acids 153-446), a loop region (generally amino acids 447-453) and a C-terminal domain ("V" domain, generally amino acids 454-692).

[0053] Some embodiments of the invention relate to the discovery that the ability of PCSK9 (or variants thereof) to bind to LDLR can be separated from the ability of PCSK9 to effectively degrade or reduce the amount of available LDLR. It has been discovered that while parts of the Pro and/or Cat domains are involved in binding to PCSK9, the V domain is important for the effective degradation of LDLR. Furthermore, variants of PCSK9 that include an active part of the Pro and/or Cat domain can be used to block native PCSK9 from binding to LDLR. Thus, in some embodiments, the invention relates to a neutralizing PCSK9 variant that can block native PCSK9 from binding to LDLR, while the neutralizing PCSK9 variant itself will not effectively degrade LDLR. In some embodiments, the invention comprises a variant of PCSK9 that still includes an active Pro/Cat domain and that lacks a functional V domain (and thus lacks the ability to effectively lower LDLR in a subject). This variant can be used to prevent or reduce native PCSK9 from binding to LDLR. In turn, this can effectively elevate the level of LDLR in a subject and result in lower levels of LDL in the serum.

[0054] Some embodiments of the invention relate to the discovery that using a neutralizing PCSK9 variant (*e.g.*, a variant that includes an active Pro/Cat domain and an inactive V domain) can result in the neutralizing PCSK9 variant competitively blocking and preventing native PCSK9 from binding to and degrading LDLR, while still allowing LDLR to perform its beneficial role of sequestering LDL. As such, neutralizing variants of PCSK9 can be used to lower serum LDL in a subject. Thus, in some embodiments, the invention comprises a neutralizing PCSK9 variant (or its use) that can bind to LDLR and prevent native PCSK9 from binding to LDLR, while still allowing LDLR to bind to and act on LDL.

[0055] Some embodiments of the invention relate to the discovery that using a neutralizing PCSK9 variant (*e.g.*, a variant that includes an active Pro/Cat domain and an inactive V domain) can result in the neutralizing PCSK9 variant competitively blocking and preventing native PCSK9 from binding to and degrading LDLR, while still allowing LDLR to

recycle (e.g., be endocytosed and then return back to the plasma membrane). Thus, in some embodiments, the invention comprises a neutralizing PCSK9 variant (or its use) that can bind to LDLR and prevent native PCSK9 from binding to LDLR, while still allowing LDLR to recycle.

[0056] In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of some or all of the Pro and/or Cat domains of PCSK9. In some embodiments, the neutralizing PCSK9 variant does not include some or all of the V domain. In some embodiments the neutralizing PCSK9 variant does not have a fully functional LDLR degrading V domain. In some embodiments the neutralizing PCSK9 variant has an inactive V domain. As will be appreciated by one of skill in the art, some of these embodiments can be beneficial in situations in which one wishes to lower the serum cholesterol in a subject, such as in hypercholesterolemia. Neutralizing PCSK9 variants can be used in various methods and compositions for treating subjects with elevated serum cholesterol levels, at risk of elevated serum cholesterol levels, or in those that could benefit from a reduction in their serum cholesterol levels. Thus, various methods and techniques for lowering, maintaining, or preventing an increase in serum cholesterol are also described herein.

[0057] Exemplary human PCSK9 amino acid sequences are presented as SEQ ID NOs: 1 and 3. An exemplary human PCSK9 coding sequence is presented as SEQ ID NO: 2, in FIG. 1A (depicting the “pro” domain of the protein as underlined) and FIG. 1B (depicting the signal sequence in bold and the pro domain underlined). Additional variants of PCSK9 (or the Cat domain of PCSK9) are shown in FIGs. 1C-1H. The structure of the PCSK9 protein has recently been solved by two groups (Cunningham et al., Nature Structural & Molecular Biology, 2007, and Piper et al., Structure, 15:1-8, 2007), the entireties of both of which are herein incorporated by reference.

[0058] For convenience, the following sections generally outline the various meanings of the terms used herein. Following this discussion, general aspects regarding neutralizing PCSK9 variants are discussed, followed by specific examples.

Definitions and Embodiments

[0059] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless

specifically stated otherwise. In this disclosure, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. Also, the use of the term “portion” can include part of a moiety or the entire moiety.

[0060] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose. As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0061] The term “proprotein convertase subtilisin kexin type 9” or “PCSK9” refers to a polypeptide as set forth in SEQ ID NO: 1 and/or 3 or fragments thereof, as well as related polypeptides, which include, but are not limited to, allelic variants, splice variants, derivative variants, substitution variants, and/or insertion variants including the addition of an N-terminal methionine, fusion polypeptides, and interspecies homologs. Examples of related proteins are put forth in FIGs. 1C-1H. In some embodiments, a PCSK9 polypeptide includes terminal residues, such as, but not limited to, leader sequence residues, targeting residues, amino terminal methionine residues, lysine residues, tag residues and/or fusion protein residues. “PCSK9” has also been referred to as FH3, NARC1, HCHOLA3, proprotein convertase subtilisin/kexin type 9, and neural apoptosis regulated convertase 1. The PCSK9 gene encodes a proprotein convertase protein that belongs to the proteinase K subfamily of the secretory subtilase family. The term “PCSK9” denotes both the proprotein and the product generated following autocatalysis of the proprotein. When only the autocatalyzed product is being referred to, the protein can be referred to as the “cleaved” or “processed” PCSK9. When only the inert form is being referred to, the protein can be referred to as the “inert”, “pro-form”, or “unprocessed” form of PCSK9. The term PCSK9 as used herein also includes naturally occurring alleles, such as the mutations D374Y, D374H, S127R, F216L, R46L, R237W, L253F, A443T, H553R, and others (Kotowski IK et al, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol, *Am J. Hum. Genet.* 2006; 78:410-422). The term PCSK9 also encompasses PCSK9 molecules

incorporating post-translational modifications of the PCSK9 amino acid sequence, such as PCSK9 sequences that have been glycosylated, PEGylated, PCSK9 sequences from which its signal sequence has been cleaved, PCSK9 sequence from which its pro domain has been cleaved from the catalytic domain but not separated from the catalytic domain (e.g., FIGs. 1A and 1B).

[0062] The term “PCSK9 activity” includes any biological effect of PCSK9. In some embodiments, PCSK9 activity includes the ability of PCSK9 to interact or bind to a substrate or receptor. In some embodiments, PCSK9 activity is represented by the ability of PCSK9 to bind to a LDL receptor (LDLR). In some embodiments, PCSK9 binds to and catalyzes a reaction involving LDLR. In some embodiments, PCSK9 activity includes the ability of PCSK9 to alter (e.g., reduce) the availability of LDLR. In some embodiments, PCSK9 activity includes the ability of PCSK9 to increase the amount of LDL in a subject. In some embodiments, PCSK9 activity includes the ability of PCSK9 to decrease the amount of LDLR that is available to bind to LDL. In some embodiments, “PCSK9 activity” includes any biological activity resulting from PCSK9 signaling. Exemplary activities include, but are not limited to, PCSK9 binding to LDLR, PCSK9 enzyme activity that cleaves LDLR or other proteins, PCSK9 binding to proteins other than LDLR that facilitate PCSK9 action, PCSK9 altering APOB secretion (Sun X-M et al, “Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolemia, *Human Molecular Genetics* 14: 1161-1169, 2005 and Ouguerram K et al, “Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9, *Arterioscler thromb Vasc Biol.* 24: 1448-1453, 2004), PCSK9’s role in liver regeneration and neuronal cell differentiation (Seidah NG et al, “The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation” *PNAS* 100: 928-933, 2003), and PCSK9s role in hepatic glucose metabolism (Costet et al., “Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c” *J. Biol. Chem.* 281(10):6211-18, 2006). PCSK9 activity can be distinct from the terms “active Pro/Cat domain” or “inactive V domain” as defined herein.

[0063] The term “hypercholesterolemia,” as used herein, refers to a condition in which cholesterol levels are elevated above a desired level. In some embodiments, this denotes that serum cholesterol levels are elevated. In some embodiments, the desired level takes into

account various “risk factors” that are known to one of skill in the art (and are described or referenced herein).

[0064] The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate and phosphoroamidate.

[0065] The term “oligonucleotide” means a polynucleotide comprising 200 or fewer nucleotides. In some embodiments, oligonucleotides are 10 to 60 bases in length. In other embodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides can be single stranded or double stranded, *e.g.*, for use in the construction of a mutant gene. Oligonucleotides can be sense or antisense oligonucleotides. An oligonucleotide can include a label, including a radiolabel, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes.

[0066] An “isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, or is linked to a polynucleotide to which it is not linked in nature. For purposes of this disclosure, it should be understood that “a nucleic acid molecule comprising” a particular nucleotide sequence does not encompass intact chromosomes. Isolated nucleic acid molecules “comprising” specified nucleic acid sequences can include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty other proteins or portions thereof, or can include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequences, and/or can include vector sequences.

[0067] Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions

on the DNA strand having the same sequence as the RNA transcript that are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences;" sequence regions on the DNA strand having the same sequence as the RNA transcript that are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences."

[0068] The term "control sequence" refers to a polynucleotide sequence that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences can depend upon the host organism. In particular embodiments, control sequences for prokaryotes can include a promoter, a ribosomal binding site, and a transcription termination sequence. For example, control sequences for eukaryotes can include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequence. "Control sequences" can include leader sequences and/or fusion partner sequences.

[0069] The term "vector" means any molecule or entity (*e.g.*, nucleic acid, plasmid, bacteriophage or virus) used to transfer protein coding information into a host cell.

[0070] The term "expression vector" or "expression construct" refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control (in conjunction with the host cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct can include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto.

[0071] As used herein, "operably linked" means that the components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. For example, a control sequence in a vector that is "operably linked" to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.

[0072] The term "host cell" means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.

[0073] The term “transfection” means the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham *et al.*, 1973, *Virology* 52:456; Sambrook *et al.*, 2001, *Molecular Cloning: A Laboratory Manual*, *supra*; Davis *et al.*, 1986, *Basic Methods in Molecular Biology*, Elsevier; Chu *et al.*, 1981, *Gene* 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

[0074] The term “transformation” refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed where it is genetically modified from its native state by introducing new genetic material *via* transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA can recombine with that of the cell by physically integrating into a chromosome of the cell, or can be maintained transiently as an episomal element without being replicated, or can replicate independently as a plasmid. A cell is considered to have been “stably transformed” when the transforming DNA is replicated with the division of the cell.

[0075] The terms “polypeptide” or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring and non-recombinant cell; or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally-occurring amino acid and polymers. The terms “polypeptide” and “protein” specifically encompass neutralizing PCSK9 variants, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of the PCSK9 protein or variant. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. In some embodiments, fragments are about five to 500 amino acids long. For example, fragments can be at least 5, 6, 7, 8, 9, 10, 10-14, 14-20, 20-50, 50-70,

70-100, 100-110, 110-150, 150-200, 200-250, 250-300, 300-350, 350-400, or 400-450 amino acids long.

[0076] The term “isolated protein” means that a subject protein (1) is free of at least some other proteins with which it would normally be found, (2) is essentially free of other proteins from the same source, *e.g.*, from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (6) does not occur in nature. Typically, an “isolated protein” constitutes at least about 5%, at least about 10%, at least about 25%, or at least about 50% of a given sample. Genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof can encode such an isolated protein. Preferably, the isolated protein is substantially free from proteins or polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic, research or other use.

[0077] The term “amino acid” includes its normal meaning in the art and includes both naturally and non-naturally occurring amino acids.

[0078] A “variant” of a polypeptide (*e.g.*, a neutralizing PCSK9 variant) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and/or substituted into the amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins.

[0079] The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (*i.e.*, an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in *Computational Molecular Biology*, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; *Biocomputing Informatics and Genome Projects*, (Smith, D. W., ed.), 1993, New York: Academic Press; *Computer Analysis of Sequence Data*, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje,

G., 1987, *Sequence Analysis in Molecular Biology*, New York: Academic Press; *Sequence Analysis Primer*, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo *et al.*, 1988, *SIAM J. Applied Math.* 48:1073.

[0080] In calculating percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux *et al.*, 1984, *Nucl. Acid Res.* 12:387; Genetics Computer Group, University of Wisconsin, Madison, WI). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In some embodiments, a standard comparison matrix (*see*, Dayhoff *et al.*, 1978, *Atlas of Protein Sequence and Structure* 5:345-352 for the PAM 250 comparison matrix; Henikoff *et al.*, 1992, *Proc. Natl. Acad. Sci. U.S.A.* 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

[0081] Examples of parameters that can be employed in determining percent identity for polypeptides or nucleotide sequences using the GAP program are the following:

- Algorithm: Needleman *et al.*, 1970, *J. Mol. Biol.* 48:443-453
- Comparison matrix: BLOSUM 62 from Henikoff *et al.*, 1992, *supra*
- Gap Penalty: 12 (but with no penalty for end gaps)
- Gap Length Penalty: 4
- Threshold of Similarity: 0

[0082] Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted

if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.

[0083] As used herein, the twenty conventional (*e.g.*, naturally occurring) amino acids and their abbreviations follow conventional usage. See *Immunology--A Synthesis* (2nd Edition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference for any purpose. Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids can also be suitable components for polypeptides. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

[0084] Similarly, unless specified otherwise, the left-hand end of single-stranded polynucleotide sequences is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences."

[0085] Conservative amino acid substitutions can encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.

[0086] Naturally occurring residues can be divided into classes based on common side chain properties:

- 1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
- 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

- 3) acidic: Asp, Glu;
- 4) basic: His, Lys, Arg;
- 5) residues that influence chain orientation: Gly, Pro; and
- 6) aromatic: Trp, Tyr, Phe.

For example, non-conservative substitutions can involve the exchange of a member of one of these classes for a member from another class. Such substituted residues can be introduced, for example, into regions of a PCSK9 protein that are homologous with non-human PCSK9 proteins, or into the non-homologous regions of the molecule.

[0087] In making changes to the PCSK9 protein or variant thereof, according to certain embodiments, the hydropathic index of amino acids can be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[0088] The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art. Kyte *et al.*, J. Mol. Biol., 157:105-131 (1982). It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, in some embodiments, the substitution of amino acids whose hydropathic indices are within ± 2 is included. In some embodiments, those which are within ± 1 are included, and in some embodiments, those within ± 0.5 are included.

[0089] It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. In some embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.

[0090] The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-

0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5) and tryptophan (-3.4). In making changes based upon similar hydrophilicity values, in some embodiments, the substitution of amino acids whose hydrophilicity values are within ± 2 is included, in some embodiments, those which are within ± 1 are included, and in some embodiments, those within ± 0.5 are included. One can also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as "epitopic core regions."

[0091] Exemplary amino acid substitutions are set forth in Table 1.

TABLE 1
Amino Acid Substitutions

Original Residues	Exemplary Substitutions	Preferred Substitutions
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln	Gln
Asp	Glu	Glu
Cys	Ser, Ala	Ser
Gln	Asn	Asn
Glu	Asp	Asp
Gly	Pro, Ala	Ala
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleucine	Leu
Leu	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, 1,4 Diamino-butyric Acid, Gln, Asn	Arg
Met	Leu, Phe, Ile	Leu
Phe	Leu, Val, Ile, Ala, Tyr	Leu
Pro	Ala	Gly

Original Residues	Exemplary Substitutions	Preferred Substitutions
Ser	Thr, Ala, Cys	Thr
Thr	Ser	Ser
Trp	Tyr, Phe	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

[0092] The term “derivative” refers to a molecule that includes a chemical modification other than an insertion, deletion, or substitution of amino acids (or nucleic acids). In some embodiments, derivatives comprise covalent modifications, including, but not limited to, chemical bonding with polymers, lipids, or other organic or inorganic moieties. In some embodiments, a chemically modified neutralizing PCSK9 variant can have a greater circulating half-life than a neutralizing PCSK9 variant that is not chemically modified. In some embodiments, a chemically modified neutralizing PCSK9 variant can have improved targeting capacity for desired cells, tissues, and/or organs. In some embodiments, a derivative neutralizing PCSK9 variant is covalently modified to include one or more water soluble polymer attachments, including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. *See, e.g.*, U.S. Patent Nos: 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 and 4,179,337. In some embodiments, a derivative neutralizing PCSK9 variant comprises one or more polymer, including, but not limited to, monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures of such polymers.

[0093] In some embodiments, a derivative is covalently modified with polyethylene glycol (PEG) subunits. In some embodiments, one or more water-soluble polymer is bonded at one or more specific position, for example at the amino terminus, of a derivative. In some embodiments, one or more water-soluble polymer is randomly attached to one or more side chains of a derivative. In some embodiments, PEG is used to improve the therapeutic capacity

for a neutralizing PCSK9 variant. In some embodiments, PEG is used to improve the therapeutic capacity of a molecule. Certain such methods are discussed, for example, in U.S. Patent No. 6,133,426, which is hereby incorporated by reference for any purpose.

[0094] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics." Fauchere, J., *Adv. Drug Res.*, 15:29 (1986); Veber & Freidinger, *TINS*, p.392 (1985); and Evans *et al.*, *J. Med. Chem.*, 30:1229 (1987), which are incorporated herein by reference for any purpose. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides can be used to produce a similar therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from: --CH₂ NH--, --CH₂ S--, --CH₂ -CH₂ --, --CH=CH-(cis and trans), --COCH₂ --, --CH(OH)CH₂ --, and --CH₂ SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used in some embodiments to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation can be generated by methods known in the art (Rizo and Gierasch, *Ann. Rev. Biochem.*, 61:387 (1992), incorporated herein by reference for any purpose); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

[0095] The term "naturally occurring" as used throughout the specification in connection with biological materials such as polypeptides, nucleic acids, host cells, and the like, refers to materials which are found in nature or a form of the materials that is found in nature.

[0096] A "recombinant neutralizing PCSK9 variant" is a protein made using recombinant techniques, *i.e.*, through the expression of a recombinant nucleic acid as described herein. Methods and techniques for the production of recombinant proteins are well known in the art.

[0097] The term "neutralizing PCSK9 variant" refers to a PCSK9 variant that associates and/or binds to LDLR competitively with a full length human PCSK9. The

neutralizing PCSK9 variant also has a reduced ability to degrade or remove LDLR from a system compared to wild-type PCSK9 (*e.g.*, SEQ ID NO: 3). In some embodiments, the neutralizing PCSK9 variant lacks a fully functional LDLR degrading V domain (*e.g.*, the PCSK9 protein has an inactive V domain). In some embodiments, the neutralizing PCSK9 variant has a reduced ability to degrade or take LDLR out of a system compared to a similar variant lacking a fully functional V domain. Stated another way, a neutralizing PCSK9 variant has the ability to directly or indirectly reduce the degradation of LDLR and thus maintain or increase LDLR levels in a system.

[0098] The term “pro” or “pro domain” is used to refer to at least a part of the prodomain of PCSK9. In some embodiments, the prodomain of PCSK9 is involved (either directly or indirectly (such as by allowing proper folding of the Cat domain)) in the binding of PCSK9 to LDLR. While the exact starting and ending residue of the pro domain can vary based on the specific embodiment, the pro domain will at least comprise residues 61-152 of SEQ ID NO: 3 and variants thereof. In some embodiments, the pro domain comprises amino acids 31-152 of SEQ ID NO: 3, or variants thereof. Variants of the Pro domain can be 50% or more (*e.g.*, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent identical to the corresponding Pro domain of SEQ ID NO: 3 and/or a consensus sequence (*e.g.*, shown in FIG. 1C-1E).

[0099] The term “Cat” or “cat domain” is used to refer to at least a part of the catalytic domain of PCSK9. In some embodiments, the “cat domain” is involved in the binding of PCSK9 to LDLR. While the exact starting and ending residue of the Cat domain can vary based on the specific embodiment, the Cat domain will at least comprise residues 153-381 and in some embodiments will comprise at least residues 153-445 of SEQ ID NO: 3 and variants thereof. Variants of the Cat domain can be 50% or more (*e.g.*, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent) identical to the corresponding Cat domain of SEQ ID NO: 3. In some embodiments, the cat domain can start at residue 153 of SEQ ID NO: 3 (and variants thereof) and ends at any one of residues 447, 448, 449, 450, 451, 452, or 453 of SEQ ID NO: 3 (and variants thereof). Thus, the Cat domain can include residues 153-447, 153-448, 153-449, 153-450, 153-451, 153-452, 153-453, or 153-454 of SEQ ID NO: 3 (and variants thereof) and/or a consensus sequences (*e.g.*, shown in FIGs. 1C-1H and FIGs. 1R₁-1R₂, SEQ ID NOs: 9, 11, 13, 15, and 30 where FIGs. 1F-1H display examples of a Cat domain).

[0100] The term “Pro/Cat” or “Pro/Cat domain” is used to refer to the section of PCSK9 that is involved in binding to LDLR. The “Pro/Cat domain” need not include both the Pro and Cat domain. In particular, something referred to as the “Pro/Cat domain” can comprise the Pro domain without the Cat domain, or the Cat domain without the Pro domain. While the term also encompasses a PCSK9 protein that includes both the Pro and the Cat domain, when both of these domains are required to be present the phrase “Pro domain and Cat domain” or similar phrase is generally employed. In some embodiments, the pro/cat domain can start at residues 31 or 61 of SEQ ID NO: 3 (and variants thereof) and end at any one of residues 447, 448, 449, 450, 451, 452, or 453 of SEQ ID NO: 3 (and variants thereof). Thus, in some embodiments, the Pro/Cat domain can include residues 31-447, 31-448, 31-449, 31-450, 31-451, 31-452, 31-453, 61-447, 61-448, 61-449, 61-450, 61-451, 61-452, and 61-453 of SEQ ID NO: 3 (and variants thereof), and/or SEQ ID NOS: 4, 5, 6, 7, 8, 24-29 and/or 31 and/or a consensus sequence (*e.g.*, shown in FIGs. 1C-1E and 1R₁-1R₂ SEQ ID NOS: 9 and 30 (and F-H for the Cat domain, SEQ ID Nos: 11, 13, and 15)). Of course, the “pro/cat” domain can also simply include the pro or cat regions noted above. In some embodiments, variants of the pro/cat domain can be 50% or more (*e.g.*, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent) identical to the corresponding pro/cat domain of SEQ ID NO: 3. In some embodiments, the pro/cat domain is at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or more percent identical for the conserved sections of the pro/cat domain. In some embodiments, while the sections of the pro/cat domain that are 100% conserved (shown in FIGs. 1C-1E) are conserved in the pro/cat variant, the remaining positions can be changed. In some embodiments, the changes in these remaining positions can result in a pro/cat variant that is 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent identical to the corresponding pro/cat domain of SEQ ID NO: 3. In some embodiments, the variable positions are those shown as spaces or gaps in the consensus sequence in FIGs. 1C-1E and FIG. 1R₁-1R₂ or non specific amino acids in FIGs. 1F-1H (and/or shown as “Xaa” in SEQ ID NOS: 9, 11, 13, 15, and 30).

[0101] As will be appreciated by one of skill in the art, the sequence alignment shown in the attached figures (1C-1H and 1I-1L) denote the residues that, in some embodiments (including various neutralizing PCSK9 variants), can be conserved in order to obtain a functional Pro, Cat, Pro/Cat, or LDLR domain or protein and those that can be changed (and how they can be changed). In some embodiments, the sections denoted by spaces in the consensus sequences

are amino acid(s) where conservation is not required and any or no amino acid can be used at these locations (*e.g.*, variation is readily allowable at these locations). In some embodiments, the sections denoted by “+” can similarly be altered with any amino acid. In some embodiments, the sections denoted by “+” are conservative replacements, or the replacements noted for that position in the sequence listing (or in the various organisms for the sequence alignment). As noted herein, various consensus sequences are disclosed within FIGs. 1C-1L. Thus, consensus sequences in addition to the consensus sequence explicitly identified in the figures are also disclosed herein.

[0102] The term “V” or “V domain” is used to refer the section of the PCSK9 protein that is involved in the effective degradation of LDLR. While the exact starting and ending residues of the V domain can vary based on the specific embodiment, the V domain will at least comprise residues 455-682 of SEQ ID NO: 3 and variants thereof. In some embodiment the V domain will at least comprise residues 457-679, 454-692, 457-692, 457-682, 455-692, 455-679, 454-682, or 454-679. Variants of the V domain can be 55% or more (*e.g.*, 55-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent identical to the corresponding V domain of SEQ ID NO: 3. Simply because there is an amino acid sequence on the c-terminal end of a pro/cat domain does not make that sequence a V domain or an active V domain. An active V domain will also have the above noted function in regard to LDLR. As will be appreciated by one of skill in the art, inactive V domains encompass a broader scope of possible domains, sequences, and structures than do active V domains. Any protein, or a lack of PCSK9 protein, that does not achieve the V domain’s function noted above can be characterized as an inactive V domain.

[0103] The term “loop” is used to refer to the section between the V domain and the Cat domain. This section need not be called out explicitly in every embodiment. While the exact starting and ending residues of the loop can vary based on the specific embodiment, the loop can comprise residues 447-453 of SEQ ID NO: 3 and variants thereof. Variants of the loop can be 0% or more (*e.g.*, 0-10, 10-20, 20-30, 30-40, 40-50 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, 99 percent identical to the loop of SEQ ID NO: 3. In some embodiments, any structure or section connecting the V domain to the Cat domain can be considered as a loop section. In some embodiments, the loop domain is not explicitly denoted as such and is simply part of either the Cat domain or the V domain.

[0104] The phrase “LDLR degrading” refers to the ability of the V domain (or subpart thereof), when part of a whole PCSK9 protein, to promote the degradation of LDLR. As will be appreciated by one of skill in the art in light of the present disclosure, the LDLR degrading ability of the V domain need not be a direct role. In particular, it can be possible for LDLR to be degraded by PCSK9 variants that lack the V domain. Thus, the LDLR “degrading role” or “ability” of the V domain denotes that this section of the PCSK9 protein is involved in the effective degradation of LDLR. The removal of the V domain need not completely prevent all LDLR degradation under all possible variables and circumstances (and, as noted below in the examples, in some circumstances, does not).

[0105] The phrase “fully functional LDLR degrading” or “fully functional LDLR degradation” refers to the amount of LDLR degradation that occurs from a PCSK9 protein that has the wild-type V domain following amino acid 450 of SEQ ID NO: 3. Thus, a “fully functional LDLR degrading V domain” will degrade LDLR at a rate equal to and/or greater than wild type PCSK9 (for example, SEQ ID NO: 3). Proteins that are not fully functional for LDLR degradation, that have an inactive V domain, or that lack a fully functional LDLR degrading V domain will degrade LDLR less effectively than the wild type PCSK9. Thus, for example, a variant of PCSK9 that is only 90% as effective as wild-type PCSK9 can be characterized as lacking a fully functional LDLR degrading V domain or as having an inactive V domain. A PCSK9 variant that lacks a V domain can also be described as lacking a fully functional LDLR degrading V domain or as having an inactive V domain. A PCSK9 protein that lacks a fully functional LDLR degrading V domain, that has an inactive V domain, or that lacks a V domain is less than 100% as effective as the wild type PCSK9 (SEQ ID NO: 3), include, for example, PCSK9 proteins that are 99-90, 90-80, 80-70, 70-60, 60-50, 50-40, 40-30, 30-20, 20-10, 10-5, 5-1, 1-0.1, 0.1-0.01, 0.01-0.001, 0.001-0.0001, and 0.0001 to 0% as effective as the wild type PCSK9 protein. As will be appreciated by one of skill in the art, a neutralizing PCSK9 variant can contain some or all of the V domain, as long as the V domain is not fully functional for LDLR degradation. The functionality of the V domain can be adjusted by various approaches, including, for example, removal, point mutations, insertions, deletions, etc.

[0106] The phrase term “active” as used in “active Pro domain,” “active Pro/Cat domain,” or “active Cat domain” denotes that the protein can bind to LDLR.

[0107] The term “inactive” as used in “inactive V domain” denotes that the molecule in question does not have a PCSK9 V domain that functions in LDLR degradation as effectively as the V domain in wild-type PCSK9. An inactive V domain does not require that the sequence of the V domain be present. In some embodiments, a neutralizing PCSK9 variant will have an inactive V domain if it lacks a V domain protein sequence.

[0108] The phrase “has an inactive V domain” denotes that the section of the V domain, if any section is present, is not as effective at degrading LDLR as the V domain in the full length PCSK9 protein. This does not require that any part of the V domain actually be present. Thus, a PCSK9 protein that lacks the entire V domain can also be characterized as “having an inactive V domain.” As above, the definition does not require that the protein with the inactive V domain exhibit a complete absence of LDLR degrading ability. A PCSK9 protein that has an inactive V domain will be less than 100% as effective as the wild type PCSK9 (SEQ ID NO: 3). Examples of such lower levels of effectiveness include, for example, PCSK9 proteins having V domains that are 99-90, 90-80, 80-70, 70-60, 60-50, 50-40, 40-30, 30-20, 20-10, 10-5, 5-1, 1-0.1, 0.1-0.01, 0.01-0.001, 0.001-0.0001, and 0.0001 to 0% as effective as the wild type PCSK9 protein. Nonlimiting examples of inactive or inactivated V domains include, for example, proteins that lack V domains (*e.g.*, the entire V domain is absent from the PCSK9 protein), proteins that lack 14 or more amino acids from the end (c-terminal) of the PCSK9 protein (*e.g.*, SEQ ID NO: 3), proteins in which the V domain is improperly folded (in comparison to wild-type PCSK9; *e.g.*, the C679X mutation).

[0109] The phrase “lacks the entirety of amino acids ###-###” denotes that the entire and exact amino acid sequence defined therein is absent from the protein. Subparts of the amino acid sequence or range can be present. For example, if the protein “lacks the entirety of amino acids 10-100 of SEQ ID NO: X,” then amino acids 10-99 or 11-100 of SEQ ID NO: X can be present, although 10-100 are excluded from being present.

[0110] The phrase “attached adjacent to an amino acid ### of SEQ ID NO: X” denotes that whatever is (or is not) to be attached is (or is not) attached immediately adjacent to a specific amino acid (###). When the phrase is being used in a negative context (for example as an exclusion), then it denotes that, if amino acid ### is present, then the item in question is not attached adjacent to it. However, the use of this phrase does not imply or require that amino acid ### is actually present when used in its negative context. As an example, the phrase “lacks the

entirety of amino acids 10-100 of SEQ ID NO: X attached adjacent to an amino acid 9 of SEQ ID NO: X” denotes that all 91 amino acids of amino acids 10-100 of SEQ ID NO: X are missing from the position adjacent to amino acid 9 of SEQ ID NO: X (if amino acid 9 is present). Thus, amino acids 11-100 can be present and attached adjacent to amino acid 9, amino acids 10-99 can be present and attached adjacent to amino acid 9, or amino acids 10-100 can be present and attached to either amino acid 8 or 11 of SEQ ID NO: 3. It is noted that, for the above type of exclusion, amino acid 9 does not need to be present. Thus, amino acids 1-5 of SEQ ID NO: X would also meet the above description, (as there is no amino acid 9 and there can be no amino acid adjacent to it). In addition, unless explicitly noted, the position “adjacent to” a specific amino acid is only the position that is greater than the noted amino acid. Thus, if the relevant amino acid is 9, then the only position adjacent to 9 is 10 (and thus position 8 is not considered “adjacent” to position 9 for the purposes of this definition). In other words, adjacent to only applies to the amino acid in the carboxy direction, not in the amino direction.

[0111] The phrase “at the appropriate position” as used in the phrase “at the appropriate position in the variant,” denotes that, the appropriate position is present in the variant. For example, the phrase, “the neutralizing PCSK9 variant has a cysteine at position 30” denotes that the variant has an amino acid at position 30 and that it is a cysteine. When the phrase is used in reference to another SEQ ID NO:, it denotes that the variant is (or is not) similar to that other SEQ ID NO: in the manner described. When the phrase is used as an exclusion, then, as noted in the above definition, the position itself need not be present in the variant, but if it is, then it will not be the item described.

[0112] The term “target” refers to a molecule or a portion of a molecule capable of being bound by a neutralizing PCSK9 variant.

[0113] The terms “compete” or “competitive,” when used in reference to “neutralizing PCSK9 variant” refers to the competition between a) native PCSK9 and b) PCSK9 variants for LDLR. Numerous types of competitive binding assays can be used to determine if one neutralizing PCSK9 variant competes with native PCSK9, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (*see, e.g.,* Stahli *et al.*, 1983, *Methods in Enzymology* 9:242-253); solid phase direct biotin-avidin EIA (*see, e.g.,* Kirkland *et al.*, 1986, *J. Immunol.* 137:3614-3619) solid phase direct labeled assay, solid phase direct labeled sandwich assay (*see, e.g.,* Harlow and

Lane, 1988, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press); solid phase direct label RIA using I-125 label (*see, e.g., Morel et al., 1988, Molec. Immunol.* 25:7-15); solid phase direct biotin-avidin EIA (*see, e.g., Cheung, et al., 1990, Virology* 176:546-552); and direct labeled RIA (Moldenhauer *et al.*, 1990, *Scand. J. Immunol.* 32:77-82).

[0114] As used herein, “substantially pure” means that the described species of molecule is the predominant species present, that is, on a molar basis it is more abundant than any other individual species in the same mixture. In some embodiments, a substantially pure molecule is a composition wherein the object species comprises at least 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise at least 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In other embodiments, the object species is purified to essential homogeneity wherein contaminating species cannot be detected in the composition by conventional detection methods and thus the composition consists of a single detectable macromolecular species.

[0115] The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

[0116] As used herein, the terms “label” or “labeled” refers to incorporation of a detectable marker. Examples include incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotin moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In some embodiments, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and can be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0117] The term “biological sample”, as used herein, includes, but is not limited to, any quantity of a substance from a living thing or formerly living thing. Such living things

include, but are not limited to, humans, mice, monkeys, rats, rabbits, and other animals. Such substances include, but are not limited to, blood, serum, urine, cells, organs, tissues, bone, bone marrow, lymph nodes, and skin.

[0118] The term “pharmaceutical agent composition” (or agent or drug) as used herein refers to a chemical compound, composition, agent or drug capable of inducing a desired therapeutic effect when properly administered to a patient. It does not necessarily require more than one type of ingredient.

[0119] The term “therapeutically effective amount” refers to the amount of a neutralizing PCSK9 variant determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertained by one of ordinary skill in the art.

[0120] The term “modulator,” as used herein, is a substance that changes or alters the activity or function of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a certain activity or function of a molecule compared to the magnitude of the activity or function observed in the absence of the modulator. In some embodiments, a modulator is an inhibitor, which decreases the magnitude of at least one activity or function of a molecule. Certain exemplary activities and functions of a molecule include, but are not limited to, binding affinity, enzymatic activity, and signal transduction. Certain exemplary inhibitors include, but are not limited to, proteins, peptides, antibodies, peptibodies, carbohydrates or small organic molecules. Peptibodies are described in, e.g., U.S. Patent No. 6,660,843 (corresponding to PCT Application No. WO 01/83525).

[0121] The terms “patient” and “subject” are used interchangeably and include human and non-human animal subjects as well as those with formally diagnosed disorders, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc.

[0122] The term “treat” and “treatment” includes therapeutic treatments, prophylactic treatments, and applications in which one reduces the risk that a subject will develop a disorder or other risk factor. Treatment does not require the complete curing of a disorder and encompasses embodiments in which one reduces symptoms and/or underlying risk factors.

[0123] The term “prevent” does not require the 100% elimination of the possibility of an event. Rather, it denotes that the likelihood of the occurrence of the event has been reduced in the presence of the compound or method.

[0124] The term "native Fc" refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Native Fc's are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison et al. (1982), *Nucleic Acids Res.* 10: 4071-9). The term "native Fc" as used herein is generic to the monomeric, dimeric, and multimeric forms.

[0125] The term "Fc variant" refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn. International applications WO 97/34631 (published Sep. 25, 1997) and WO 96/32478 describe exemplary Fc variants, as well as interaction with the salvage receptor, and are hereby incorporated by reference. Thus, the term "Fc variant" comprises a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises sites that can be removed because they provide structural features or biological activity that are not required for the fusion molecules of PCSK9. Thus, the term "Fc variant" comprises a molecule or sequence that lacks one or more native Fc sites or residues that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.

[0126] The term "Fc domain" encompasses native Fc and Fc variant molecules and sequences as defined above. As with Fc variants and native Fc's, the term "Fc domain" includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means. In some embodiments, an Fc domain can be associated to a neutralizing PCSK9 variant (e.g., via a covalent bond between the Fc domain and the neutralizing PCSK9 variant).

[0127] The term "multimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more polypeptide chains associated covalently,

noncovalently, or by both covalent and non-covalent interactions. IgG molecules typically form dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dimers, trimers, or tetramers. Multimers can be formed by exploiting the sequence and resulting activity of the native Ig source of the Fc or by derivatizing (as defined below) such a native Fc.

[0128] The term "dimer" as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently.

[0129] Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. *See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose. Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

Neutralizing PCSK9 Variants

[0130] In some embodiments, the neutralizing PCSK9 variant provided herein is capable of inhibiting native PCSK9 from binding to LDLR. In some embodiments, this blocking results in a decrease in the degradation of LDLR *in vivo*; thereby resulting in a lowering of serum LDL in a subject.

[0131] As noted above, the ability of PCSK9 to bind to LDLR and the ability of wild-type PCSK9 to effectively degrade LDLR appear to be due to two different sections of the PCSK9 protein. As noted in the examples below, the ability of PCSK9 to effectively degrade LDLR appears to be linked to the V domain of PCSK9. Thus, in some embodiments, variants of

PCSK9 that lack fully functional LDLR degrading V domains (or have an inactive V domain) can be introduced into a system or subject without adversely increasing the amount of LDLR degradation. Moreover, as described herein, the binding of PCSK9 to LDLR is mediated by sections of the Pro and/or Cat domains of PCSK9. Thus, neutralizing PCSK9 variants that contain sufficient sections of the Pro and/or Cat domain(s) can still bind to LDLR and compete with native PCSK9 for binding to LDLR. In some embodiments, when the variant also lacks a fully functional LDLR degrading V domain (or have an inactive V domain), then the PCSK9 variant will not only block native PCSK9, but will do so while lowering LDLR degradation, thereby increasing LDLR availability and in turn decreasing the amount of LDL in the serum. Thus, in some embodiments, a neutralizing PCSK9 variant is a PCSK9 protein that has an active Pro/Cat domain and an inactive V domain.

[0132] In some embodiments, the neutralizing PCSK9 variant includes, consists, or consists essentially of the Pro and/or Cat domain(s) of PCSK9. In some embodiments, the variant includes a signal sequence (for example, amino acids 1-30 of SEQ ID NO: 3). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 31-447 of SEQ ID NO: 3 (or a variant of amino acids 31-447). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 153-374 of SEQ ID NO: 3 (or a variant of amino acids 153-374). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 31-374 of SEQ ID NO: 3 (or a variant of amino acids 31-374). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 153-454 of SEQ ID NO: 3 (or a variant of amino acids 153-454). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 31-449 of SEQ ID NO: 3 (or a variant of amino acids 31-449). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 153-381 of SEQ ID NO: 3 (or a variant of amino acids 153-381). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 31-381 of SEQ ID NO: 3 (or a variant of amino acids 31-381). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of amino acids 153-382 of SEQ ID NO: 3 (or a variant of amino acids 153-382). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of

amino acids 31-382 of SEQ ID NO: 3 (or a variant of amino acids 31-382). In some embodiments, the neutralizing PCSK9 variant comprises, consists, or consists essentially of an amino acid starting at either position 31, 61, or 153 of SEQ ID NO: 3 and ending at position 374, 381, 382, 447, 448, 449, 450, 451, 452, 453, 454, or 455 of SEQ ID NO: 3 (or a variant thereof). In some embodiments, variants can be at least 50 percent identical, for example 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99 or greater identity, to the relevant section (*e.g.*, any of the above noted sections) of SEQ ID NO: 3. In some embodiments, variants can have at least 70% homology, for example 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99 or greater homology, to the relevant section of SEQ ID NO: 3.

[0133] In some embodiments, the V domain can be entirely removed. In some embodiments, a section of the V domain can be removed or altered. The section can be sufficient to prevent the neutralizing PCSK9 variant from significantly degrading LDLR

[0134] In some embodiments, the variant lacks some or all of the V domain. In some embodiments, the V domain will be inactive and will not allow for wild-type levels of degradation of LDLR. In some embodiments, the neutralizing PCSK9 variant lacks the V domain completely. In some embodiments, the variant lacks residues 447-692, 448-692, 449-692, 450-692, 451-692, 452-692, 453-692, or 454-692 of SEQ ID NO: 3. In some embodiments, any of the above missing sections, can be present in the variant, but will not be placed immediately adjacent to the amino acid positioned in front of it in SEQ ID NO: 3. Thus, for example, 453-692, 454-692, 450-692, or 447-692 of SEQ ID NO: 3 can be present in the variant, but will not be positioned following amino acid 452, 453, 449, or 446 respectively of SEQ ID NO: 3. In some embodiments, at least the last 14 amino acids from the C-terminus of SEQ ID NO: 3 are missing (or different from the amino acids in SEQ ID NO: 3), thereby creating an inactive V domain. For example, 14-16, 16-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-120, 120-140, 140-160, 160-200, 200-220, 220-225 amino acids can be deleted from the C terminal portion of the V domain to produce an inactive V domain.

[0135] In some embodiments, the neutralizing PCSK9 variant includes a point mutation. In some embodiments, the point mutation is the D374Y point mutation that has an increased binding affinity to LDLR. In some embodiments, one or more other point mutations are also included in the neutralizing PCSK9 variant. For example, mutations such as I474V, R273W, H87N, A103D, G308R, S376G, D480G, R499C, D374X, where X can be Y, A, H, R,

E, F, K, L,, Y142X, C679X, R46L, L253F, A443T, A53V, H553R, Q619P, E670G and those disclosed in Kotowski IK et al, Am. J. Hum. Genet. 2006;78:410-422, (incorporated herein by reference).

[0136] In some embodiments, any of the above variations (including mutations) and lengths of the V domain can be included or excluded from any of the above variations (including mutations) in the above noted pro and/or cat domains in order to produce a neutralizing PCSK9 variant. Thus, for example, the neutralizing variant can lack residues 453-692, 454-692, 450-692, or 447-692 of SEQ ID NO: 3 (or a variant thereof) positioned next to positions 452, 453, 449, or 446 respectively of SEQ ID NO: 3, while having any one of the above pro and/or cat regions (for example, 331-454, 31-447, 31-449, 153-374, 153-454, and 31-374 of SEQ ID NO: 3 (or a variant thereof)). In addition, any of the herein disclosed neutralizing PCSK9 variants can include a valine at 474 (instead of an isoleucine), a glycine at 670 (instead of a glutamate), and/or a glutamate at 620 (instead of a glycine). In some embodiments, the wild-type PCSK9 protein is that sequence defined in Genbank sequence NM_174936. Other SNP variants can be found in Kotowski IK et al, Am. J. Hum. Genet. 2006; 78:410-422 and include R46L, A53V, L253F, R237W, A443T, I474V, Q619P, E670G, and others.

[0137] In some embodiments, variants of neutralizing PCSK9 proteins are selected by comparing various PCSK9 sequences to one another in order to determine those positions that are conserved and those positions that vary between PCSK9 sequences. In some embodiments, amino acids in the pro and/or cat domains that are conserved between various organisms are conserved while amino acids that are not conserved across two or more species are allowed to vary. Such variants can still have pro and/or cat domain(s) that still compete with native PCSK9 for binding. An example of a sequence alignment between PCSK9 proteins of various organisms can be found in FIGs. 1C to 1E. As will be appreciated by one of skill in the art, the space(s) in the consensus sequence can be filled with any of the other amino acids in the comparison at the corresponding location, or, in some embodiments, any amino acid. FIGs. 1F-1H depict another series of alignments of just the cat domain (the top sequence in the figures are from SEQ ID NO: 3, where amino acid 1-153 (of SEQ ID NO: 3) and amino acid 321-454 (of SEQ ID NO: 3)). As will be appreciated by one of skill in the art, the space(s) in the consensus sequences can be filled with any of the other amino acids in the comparison at the corresponding location, or, in some embodiments, any amino acid. Given the similarity between the sequences in FIG. 1C-1H and

SEQ ID NO: 3, the present invention contemplates that any of the above pro and/or cat domains can function as desired in a neutralizing PCSK9 variant (including variants that contain any one of the identified consensus sequences). As such, in some embodiments, any position that varies between the different PCSK9 sequences can be a position that can be altered in a neutralizing PCSK9 variant. In some embodiments, the position is altered to the other amino acid noted in the alignment. In some embodiments, the position is altered to a different amino acid. It is noted that the human PCSK9 sequence in FIGs. 1C-1E, while similar to SEQ ID NO: 3, includes an extra series of amino acids on the end of the sequence, including a glycine, followed by a proline, followed by 8 histidines. While the glycine or proline can be present or can be absent in various embodiments, the histidines are just part of a histidine tag, and are not a necessary part of the alignment or any of the proteins in the alignment. Thus, the consensus sequence need not have any of the histidines in it (all 8 can be removed in some embodiments as these are not structural elements of the protein). In some embodiments, the rat sequence in FIGs. 1C-1E has a glycine, followed by a proline, followed by 8 histidines on its end, just like the other sequences shown in FIG. 1E. Additional embodiments of PCSK9 sequences can be found in FIGs. 1M₁-1S₂, SEQ ID Nos: 25-31.

[0138] As noted above, the consensus sequences shown in the attached figures (1C-1H) indicate the residues that, in some embodiments, can be conserved in order to obtain a functional Pro/Cat domain and those that can be changed (and how they can be changed). In some embodiments, the sections of the consensus sequence denoted by spaces are amino acid(s) where conservation is not required and any or no amino acid can be used at these locations (*e.g.*, variation is readily allowable at these locations). In some embodiments, the sections denoted by “+” can similarly be altered with any amino acid. In some embodiments, the sections denoted by “+” are conservative replacements, or the replacements noted for that position in the sequence listing (or in the various organisms for the sequence alignment).

[0139] In FIGs. 1C-1E, as more than two amino acid sequences have been aligned, the consensus sequence does not display spaces at each amino acid position that can be varied without the Pro/Cat domain losing its functionality. Thus, in this alignment, for some embodiments, even amino acids designated as a specific amino acid in the explicitly noted consensus sequence can be varied and still result in a functioning Pro/Cat domain. For example, in some embodiments, an amino acid position that is assigned a specific amino acid in the

consensus sequence (in FIGs. 1C-1E), but varies between the various organisms, can be altered. Thus, in some embodiments, amino acid positions that are conserved between organisms (for example, as shown in FIGs. 1C-1E), are conserved in the neutralizing PCSK9 variant, but the other amino acid positions (those that are different between the various organisms) can be replaced with amino acids that are different from the amino acid denoted in their particular position of the consensus sequence. In some embodiments, the amino acid that replaces the amino acid in the consensus sequence is any amino acid (or none) and need not be limited to those amino acids appearing in the different sequences shown in FIGs. 1C-1E. In some embodiments, the amino acid change is to an amino acid that is the same as at least one of the amino acids shown in that position in the various amino acid sequences shown. In some embodiments, if the amino acids aligned for one position are different, but are conserved, then the amino acid position in the consensus sequence can be any amino acid having conserved properties (e.g., polar). In some embodiments, while amino acids that are identical between one or more of the species are present in the neutralizing PCSK9 variant, one or more of the other amino acids at the other position(s) are varied. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, or more amino acids that are not identical between the various organisms in FIGs. 1C-1E can be replaced by any other amino acid. In some embodiments, while the amino acids that are identical across all of the species noted in the figures are kept the same, the amino acids at the other positions are allowed to vary, with as much as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% of these amino acids being altered to another amino acid. In some embodiments, the conserved amino acids noted in the figures can be altered or replaced by another amino acid(s).

[0140] In some embodiments, in creating a neutralizing PCSK9 variant, amino acids in the V domain that are conserved between various PCSK9 proteins of various organisms are

altered while amino acids that are not conserved across one or more species are conserved, thereby producing a protein where the V domain is not active (or is inactive). An example of this comparison, between PCSK9 from various animals, can be found in FIGs. 1C to 1E. Thus, in some embodiments, any of the conserved amino acids in the V domain of PCSK9 can be altered while the conserved amino acids in the pro and/or cat domains can be maintained in order to produce a neutralizing PCSK9 variant. In some embodiments, the amino acid is altered to the other amino acid noted in the alignment. In some embodiments, the amino acid is altered to a different amino acid.

[0141] In some embodiments, residues that are important in the binding of PCSK9 to LDLR are maintained in the pro and/or cat domain(s). For example, those residues identified herein as part of the binding surface between LDLR and LDL or LDLR and PCSK9, or involved in the creation of the binding surface, as well as those residues discussed in “Molecular basis for LDL recognition by PCSK9” (PNAS, 105:1820-1825, 2008), such as Arg 194 and Phe 379 are maintained, if present within the fragment sequence. In some embodiments, the neutralizing PCSK9 variant includes at least residues 194-379.

[0142] In some embodiments, a neutralizing PCSK9 variant can inhibit, interfere with or modulate one or more biological activities of PCSK9. In one embodiment, the neutralizing PCSK9 variant competes with native PCSK9 for binding to LDLR. In some embodiments, the neutralizing PCSK9 variant reduces binding of native PCSK9 to LDLR by at least 1%, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent reduction of native PCSK9 binding to LDLR.

[0143] In some embodiments, the neutralizing PCSK9 variant has an IC_{50} for blocking the binding of native PCSK9 to LDLR of less than 1 microMolar, 1000 nM to 100 nM, 100nM to 10 nM, 10nM to 1 nM, 1000pM to 500pM, 500 pM to 200 pM, less than 200 pM, 200 pM to 150 pM, 200 pM to 100 pM, 100 pM to 10 pM, 10 pM to 1 pM. This IC_{50} can be measured between native PCSK9 to LDLR and the neutralizing PCSK9 variant to LDLR.

[0144] In some embodiments, a neutralizing PCSK9 variant does not include a C679X and/or a Q554E point mutation. In some embodiments, the neutralizing PCSK9 variant

does not include a His tag. In some embodiments, the neutralizing PCSK9 variant does not include a GST tag. In some embodiments, the neutralizing PCSK9 variant includes residue 453 of SEQ ID NO: 3, at the corresponding position in the variant. In some embodiments, the PCSK9 variant does not have the entirety of residues 453-692 removed from the protein. For example, in some embodiments, the neutralizing PCSK9 variant includes residues 31-453. In some embodiments, the neutralizing PCSK9 variant lacks residues such as 447, 448, 449, 450, 451, and 452 (or some combination thereof) of SEQ ID NO: 3. In some embodiments, the neutralizing PCSK9 variant lacks any amino acid at these positions. In some embodiments, the neutralizing PCSK9 variant lacks the corresponding amino acid at the specific position identified above in regard to SEQ ID NO: 3. In some embodiments, when explicitly stated, the neutralizing PCSK9 variants can exclude the PCSK9 variants disclosed in U.S. application 12/197093, filed August 22, 2008, hereby incorporated by reference in its entirety and especially in regard to its disclosure regarding antigen binding proteins and PCSK9 proteins and variants thereof. For example, when explicitly stated, the neutralizing PCSK9 variants can exclude a PCSK9 proteins/variants such as PCSK9 ProCat 31-449 and/or PCSK9 ProCat 31-454, with or without a his tag. In some embodiments, when explicitly stated, the neutralizing PCSK9 variants can exclude the PCSK9 variants that consist of residues 1-452 (having a His tag or a GST tag, (sequence numbering as defined in Fan et al., American Chemical Society, "Self-Association of Human PCSK9 Correlates with its LDLR-Degrading Activity"); residues 1-454, and 1-681 219-692 (sequence numbering as defined in Benjannet et al., Journal of Biological Chemistry, "NARC-1/PCSK9 and Its Natural Mutants," 279:48865-48875, 2004); residues 219-692 (sequence numbering as defined in Benhannet et al., J. of Biol. Chemistry, "The Proprotein Convertase (PC) PCSK9 is Inactivated by Furin and/or PC5/6A," 281 (41):30561-30572 (2006); residues 1-452 and 423-692 (sequence numbering as defined in Fan et al., Biochemistry, "Self-Association of Human PCSK9 Correlates with its LDLR-Degrading Activity," 47:1631-1639 2008); residues 1-455, 1-454, and/or residues 31-454 (sequence numbering as defined by Nassoury et al., Traffic, "The Cellular Trafficking of Secretory Proprotein Convertase PCSK9 and its Dependence on the LDLR," 8:718-732, 2007); any C terminal deletions in WO 2007/128121; residues 1-454 (sequence numbering as defined by Zhang et al., PNAS, "Structural Requirements for PCSK9-mediated degradation of the low-density lipoprotein Receptor," 105:13045-13050, 2008); residues 1-425, 1-453, 1-694, 31-453, and 1-507 (sequence

numbering as defined by Naureckiene S. et al, Archives of Biochemistry and Biophysics, "Functional Characterization of Narcl, a Novel Proteinase Related to Proteinase K", 420:55-67, 2003); residues 31-451 and/or residues 53-451 (including variants of either of these, such as the following: P155G, W156L, N157K, L158A, I161A, R194A, D238A, D374Y, S386A, with or without a his tag)(sequence numbering as defined in Bottomley et al., J. of Biological Chemistry, "Structural and Biochemical Characterization of the Wild Type PCSK9/EGF-AB Complex and Natural FH mutants," 284:1313-23, 2008); an in-frame deletion of the eighth exon of 58 amino acids, *e.g.*, deletion of residues 395-452 (keeping 1-394 and 453 to the end, as described in Schmidt et al., DNA and Cell Biology, "A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9, 27:183-189, 2008); and/or residues 1-692 (human), 1-691 (rat), 1-316 (rat), 1-390 (rat), 1-390 (S385A, rat), 1-425 (rat), 1-453 (rat), 1-507 (rat), 31-691 (rat), 148-691 (rat), 1-691 (rat, including optional deletion of 31-147, optional deletion of 148-425, optional deletion of 219-395, histidine 225 to tryptophan, serine 385 to alanine, or histidine 225 to tryptophan and serine 385 to alanine), 1-142, and/or 1-679 (sequence numbering as defined in Bingham et al., Cytometry A, "Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase," 69(11):1123-31, 2006). The entirety of the disclosure of each of the above noted references is incorporated herein by reference, especially in regard to their disclosures of the various PCSK9 sequences and discussion thereof. In some embodiments, any one or more of the abovevariants are encompassed within the group of useful neutralizing PCSK9 variants. In some embodiments, any or all of the above can be combined with or in a pharmaceutically acceptable carrier or be used for the preparation of a medicament.

[0145] In some embodiments, the neutralizing PCSK9 variant has a pro/cat domain that is different from the pro/cat domain in the cDNA sequence of NM-174936 or gi31317306. In some embodiments, the neutralizing PCSK9 variant includes point mutations at least one of the following positions: 474, 620, or 670. In some embodiments, the point mutation is Val474Iso, Gly670Glu, and/or Glu620Gly.

Vehicles

[0146] The term "vehicle" refers to a molecule that prevents degradation and/or increases half-life, reduces toxicity, reduces immunogenicity, or increases biological activity of a therapeutic protein when covalently or non-covalently bound to the therapeutic protein.

Exemplary vehicles include an Fc domain (including, for example, native Fcs, Fc variants, Fc domains, multimers, and dimers) as well as a linear polymer (e.g., polyethylene glycol (PEG), polylysine, dextran, etc.); a branched-chain polymer (see, for example, U.S. Pat. No. 4,289,872 to Denkenwalter et al., issued Sep. 15, 1981; U.S. Pat. No. 5,229,490 to Tam, issued Jul. 20, 1993; WO 93/21259 by Frechet et al., published Oct. 28, 1993); a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor. Vehicles are further described in U.S. Pat. No. 6,660,843, herein incorporated by reference in its entirety. In some embodiments, multiple vehicles are used, for example, Fc's at each terminus or an Fc at a terminus and a PEG group at the other terminus or a sidechain. In some embodiments, the neutralizing PCSK9 variant is combined, associated, mixed, or bonded to any one or more of the above vehicles.

[0147] An alternative vehicle would be a protein, polypeptide, peptide, antibody, antibody fragment, or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor. For example, one could use as a vehicle a polypeptide as described in U.S. Pat. No. 5,739,277, issued Apr. 14, 1998 to Presta et al. Peptides could also be selected by phage display for binding to the FcRn salvage receptor. Such salvage receptor-binding compounds are also included within the meaning of "vehicle" and are within the scope of this invention. Such vehicles should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immunogenic sequences, as discovered in antibody humanization).

[0148] As noted above, polymer vehicles can also be used. Various means for attaching chemical moieties useful as vehicles are currently available, see e.g., Patent Cooperation Treaty ("PCT") International Publication No. WO 96/11953, entitled "N-Terminally Chemically Modified Protein Compositions and Methods," herein incorporated by reference in its entirety. This PCT publication discloses, among other things, the selective attachment of water soluble polymers to the N-terminus of proteins.

[0149] In some embodiments, the polymer vehicle is polyethylene glycol (PEG). The PEG group can be of any convenient molecular weight and can be linear or branched. The average molecular weight of the PEG will preferably range from about 2 kiloDalton ("kD") to about 100 kDa and more preferably from about 5 kDa to about 50 kDa. The PEG groups will generally be attached to the neutralizing PCSK9 variant via acylation or reductive alkylation

through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group).

[0150] In some embodiments, a useful strategy for the PEGylation of synthetic peptides involves combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis. The peptides are "preactivated" with an appropriate functional group at a specific site. The precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylated peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.

[0151] Polysaccharide polymers are another type of water soluble polymer which can be used for protein modification. Dextran is polysaccharide polymers comprised of individual subunits of glucose predominantly linked by alpha 1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kD to about 70 kD. Dextran is a suitable water soluble polymer for use as a vehicle by itself or in combination with another vehicle (e.g., Fc). See, for example, WO 96/11953 and WO 96/05309. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins has been reported; see, for example, European Patent Publication No. 0 315 456, which is hereby incorporated by reference. Dextran of about 1 kD to about 20 kD can be used.

[0152] In another embodiment a vehicle is a non-Fc peptide or polypeptide known or believed to prevent degradation and/or increases half-life, reduces toxicity, reduces immunogenicity, or increases biological activity of a therapeutic protein. Example of such a protein vehicle include transthyretin or HSA protein fusions. These vehicles can be fused to a PCSK9 variant.

Linkers

[0153] Any "linker" group is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer. The linker can be made up of amino acids linked together by peptide bonds. Thus, in some embodiments, the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally

occurring amino acids. Some of these amino acids can be glycosylated, as is well understood by those in the art. In some embodiments, the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. In some embodiments, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. In some embodiments, linkers are polyglycines (particularly (Gly)₄, (Gly)₅), poly(Gly-Ala), and polyalanines. Other specific examples of linkers are: (Gly)₃ Lys(Gly)₄; (Gly)₃ AsnGlySer(Gly)₂; (Gly)₃ Cys(Gly)₄; and GlyProAsnGlyGly.

[0154] To explain the above nomenclature, for example, (Gly)₃ Lys(Gly)₄ means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly. Combinations of Gly and Ala are also preferred. The linkers shown here are exemplary and can be much longer and can include other residues.

[0155] Non-peptide linkers are also possible. For example, alkyl linkers such as --NH--(CH₂)_s--C(O)--, wherein s=2-20 could be used. These alkyl linkers can further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C₁--C₆) lower acyl, halogen (e.g., Cl, Br), CN, NH₂, phenyl, etc. An exemplary non-peptide linker is a PEG linker, wherein the linker has a molecular weight of 100 to 5000 kD, for example, 100 to 500 kD. The peptide linkers can be altered to form derivatives in the same manner as described above.

Derivatives

[0156] In some embodiments, the neutralizing PCSK9 variant (and/or the vehicle) is derivatized. Such derivatives can improve the solubility, absorption, biological half life, and the like of the compounds. The moieties can alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like. In some embodiments, the moiety can add additional properties to the molecule as a whole. Exemplary derivatives are provided herein.

[0157] The neutralizing PCSK9 variant or some portion thereof is cyclic. For example, the peptide portion can be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation.

[0158] The neutralizing PCSK9 variant is cross-linked or is rendered capable of cross-linking between molecules. For example, the peptide portion can be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a like molecule. The compound can also be cross-linked through its C-terminus.

[0159] One or more peptidyl [--C(O)NR--] linkages (bonds) is replaced by a non-peptidyl linkage. Exemplary non-peptidyl linkages are --CH₂ -carbamate [--CH₂ --OC(O)NR--], phosphonate, --CH₂ -sulfonamide [--CH₂ --S(O)₂ NR--], urea [--NHC(O)NH--], --CH₂ -secondary amine, and alkylated peptide [--C(O)NR₆ -- wherein R₆ is lower alkyl].

[0160] The N-terminus is derivatized. Typically, the N-terminus can be acylated or modified to a substituted amine. Exemplary N-terminal derivative groups include --NRR₁ (other than --NH₂), --NRC(O)R₄, --NRC(O)OR₁, --NRS(O)₂ R₁, --NHC(O)NHR₁, succinimide, or benzyloxycarbonyl-NH-- (CBZ--NH--), wherein R and R₁ are each independently hydrogen or lower alkyl and wherein the phenyl ring can be substituted with 1 to 3 substituents selected from the group consisting of C₁ -C₄ alkyl, C₁ -C₄ alkoxy, chloro, and bromo.

[0161] The free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated. For example, one can use methods described in the art to add (NH--CH₂ --CH₂ --NH₂)₂ to neutralizing PCSK9 variants. Likewise, one can use methods described in the art to add --NH₂ to neutralizing PCSK9 variants. Exemplary C-terminal derivative groups include, for example, --C(O)R₂ wherein R₂ is lower alkoxy or --NR₃ R₄ wherein R₃ and R₄ are independently hydrogen or C₁ -C₈ alkyl (preferably C₁ -C₄ alkyl).

[0162] A disulfide bond is replaced with another, preferably more stable, cross-linking moiety (*e.g.*, an alkylene). See, *e.g.*, Bhatnagar et al. (1996), J. Med. Chem. 39: 3814-9; Alberts et al. (1993) Thirteenth Am. Pep. Symp., 357-9. 8. One or more individual amino acid residues are modified. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.

[0163] Lysiny residues and amino terminal residues can be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysiny residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate. Arginy residues can be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginy residues requires that the reaction be performed in alkaline conditions because of the high pK_a of the guanidine functional group. Furthermore, these reagents can react with the groups of lysine as well as the arginine epsilon-amino group.

Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Carboxyl sidechain groups (aspartyl or glutamyl) can be selectively modified by reaction with carbodiimides ($R'-N=C=N-R''$) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions. Glutaminyl and asparaginyl residues can be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. See, e.g., Bhatnagar et al. (1996), J. Med. Chem. 39: 3814-9.

[0164] Derivatization with bifunctional agents can be useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular vehicles. Commonly used cross-linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl)propionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimide yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

[0165] Carbohydrate (oligosaccharide) groups can be attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably one of the 19 naturally occurring amino acids other than proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found

in each type are different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, can confer acidic properties to the glycosylated compound. Such site(s) can be incorporated in the linker of the neutralizing PCSK9 variant and can be glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites can further be glycosylated by synthetic or semi-synthetic procedures known in the art.

[0166] Other possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, *Proteins: Structure and Molecule Properties* (W. H. Freeman & Co., San Francisco), pp. 79-86 (1983).

[0167] In some embodiments, cysteine(s), arginine(s), and/or lysine(s) can be introduced into the neutralizing PCSK9 variant as a site(s) of pegylation.

[0168] Neutralizing PCSK9 variants can be changed at the DNA level, as well. The DNA sequence of any portion of the compound can be changed to codons more compatible with the chosen host cell. Codons can be substituted to eliminate restriction sites or to include silent restriction sites, which can aid in processing of the DNA in the selected host cell. The vehicle, linker and peptide DNA sequences can be modified to include any of the foregoing sequence changes.

[0169] In some embodiments, neutralizing PCSK9 variants include glycosylation wherein the number and/or type of glycosylation site has been altered compared to the amino acid sequences of a parent polypeptide. In some embodiments, protein variants comprise a greater or a lesser number of N-linked glycosylation sites than the native protein. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X can be any amino acid residue except proline. The substitution of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional

preferred variants include cysteine variants wherein one or more cysteine residues are deleted from or substituted for another amino acid (e.g., serine) as compared to the parent amino acid sequence. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

[0170] In some embodiments, the neutralizing PCSK9 variant is associated with at least a part of an antibody. In some embodiments, the neutralizing PCSK9 variant is part of an antibody fusion protein. As will be appreciated by one of skill in the art, a fusion protein can include various antibody sequences. In some embodiments, the neutralizing PCSK9 variant is fused to a full length antibody. In some embodiments, the neutralizing PCSK9 variant is fused to an antibody that binds to LDLR, thereby further increasing the likelihood that the neutralizing PCSK9 variant will be directed to its target. Non-neutralizing antibody fusions also form an aspect of the present invention. In this embodiment the non-neutralizing antibody fused to a PCSK9 variant can perform the function of increasing the half life of the PCSK9 variant.

[0171] In some embodiments, as noted above, the neutralizing PCSK9 variant is fused to a fragment of an antibody, such as a Fc domain. In some embodiments, the fusion protein will comprise, consist, or consist essentially of a Fc domain. In some embodiments, the fusion protein will comprise, consist, or consist essentially of a native Fc region. In some embodiments, the antibody or binding fragment thereof that is attached or fused to the neutralizing PCSK9 variant will bind to LDLR.

[0172] In some embodiments, any of the herein disclosed neutralizing PCSK9 variants, including antibody fusions, can be made from nucleic acid sequences encoding such protein sequences. Thus, nucleic acid sequences, vectors, and cells comprising these compounds are also contemplated herein.

[0173] In some embodiments, the neutralizing PCSK9 variant binds to a LDLR variant. In some embodiments, the variants of LDLR are at least 50% identical to human LDLR. It is noted that variants of LDLR are known to those of skill in the art (e.g., Brown MS et al, "Calcium cages, acid baths and recycling receptors" Nature 388: 629-630, 1997). In some embodiments, the neutralizing PCSK9 variant can raise the level of effective LDLR in heterozygote familial hypercholesterolemia (where a loss-of function variant of LDLR is present). Three exemplary LDLR sequences are shown in FIGS. 1I-1L (mouse, cynomolgus monkey, and human amino acid sequences). In some embodiments, the neutralizing PCSK9

variant will bind to a protein comprising at least one of the sequences in FIG. 1I-1L. In some embodiments the native PCSK9 variant will bind to a LDLR variant that comprises, consists, or consists essentially of the consensus sequence in FIGS. 1I-1L. In some embodiments, the LDLR variant will comprise each of the conserved amino acids identified in the consensus sequence in FIGS. 1I-1L. As will be appreciated by one of skill in the art, the space(s) in the consensus sequence can be filled with any of the other amino acids in the comparison at the corresponding location, or, in some embodiments, any amino acid.

[0174] In some embodiments, the neutralizing PCSK9 variant binds to and blocks LDLR from binding to other variants of PCSK9. These variants of PCSK9 are at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, or greater percent identity to the form of PCSK9 depicted in FIG. 1A. In some embodiments, the neutralizing PCSK9 variant is a human variant, such as variants at position 474. In some embodiments, the amino acid at position 474 is valine (as in other humans) or threonine (as in cyno and mouse).

[0175] In some embodiments, variants of PCSK9 are contemplated, wherein one freely mutates the amino acids on the exterior of PCSK9, while conservatively altering those inside of PCSK9. In some embodiments, variants of PCSK9 are contemplated where one does not or only conservatively alters those residues on the binding surface between PCSK9 and LDLR, while freely or conservatively altering the residues on the rest of the PCSK9 surface or the inside of the protein. Various neutralizing PCSK9 variants are discussed herein and in the above sections.

[0176] In some embodiments, the neutralizing PCSK9 variant comprises a protein that has a sequence that start at residues 31 or 61 of SEQ ID NO: 3 (and variants thereof) and ends at any one of residues 447, 448, 449, 450, 451, 452, or 453 of SEQ ID NO: 3 (and variants thereof). Thus, in some embodiments, the neutralizing PCSK9 variant can include residues 31-447, 31-448, 31-449, 31-450, 31-451, 31-452, 31-453, 61-447, 61-448, 61-449, 61-450, 61-451, 61-452, and 61-453 of SEQ ID NO: 3 (and variants thereof) and/or a consensus sequence (*e.g.*, shown in FIGs. 1C-1E, FIG. 1R₁-1R₂ (SEQ ID NO: 30) and FIG. F-H (for the Cat domain)). In some embodiments, variants can be 50% or more (*e.g.*, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent) identical to the pro/cat domain of SEQ ID NO: 3 over the specific sequence length. In some embodiments, the neutralizing PCSK9 variant is at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99%, or more identical for the conserved sections of the pro/cat

domain. In some embodiments, while the sections of the pro/cat domain in the neutralizing PCSK9 variant that are 100% conserved (e.g., as shown in FIGs. 1C-1E) are present, the remaining positions can be changed. In some embodiments, the changes in these remaining positions can result in a pro/cat section in the neutralizing PCSK9 variant that is 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, or 99-100 percent identical to the corresponding pro/cat domain of SEQ ID NO: 3.

[0177] Additionally, one skilled in the art can review structure-function studies identifying residues in similar polypeptides that are important for activity or structure. In view of such a comparison, one can predict the importance of amino acid residues in a protein that correspond to amino acid residues which are important for activity or structure in similar proteins. One skilled in the art can opt for chemically similar amino acid substitutions for such predicted important amino acid residues.

[0178] One skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure. In view of such information, one skilled in the art can predict the alignment of amino acid residues of a protein fragment with respect to its three dimensional structure. In some embodiments, one skilled in the art can choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, since such residues can be involved in important interactions with other molecules. Moreover, one skilled in the art can generate and test variants containing a single amino acid substitution at each desired amino acid residue. The variants can then be screened using activity assays known to those skilled in the art, or as described in the Examples disclosed herein. Such variants can be used to gather information about suitable variants. For example, if one discovered that a change to a particular amino acid residue resulted in destroyed, undesirably reduced, or unsuitable activity, variants with such a change can be avoided. In other words, based on information gathered from such routine experiments, one skilled in the art can readily determine the amino acids where further substitutions should be avoided either alone or in combination with other mutations.

[0179] A number of scientific publications have been devoted to the prediction of secondary structure. See Moulton J., *Curr. Op. in Biotech.*, 7(4):422-427 (1996), Chou *et al.*, *Biochemistry*, 13(2):222-245 (1974); Chou *et al.*, *Biochemistry*, 113(2):211-222 (1974); Chou *et al.*, *Adv. Enzymol. Relat. Areas Mol. Biol.*, 47:45-148 (1978); Chou *et al.*, *Ann. Rev. Biochem.*,

47:251-276 and Chou *et al.*, *Biophys. J.*, 26:367-384 (1979). Moreover, computer programs are currently available to assist with predicting secondary structure. One method of predicting secondary structure is based upon homology modeling. For example, two polypeptides or proteins which have a sequence identity of greater than 30%, or similarity greater than 40% often have similar structural topologies. The recent growth of the protein structural database (PDB) has provided enhanced predictability of secondary structure, including the potential number of folds within a polypeptide's or protein's structure. See Holm *et al.*, *Nucl. Acid. Res.*, 27(1):244-247 (1999).

[0180] Additional methods of predicting secondary structure include "threading" (Jones, D., *Curr. Opin. Struct. Biol.*, 7(3):377-87 (1997); Sippl *et al.*, *Structure*, 4(1):15-19 (1996)), "profile analysis" (Bowie *et al.*, *Science*, 253:164-170 (1991); Gribskov *et al.*, *Meth. Enzym.*, 183:146-159 (1990); Gribskov *et al.*, *Proc. Nat. Acad. Sci. USA*, 84(13):4355-4358 (1987)), and "evolutionary linkage" (See Holm, *supra* (1999), and Brenner, *supra* (1997)).

[0181] According to certain embodiments, amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and/or (4) confer or modify other physicochemical or functional properties on such polypeptides. According to certain embodiments, single or multiple amino acid substitutions (in some embodiments, conservative amino acid substitutions) can be made in the naturally-occurring sequence (in some embodiments, in the portion of the polypeptide outside the domain(s) forming intermolecular contacts). In some embodiments, a conservative amino acid substitution typically may not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C. Branden & J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton *et al.*, *Nature*, 354:105 (1991), which are each incorporated herein by reference.

[0182] In some embodiments, the neutralizing PCSK9 variant (or nucleic acid sequence encoding it) is a variant if the nucleic acid sequence that encodes the particular neutralizing PCSK9 variant can selectively hybridize to any of the nucleic acid sequences that

encode the protein in SEQ ID NO: 3 under moderately stringent or stringent conditions. In one embodiment, suitable moderately stringent conditions include prewashing in a solution of 5XSSC; 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C, -65° C, 5xSSC, overnight or, in the event of cross-species homology, at 45° C with 0.5xSSC; followed by washing twice at 65° C for 20 minutes with each of 2x, 0.5x and 0.2xSSC containing 0.1% SDS. Such hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode a variant that is encoded by a hybridizing DNA sequence and the amino acid sequences that are encoded by these nucleic acid sequences. In some embodiments, suitable high stringency conditions are used and include hybridization at about 65° C in 0.1xSSC. In some embodiments, suitable high stringency conditions include washing in 0.1xSSPE and 0.2% SDS at 65° C for 15 minutes. In some embodiments, suitable high stringency conditions include 31% v/v to 50% v/v formamide and 0.01M to 0.15M salt at 42° C and washing conditions of 0.1xSSC, 0.5% w/v SDS at 60° C. Such hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode a variant that is encoded by a hybridizing DNA sequence and the amino acid sequences that are encoded by these nucleic acid sequences.

[0183] The phrase "selectively hybridize" referred to in this context means to detectably and selectively bind. Such, polynucleotides, oligonucleotides, and fragments thereof selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more

than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M. O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

[0184] For example, a "conservative amino acid substitution" can involve a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide can also be substituted with alanine and/or arginine, as has been previously described for "alanine scanning mutagenesis" and "arginine scanning mutagenesis."

[0185] Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. In some embodiments, amino acid substitutions can be used to identify important residues of PCSK9, or to increase or decrease the affinity of the neutralizing PCSK9 variant as described herein.

Antibodies to Neutralizing PCSK9 Variants

[0186] In some embodiments, antibodies to any of the sequences or neutralizing PCSK9 variants described herein can be made and used. These antibodies are selective for the neutralizing PCSK9 variant over native PCSK9. In some embodiments, the antibody binds to a neutralizing PCSK9 variant that consists essentially of the Pro/Cat domain of PCSK9. In some embodiments, the antibody is selective for this neutralizing PCSK9 variant over wild-type PCSK9.

[0187] As will be appreciated by one of skill in the art, the antibodies can be created by raising antibodies to the neutralizing PCSK9 variant and then identifying those antibodies that

will not bind (or will not bind as effectively as antibodies to native PCSK9) to native PCSK9. In some embodiments, the antibodies will bind to the neutralizing PCSK9 variant with a K_D that is at least 1, 1-10, 10-50, or 50-100% better than the K_D of the antibody to human PCSK9. In some embodiments, the antibodies will bind to the neutralizing PCSK9 variant with a K_D that is at least 2-5, 5-10, 10-50, 50-100, 100-1000, 1000-10,000, 10,000-100,000, or 100,000- 10^6 better than the K_D of the antibody for the native PCSK9. As will be appreciated by one of skill in the art, as the neutralizing PCSK9 variant will have an inactive V domain that can be structurally different (and even absent) from the wild type PCSK9 protein, such selective antibodies will be readily attainable given the present disclosure. In some embodiments, an adjuvant is used with the neutralizing PCSK9 variant to create the above antibodies.

[0188] As will be appreciated by one of skill in the art, the antibodies can be used to selectively observe the amount of the neutralizing PCSK9 variant without inadvertently detecting native PCSK9 as well.

Cell Lines and Expression of Neutralizing PCSK9 Variants

[0189] In some embodiments, neutralizing PCSK9 variants can be expressed in cell lines. In some embodiments, sequences encoding particular neutralizing PCSK9 variants can be used for transformation of a suitable mammalian host cell. According to certain embodiments, transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference for any purpose). In some embodiments, the transformation procedure used can depend upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

[0190] Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO)

cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. In some embodiments, cell lines can be selected through determining which cell lines have high expression levels. Appropriate expression vectors for mammalian host cells are well known.

[0191] In some embodiments, any of a variety of expression vector/host systems can be utilized to express polynucleotide molecules encoding polypeptides comprising one or more protein segments. Such systems include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV, tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti or pBR322 plasmid); or animal cell systems.

[0192] In some embodiments, a polypeptide comprising one or more neutralizing PCSK9 variant is recombinantly expressed in yeast. Certain such embodiments use commercially available expression systems, e.g., the *Pichia* Expression System (Invitrogen, San Diego, CA), following the manufacturer's instructions. In some embodiments, such a system relies on the pre-pro-alpha sequence to direct secretion. In some embodiments, transcription of the insert is driven by the alcohol oxidase (AOX1) promoter upon induction by methanol.

[0193] In some embodiments, a secreted polypeptide comprising one or more neutralizing PCSK9 variant is purified from yeast growth medium. In some embodiments, the methods used to purify a polypeptide from yeast growth medium is the same as those used to purify the polypeptide from bacterial and mammalian cell supernatants.

[0194] In some embodiments, a nucleic acid encoding a polypeptide comprising one or more neutralizing PCSK9 variant is cloned into a baculovirus expression vector, such as pVL1393 (PharMingen, San Diego, CA). In some embodiments, such a vector can be used according to the manufacturer's directions (PharMingen) to infect *Spodoptera frugiperda* cells in sf9 protein-free media and to produce recombinant polypeptide. In some embodiments, a polypeptide is purified and concentrated from such media using a heparin-Sepharose column (Pharmacia).

[0195] In some embodiments, a polypeptide comprising one or more neutralizing PCSK9 variant is expressed in an insect system. Certain insect systems for polypeptide

expression are well known to those of skill in the art. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. In some embodiments, a nucleic acid molecule encoding a polypeptide can be inserted into a nonessential gene of the virus, for example, within the polyhedrin gene, and placed under control of the promoter for that gene. In some embodiments, successful insertion of a nucleic acid molecule will render the nonessential gene inactive. In some embodiments, that inactivation results in a detectable characteristic. For example, inactivation of the polyhedrin gene results in the production of virus lacking coat protein.

[0196] In some embodiments, recombinant viruses can be used to infect *S. frugiperda* cells or *Trichoplusia* larvae. See, e.g., Smith *et al.*, J. Virol., 46: 584 (1983); Engelhard *et al.*, Proc. Nat. Acad. Sci. (USA), 91: 3224-7 (1994).

[0197] In some embodiments, polypeptides comprising one or more neutralizing PCSK9 variant made in bacterial cells are produced as insoluble inclusion bodies in the bacteria. In some embodiments, host cells comprising such inclusion bodies are collected by centrifugation; washed in 0.15 M NaCl, 10 mM Tris, pH 8, 1 mM EDTA; and treated with 0.1 mg/ml lysozyme (Sigma, St. Louis, MO) for 15 minutes at room temperature. In some embodiments, the lysate is cleared by sonication, and cell debris is pelleted by centrifugation for 10 minutes at 12,000 X g. In some embodiments, the polypeptide-containing pellet is resuspended in 50 mM Tris, pH 8, and 10 mM EDTA; layered over 50% glycerol; and centrifuged for 30 minutes at 6000 X g. In some embodiments, that pellet can be resuspended in standard phosphate buffered saline solution (PBS) free of Mg^{++} and Ca^{++} . In some embodiments, the polypeptide is further purified by fractionating the resuspended pellet in a denaturing SDS polyacrylamide gel (See, e.g., Sambrook *et al.*, *supra*). In some embodiments, such a gel can be soaked in 0.4 M KCl to visualize the protein, which can be excised and electroeluted in gel-running buffer lacking SDS. According to certain embodiments, a Glutathione-S-Transferase (GST) fusion protein is produced in bacteria as a soluble protein. In some embodiments, such GST fusion protein is purified using a GST Purification Module (Pharmacia).

[0198] In some embodiments, it is desirable to "refold" certain polypeptides, e.g., polypeptides comprising one or more neutralizing PCSK9 variant. In some embodiments, such polypeptides are produced using certain recombinant systems discussed herein. In some

embodiments, polypeptides are “refolded” and/or oxidized to form desired tertiary structure and/or to generate disulfide linkages. In some embodiments, such structure and/or linkages are related to certain biological activity of a polypeptide. In some embodiments, refolding is accomplished using any of a number of procedures known in the art. Exemplary methods include, but are not limited to, exposing the solubilized polypeptide agent to a pH typically above 7 in the presence of a chaotropic agent. An exemplary chaotropic agent is guanidine. In some embodiments, the refolding/oxidation solution also contains a reducing agent and the oxidized form of that reducing agent. In some embodiments, the reducing agent and its oxidized form are present in a ratio that will generate a particular redox potential that allows disulfide shuffling to occur. In some embodiments, such shuffling allows the formation of cysteine bridges. Exemplary redox couples include, but are not limited to, cysteine/cystamine, glutathione/dithiobisGSH, cupric chloride, dithiothreitol DTT/dithiane DTT, and 2-mercaptoethanol (bME)/dithio-bME. In some embodiments, a co-solvent is used to increase the efficiency of refolding. Exemplary cosolvents include, but are not limited to, glycerol, polyethylene glycol of various molecular weights, and arginine.

[0199] In some embodiments, a polypeptide comprising one or more neutralizing PCSK9 variants is substantially purified. Certain protein purification techniques are known to those of skill in the art. In some embodiments, protein purification involves crude fractionation of polypeptide fractionations from non-polypeptide fractions. In some embodiments, polypeptides are purified using chromatographic and/or electrophoretic techniques. Exemplary purification methods include, but are not limited to, precipitation with ammonium sulphate; precipitation with PEG; immunoprecipitation; heat denaturation followed by centrifugation; chromatography, including, but not limited to, affinity chromatography (e.g., Protein-A-Sepharose), ion exchange chromatography, exclusion chromatography, and reverse phase chromatography; gel filtration; hydroxyapatite chromatography; isoelectric focusing; polyacrylamide gel electrophoresis; and combinations of such and other techniques. In some embodiments, a polypeptide is purified by fast protein liquid chromatography or by high pressure liquid chromatography (HPLC). In some embodiments, purification steps can be changed or certain steps can be omitted, and still result in a suitable method for the preparation of a substantially purified polypeptide.

[0200] In some embodiments, one quantitates the degree of purification of a polypeptide preparation. Certain methods for quantifying the degree of purification are known to those of skill in the art. Certain exemplary methods include, but are not limited to, determining the specific binding activity of the preparation and assessing the amount of a polypeptide within a preparation by SDS/PAGE analysis. Certain exemplary methods for assessing the amount of purification of a polypeptide preparation comprise calculating the binding activity of a preparation and comparing it to the binding activity of an initial extract. In some embodiments, the results of such a calculation are expressed as “fold purification.” The units used to represent the amount of binding activity depend upon the particular assay performed.

[0201] In some embodiments, a polypeptide comprising one or more neutralizing PCSK9 variants is partially purified. In some embodiments, partial purification can be accomplished by using fewer purification steps or by utilizing different forms of the same general purification scheme. For example, in some embodiments, cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater “fold purification” than the same technique utilizing a low-pressure chromatography system. In some embodiments, methods resulting in a lower degree of purification can have advantages in total recovery of polypeptide, or in maintaining binding activity of a polypeptide.

[0202] In certain instances, the electrophoretic migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS/PAGE. *See, e.g., Capaldi et al., Biochem. Biophys. Res. Comm., 76: 425 (1977).* It will be appreciated that under different electrophoresis conditions, the apparent molecular weights of purified or partially purified polypeptide can be different.

Examples of Therapeutic Uses and Pharmaceutical Compositions

[0203] In certain instances, PCSK9 activity correlates with a number of human disease states. For example, in certain instances, too much or too little PCSK9 activity correlates with certain conditions, such as hypercholesterolemia. Therefore, in certain instances, modulating PCSK9 activity can be therapeutically useful.

[0204] In some embodiments, a neutralizing PCSK9 variant is used to modulate at least one native PCSK9 activity (*e.g.*, binding of native PCSK9 to LDLR). Such methods can

treat and/or prevent and/or reduce the risk of disorders that relate to elevated serum cholesterol levels or in which elevated cholesterol levels are relevant.

[0205] As will be appreciated by one of skill in the art, in light of the present disclosure, disorders that relate to, involve, or can be influenced by varied cholesterol, LDL, or LDLR levels can be addressed by various embodiments of the neutralizing PCSK9 variants. The neutralizing PCSK9 variants can be used in a variety of therapeutic applications. For example, in some embodiments the neutralizing PCSK9 variants are useful for treating conditions associated with PCSK9, such as cholesterol related disorders (or “serum cholesterol related disorders”) such as hypercholesterolemia, as further described herein. Some of the neutralizing PCSK9 variants described herein are useful in treating consequences, symptoms, and/or the pathology associated with PCSK9 activity.

[0206] In some embodiments, a “cholesterol related disorder” (which includes “serum cholesterol related disorders”) includes any one or more of the following: hypercholesterolemia, heart disease, metabolic syndrome, diabetes, coronary heart disease, stroke, cardiovascular diseases, Alzheimers disease and generally dyslipidemias, which can be manifested, for example, by an elevated total serum cholesterol, elevated LDL, elevated triglycerides, elevated VLDL, and/or low HDL. Some non-limiting examples of primary and secondary dyslipidemias that can be treated using a neutralizing PCSK9 variant, either alone, or in combination with one or more other agents include the metabolic syndrome, diabetes mellitus, familial combined hyperlipidemia, familial hypertriglyceridemia, familial hypercholesterolemias, including heterozygous hypercholesterolemia, homozygous hypercholesterolemia, familial defective apolipoprotein B-100; polygenic hypercholesterolemia; remnant removal disease, hepatic lipase deficiency; dyslipidemia secondary to any of the following: dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome, chronic renal failure, Cushing's syndrome, primary biliary cirrhosis, glycogen storage diseases, hepatoma, cholestasis, acromegaly, insulinoma, isolated growth hormone deficiency, and alcohol-induced hypertriglyceridemia. Neutralizing PCSK9 variants can also be useful in preventing or treating atherosclerotic diseases, such as, for example, coronary heart disease, coronary artery disease, peripheral arterial disease, stroke (ischemic and hemorrhagic), angina pectoris, or cerebrovascular disease and acute coronary syndrome, myocardial infarction. In some embodiments, the neutralizing PCSK9 variant is

useful in reducing the risk of: nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, chest pain in patients with heart disease, and/or cardiovascular events because of established heart disease such as prior heart attack, prior heart surgery, and/or chest pain with evidence of clogged arteries. In some embodiments, a neutralizing PCSK9 variant of PCSK9 and methods can be used to reduce the risk of recurrent cardiovascular events.

[0207] As will be appreciated by one of skill in the art, diseases or disorders that are generally addressable (either treatable or preventable) through the use of statins can also benefit from the application of the instant neutralizing PCSK9 variants. In addition, in some embodiments, disorders or diseases that can benefit from the prevention of cholesterol synthesis or increased LDLR expression can also be treated by various embodiments of the neutralizing PCSK9 variants. In addition, as will be appreciated by one of skill in the art, the use of the neutralizing PCSK9 variants can be especially useful in the treatment of Diabetes. Not only is Diabetes a risk factor for coronary heart disease, but insulin increases the expression of PCSK9. That is, people with Diabetes have elevated plasma lipid levels (which can be related to high PCSK9 levels) and can benefit from lowering those levels or modulating the activity of those levels. This is generally discussed in more detail in Costet et al. ("Hepatic PCSK9 Expression is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1C", J. Biol. Chem., 281: 6211-6218, 2006), the entirety of which is incorporated herein by reference.

[0208] In some embodiments, the neutralizing PCSK9 variant is administered to those who have diabetes mellitus, abdominal aortic aneurysm, atherosclerosis and/or peripheral vascular disease in order to decrease their serum cholesterol levels to a safer range. In some embodiments, the neutralizing PCSK9 variant is administered to patients at risk of developing any of the herein described disorders. In some embodiments, the neutralizing PCSK9 variants are administered to subjects that smoke, have hypertension or a familial history of early heart attacks.

[0209] In some embodiments, a subject is administered a neutralizing PCSK9 variant if they are at a moderate risk or higher on the 2004 NCEP treatment goals. In some embodiments, the neutralizing PCSK9 variant is administered to a subject if the subject's LDL cholesterol level is greater than 160 mg/dl. In some embodiments, the neutralizing PCSK9 variant is administered if the subject's LDL cholesterol level is greater than 130 (and they have a

moderate or moderately high risk according to the 2004 NCEP treatment goals). In some embodiments, the neutralizing PCSK9 variant is administered if the subjects LDL cholesterol level is greater than 100 (and they have a high or very high risk according to the 2004 NCEP treatment goals). In some embodiments, the neutralizing PCSK9 variant is administered if the subjects LDL cholesterol level does not reach a goal of less than 90, or less than 80, or less than 70 mg/dl. In some embodiments, the neutralizing PCSK9 variant is administered if the subject is intolerant or resistant to other lipid modifying regimens and medications.

[0210] A physician will be able to select an appropriate treatment based on the indications and target lipid levels depending on the individual profile of a particular patient. One well-accepted standard for guiding treatment of hyperlipidemia is the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of the High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, National Institutes of Health, NIH Publication No. 02-5215 (2002), the printed publication of which is hereby incorporated by reference in its entirety.

[0211] In some embodiments, neutralizing PCSK9 variants to PCSK9 are used to decrease the amount of PCSK9 activity (degradation of PCSK9) from an abnormally high level or even a normal level. In some embodiments, neutralizing PCSK9 variants to PCSK9 are used to treat or prevent hypercholesterolemia and/or in the preparation of medicaments therefore and/or for other cholesterol related disorders (such as those noted herein). In some embodiments, a neutralizing PCSK9 variant is used to treat or prevent conditions such as hypercholesterolemia in which PCSK9 activity is normal. In such conditions, for example, reduction of PCSK9 activity to below normal can provide a therapeutic effect.

[0212] In some embodiments, more than one neutralizing PCSK9 variant is used to modulate native PCSK9 activity.

[0213] In some embodiments, methods are provided of treating a cholesterol related disorder, such as hypercholesterolemia comprising administering a therapeutically effective amount of one or more neutralizing PCSK9 variants and another therapeutic agent.

[0214] In some embodiments, a neutralizing PCSK9 variant is administered alone. In some embodiments, a neutralizing PCSK9 variant is administered prior to the administration of at least one other therapeutic agent. In some embodiments, a neutralizing PCSK9 variant is administered concurrent with the administration of at least one other therapeutic agent. In some

embodiments, a neutralizing PCSK9 variant is administered subsequent to the administration of at least one other therapeutic agent. In other embodiments, a neutralizing PCSK9 variant is administered prior to the administration of at least one other therapeutic agent. Therapeutic agents (apart from the neutralizing PCSK9 variant), include, but are not limited to, at least one other cholesterol-lowering (serum and/or total body cholesterol) agent or an agent. In some embodiments, the agent increases the expression of LDLR, have been observed to increase serum HDL levels, lower serum LDL levels or lower triglyceride levels. Exemplary agents include, but are not limited to, statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), Nicotinic acid (Niacin) (NIACOR, NIASPAN (slow release niacin), SLO-NIACIN (slow release niacin)), Fibric acid (LOPID (Gemfibrozil), TRICOR (fenofibrate), Bile acid sequestrants (QUESTRAN (cholestyramine), colestevlam (WELCHOL), COLESTID (colestipol)), Cholesterol absorption inhibitors (ZETIA (ezetimibe)), Combining nicotinic acid with statin (ADVICOR (LOVASTATIN and NIASPAN), Combining a statin with an absorption inhibitor (VYTORIN (ZOCOR and ZETIA) and/or lipid modifying agents. In some embodiments, the neutralizing PCSK9 variant is combined with PPAR gamma agonists, PPAR alpha/gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents (such as sulphonyl ureas, insulin, GLP-1 analogs, DDPIV inhibitors), ApoB modulators, MTP inhibitors and /or arteriosclerosis obliterans treatments. In some embodiments, the neutralizing PCSK9 variant is combined with an agent that increases the level of LDLR protein in a subject, such as statins, certain cytokines like oncostatin M, estrogen, and/or certain herbal ingredients such as berberine. In some embodiments, the neutralizing PCSK9 variant is combined with an agent that increases serum cholesterol levels in a subject (such as certain anti-psycotic agents, certain HIV protease inhibitors, dietary factors such as high fructose, sucrose, cholesterol or certain fatty acids and certain nuclear receptor agonists and antagonists for RXR, RAR, LXR, FXR). In some embodiments, the neutralizing PCSK9 variant is combined with an agent that increases the level of PCSK9 in a subject, such as statins and/or insulin. The combination of the two can allow for the undesirable side-effects of other agents to be mitigated by the neutralizing PCSK9 variant. As will be appreciated by one of skill in the art, in some embodiments, the neutralizing PCSK9 variant is combined with the other agent/compound. In some embodiments, the neutralizing PCSK9 variant and other agent are administered concurrently. In some embodiments, the

neutralizing PCSK9 variant and other agent are not administered simultaneously, with the neutralizing PCSK9 variant being administered before or after the agent is administered. In some embodiments, the subject receives both the neutralizing PCSK9 variant and the other agent (that increases the level of LDLR) during a same period of prevention, occurrence of a disorder, and/or period of treatment.

[0215] Pharmaceutical compositions can be administered in combination therapy, *i.e.*, combined with other agents. In some embodiments, the combination therapy comprises a neutralizing PCSK9 variant, in combination with at least one anti-cholesterol agent. Agents include, but are not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, and combinations and conjugates thereof. In some embodiments, an agent can act as an agonist, antagonist, allosteric modulator, or toxin. In some embodiments, an agent can act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition), and thereby promote increased expression of LDLR or decrease serum cholesterol levels.

[0216] In some embodiments, a neutralizing PCSK9 variant can be administered prior to, concurrent with, and subsequent to treatment with a cholesterol-lowering (serum and/or total cholesterol) agent. In some embodiments, a neutralizing PCSK9 variant can be administered prophylactically to prevent or mitigate the onset of hypercholesterolemia, heart disease, diabetes, and/or any of the cholesterol related disorder. In some embodiments, a neutralizing PCSK9 variant can be administered for the treatment of an existing hypercholesterolemia condition. In some embodiments, the neutralizing PCSK9 variant delays the onset of the disorder and/or symptoms associated with the disorder. In some embodiments, the neutralizing PCSK9 variant is provided to a subject lacking any symptoms of any one of the cholesterol related disorders or a subset thereof.

[0217] In some embodiments, a neutralizing PCSK9 variant is used with particular therapeutic agents to treat various cholesterol related disorders, such as hypercholesterolemia. In some embodiments, in view of the condition and the desired level of treatment, two, three, or more agents can be administered. In some embodiments, such agents can be provided together by inclusion in the same formulation. In some embodiments, such agent(s) and a neutralizing PCSK9 variant can be provided together by inclusion in the same formulation. In some embodiments, such agents can be formulated separately and provided together by inclusion in a treatment kit. In some embodiments, such agents and a neutralizing PCSK9 variant can be

formulated separately and provided together by inclusion in a treatment kit. In some embodiments, such agents can be provided separately. In some embodiments, when administered by gene therapy, the genes encoding protein agents and/or a neutralizing PCSK9 variant can be included in the same vector. In some embodiments, the genes encoding protein agents and/or a neutralizing PCSK9 variant can be under the control of the same promoter region. In some embodiments, the genes encoding protein agents and/or a neutralizing PCSK9 variant can be in separate vectors.

[0218] In some embodiments, a pharmaceutical composition comprising a neutralizing PCSK9 variant is combined with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant.

[0219] In some embodiments, a pharmaceutical compositions comprising a neutralizing PCSK9 variant and a therapeutically effective amount of at least one additional therapeutic agent are combined together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant.

[0220] In some embodiments, a neutralizing PCSK9 variant can be used with at least one therapeutic agent for inflammation. In some embodiments, a neutralizing PCSK9 variant can be used with at least one therapeutic agent for an immune disorder. Exemplary therapeutic agents for inflammation and immune disorders include, but are not limited to cyclooxygenase type 1 (COX-1) and cyclooxygenase type 2 (COX-2) inhibitors small molecule modulators of 38 kDa mitogen-activated protein kinase (p38-MAPK); small molecule modulators of intracellular molecules involved in inflammation pathways, wherein such intracellular molecules include, but are not limited to, jnk, IKK, NF- κ B, ZAP70, and I κ k. Certain exemplary therapeutic agents for inflammation are described, e.g., in C.A. Dinarello & L.L. Moldawer *Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis: A Primer for Clinicians* Third Edition (2001) Amgen Inc. Thousand Oaks, CA.

[0221] In some embodiments, pharmaceutical compositions will include more than one different neutralizing PCSK9 variant(s). In some embodiments, pharmaceutical compositions will include more than one neutralizing PCSK9 variant wherein the neutralizing PCSK9 variants bind more than one epitope. In some embodiments, the various neutralizing PCSK9 variants will not compete with one another for binding to PCSK9.

[0222] In some embodiments, acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed. In some embodiments, the formulation material(s) are for s.c. and/or I.V. administration. In some embodiments, the pharmaceutical composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In some embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrans); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. (*Remington's Pharmaceutical Sciences*, 18th Edition, A.R. Gennaro, ed., Mack Publishing Company (1995)).

[0223] As noted above, in some embodiments, a neutralizing PCSK9 variant and/or a therapeutic molecule is linked to a half-life extending vehicle known in the art. Such vehicles include, but are not limited to, polyethylene glycol, glycogen (e.g., glycosylation of the neutralizing PCSK9 variant), and dextran. Such vehicles are described, e.g., in U.S. Application

Serial No. 09/428,082, now US Patent No. 6,660,843 and published PCT Application No. WO 99/25044, which are hereby incorporated by reference for any purpose.

[0224] In some embodiments, the optimal pharmaceutical composition can be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format and desired dosage. See, for example, *Remington's Pharmaceutical Sciences, supra*. In some embodiments, such compositions may influence the physical state, stability, rate of *in vivo* release and rate of *in vivo* clearance of the variants of PCSK9.

[0225] In some embodiments, the primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, in some embodiments, a suitable vehicle or carrier can be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. In some embodiments, the saline comprises isotonic phosphate-buffered saline. In some embodiments, neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. In some embodiments, pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute therefore. In some embodiments, a composition comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agents, can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (*Remington's Pharmaceutical Sciences, supra*) in the form of a lyophilized cake or an aqueous solution. Further, in some embodiments, a composition comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0226] In some embodiments, the pharmaceutical composition can be selected for parenteral delivery. In some embodiments, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the ability of one skilled in the art.

[0227] In some embodiments, the formulation components are present in concentrations that are acceptable to the site of administration. In some embodiments, buffers

are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0228] In some embodiments, when parenteral administration is contemplated, a therapeutic composition can be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising a desired neutralizing PCSK9 variant, with or without additional therapeutic agents, in a pharmaceutically acceptable vehicle. In some embodiments, a vehicle for parenteral injection is sterile distilled water in which a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, is formulated as a sterile, isotonic solution, properly preserved. In some embodiments, the preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads or liposomes, that can provide for the controlled or sustained release of the product which can then be delivered via a depot injection. In some embodiments, hyaluronic acid can also be used, and can have the effect of promoting sustained duration in the circulation. In some embodiments, implantable drug delivery devices can be used to introduce the desired molecule.

[0229] In some embodiments, a pharmaceutical composition can be formulated for inhalation. In some embodiments, a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, can be formulated as a dry powder for inhalation. In some embodiments, an inhalation solution comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, can be formulated with a propellant for aerosol delivery. In some embodiments, solutions can be nebulized. Pulmonary administration is further described in PCT application no. PCT/US94/001875, which describes pulmonary delivery of chemically modified proteins.

[0230] In some embodiments, it is contemplated that formulations can be administered orally. In some embodiments, a neutralizing PCSK9 variant, with or without at least one additional therapeutic agents, that is administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. In some embodiments, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. In some embodiments, at least one additional agent can be included to facilitate absorption of a neutralizing PCSK9 variant and/or

any additional therapeutic agents. In some embodiments, diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0231] In some embodiments, a pharmaceutical composition can involve an effective quantity of a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. In some embodiments, by dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. In some embodiments, suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0232] Additional pharmaceutical compositions will be evident to those skilled in the art, including formulations involving neutralizing PCSK9 variants, with or without at least one additional therapeutic agent(s), in sustained- or controlled-delivery formulations. In some embodiments, techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT Application No. PCT/US93/00829 which describes the controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions. In some embodiments, sustained-release preparations can include semipermeable polymer matrices in the form of shaped articles, *e.g.* films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides (U.S. 3,773,919 and EP 058,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, Biopolymers, 22:547-556 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, J. Biomed. Mater. Res., 15:167-277 (1981) and Langer, Chem. Tech., 12:98-105 (1982)), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). In some embodiments, sustained release compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, *e.g.*, Eppstein *et al.*, Proc. Natl. Acad. Sci. USA, 82:3688-3692 (1985); EP 036,676; EP 088,046 and EP 143,949.

[0233] The pharmaceutical composition to be used for *in vivo* administration typically is sterile. In some embodiments, this can be accomplished by filtration through sterile

filtration membranes. In some embodiments, where the composition is lyophilized, sterilization using this method can be conducted either prior to or following lyophilization and reconstitution. In some embodiments, the composition for parenteral administration can be stored in lyophilized form or in a solution. In some embodiments, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. In some embodiments, the pharmaceutical composition is sterile.

[0234] In some embodiments, the pharmaceutical composition will comprise at least a sufficient amount of the neutralizing PCSK9 variant to reduce an amount of native PCSK9 from binding in a human, *in vivo*. In some embodiments the pharmaceutical composition will comprise at least a sufficient amount of the neutralizing PCSK9 variant to reduce a symptom of a “cholesterol related disorder” (which includes “serum cholesterol related disorders”). In some embodiments the pharmaceutical composition will comprise at least a sufficient amount of the neutralizing PCSK9 variant to modulate at least one native PCSK9 activity (*e.g.*, binding of native PCSK9 to LDLR).

[0235] In some embodiments, the pharmaceutical composition comprises at least an amount of a neutralizing PCSK9 variant sufficient for treating any one or more of the cholesterol related disorders disclosed herein.

[0236] In some embodiments, the pharmaceutical composition comprises at least an amount of a neutralizing PCSK9 variant sufficient to treat a symptom of a cholesterol related disorder of an adult male and/or female. In some embodiments the amount of the neutralizing PCSK9 variant is at least sufficient to treat (*e.g.*, reduce a symptom of) an adult male weighing between 10 and 250 kg. In some embodiments, the amount is at least sufficient to treat a 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 kg subject so as to lessen a symptom of at least any one of the cholesterol related disorders, to raise the level of LDLR in the subject, or to lower the level of LDL in the subject. In some embodiments, the amount of a neutralizing PCSK9 variant present in the pharmaceutical composition is at least sufficient to raise the level of LDLR in a subject by some detectable amount. In some embodiments, the level of LDLR in a subject is raised by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 percent. In some embodiments the level of LDLR in a

subject is increased by at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 fold over an untreated healthy subject and/or over an untreated subject that has a cholesterol related disorder. In yet other embodiments the neutralizing PCSK9 variant is sufficient to maintain the level of LDLR in a subject at a desired level. The appropriate level can be determined by the subject's health care provider and can take into account particular aspects of the subject's physical condition and health issues and concerns.

[0237] In some embodiments, the amount of neutralizing PCSK9 variant present in the pharmaceutical composition is at least sufficient to block a significant amount of the activity of the native PCSK9 *in vivo*. In some embodiments, the amount is sufficient to block at least 1% of the activity of native PCSK9, for example, at least 1, 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, 99-100 percent of the native PCSK9 is blocked by the amount of PCSK9 present in the pharmaceutical composition.

[0238] In some embodiments, the amount of neutralizing PCSK9 variant present in the pharmaceutical composition is at least sufficient to lower serum LDL in a subject. In some embodiments, the amount is sufficient to lower the amount of serum LDL in a subject by at least 1% of the native level of serum LDL, for example, at least 1, 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-95, 95-98, 98-99, 99-100 percent of the level of serum LDL for the subject, for a subject having a cholesterol related disorder, or for a healthy subject.

[0239] In some embodiments, the amount of neutralizing PCSK9 variant present in the pharmaceutical composition is a significant amount. In some embodiments, the amount of neutralizing PCSK9 variant present in a pharmaceutical dose to be given to a subject is at least 1 ng, for example, the amount is at least 1, 10, 20, 50, 100, 500, 1000, 10,000, 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , or 10^{11} nanograms, including any amount defined between any two of the previous numbers and any amount above any of the previous numbers. In some embodiments the amount is in a single pill. In some embodiments, the amount is in multiple pills. In some embodiments, the amount of the neutralizing PCSK9 variant administered is from about 1 to 500 mg, 50 to 400 mg, or 100 to 300 mg.

[0240] In some embodiments, the neutralizing PCSK9 variant is included in a solid form, such as in a tablet or pill.

[0241] In some embodiments, the amount of the neutralizing PCSK9 variant is a dosage sufficient to achieve any of the herein described goals (or amounts) for at least 1 hour. In

some embodiments, the amount is sufficient to treat a cholesterol related disorder for at least one hour, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours. In some embodiments, the amount of the neutralizing PCSK9 variant that is present is sufficient to achieve any of the herein described goals for at least one day. Thus, in some embodiments, the dosage is a once daily amount.

[0242] In some embodiments, the neutralizing PCSK9 variant is relatively pure. In some embodiments, apart from a pharmaceutical acceptable carrier or diluent and the neutralizing PCSK9 variant, nothing else is present in the composition. In some embodiments, a compound comprising the neutralizing PCSK9 variant is at least 0.01% neutralizing PCSK9 variant (by weight). In some embodiments, at least 1×10^{-8} , 1×10^{-7} , 1×10^{-6} , 1×10^{-5} , 0.0001, 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99, or 100 percent of the compound is a neutralizing PCSK9 variant. In some embodiments, the percent is a range defined between any two of the previous percents.

[0243] As will be appreciated by one of skill in the art, any of the above parameters describing the amount of the neutralizing PCSK9 variant present can be combined with any of the other parameters. For example, any of the parameters regarding the percent of native PCSK9 blocked *in vivo* can be combined for any of the specific weights supplied for the subjects.

[0244] In some embodiments, the pharmaceutical composition does not include ingredients that are harmful to a subject.

[0245] In some embodiments, the pharmaceutical composition does not include 50 mM sodium phosphate and/or 50 mM sodium chloride. In some embodiments, the pharmaceutical composition does not include sodium phosphate and/or sodium chloride. In some embodiments the pharmaceutical composition does not contain cell lysates. In some embodiments the pharmaceutical composition does not contain cell medium. In some embodiments, the pharmaceutical composition does not include BS3 (bis[sulfosuccinimidyl]suberate). In some embodiments, the pharmaceutical composition does not include potassium formate. In some embodiments, the pharmaceutical composition does not include PEG 3350. In some embodiments, the pharmaceutical composition does not include 0.2 M potassium formate. In some embodiments, the pharmaceutical composition does not include 20% PEG 3350. In some embodiments, the pharmaceutical composition does not include 50 mM Tris. In some embodiments, the pharmaceutical composition does not include 4 mM

EDTA. In some embodiments, the pharmaceutical composition does not include 0.01-2% Triton X-100. In some embodiments, the pharmaceutical composition does not include 0.5 sodium deoxycholate. In some embodiments, the pharmaceutical composition does not include 0.1-2% sodium dodecyl sulfate. In some embodiments, the pharmaceutical composition does not include 10-20% glycerol. In some embodiments, the pharmaceutical composition does not include 1M NDSB. In some embodiments, the pharmaceutical composition does not include 1-20 mM calcium chloride. In some embodiments, the pharmaceutical composition does not include $\text{KH}_2\text{PO}_4/\text{NaOH}$. In some embodiments, the pharmaceutical composition does not include citric acid and sodium phosphate. In some embodiments, the pharmaceutical composition does not include Na_2HPO_4 and NaOH. In some embodiments, the pharmaceutical composition does not include the combination of two or more of the above ingredients. In some embodiments, the pharmaceutical composition does not include the combination of three or more of the above ingredients. In some embodiments, the pharmaceutical composition does not include the combination of four or more of the above ingredients. In some embodiments, the pharmaceutical composition does include one or more of the above ingredients.

[0246] In some embodiments, the neutralizing PCSK9 variant is not created in *E. coli*. In some embodiments, any of the herein disclosed neutralizing PCSK9 variants is a self-processed or self-cleaved protein. In some embodiments, any of the herein disclosed neutralizing PCSK9 variants is a processed or cleaved protein.

[0247] In some embodiments, once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. In some embodiments, such formulations can be stored either in a ready-to-use form or in a form (*e.g.*, lyophilized) that is reconstituted prior to administration.

[0248] In some embodiments, kits are provided for producing a single-dose administration unit. In some embodiments, the kit can contain both a first container having a dried protein and a second container having an aqueous formulation. In some embodiments, kits containing single and multi-chambered pre-filled syringes (*e.g.*, liquid syringes and lyosyringes) are included.

[0249] In some embodiments, the effective amount of a pharmaceutical composition comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, to be employed therapeutically will depend, for example, upon the therapeutic context and

objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment, according to certain embodiments, will thus vary depending, in part, upon the molecule delivered, the indication for which a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, is being used, the route of administration, and the size (body weight, body surface or organ size) and/or condition (the age and general health) of the patient. In some embodiments, a clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. In some embodiments, a typical dosage can range from about 0.1 µg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In some embodiments, the dosage can range from 0.1 µg/kg up to about 100 mg/kg; or 1 µg/kg up to about 100 mg/kg; or 5 µg/kg up to about 100 mg/kg.

[0250] In some embodiments, the frequency of dosing will take into account the pharmacokinetic parameters of a neutralizing PCSK9 variant and/or any additional therapeutic agents in the formulation used. In some embodiments, a clinician will administer the composition until a dosage is reached that achieves the desired effect. In some embodiments, the composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. In some embodiments, appropriate dosages can be ascertained through use of appropriate dose-response data. In some embodiments, the amount and frequency of administration can take into account the desired cholesterol level (serum and/or total) to be obtained and the subject's present cholesterol level, LDL level, and/or LDLR levels, all of which can be obtained by methods that are well known to those of skill in the art.

[0251] In some embodiments, the route of administration of the pharmaceutical composition is in accord with known methods, *e.g.* orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, subcutaneously, intra-ocular, intraarterial, intraportal, or intralesional routes; by sustained release systems or by implantation devices. In some embodiments, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device. In some embodiments, the composition is configured for administration via any of these routes.

[0252] In some embodiments, the composition can be administered locally via implantation of a membrane, sponge or another appropriate material onto which the desired molecule has been absorbed or encapsulated. In some embodiments, where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

[0253] In some embodiments, it can be desirable to use a pharmaceutical composition comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, in an *ex vivo* manner. In such instances, cells, tissues and/or organs that have been removed from the patient are exposed to a pharmaceutical composition comprising a neutralizing PCSK9 variant, with or without at least one additional therapeutic agent, after which the cells, tissues and/or organs are subsequently implanted back into the patient.

[0254] In some embodiments, a neutralizing PCSK9 variant and/or any additional therapeutic agents can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein, to express and secrete the polypeptides. In some embodiments, such cells can be animal or human cells, and can be autologous, heterologous, or xenogeneic. In some embodiments, the cells can be immortalized. In some embodiments, in order to decrease the chance of an immunological response, the cells can be encapsulated to avoid infiltration of surrounding tissues. In some embodiments, the encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

[0255] Based on the ability of a neutralizing PCSK9 variant to significantly neutralize PCSK9 activity (as demonstrated in the Examples below), these neutralizing PCSK9 variants will have therapeutic effects in treating and preventing symptoms and conditions resulting from PCSK9-mediated activity, such as hypercholesterolemia.

EXAMPLES

[0256] The following examples, including the experiments conducted and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the present invention.

EXAMPLE 1

Demonstration of a Neutralizing PCSK9 variant binding to the LDL receptor - LDLR

Competition assay

[0257] This example is directed to the ability of a neutralizing PCSK9 variant to compete with full length PCSK9 for binding to LDLR.

[0258] Clear, 96 well plates (Nunc) were coated overnight with 2 micrograms/ml of goat anti-LDL receptor antibody (R&D Systems) diluted in buffer A (100 mM sodium cacodylate, pH 7.4). Plates were washed thoroughly with buffer A and then blocked for 2 hours with buffer B (1% milk in buffer A). After washing, plates were incubated for 1.5 hours with 2.0 ug/ml of LDL receptor (R&D Systems) diluted in buffer C (buffer B supplemented with 10 mM CaCl₂). Concurrent with this incubation, 100 ng/ml of biotinylated wild-type human PCSK9 (hPCSK9), diluted in buffer C, was incubated with various concentrations of non-biotinylated competitor proteins (e.g. 31-447 of PCSK9 (SEQ ID NO: 3), full length PCSK9, and the V-domain of PCSK9, residues 450-692) also diluted in buffer C, or buffer C alone (control). The LDL receptor containing plates were washed. The biotinylated PCSK9/competitor protein mixture was transferred to the plates and incubated for 1 hour at room temperature. Binding of the biotinylated PCSK9 to the LDL receptor was detected by incubation with streptavidin-HRP (Biosource) at 500 ng/ml in buffer C followed by TMB substrate (KPL). The absorbance at 650 nm was measured.

[0259] The results are presented in FIG. 2. Both the neutralizing PCSK9 variant (amino acids 31-447 of SEQ ID NO: 3), and the full length PCSK9 (fl PCSK9), competed against biotin-labeled full length PCSK9 for binding to the immobilized LDLR. The V-domain protein did not. This data demonstrates that no more than amino acids 31-447 (of SEQ ID NO: 3) are required for binding to the LDLR.

EXAMPLE 2

Effect of a Neutralizing PCSK9 variant on Cell LDL uptake

[0260] The example is directed to the ability of one neutralizing PCSK9 variant to impact LDL uptake. HepG2 cells were seeded in 96-well plates (Costar) at a concentration of 5×10^5 cells per well in DMEM medium (Mediatech, Inc) supplemented with 10% fetal bovine serum (FBS) and incubated overnight at 37°C (5% CO₂). The next day, cells were washed twice

with PBS. A serial 1:2 dilution of wild-type PCSK9 or the neutralizing PCSK9 variant (31-447 of SEQ ID NO: 3) was made, ranging from 1.6 ug/ml to 50ug/ml, and was added to cells. Following the addition of 6ug/ml of BODIPY-LDL (Invitrogen) and incubation for 3 hours at 37°C (5% CO₂), the cells were washed thoroughly with PBS. Lastly, the cellular associated fluorescence signal was detected by Safire (TECAN) at 480~520nm (excitation) and 520~600nm (emission).

[0261] The results are presented in FIGs. 3A and 3B which represent two separate experiments of identical design performed on different dates. As can be observed in the figures, full length PCSK9 (having a H8 histidine purification tag) blocked the uptake of labeled LDL in to the cultured cells as evidenced by the decrease in fluorescence from the cells with increasing PCSK9 levels added to the culture medium. In contrast, the neutralizing PCSK9 variant allows for the cells to take up LDL.

EXAMPLE 3

Western Blot Analysis of the Cellular Effects of a Neutralizing PCSK9 Variant

[0262] This example is directed to the cellular effects of the presence of a neutralizing PCSK9 variant.

[0263] HepG2 cells in 6 well plates were grown to confluency at 37°C in DMEM medium with 10% fetal bovine serum (FBS). Some cells were pretreated for 30 minutes with 100 uM chloroquine to inhibit acidification of endosomes. Cells were then treated with either vehicle (PBS, less than 50 ul), full length PCSK9 (50 ug/ml, 0.65 uM), or neutralizing PCSK9 variant (31-447 of SEQ ID NO: 3) (30 micrograms/ml, 0.65 uM) in 750 ul of DMEM with 1% FBS for 4 hours at 37°C. Cells were washed three times with PBS and whole cell lysate was prepared using lysis buffer (125 mM Tris, 2 mM CaCl₂, 1% triton X-100, pH 8.5). Fifty ug of cell supernatant protein was resolved by SDS PAGE and LDLR levels determined using rabbit anti-human LDLR polyclonal antibody (RDI-PRO61099, Fitzgerald Industries International Inc.). Recombinant PCSK9 associated with the cells was detected by anti-human PCSK9 monoclonal antibody that detects the ~ 14 kDa prodomain of PCSK9. HRP-conjugated secondary antibodies (Santa Cruz Biotechnology Inc.) and ECL (GE Healthcare) were used for detecting signal. (Veh=vehicle (PBS), FL=full length, PC9=PCSK9).

[0264] The results are shown in FIG. 4. As can be seen in the figure, the neutralizing PCSK9 variant (31-447 of SEQ ID NO: 3) associated with cells but did not cause degradation of LDLR, unlike full length PCSK9.

[0265] As will be appreciated by one of skill in the art, the data from the above Examples indicate that while a neutralizing PCSK9 variant (*e.g.*, 31-447 of SEQ ID NO: 3) can bind to the LDLR it does not prevent LDL binding and LDL uptake by cells and does not cause LDLR degradation. In addition, the neutralizing PCSK9 variant (31-447 of SEQ ID NO: 3) allows LDLR recycling, preserving the normal function of the LDLR.

[0266] Given the present results, it is apparent that neutralizing PCSK9 variants can bind to the LDLR at the cell surface preventing the interaction of full length (wild-type) PCSK9 with the LDLR. Because the neutralizing PCSK9 variant preserves normal LDLR function it acts as a therapeutic protecting the LDLR from the effects of endogenous full length PCSK9.

EXAMPLE 4

Uses of a Neutralizing PCSK9 Variant for the Treatment of Cholesterol Related Disorders

[0267] A human patient exhibiting a Cholesterol Related Disorder (in which a reduction in cholesterol (such as serum cholesterol) can be beneficial) is administered a therapeutically effective amount of a neutralizing PCSK9 variant. At periodic times during the treatment, the patient is monitored to determine whether a symptom of the disorder has subsided. Following treatment, it is found that patients undergoing treatment with the neutralizing PCSK9 variant have reduced serum cholesterol levels, in comparison to patients that are not treated.

EXAMPLE 5

Uses of a Neutralizing PCSK9 Variant for the Treatment of Hypercholesterolemia

[0268] A human patient exhibiting symptoms of hypercholesterolemia is administered a therapeutically effective amount of a neutralizing PCSK9 variant. At periodic times during the treatment, the human patient is monitored to determine whether the serum cholesterol level (either as total cholesterol or more specifically LDL cholesterol) has declined. Following treatment, it is found that the patient receiving the treatment with a neutralizing

PCSK9 variant has reduced serum cholesterol levels in comparison to arthritis patients not receiving the treatment.

EXAMPLE 6

Uses of a Neutralizing PCSK9 Variant for the Prevention of Coronary Heart Disease and/or Recurrent Cardiovascular Events

[0269] A human patient at risk of developing coronary heart disease is identified. The patient is administered a therapeutically effective amount of a neutralizing PCSK9 variant, either alone, concurrently or sequentially with a statin, *e.g.*, simvastatin. At periodic times during the treatment, the human patient is monitored to determine whether the patient's total serum cholesterol level changes. Throughout the preventative treatment, it is found that the patient receiving the treatment with the neutralizing PCSK9 variant has reduced serum cholesterol thereby reducing their risk to coronary heart diseases or recurrent cardiovascular events in comparison to patients not receiving the treatment.

EXAMPLE 7

Use of a Neutralizing PCSK9 Variant for the Prevention of Hypercholesterolemia

[0270] A human patient exhibiting a risk of developing hypercholesterolemia is identified via family history analysis and/or lifestyle, and/or current cholesterol levels. The subject is regularly administered (*e.g.*, one time weekly) a therapeutically effective amount of a neutralizing PCSK9 variant. At periodic times during the treatment, the patient is monitored to determine whether serum cholesterol levels have decreased. Following treatment, it is found that subjects undergoing preventative treatment with a neutralizing PCSK9 variant have lowered serum cholesterol levels, in comparison to subjects that are not treated.

EXAMPLE 8

Mouse Model for PCSK9

[0271] The present example describes how to generate a mouse model for testing various neutralizing PCSK9 variants. To generate mice which over-expressed human PCSK9, three week old WT C57Bl/6 mice were injected via tail vein administration with various concentrations of adenoassociated virus (AAV), recombinantly modified to express human

PCSK9, to determine the correct titer which would provide a measurable increase of LDL-cholesterol in the mice. Using this particular virus which expressed human PCSK9, it was determined that 4.5×10^{12} pfu of virus would result in an LDL-cholesterol level of approximately 40mg/dL in circulating blood (normal levels of LDL in a WT mice are approximately 10mg/dL). The human PCSK9 levels in these animals were found to be approximately 13ug/mL. A colony of mice was generated using this injection criteria.

[0272] One week after injection, mice were assessed for LDL-cholesterol levels.

EXAMPLE 9

[0273] The mice from Example 8 can be used to test various neutralizing PCSK9 variants to determine how effective they are and which variants work *in vivo*.

[0274] A neutralizing PCSK9 variant can be administered, via tail vein injection, in a single bolus injection, or by AAV induced over-expression. Subgroups of animals (n=6-7) can then be euthanized at 24 and 48 hours after neutralizing PCSK9 variant administration. LDL levels can then be examined and optionally compared with various controls (e.g., wild-type PCSK9, a water or unrelated protein injection, and the pro/cat domain). Complete PCSK9 variants that result in mice with lower serum LDL levels will be variants that can be effective in lowering serum LDL levels.

EXAMPLE 10

The LDLR EGFa Domain Binds to the Catalytic Domain of PCSK9

[0275] The present example presents the solved crystal structure of PCSK9 Pro/Cat (31-454) bound to the LDLR EGFa domain (293-334) at 2.9 Å resolution (the conditions for which are described in the below Examples).

[0276] A representation of the structure of PCSK9 bound to EGFa is shown in FIG. 5. The crystal structure (and its depiction in FIG. 5) reveals that the EGFa domain of LDLR binds to the catalytic domain of PCSK9. In addition, the interaction of PCSK9 and EGFa appears to occur across a surface of PCSK9 that is between residues D374 and S153 in the structure depicted in FIG. 5.

[0277] Specific core PCSK9 amino acid residues of the interaction interface with the LDLR EGFa domain were defined as PCSK9 residues that are within 5 Å of the EGFa domain.

The core residues are as follows: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, and S381.

[0278] Boundary PCSK9 amino acid residues of the interaction interface with the LDLR EGFa domain were defined as PCSK9 residues that are 5-8 Å from the EGFa domain. The boundary residues are as follows: W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, and Q382. Residues that are underlined are nearly or completely buried within PCSK9.

[0279] As will be appreciated by one of skill in the art, the results from this example demonstrate where PCSK9 and EGFa interact. Thus, neutralizing PCSK9 variants that interact with or block any of these residues can be useful to inhibit the interaction between native PCSK9 and the EGFa domain of LDLR (and/or LDLR generally). In some embodiments, neutralizing PCSK9 variants that, when bound to PCSK9, interact with or block any of the above residues or are within 15-8, 8, 8-5, or 5 angstroms of the above residues are contemplated to provide useful inhibition of PCSK9 binding to LDLR.

EXAMPLE 11

Structural Interaction of LDLR and PCSK9

[0280] A model of full length PCSK9 protein bound to a full length representation of the LDLR was made using the PCSK9 Pro/Cat 31-454/EGFa complex structure. The structure of full length PCSK9 (Piper, D.E. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. *Structure* 15, 545-52 (2007)) was overlaid onto the PCSK9 Pro/Cat 31-454 from the complex and the structure of the LDLR in its low pH conformation (Rudenko, G. et al. Structure of the LDL receptor extracellular domain at endosomal pH. *Science* 298, 2353-8 (2002)) was overlaid onto the EGFa domain from the complex. Depictions of the model are shown in FIGs. 6 and 7. The EGFa domain from the PCSK9 Pro/Cat 31-454 / EGFa complex is enclosed within the box. The figures show regions of the LDLR outside of the immediate EGFa binding domain that lie in close proximity to PCSK9.

EXAMPLE 12

Expression and Purification of Protein Samples

[0281] The present example describes some methods by which the various embodiments of the PCSK9 proteins/variants were made and purified (including the LDLR EGFA domain). PCSK9 proteins/variants (*e.g.*, PCSK9 31-692 N533A, PCSK9 449TEV and PCSK9 Pro/Cat 31-454) were expressed in baculovirus infected Hi-5 insect cells with an N-terminal honeybee melittin signal peptide followed by a His₆ tag. The PCSK9 proteins were purified by nickel affinity chromatography, ion exchange chromatography and size exclusion chromatography. The melittin-His₆ tag was removed during purification by cleavage with TEV protease. The construct PCSK9 449TEV was used to generate PCSK9 Pro/Cat (31-449 and V domain (450-692) samples. This construct had a TEV protease cleavage site inserted between PCSK9 residues 449 and 450.

[0282] The LDLR EGFA domain (293-334) was expressed as a GST fusion protein in *E. coli*. The EGFA domain was purified by ion exchange chromatography, glutathione sepharose affinity chromatography and size exclusion chromatography. The GST protein was removed during the purification by cleavage with PreScission protease.

EXAMPLE 13

Complex Formation and Crystallization

[0283] The present example describes how complexes and crystals used in the above structure examination Examples were made.

[0284] The PCSK9 31-454 / EGFA complex was made by mixing a 1.2 molar excess of EGFA domain with PCSK9 31-454. The PCSK9 31-454 / EGFA domain complex crystallized in 0.2 M potassium formate, 20% PEG 3350.

EXAMPLE 14

Data Collection and Structure Determination

[0285] The present example describes how the datasets were collected and the structures determined for the above structure examination Examples.

[0286] The PCSK9 31-454 / EGFA dataset was collected at the Berkeley Advanced Light Source beamline 5.0.2. All datasets were processed with denzo/scalepack or HKL2000 (Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities. *Acta Crystallogr A* 59, 228-34 (2003)).

[0287] PCSK9 / EGFa domain crystals grew in the space group P6₅22 with unit cell dimensions a=b=70.6, c=321.8 Å and diffract to 2.9 Å resolution. The PCSK9 / EGFa domain structure was solved by molecular replacement with the program MOLREP using the PCSK9 Pro/Cat as the starting search model. Analysis of the electron density maps showed clear electron density for the EGFa domain. The LDLR EGFa domain was fit by hand and the model was improved with multiple rounds of model building with Quanta and refinement with cnx.

[0288] Core interaction interface amino acids were determined as being all amino acid residues with at least one atom less than or equal to 5 Å from the PCSK9 partner protein. 5 Å was chosen as the core region cutoff distance to allow for atoms within a van der Waals radius plus a possible water-mediated hydrogen bond. Boundary interaction interface amino acids were determined as all amino acid residues with at least one atom less than or equal to 8 Å from the PCSK9 partner protein but not included in the core interaction list. Less than or equal to 8 Å was chosen as the boundary region cutoff distance to allow for the length of an extended arginine amino acid. Amino acids that met these distance criteria were calculated with the program PyMOL. (DeLano, W.L. The PyMOL Molecular Graphics System. (Palo Alto, 2002)).

[0289] The coordinates for the crystal structures discussed in the above Examples are presented in Table 35.2 of U.S. Prov. Pat. App. No. 61/010630, filed Jan. 9, 2008, the entirety of which is incorporated by reference. Neutralizing PCSK9 variants that interact with the relevant areas or residues of the structure of PCSK9 (including those areas or residues within 15, 15-8, 8, 8-5, 5, or fewer angstroms from where EGFa interacts with PCSK9) depicted in the figures and/or their corresponding positions on the structures from the coordinates are also contemplated.

EXAMPLE 15

Additional Neutralizing PCSK9 Variants

[0290] This example describes the ability of the D374Y point mutation in a neutralizing PCSK9 variant (amino acids 31-447 of SEQ ID NO: 3) to alter cell LDL uptake (FIG. 8) and compete with full length PCSK9 for binding to the LDLR (FIG. 9).

[0291] The protocol followed was generally similar to that outlined above regarding LDL uptake in the presence of the neutralizing PCSK9 variant (amino acids 31-447 of SEQ ID NO: 3), except that full length D374Y PCSK9, a neutralizing PCSK9 variant (amino acids 31-

447 of SEQ ID NO: 3) having the D374Y point mutation, and a full length wild-type hPCSK9 were used. The results are shown in FIG. 8.

[0292] In addition to the above experiment, LDLR was also captured in an ELISA plate via an LDLR antibody (2 ug/ml). Following this, biotin-WT_PCSK9 (100 ng/ml) and various concentrations of unbiotinylated full length D374Y PCSK9, V domain (V domain), and D374Y Pro/Cat (31-447) were added to the plate. Bound biotin-PCSK9 was detected by streptavidin-HRP. The results are presented in FIG. 9 and demonstrate the ability of the D374Y Pro/Cat domain and the D374Y full length PCSK9 to compete with the full length WT PCSK9 for binding to the LDLR.

[0293] As can be seen in the results displayed in FIGs. 8 and 9, neutralizing PCSK9 variants will also work to increase the amount of LDL uptake with respect to uptake that occurs in the presence of other forms of PCSK9.

Incorporation by Reference

[0294] All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control.

Equivalents

[0295] The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The foregoing description and examples detail certain embodiments of the invention. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways.

CLAIMS

1. An isolated neutralizing PCSK9 variant comprising:
 - (a) a Pro/Cat domain, or fragment thereof; and
 - (b) an inactive V domain,wherein the Pro/Cat domain or the fragment thereof
 - i) lacks amino acids 1-60 of SEQ ID NO: 3; or
 - ii) lacks amino acids 1-30 of SEQ ID NO: 3; andwherein the neutralizing PCSK9 variant lacks at least 14 C-terminal amino acids of SEQ ID NO: 3, preferably the PCSK9 variant lacks the protein sequence defined from amino acids 453 to 692 of SEQ ID NO: 3.
2. An isolated nucleic acid molecule encoding the neutralizing PCSK9 variant according to Claim 1, preferably operably linked to a control sequence.
3. A vector comprising a nucleic acid molecule according to Claim 2.
4. A host cell comprising the nucleic acid molecule according to Claim 2 or the vector according to Claim 3.
5. The isolated neutralizing PCSK9 variant of claim 1, wherein said isolated neutralizing PCSK9 variant has no V domain.
6. The isolated neutralizing PCSK9 variant of Claim 1 or Claim 5, further comprising an antibody, or fragment thereof, conjugated to the neutralizing PCSK9 variant, wherein the antibody or fragment thereof preferably comprises an Fc domain of an antibody or optionally the fragment of the antibody consists of an Fc domain of an antibody.
7. A pharmaceutical composition comprising at least one neutralizing PCSK9 variant according to any one of Claims 1, 5 or 6, and a pharmaceutically acceptable excipient, optionally further comprising an additional active agent, preferably selected from the group consisting of a radioisotope, radionuclide, a toxin, or a therapeutic and a chemotherapeutic group.
8. A method for treating or preventing a condition associated with elevated serum cholesterol in a patient, comprising administering to a patient in thereof an effective amount of

at least one neutralizing PCSK9 variant according to any one of Claims 1, 5 or 6, wherein the condition preferably is hypercholesterolemia.

9. A method of inhibiting binding of PCSK9 to LDLR in a patient comprising administering an effective amount of a neutralizing PCSK9 variant according to any one of Claims 1, 5 or 6.

10. A method for treating or preventing a condition associated with elevated serum cholesterol in a subject, said method comprising administering to a subject in need thereof an effective amount of at least one neutralizing PCSK9 variant according to any one of Claims 1, 5 or 6 simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein,

wherein the agent that elevates the availability of LDLR protein optionally comprises a statin, preferably selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

11. A method of lowering serum cholesterol in a subject, said method comprising administering to a subject an effective amount of at least one isolated neutralizing PCSK9 variant according to any one of Claims 1, 5 or 6, preferably simultaneously or sequentially with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.

12. Use of a neutralizing PCSK9 variant of Claim 1, 5 or 6 in the manufacture of a medicament for the treatment of hypercholesterolemia.

13. Use of a neutralizing PCSK9 variant of Claim 1, 5 or 6 in the manufacture of a medicament for inhibiting binding of PCSK9 to LDLR.

14. Use of a neutralizing PCSK9 variant of Claim 1, 5 or 6 in the manufacture of a medicament for treating a condition associated with elevated serum cholesterol in a subject, wherein said medicament is adapted for simultaneous or sequential administration with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein,

wherein the agent that elevates the availability of LDLR protein optionally comprises a statin, preferably selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

15. Use of a neutralizing PCSK9 variant of Claim 1, 5 or 6 in the manufacture of a medicament for lowering serum cholesterol in a subject, wherein said medicament is adapted for simultaneous or sequential administration with an agent that elevates the availability of low density lipoprotein receptor (LDLR) protein.
16. The neutralizing PCSK9 variant of Claim 1, 5 or 6 when used as a medicament.
17. The neutralizing PCSK9 variant of Claim 1, 5 or 6 when used in treating hypercholesterolemia.
18. A pharmaceutical composition comprising at least one neutralizing PCSK9 variant according to any of the Claims, 5, 6, 16 or 17, wherein the neutralizing PCSK9 variant is present in an amount effective for the treatment of a cholesterol related disorder.
19. The pharmaceutical composition of Claim 18, wherein the effective amount comprises:
 - (i) an amount effective for lowering the level of LDL in a human; and/or
 - (ii) an amount that elevates the availability of low density lipoprotein receptor (LDLR) protein in a human, wherein the elevation is preferably at least 5%, at least 20%, at least 50%, at least 100%, or at least 300%.
20. The pharmaceutical composition of Claim 19, wherein the human is a 100 kg male or a 50 kg male.
21. A pharmaceutical composition comprising:
 - (a) a Pro/Cat domain, or fragment thereof;
 - (b) an inactive V domain; and
 - (c) a pharmaceutically acceptable carrier or diluent,wherein the Pro/Cat domain, or the fragment thereof
 - (i) lacks amino acids 1-60 of SEQ ID NO: 3; or
 - (ii) lacks amino acids 1-30 of SEQ ID NO: 3; andwherein the neutralizing PCSK9 variant lacks at least 14 C-terminal amino acids of SEQ ID NO: 3, preferably the PCSK9 variant lacks the protein sequence defined from amino acids 453 to 692 of SEQ ID NO: 3.

22. A pharmaceutical composition comprising a Pro/Cat domain, or fragment thereof, and an inactive V domain, wherein the Pro/Cat domain is present in an amount sufficient for the treatment of a cholesterol related disorder,

wherein the Pro/Cat domain:

- (i) comprises the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (ii) consists of the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (iii) consists essentially of the amino acid sequence of the Pro/Cat domain in SEQ ID NO: 9 or 30; or
- (iv) comprises the Cat domain of at least one of the amino acids sequences of SEQ ID NOs: 9, 11, 13, 15 or 3.

23. An isolated neutralizing PCSK9 variant according of Claim 1; an isolated nucleic acid molecule of Claim 2; a vector of Claim 3; a host cell of Claim 4; a pharmaceutical composition of any one of Claims 7, 18, 21 or 22; a method of any one of Claims 8 to 11; or use of any one of Claims 12 to 15, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.

1 / 38

QEDEDGDYEELVLA LRSEEDGLAE APEHGT TATFHRC AKDPWRLPGTYVVVLKEETHLSQS
ERTARRLQAQAARRGYLTKILHVFHGLLP GFLVKMSGDLLELALKLPHVDYIEEDSSVFAQ
SIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTD FENVPEEDG
TRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKS
QLVQPVGPLVLLPLAGGYSRVLNAA CQRLARAGVVLVTAAGNFRDDACLYSPASAPEVIT
VGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDII GASSDCSTCFVSQSGTSQAAAHVAGIA
AMMLSAEPELT LAELRQRLIHFS AKDVINEAWFPEDQRVLT PNLVAALPPSTHGAGWQLFC
RTVWSAHSGPTRMATAIARCAPDEELLSCSSFSRSGKRRGERMEAQGCKLVCRAHNAFGGE
GVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVL
RPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQGQVTVACEEGWTLTGCSALPG
TSHVLGAYAVDNTCVVRSRDVSTTGSTSEEAVTAVAICCRSRHLAQASQELQ

SEQ ID NO:1**FIG. 1A**

2 / 38

	10	20	30	40	50	
Query	----- ----- ----- ----- -----					SEQ ID NO:2
Frame1	atgggcaccgtcagctccaggcggtcctggcgcgtgccactgtgtgct					SEQ ID NO:3
	60	70	80	90	100	
Query	----- ----- ----- ----- -----					
Frame1	gctgtgtgtgtgtgtcctgggtcccgcgggcgccgtgcgcaggaggacg					
	110	120	130	140	150	
Query	----- ----- ----- ----- -----					
Frame1	aggacggcgcactacgaggagctgggtgctagccttgcgctccgaggaggac					
	50	160	170	180	190	200
Query	----- ----- ----- ----- -----					
Frame1	ggcctggccgaagcaccgcgagcacggaaccacagccaccttccaccgctg					
	210	220	230	240	250	
Query	----- ----- ----- ----- -----					
Frame1	cgccaaggatccgtggaggttgccctggcacctacgtgggtgggtgctgaagg					
	50	260	270	280	290	300
Query	----- ----- ----- ----- -----					
Frame1	aggagacccacctctcgcagtcagagcgcactgcccgcgcctgcaggcc					
	310	320	330	340	350	
Query	----- ----- ----- ----- -----					
Frame1	caggetgcccgcgcggggatacctcaccaagatcctgcatgtcttccatgg					
	50	360	370	380	390	400
Query	----- ----- ----- ----- -----					
Frame1	ccttcttccctggcttccctgggtgaagatgagtggcgacctgctggagctgg					
	410	420	430	440	450	
Query	----- ----- ----- ----- -----					
Frame1	ccttgaagttgccccatgtgcactacatcgaggaggactcctctgtcttt					
	50	460	470	480	490	500
Query	----- ----- ----- ----- -----					
Frame1	gcccagagcatcccgtggaacctggagcggattacccctccgcggtaccg					
	510	520	530	540	550	
Query	----- ----- ----- ----- -----					
Frame1	ggcggatgaataccagccccccgcagcggaggcagcctgggtggaggtgtatc					

FIG. 1B₁

SUBSTITUTE SHEET (RULE 26)

3 / 38

```

      50      560      570      580      590      600
      -----|-----|-----|-----|-----|
Query  : tcctagacaccagcatacacagagtgaccaccgggaaatcgagggcagggtc
Frame1 :  L D T S I Q S D H R E I E G R V

      610      620      630      640      650
      -----|-----|-----|-----|-----|
Query  : atggtcaccgacttcgagaatgtgcccaggaggacgggacccgcttcca
Frame1 :  M V T D F E N V P E E D G T R F H

      50      660      670      680      690      700
      -----|-----|-----|-----|-----|
Query  : cagacaggccagcaagtgtgacagtcattggcacccacctggcaggggtgg
Frame1 :  R Q A S K C D S H G T H L A G V V

      710      720      730      740      750
      -----|-----|-----|-----|-----|
Query  : tcagcggccgggatgccggcggtggccaagggtgccagcatgcgcagcctg
Frame1 :  S G R D A G V A K G A S M R S L

      50      760      770      780      790      800
      -----|-----|-----|-----|-----|
Query  : cgcgtgctcaactgccaaagggaagggcacgggttagcggcaccctcatagg
Frame1 :  R V L N C Q G K G T V S G T L I G

      810      820      830      840      850
      -----|-----|-----|-----|-----|
Query  : cctggagtttatttcgaaaagccagctgggtccagcctgtggggccactgg
Frame1 :  L E F I R K S Q L V Q P V G P L V

      50      860      870      880      890      900
      -----|-----|-----|-----|-----|
Query  : tgggtgctgctgcccctggcgggtgggtacagccgcgtcctcaacgccgcc
Frame1 :  V L L P L A G G Y S R V L N A A

      910      920      930      940      950
      -----|-----|-----|-----|-----|
Query  : tgccagcgctggcgagggtggtggtgctggtggtcaccgctgccggcaa
Frame1 :  C Q R L A R A G V V L V T A A G N

      50      960      970      980      990      1000
      -----|-----|-----|-----|-----|
Query  : cttccgggacgatgcctgcctctactccccagcctcagctcccagggtca
Frame1 :  F R D D A C L Y S P A S A P E V I

      1010      1020      1030      1040      1050
      -----|-----|-----|-----|-----|
Query  : tcacagttggggccaccaatgccaggaccagccggtgacctggggact
Frame1 :  T V G A T N A Q D Q P V T L G T

      50      1060      1070      1080      1090      1100
      -----|-----|-----|-----|-----|
Query  : ttggggaccaactttggccgctgtgtggacctctttgccccaggggagga
Frame1 :  L G T N F G R C V D L F A P G E D

```

FIG. 1B₂

SUBSTITUTE SHEET (RULE 26)

4 / 38

```

      100      1110      1120      1130      1140      1150
-----|-----|-----|-----|-----|
Query   : catcattggtgcctccagcgactgcagcacctgctttgtgtcacagagtg
Frame1  : I I G A S S D C S T C F V S Q S G

      150      1160      1170      1180      1190      1200
-----|-----|-----|-----|-----|
Query   : ggacatcacaggctgctgcccacgtggctggcattgcagccatgatgctg
Frame1  : T S Q A A A H V A G I A A M M L

      200      1210      1220      1230      1240      1250
-----|-----|-----|-----|-----|
Query   : tctgccgagccggagctcaccctggccgagttgaggcagagactgatcca
Frame1  : S A E P E L T L A E L R Q R L I H

      250      1260      1270      1280      1290      1300
-----|-----|-----|-----|-----|
Query   : cttctctgccaaagatgtcatcaatgaggcctgggtccctgaggaccagc
Frame1  : F S A K D V I N E A W F P E D Q R

      300      1310      1320      1330      1340      1350
-----|-----|-----|-----|-----|
Query   : gggtagtgacccccaaacctgggtggccgcccctgccccccagcacccatggg
Frame1  : V L T P N L V A A L P P S T H G

      350      1360      1370      1380      1390      1400
-----|-----|-----|-----|-----|
Query   : gcaggttggcagctgttttgcaggactgtgtggtcagcacactcggggcc
Frame1  : A G W Q L F C R T V W S A H S G P

      400      1410      1420      1430      1440      1450
-----|-----|-----|-----|-----|
Query   : tacacggatggccacagccatcgcccgtgcgccccagatgaggagctgc
Frame1  : T R M A T A I A R C A P D E E L L

      450      1460      1470      1480      1490      1500
-----|-----|-----|-----|-----|
Query   : tgagctgctccagtttctccaggagtgggaagcggcggggcgagcgcatg
Frame1  : S C S S F S R S G K R R G E R M

      500      1510      1520      1530      1540      1550
-----|-----|-----|-----|-----|
Query   : gaggcccaagggggcaagctgggtctgccggggcccacaacgcttttggggg
Frame1  : E A Q G G K L V C R A H N A F G G

      550      1560      1570      1580      1590      1600
-----|-----|-----|-----|-----|
Query   : tgagggtgtctacgccattgccagggtgctgctgctaccccaggccaact
Frame1  : E G V Y A I A R C C L L P Q A N C

      600      1610      1620      1630      1640      1650
-----|-----|-----|-----|-----|
Query   : gcagcgtccacacagctccaccagctgaggccagcatgggggacccgtgtc
Frame1  : S V H T A P P A E A S M G T R V
```

FIG. 1B₃

SUBSTITUTE SHEET (RULE 26)

5 / 38

```

      650      1660      1670      1680      1690      1700
      -----|-----|-----|-----|-----|
Query   : cactgccaccaacagggccacgtcctcacaggctgcagctcccactggga
Frame1  : H  C  H  Q  Q  G  H  V  L  T  G  C  S  S  H  W  E

      700      1710      1720      1730      1740      1750
      -----|-----|-----|-----|-----|
Query   : ggtggaggaccttggcaccacacaagccgcctgtgctgaggccacgaggtc
Frame1  : V  E  D  L  G  T  H  K  P  P  V  L  R  P  R  G  Q

      750      1760      1770      1780      1790      1800
      -----|-----|-----|-----|-----|
Query   : agcccaaccagtgcgtgggccacagggaggccagcatccacgcttctctgc
Frame1  :   P  N  Q  C  V  G  H  R  E  A  S  I  H  A  S  C

      800      1810      1820      1830      1840      1850
      -----|-----|-----|-----|-----|
Query   : tgccatgccccaggtctggaatgcaaagtcaaggagcatggaatcccggc
Frame1  : C  H  A  P  G  L  E  C  K  V  K  E  H  G  I  P  A

      850      1860      1870      1880      1890      1900
      -----|-----|-----|-----|-----|
Query   : ccctcaggggcaggtgaccgtggcctgcgaggagggtggaccctgactg
Frame1  : P  Q  G  Q  V  T  V  A  C  E  E  G  W  T  L  T  G

      900      1910      1920      1930      1940      1950
      -----|-----|-----|-----|-----|
Query   : gctgcagcgcctccctgggacctcccacgtcctgggggcctacgccgta
Frame1  :   C  S  A  L  P  G  T  S  H  V  L  G  A  Y  A  V

      950      1960      1970      1980      1990      2000
      -----|-----|-----|-----|-----|
Query   : gacaacacgtgtgtagtcaggagccgggacgtcagcactacaggcagcac
Frame1  : D  N  T  C  V  V  R  S  R  D  V  S  T  T  G  S  T

      2010      2020      2030      2040      2050
      -----|-----|-----|-----|-----|
Query   : cagcgaagaggccgtgacagccgttgccatctgctgccggagccggcacc
Frame1  : S  E  E  A  V  T  A  V  A  I  C  C  R  S  R  H  L

      2060      2070      2080      2090      2100
      -----|-----|-----|-----|-----|
Query   : tggcgcaggcctcccaggagctccag
Frame1  :   A  Q  A  S  Q  E  L  Q
SEQ ID NO: 2
SEQ ID NO: 3
```

FIG. 1B₄

SUBSTITUTE SHEET (RULE 26)

1	MGIRCS	WLRWPLS	-----PQLLLLLLLCPTG	SRAQDE	GDYEE	IMLALPS	50
	MGTVSS	RRSWWPLP	---LPLLLLLLLGPAGARA	QED	GDYEE	IVLALRS	
	MGTVSS	RRSWWPLP	---LLLLLLLLLPAGARA	QED	GDYEE	IVLALRS	
	MRTRGP	PAPAWPML	-----LLMLGPAPAGA	QARD	SEGD	HEGLAF	FPP
	MGTS	SARPRWLLS	-----PLLLLLLLRYM	GASAQ	DEDAE	YEEIML	TLQS
	MGTHCS	AWLRWPLP	LLPLPLLLLLLLCPTG	AGAQ	DE	GDYEE	IMLALPS
	MGT	CSARSWWPL	PLLLLLLLLPAGAAA	QDE	GDYEE	IMLALPS	100
51	QEDSLV	DEASHV	---ATATF	RRC	SK	EA	WRLPGTYV
	VED	GLAD	AP	EHG	---ATATF	HRC	AKDPWRLPGTYV
	VED	GLAE	AP	EHG	---TTATF	HRC	AKDPWRLPGTYV
	EEDG	PAE	A	PHVP	---TAPF	HRC	SKDAWRLPGTYL
	QDDG	LAD	ET	DEAP	Q	GATAA	FHRCPEE
	QEDG	LAD	EA	AHV	---ATATF	RRC	SK
	QEDG	LAD	EA	AHV	ATATF	HRC	SKDAWRLPGTYV
101	AHRLQ	TWA	AARRG	VYIK	LVH	FYDL	PGFL
	ARRLQ	A	AARRG	YLT	KIL	HV	FHLLPGFL
	ARRLQ	A	AARRG	YLT	KIL	HV	FHLLPGFL
	AHRLQ	A	AARRG	YVTT	VLH	FHLL	PGFL
	MHRLQ	T	AARRG	VYIK	IQ	HI	FYDL
	AHRLQ	T	AARRG	VYIK	LVH	FYDL	PGFL
	AHRLQ	T	AARRG	VYIK	LVH	FHLL	PGFL
151	EDSLV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
	EDSV	FAQS	IPWN	LRIIP	AWQ	Q	TEEDSS
201	SGHRE	IEGR	VTIT	DFNS	V	PEE	DGTR
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
250	SGHRE	IEGR	VTIT	DFNS	V	PEE	DGTR
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE
	SDHRE	IEGR	VM	VTDF	NS	V	PEE

FIG. 1C

251	rat PCSK9	(240)	VAKGTSLSHSLRVLNCQKGT	251	VAKGTSLSHSLRVLNCQKGT	300	VAKGTSLSHSLRVLNCQKGT
	cyno PCSK9	(241)	VAKGAGLSRLVNCQKGT		VAKGAGLSRLVNCQKGT		VAKGAGLSRLVNCQKGT
	human PCSK9	(241)	VAKGASMRSLRVNCQKGT		VAKGASMRSLRVNCQKGT		VAKGASMRSLRVNCQKGT
	guinea pig PCSK9	(237)	VAKGAGLSRLVNCQKGT		VAKGAGLSRLVNCQKGT		VAKGAGLSRLVNCQKGT
	hamster PCSK9	(247)	VAKGTILHGLRVLNCQKGT		VAKGTILHGLRVLNCQKGT		VAKGTILHGLRVLNCQKGT
	mouse PCSK9	(244)	VAKGTSLSHSLRVLNCQKGT		VAKGTSLSHSLRVLNCQKGT		VAKGTSLSHSLRVLNCQKGT
	Consensus	(251)	VAKGTSLSRLRVLNCQKGT		VAKGTSLSRLRVLNCQKGT		VAKGTSLSRLRVLNCQKGT
	rat PCSK9	(290)	GGYSRIILNTACORLAR	301	GGYSRIILNTACORLAR	350	GGYSRIILNTACORLAR
	cyno PCSK9	(291)	GGYSRVFNAACQRLAR		GGYSRVFNAACQRLAR		GGYSRVFNAACQRLAR
	human PCSK9	(291)	GGYSRVLNAAQRLAR		GGYSRVLNAAQRLAR		GGYSRVLNAAQRLAR
	guinea pig PCSK9	(287)	GGYSRTLNAAACHLLAR		GGYSRTLNAAACHLLAR		GGYSRTLNAAACHLLAR
	hamster PCSK9	(297)	GRYSRVLNTACQHLART		GRYSRVLNTACQHLART		GRYSRVLNTACQHLART
	mouse PCSK9	(294)	GGYSRIILNAAACRHLART		GGYSRIILNAAACRHLART		GGYSRIILNAAACRHLART
	Consensus	(301)	GGYSRVLNAAACQRLAR		GGYSRVLNAAACQRLAR		GGYSRVLNAAACQRLAR
	rat PCSK9	(340)	AQDQPVTLGTLGTFN	351	AQDQPVTLGTLGTFN	400	AQDQPVTLGTLGTFN
	cyno PCSK9	(341)	AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN
	human PCSK9	(341)	AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN
	guinea pig PCSK9	(337)	AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN
	hamster PCSK9	(347)	VQDQPVTLGTLGTFN		VQDQPVTLGTLGTFN		VQDQPVTLGTLGTFN
	mouse PCSK9	(344)	AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN
	Consensus	(351)	AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN		AQDQPVTLGTLGTFN
	rat PCSK9	(390)	HVAGIVAMMLNRDPALT	401	HVAGIVAMMLNRDPALT	450	HVAGIVAMMLNRDPALT
	cyno PCSK9	(391)	HVAGIAAMMLSAEPELT		HVAGIAAMMLSAEPELT		HVAGIAAMMLSAEPELT
	human PCSK9	(391)	HVAGIAAMMLSAEPELT		HVAGIAAMMLSAEPELT		HVAGIAAMMLSAEPELT
	guinea pig PCSK9	(387)	HVAGIVTMMLTAQPKLT		HVAGIVTMMLTAQPKLT		HVAGIVTMMLTAQPKLT
	hamster PCSK9	(397)	HVAGIVAMMLTLEPELT		HVAGIVAMMLTLEPELT		HVAGIVAMMLTLEPELT
	mouse PCSK9	(394)	HVAGIVARMLSREPTLT		HVAGIVARMLSREPTLT		HVAGIVARMLSREPTLT
	Consensus	(401)	HVAGIVAMMLSAEPELT		HVAGIVAMMLSAEPELT		HVAGIVAMMLSAEPELT
	rat PCSK9	(440)	VATLPPSTQETGGQLLCRT	451	VATLPPSTQETGGQLLCRT	500	VATLPPSTQETGGQLLCRT
	cyno PCSK9	(441)	VAAALPPSTHRAGWQ		VAAALPPSTHRAGWQ		VAAALPPSTHRAGWQ
	human PCSK9	(441)	VAAALPPSTHGAGWQ		VAAALPPSTHGAGWQ		VAAALPPSTHGAGWQ
	guinea pig PCSK9	(437)	VATLPPSTRGAGGRLLCRT		VATLPPSTRGAGGRLLCRT		VATLPPSTRGAGGRLLCRT
	hamster PCSK9	(447)	VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT
	mouse PCSK9	(444)	VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT
	Consensus	(451)	VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT		VATLPPSTHGTGGQLLCRT

FIG. 1D

Query	1	SIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFFENVPEED	60
		SIPWNL+RI R++EY PP+ G VEVYLLDTS+QS HREIEG+V V DFE+VP+ED	
Sbjct	368	SIPWNLDRIVLAPSRSEEYSPPNKGDQVEVYLLDTSLSQSGHREIEGKVTVADFEDVDPDED	427
Query	61	GTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQKGTVSGTLIGLEFIR	120
		G +FH QASKC+SHGTH+AGV+SGRDAGVA+ A++RS+RVLNCQKGTVSGT GLEFIR	
Sbjct	428	GAQFHSQASKCESHGTHVAGVLSGRDAGVARAAAARSVRVLNCQKGTVSGTARGLEFIR	487
Query	121	KSQLVQPVGPIVVLLPLAGGYSRVLNAAACQRLARAGVVLVTAAGNFRDDACLIYSPASAPE	180
		++QLVQP PL+VLLP AGG+SR LNAAC+ L R+G ++ AAGN+RDDAC YSPAS PE	
Sbjct	488	RTQLVQPYSPLIVLLPFAGGHSRTLNAACRLLVRSGAAVIAAAGNYRDDACSYSPASEPE	547
Query	181	VITVGATNAQDQPVTLGLTGNFGRVCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHV	240
		VITVGATNAQDQP LG LGTNFGRVCVDLFAPGEDIIGASSDC TCF SQSGTSQAAAHV	
Sbjct	548	VITVGATNAQDQPAALGALGTNFGRCVDLFAPGEDIIGASSDCGTCFTSQSGTSQAAAHV	607
Query	241	AGIAAMMLSAEPELTTLAELRQRLIHFSAKDVINEAWFPEDQRVLTLPNLVAALP	293
		AGIA+M+L+AEP LT+ ELRQRLIHFS K+ INEAWFPEDQR+LTPNLVA LP	11
Sbjct	608	AGIASMLLNAEPSLTVPPELRQRLIHFSVKNAINEAWFPEDQRLLTLPNLVARLP	660
			SEQ ID
			NO:

FIG. 1F

Query	1	SIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFFENVPEED	60
		S+PWNL+RI P + A ++ PP+ G VEVYLLDTSIQS+HREIEG+V VTDf+NVPEED	
Sbjct	144	SVPWNLDRIVPAQQMASQSPNTGDSVEVYLLDTSIQSNHREIEGKVFVTDfQNVPEED	203
Query	61	GTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQKGTVSGTLIGLEFIR	120
		GTRFHRQASKC+SHGTH+AGVV+GRDAGVAKG ++RSLRVLNCQKGKGTVSG+L GLEFIR	
Sbjct	204	GTRFHRQASKCESHGTHMAGVVNGRDAGVAKGVNVRSLRVLNCQKGKGTVSGSLTGLEFIR	263
Query	121	KSQLVQPVGPIVVLLPLAGGYSRVLNAAACQRLARAGVVLVTAAGNFRDDACLYSPASAPE	180
		K+ + QP PL+V++P GGYSR+LNAA + L GV+++ AAGN++DDACLYSPAS PE	
Sbjct	264	KTLIEQPNPLIIVIIPFVGGYSRILNAAASRALVNTGVIIIAAGNYKDDACLYSPASEPE	323
Query	181	VITVGATNAQDQPVTLGLTGNFGRVCVDLFAPGEDIIIGASSDCSTCFVSGTSQAAAHV	240
		VIT+GATN QDQP T+G LGTN+G C+DLFAPG+DIIIGASSDCSTCF S+SGTSQAAAHV	
Sbjct	324	VITIGATNYQDQPATMGVLGTNYGNCIDLFPAGDDIIIGASSDCSTCFTSKSGTSQAAAHV	383
Query	241	AGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLT PNLVAALP	293 10
		AGIAAM+L+ +P+L+++ELRQRLI FS K VINE WFPEDQR++TPN VA LP	13
Sbjct	384	AGIAAMILNDKPDLSVSELRQRLIQFSTKKVINEVWFPEDQRLITPNRVAGLP	436 14
			SEQ ID NO:

FIG. 1G

Query	3	PWNLERITPPRYRADEYQPPDGGSLVEVYLDDTSIQSDHREIEGRVMVTD FENVP EEDGT	62
		PW+L R+ PR R P G+ VEVYL+D S+ S HRE+ GRV+VTDF +VP +	
Sbjct	84	PWSLRRRLPRPRGR-----PGDGAAVEVYIMDGSVLSSHRELGGRLVTD FHSVPVGEAG	137
Query	63	RFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQKGT VSGTLIGLEFIRKS	122
		HR+AS+C HGTH+A VV G D GVA GA + +RVL+C+GKGT VSG L G+E+IR +	
Sbjct	138	G-HREASRCKGHGTHVAAVVMGSDTGVPAGARVNLVRVLD CRGKGT VSGALAGVEYIRAA	196
Query	123	QLVPVGPLVVLLPLAGGYSRVLNAAACQRLARAGVVLVTAAGNFRDDACLYSPASAPE--	180
		P G VVLLP G +SR LNAAC+ L G V+V AAGN+RDDACLYSPAS PE	
Sbjct	197	LRAHPPGAAVVLLPFTGAFSRSLNAAACRDLVNTGAVVAAAGNYRDDACLYSPASEPEVC	256
Query	181	-----VITVGATNAQDQPVTLGLTGTNFGRCVDLFA	211
		VITVGA N+ DQ V+ G GTN GRCVD+FA	
Sbjct	257	TGGSARSHTHTHTHTHLLQAVLCVCVQVITVGAVNSADQLVSQGGGTNVGRCVDVFA	316
Query	212	PGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMLSAEPELT LAELRQRLIHFSKDV	271
		PG DI+ ASSDC TCF S SGTSQAAAH AG+AA++LS+ P LT ++ Q L+ +S	
Sbjct	317	PGGDIVSASSDCDTCFASGSGTSQAAAHAAAGMAAVLLSSSPSITPVQVLQTLRLYS----	372
Query	272	INEAWFPEDQRVLT PNLVAALPP 294 17	
		++ + ++TP+LVAALPP 15	
Sbjct	373	VSLPSVSGRRGLVTPSLVAALPP 395 16	
		SEQ ID NO:	

FIG. 1H

[illegible]

FIG. 1J
Sequence of Human and Mouse LDLR

		β-Propeller 2										Section 7
		439	450	C	460	470	480	490	500	511		
(439)	hLDLR P01130	SNRIYWS	DL	SQ	RMIC	STQ	LD	RA	HGV	SS	YD	VI
(438)	hLDLR NP_034830	SNRIYWS	DL	SQ	RMIC	STQ	LD	RA	HGV	SS	YD	VI
(439)	mLDLR NP_034830	SNRIYWS	DL	SQ	RMIC	STQ	LD	RA	HGV	SS	YD	VI
(439)	Consensus	SNRIYWS	DL	SQ	RMIC	STQ	LD	RA	HGV	SS	YD	VI
		β-Propeller 3										Section 8
		512	520	530	540	550	560	570	584			
(512)	hLDLR P01130	LFRENG	SK	PR	AI	VV	DP	VH	GF	MY	WT	DW
(511)	hLDLR NP_034830	LFRENG	SK	PR	AI	VV	DP	VH	GF	MY	WT	DW
(511)	mLDLR NP_034830	LFRENG	SK	PR	AI	VV	DP	VH	GF	MY	WT	DW
(512)	Consensus	LFRENG	SK	PR	AI	VV	DP	VH	GF	MY	WT	DW
		β-Propeller 4										Section 9
		585	590	600	610	620	630	640	657			
(585)	hLDLR P01130	SISSID	VN	GG	NR	KRT	ILE	DE	KE	RL	AH	PF
(584)	hLDLR NP_034830	SISSID	VN	GG	NR	KRT	ILE	DE	KE	RL	AH	PF
(584)	mLDLR NP_034830	SISSID	VN	GG	NR	KRT	ILE	DE	KE	RL	AH	PF
(585)	Consensus	SISSID	VN	GG	NR	KRT	ILE	DE	KE	RL	AH	PF
		β-Propeller 5										Section 10
		658	670	C	680	C	690	EGF-like C	700	C	710	C
(658)	hLDLR P01130	NI	LT	QPR	GV	NW	CERT	TL	S	NGG	CQ	YL
(657)	hLDLR NP_034830	NI	LT	QPR	GV	NW	CERT	TL	S	NGG	CQ	YL
(657)	mLDLR NP_034830	NI	LT	QPR	GV	NW	CERT	TL	S	NGG	CQ	YL
(658)	Consensus	NI	LT	QPR	GV	NW	CERT	TL	S	NGG	CQ	YL
		β-Propeller 6										Section 11
		731	740	750	760	770	780	790	803			
(731)	hLDLR P01130	LK	V	S	S	T	A	V	R	-	T	Q
(729)	hLDLR NP_034830	LK	V	S	S	T	A	V	R	-	T	Q
(730)	mLDLR NP_034830	LK	V	S	S	T	A	V	R	-	T	Q
(731)	Consensus	LK	V	S	S	T	A	V	R	-	T	Q
		O-glycosylation										Section 12
		804	810	820	830	840	850	865	SEQ ID NO:			
(804)	hLDLR P01130	FL	CL	G	V	F	L	L	W	R	L	K
(801)	hLDLR NP_034830	FL	CL	G	V	F	L	W	R	L	K	N
(803)	mLDLR NP_034830	FL	CL	G	V	F	L	W	R	L	K	N
(804)	Consensus	FL	CL	G	V	F	L	W	R	L	K	N

FIG. 1K Sequence of Human and Cyno LDLR

										Section 1																																																													
(1)	1	10	20	30	40	50	60	72																																																															
hLDLR 20080009918 (1) cynLDLR 20080068365 (1) Consensus (1)	M	G	P	W	G	K	L	R	W	T	V	A	L	L	L	A	A	A	G	T	A	V	G	D	R	C	E	R	N	E	F	Q	C	D	G	K	C	I	S	Y	K	W	V	C	D	G	S	A	E	C	Q	D	G	S	D	E	S	Q	E	T	C	L	S	V	T	C	K	S	G		
	M	E	P	W	G	K	L	R	W	T	V	A	F	L	L	A	A	A	E	A	A	V	G	D	R	C	E	R	N	E	F	Q	C	E	D	G	K	C	I	S	Y	K	W	V	C	D	G	S	A	E	C	Q	D	G	S	D	E	S	Q	E	T	C	L	S	V	T	C	K	S	G	
	M	P	W	G	K	L	R	W	T	V	A	L	L	A	A	A	A	V	G	D	R	C	E	R	N	E	F	Q	C	D	G	K	C	I	S	Y	K	W	V	C	D	G	S	A	E	C	Q	D	G	S	D	E	S	Q	E	T	C	L	S	V	T	C	K	S	G						
	F	S	C	G	G	R	V	N	R	C	I	P	Q	F	W	R	C	D	G	V	D	C	E	N	G	S	D	E	Q	G	C	P	P	K	T	C	S	Q	D	E	F	R	C	H	D	G	K	C	I	S	R	Q	F	V	C	D	S	D	R	D	C	L	D	G	S	D	E	A	S	C	P
hLDLR 20080009918 (73) cynLDLR 20080068365 (73) Consensus (73)	F	S	C	G	G	R	V	N	R	C	I	P	Q	F	W	R	C	D	G	V	D	C	E	N	G	S	D	E	Q	G	C	P	P	K	T	C	S	Q	D	E	F	R	C	H	D	G	K	C	I	S	R	Q	F	V	C	D	S	D	R	D	C	L	D	G	S	D	E	A	S	C	P
	F	S	C	G	G	R	V	N	R	C	I	P	Q	F	W	R	C	D	G	V	D	C	E	N	G	S	D	E	Q	G	C	P	P	K	T	C	S	Q	D	E	F	R	C	H	D	G	K	C	I	S	R	Q	F	V	C	D	S	D	R	D	C	L	D	G	S	D	E	A	S	C	P
	F	S	C	G	G	R	V	N	R	C	I	P	Q	F	W	R	C	D	G	V	D	C	E	N	G	S	D	E	Q	C	P	P	K	T	C	S	Q	D	E	F	R	C	H	D	G	K	C	I	S	R	Q	F	V	C	D	S	D	R	D	C	L	D	G	S	D	E	A	S	C	P	
	F	S	C	G	G	R	V	N	R	C	I	P	Q	F	W	R	C	D	G	V	D	C	E	N	G	S	D	E	Q	C	P	P	K	T	C	S	Q	D	E	F	R	C	H	D	G	K	C	I	S	R	Q	F	V	C	D	S	D	R	D	C	L	D	G	S	D	E	A	S	C	P	
hLDLR 20080009918 (145) cynLDLR 20080068365 (145) Consensus (145)	V	L	T	C	G	P	A	S	F	Q	C	N	S	S	T	C	I	P	Q	L	W	A	C	N	D	P	D	C	E	D	G	S	D	E	W	P	Q	R	C	R	G	L	Y	V	F	Q	G	D	S	S	P	C	S	A	F	E	F	H	C	L	S	G	E	C	I	H	S	W	R		
	V	L	T	C	G	P	A	S	F	Q	C	N	S	S	T	C	I	P	Q	L	W	A	C	N	D	P	D	C	E	D	G	S	D	E	W	P	Q	H	C	Q	G	L	E	V	P	K	R	D	S	S	P	C	S	A	F	E	F	H	C	Q	S	G	E	C	I	H	S	G	W	R	
	V	L	T	C	G	P	A	S	F	Q	C	N	S	S	T	C	I	P	Q	L	W	A	C	N	D	P	D	C	E	D	G	S	D	E	W	P	Q	C	G	L	V	D	S	S	P	C	S	A	F	E	F	H	C	Q	S	G	E	C	I	H	S	G	W	R							
	V	L	T	C	G	P	A	S	F	Q	C	N	S	S	T	C	I	P	Q	L	W	A	C	N	D	P	D	C	E	D	G	S	D	E	W	P	Q	C	G	L	V	D	S	S	P	C	S	A	F	E	F	H	C	Q	S	G	E	C	I	H	S	W	R								
hLDLR 20080009918 (217) cynLDLR 20080068365 (217) Consensus (217)	D	G	G	P	D	C	K	D	K	S	D	E	E	N	C	A	V	A	T	C	R	P	D	E	F	Q	C	S	D	G	N	C	I	H	G	S	R	Q	C	D	R	E	Y	D	C	K	D	M	S	D	E	V	G	C	I	N	V	T	L	C	E	G	P	N	K	F	K	C	H	S	G
	D	G	G	P	D	C	K	D	K	S	D	E	E	N	C	P	V	A	T	C	R	P	D	E	F	Q	C	S	D	G	T	C	I	H	G	S	R	Q	C	D	R	E	Y	D	C	K	D	M	S	D	E	V	G	C	I	N	V	T	L	C	E	G	P	N	K	F	K	C	H	S	G
	D	G	G	P	D	C	K	D	K	S	D	E	E	N	C	V	A	T	C	R	P	D	E	F	Q	C	S	D	G	C	I	H	G	S	R	Q	C	D	R	E	Y	D	C	K	D	M	S	D	E	V	G	C	I	N	V	T	L	C	E	G	P	N	K	F	K	C	H	S	G		
	D	G	G	P	D	C	K	D	K	S	D	E	E	N	C	V	A	T	C	R	P	D	E	F	Q	C	S	D	G	C	I	H	G	S	R	Q	C	D	R	E	Y	D	C	K	D	M	S	D	E	V	G	C	I	N	V	T	L	C	E	G	P	N	K	F	K	C	H	S	G		
hLDLR 20080009918 (289) cynLDLR 20080068365 (289) Consensus (289)	C	I	S	L	D	K	V	C	N	M	A	R	D	C	R	D	W	S	D	E	P	I	K	E	C	G	T	N	E	C	L	D	N	N	G	G	C	S	H	I	C	N	D	L	K	I	G	Y	E	C	L	C	P	D	G	F	Q	L	V	A	Q	R	R	C	E	D	I	D	E	C	Q
	C	I	S	L	D	K	V	C	N	M	A	R	D	C	R	D	W	S	D	E	P	I	K	E	C	G	T	N	E	C	L	D	N	N	G	G	C	S	H	I	C	N	D	L	K	I	G	Y	E	C	L	C	P	D	G	F	Q	L	V	A	Q	R	R	C	E	D	I	D	E	C	Q
	C	I	S	L	D	K	V	C	N	M	A	R	D	C	R	D	W	S	D	E	P	I	K	E	C	G	T	N	E	C	L	D	N	N	G	G	C	S	H	I	C	N	D	L	K	I	G	Y	E	C	L	C	P	D	G	F	Q	L	V	A	Q	R	R	C	E	D	I	D	E	C	Q
	C	I	S	L	D	K	V	C	N	M	A	R	D	C	R	D	W	S	D	E	P	I	K	E	C	G	T	N	E	C	L	D	N	N	G	G	C	S	H	I	C	N	D	L	K	I	G	Y	E	C	L	C	P	D	G	F	Q	L	V	A	Q	R	R	C	E	D	I	D	E	C	Q
hLDLR 20080009918 (361) cynLDLR 20080068365 (361) Consensus (361)	P	D	T	C	S	Q	L	C	V	N	L	E	G	G	Y	K	C	Q	C	E	E	G	F	Q	L	D	P	H	T	K	A	C	A	V	G	S	I	A	Y	L	F	F	T	N	R	H	E	V	R	K	M	T	L	D	R	S	E	Y	T	S	L	I	P	N	L	R	N	V	V	A	
	P	D	T	C	S	Q	L	C	V	N	L	E	G	G	Y	K	C	Q	C	E	E	G	F	Q	L	D	P	H	T	K	A	C	A	V	G	S	I	A	Y	L	F	F	T	N	R	H	E	V	R	K	M	T	L	D	R	S	E	Y	T	S	L	I	P	N	L	R	N	V	V	A	
	P	D	T	C	S	Q	L	C	V	N	L	E	G	G	Y	K	C	Q	C	E	E	G	F	Q	L	D	P	H	T	K	A	C	A	V	G	S	I	A	Y	L	F	T	N	R	H	E	V	R	K	M	T	L	D	R	S	E	Y	T	S	L	I	P	N	L	R	N	V	V	A		
	P	D	T	C	S	Q	L	C	V	N	L	E	G	G	Y	K	C	Q	C	E	E	G	F	Q	L	D	P	H	T	K	A	C	A	V	G	S	I	A	Y	L	F	T	N	R	H	E	V	R	K	M	T	L	D	R	S	E	Y	T	S	L	I	P	N	L	R	N	V	V	A		

FIG. 1L Sequence of Human and Cyno LDLR

		Section 7																																																																																																																																																																																																																																																																																																																																																						
(433)	433	440	450	460	470	480	490	504																																																																																																																																																																																																																																																																																																																																																
hDLR 20080009918	(433)	DTEVASNRIYWSDL																			SQRMICSTQLDRAHGVSSYD																	TVISRDIQAPDGLAVDWIHSNIYWT																	SVLGT																	VSVADTK																																																																																																																																																																																																																																																																																
cynDLR 20080068365	(433)	DTEVASNRIYWSDL																			SQRMISTQLDRAHGVSSYD																			TVISRDIQAPDGLAVDWIHSNIYWT																	SVLGT																	VSVADTK																																																																																																																																																																																																																																																																														
Consensus		(433)	DTEVASNRIYWSDL																			SQRMISTQLDRAH																			VSSYD																	TVISRDIQAPDGLAVDWIHSNIYWT																	SVLGT																	VSVADTK																																																																																																																																																																																																																																																												
		Section 8																																																																																																																																																																																																																																																																																																																																																						
(505)	505	510	520	530	540	550	560	576																																																																																																																																																																																																																																																																																																																																																
hDLR 20080009918	(505)	GVKRKTLFRENGSKPRA																			IVVDPVHGFMYWTDWG																			TPAKIKKGGKGLNG																			VDIYSLVTENIQWPNGIT																			LDLLS																			GRLY																																																																																																																																																																																																																																																							
cynDLR 20080068365	(505)	GVKRKTLFRENGSKPRA																			IVVDPVHGFMYWTDWG																			TPAKIKKGGKGLNG																			VDIYSLVTENIEWPNGIT																			LDFP																			SRLY																																																																																																																																																																																																																																																							
Consensus		(505)	GVKRKTLFRENGSKPRA																			IVVDPVHGFMYWTDWG																			TPAKIKKGGKGLNG																			VDIYSLVTENI																			WPNGIT																			LTD																			SRLY																																																																																																																																																																																																																																			
		Section 9																																																																																																																																																																																																																																																																																																																																																						
(577)	577	590	600	610	620	630	648																																																																																																																																																																																																																																																																																																																																																	
hDLR 20080009918	(577)	WVDSKLHSISSIDVNGGNRKT																			LEDEKRLAHPFSLA																			FEDKVF																			WTDIINEAIF																			SANRLTGSD																			VNL																			LAENLLS																																																																																																																																																																																																																																				
cynDLR 20080068365	(577)	WVDSKLHSISSIDVNGGNRKT																			LEDEERLAHPFSLA																			FEDKVF																			WTDIINEAIF																			SANRLTGSD																			IN																			LLAENLLS																																																																																																																																																																																																																																				
Consensus		(577)	WVDSKLHSISSIDVNGGNRKT																			LEAHPFSLA																			FEDKVF																			WTDIINEAIF																			SANRLTGSD																			IN																			LLAENLLS																																																																																																																																																																																																																																			
		Section 10																																																																																																																																																																																																																																																																																																																																																						
(649)	649	660	670	680	690	700	710	720																																																																																																																																																																																																																																																																																																																																																
hDLR 20080009918	(649)	PEDMVLFHNL																			TQPRGVNWCERT																			TSLNGGCQYLC																			LPAPQIN																			PHSPKFT																			CACPDG																			MLLAK																			DMRSC																			LTEA																			EAAVA																																																																																																																																																																											
cynDLR 20080068365	(649)	PEDMVLFHNL																			TQPRGVNWCERT																			TSLNGGCQYLC																			LPAPQIN																			PQSPKFT																			CTCPD																			GMLLAK																			DMRSC																			LTEA																			EAAVA																																																																																																																																																																											
Consensus		(649)	PEDMVLFHNL																			TQPRGVNWCERT																			TSLNGGCQYLC																			LPAPQIN																			SPKFT																			C																			PDG																			MLLAK																			DMRSC																			LTEA																			EAAVA																																																																																																																																																							
		Section 11																																																																																																																																																																																																																																																																																																																																																						
(721)	721	730	740	750	760	770	780	792																																																																																																																																																																																																																																																																																																																																																
hDLR 20080009918	(721)	TQETSTVRLKVS																			TAVRTQHTTTR																			PVPDTS																			RLPGAT																			PGLTTVE																			IVTMSH																			QALGDV																			AGR																			NEKK																			PSSV																			RALSI																																																																																																																																																								
cynDLR 20080068365	(721)	TQETSTVRLMV																			SSKAVATQHTTTR																			PVPNTS																			QLPGAT																			PGLTTAET																			VTMSH																			QALGDV																			AGR																			NEKK																			PKSV																			GALS																																																																																																																																																								
Consensus		(721)	TQETSTVRL																			VSS																			AV																			TQHTTTR																			PVP																			TS																			LPGAT																			PGLTT																			E																			VTMSH																			QALGDV																			AGR																			NEKK																			P																			SV																			ALSI																																																								
		Section 12																																																																																																																																																																																																																																																																																																																																																						
(793)	793	800	810	820	830	840	850	860	SEQ ID NO:																																																																																																																																																																																																																																																																																																																																															
hDLR 20080009918	(793)	VLPIVLLVFL																			CLGVFL																			LWKNWRLK																			NINS																			INF																			DNPVYQ																			KTTE																			DEVH																			ICH																			NQD																			GYS																			PSR																			QMV																			SLED																			DVA																			18																																																									
cynDLR 20080068365	(793)	VLPTVLLVFL																			CLGAF																			LLWKNWRLK																			SINS																			INF																			DNPVYQ																			KTTE																			DEVH																			ICR																			NQD																			GYS																			PSR																			QMV																			SLED																			DVA																			19																																																									
Consensus		(793)	VLP																			VLLVFL																			CLG																			FL																			LWKNWRLK																			INS																			INF																			DNPVYQ																			KTTE																			DEVH																			IC																			NQD																			GYS																			PSR																			QMV																			SLED																			DVA																			22																		

16 / 38

Cavia porcellus PCSK9

Met	Arg	Thr	Arg	Gly	Pro	Ala	Pro	Ala	Trp	Trp	Pro	Met	Leu	Leu	Leu
1				5					10				15		
Leu	Met	Leu	Gly	Pro	Ala	Pro	Ala	Gly	Ala	Gln	Ala	Arg	Asp	Ser	Glu
			20					25				30			
Asp	Gly	Asp	His	Glu	Gly	Leu	Ala	Phe	Ala	Phe	Pro	Pro	Glu	Glu	Asp
		35					40				45				
Gly	Pro	Ala	Glu	Ala	Ala	Pro	His	Val	Pro	Thr	Ala	Pro	Phe	His	Arg
	50					55					60				
Cys	Ser	Lys	Asp	Ala	Trp	Arg	Leu	Pro	Gly	Thr	Tyr	Leu	Val	Val	Leu
65					70					75					80
Lys	Glu	Gly	Thr	His	Arg	Gly	Gln	Thr	Lys	His	Thr	Ala	His	Arg	Leu
			85						90					95	
Gln	Ala	Lys	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Thr	Thr	Val	Leu	His	Leu
			100					105					110		
Phe	His	His	Leu	Val	Pro	Gly	Phe	Leu	Val	Arg	Met	Ser	Gly	Asp	Leu
		115					120					125			
Leu	Asp	Met	Ala	Leu	Arg	Leu	Pro	Leu	Val	Gln	Tyr	Ile	Glu	Glu	Asp
	130					135					140				
Ser	Ser	Val	Phe	Ala	Gln	Ser	Val	Pro	Trp	Asn	Leu	Glu	Arg	Ile	Leu
145					150					155					160
Pro	Val	Arg	His	Gln	Ala	Lys	Glu	Tyr	Ser	Ala	Pro	Ser	His	Pro	Val
			165						170					175	
Thr	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Gly	His	Arg	Glu	Ile
			180					185					190		
Gln	Gly	Arg	Ile	Thr	Val	Thr	Asp	Phe	Glu	Ser	Val	Pro	Gln	Glu	Asp
		195					200					205			
Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr
	210					215					220				
His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly
225					230					235					240
Ala	Gly	Leu	Arg	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly	Arg	Gly	Thr
			245						250					255	
Val	Ser	Ser	Thr	Leu	Arg	Gly	Leu	Glu	Phe	Ile	Arg	Lys	Ser	Gln	Leu
			260					265					270		
Ala	Gln	Pro	Val	Glu	Pro	Leu	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Gly
		275					280					285			
Tyr	Ser	Arg	Thr	Leu	Asn	Ala	Ala	Cys	His	Leu	Leu	Ala	Arg	Ala	Gly
	290					295					300				
Val	Val	Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu
305					310					315					320
Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asn
			325						330					335	
Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly
			340					345					350		
Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Glu	Asp	Ile	Ile	Gly	Ala	Ser
		355					360					365			
Ser	Asp	Cys	Ser	Thr	Cys	Phe	Val	Ser	Arg	Ser	Gly	Thr	Ser	Gln	Ala
	370					375					380				

FIG 1M₁

SUBSTITUTE SHEET (RULE 26)

17 / 38

Ala	Ala	His	Val	Ala	Gly	Ile	Val	Thr	Met	Met	Leu	Thr	Ala	Gln	Pro
385					390					395					400
Lys	Leu	Thr	Leu	Ala	Glu	Leu	Trp	Gln	Arg	Leu	Ile	His	Phe	Ala	Ala
				405					410					415	
Lys	Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu
			420					425					430		
Thr	Pro	Asn	Leu	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	Arg	Gly	Ala	Gly
		435					440					445			
Gly	Arg	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	Arg	Ser	Gly	Pro	Arg
	450					455					460				
His	Thr	Ala	Thr	Ala	Leu	Ala	His	Cys	Thr	Pro	Gly	Glu	Glu	Leu	Leu
465					470					475					480
Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Lys	Gly	Glu	Arg	Ile
				485					490					495	
Glu	Val	Leu	Arg	Gly	Arg	Arg	Val	Cys	Val	Ala	Tyr	Asn	Ala	Phe	Gly
			500					505					510		
Gly	Lys	Gly	Val	His	Ala	Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala
		515					520					525			
Asn	Cys	Ser	Leu	His	Thr	Ala	Pro	Ala	Arg	Ala	Gly	Met	Glu	Pro	Arg
	530					535					540				
Val	His	Cys	His	Arg	Lys	Asp	Gln	Val	Leu	Thr	Gly	Cys	Ser	Ala	His
545					550					555					560
Trp	Glu	Ala	Glu	Asp	Phe	Arg	Ala	Arg	Gly	Trp	Pro	Met	Leu	Arg	Pro
				565					570					575	
Gly	Gly	Pro	Ser	Gln	Cys	Val	Gly	His	Ser	Lys	Ala	Ser	Val	His	Ala
			580					585					590		
Ser	Cys	Cys	Ser	Ala	Pro	Gly	Leu	Glu	Cys	Arg	Ile	Arg	Glu	His	Gly
		595				600						605			
Val	Pro	Trp	Pro	Ala	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Asp	Gly	Trp
	610					615					620				
Thr	Leu	Thr	Gly	Cys	Ser	Thr	Leu	Pro	Gly	Ala	Ser	Ser	Val	Leu	Gly
625					630					635					640
Thr	Tyr	Ala	Val	Asp	Asp	Met	Cys	Val	Val	Arg	Ser	Arg	Asp	Val	Lys
				645					650					655	
Ala	Leu	Asp	Arg	Thr	Arg	Gly	Glu	Ala	Leu	Ala	Ala	Ile	Ala	Ile	Cys
			660					665					670		
Cys	Arg	Ser	Gln	Ala	Ser	Glu	Gln	Ala	Ser	Pro	Glu	Arg	Gln		
		675					680					685			

SEQ ID NO: 25

FIG 1M₂

SUBSTITUTE SHEET (RULE 26)

18 / 38

Mesocricetus auratus PCSK9

Met	Gly	Thr	Ser	Cys	Ser	Ala	Arg	Pro	Arg	Trp	Leu	Leu	Ser	Pro	Leu
1				5					10					15	
Leu	Leu	Leu	Leu	Leu	Leu	Leu	Arg	Tyr	Met	Gly	Ala	Ser	Ala	Gln	Asp
			20					25					30		
Glu	Asp	Ala	Glu	Tyr	Glu	Glu	Leu	Met	Leu	Thr	Leu	Gln	Ser	Gln	Asp
		35					40					45			
Asp	Gly	Leu	Ala	Asp	Glu	Thr	Asp	Glu	Ala	Pro	Gln	Gly	Ala	Thr	Ala
	50					55					60				
Ala	Phe	His	Arg	Cys	Pro	Glu	Glu	Ala	Trp	Arg	Val	Pro	Gly	Thr	Tyr
65				70					75						80
Ile	Val	Met	Leu	Ala	Glu	Glu	Ala	Gln	Trp	Val	His	Ile	Glu	Gln	Thr
				85					90					95	
Met	His	Arg	Leu	Gln	Thr	Gln	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile	Lys
			100					105					110		
Ile	Gln	His	Ile	Phe	Tyr	Asp	Phe	Leu	Pro	Ala	Phe	Val	Val	Lys	Met
		115					120					125			
Ser	Ser	Asp	Leu	Leu	Asp	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Lys	Tyr
	130					135					140				
Ile	Glu	Glu	Asp	Ser	Leu	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Leu
145					150					155					160
Asp	Arg	Ile	Ile	Pro	Ala	Gly	Arg	Gln	Ala	Gln	Glu	Tyr	Ser	Ser	Ser
				165					170					175	
Arg	Lys	Val	Pro	Ser	Gly	Ser	Gly	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp
			180					185					190		
Thr	Ser	Ile	Gln	Ser	Asp	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Val
		195					200					205			
Thr	Asp	Phe	Asn	Ser	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg
	210					215					220				
Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr	His	Leu	Ala	Gly	Val	Val
225					230					235					240
Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly	Thr	Ile	Leu	His	Gly	Leu
				245					250					255	
Arg	Val	Leu	Asn	Cys	Gln	Gly	Lys	Gly	Ile	Val	Ser	Gly	Ile	Leu	Thr
			260					265					270		
Gly	Leu	Glu	Phe	Ile	Trp	Lys	Ser	Gln	Leu	Met	Gln	Pro	Ser	Gly	Pro
		275					280					285			
Gln	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Arg	Tyr	Ser	Arg	Val	Leu	Asn
	290					295					300				
Thr	Ala	Cys	Gln	His	Leu	Ala	Arg	Thr	Gly	Val	Val	Leu	Val	Ala	Ala
305					310					315					320
Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala
				325					330					335	
Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asp	Val	Gln	Asp	Gln	Pro	Val
			340					345					350		
Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe
		355					360					365			
Ala	Pro	Gly	Lys	Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Ala	Cys
	370					375					380				
Phe	Met	Ser	Gln	Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly
385					390					395					400

FIG 1N₁

SUBSTITUTE SHEET (RULE 26)

19 / 38

Ile	Val	Ala	Met	Met	Leu	Thr	Leu	Glu	Pro	Glu	Leu	Thr	Leu	Thr	Glu
				405					410					415	
Leu	Arg	Gln	Arg	Leu	Ile	His	Phe	Ser	Thr	Lys	Asp	Ala	Ile	Asn	Met
			420					425					430		
Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr	Pro	Asn	Leu	Val	Ala
		435					440					445			
Thr	Leu	Pro	Pro	Ser	Thr	His	Gly	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg
	450					455					460				
Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg	Ala	Ala	Thr	Ala	Thr
465					470					475					480
Ala	Arg	Cys	Ala	Pro	Gly	Glu	Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser
				485					490					495	
Arg	Ser	Gly	Arg	Arg	Arg	Gly	Asp	Arg	Ile	Glu	Ala	Ala	Gly	Thr	Gln
			500					505					510		
Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala
		515					520					525			
Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala	Asn	Cys	Ser	Ile	His	Thr
	530					535					540				
Thr	Pro	Ala	Ala	Arg	Thr	Ser	Leu	Glu	Thr	His	Ala	His	Cys	His	Gln
545					550					555					560
Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Leu	His	Trp	Glu	Val	Glu	Gly
				565					570					575	
Ile	Gly	Val	Gln	Pro	Leu	Ala	Val	Leu	Arg	Ser	Arg	His	Gln	Pro	Gly
			580					585					590		
Gln	Cys	Thr	Gly	His	Arg	Glu	Ala	Ser	Val	His	Ala	Ser	Cys	Cys	His
		595					600					605			
Ala	Pro	Gly	Leu	Glu	Cys	Lys	Ile	Lys	Glu	His	Gly	Ile	Ser	Gly	Pro
	610					615					620				
Ala	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Ala	Gly	Trp	Thr	Leu	Thr	Gly
625					630					635					640
Cys	Asn	Val	Leu	Pro	Gly	Ala	Phe	Ile	Thr	Leu	Gly	Ala	Tyr	Ala	Val
				645					650					655	
Asp	Asn	Thr	Cys	Val	Ala	Arg	Ser	Arg	Val	Thr	Asp	Thr	Ala	Gly	Arg
			660					665					670		
Thr	Gly	Glu	Glu	Ala	Thr	Val	Ala	Ala	Ala	Ile	Cys	Cys	Arg	Asn	Arg
		675					680					685			
Pro	Ser	Ala	Lys	Ala	Ser	Trp	Val	His	Gln						
	690					695									

SEQ ID NO: 26

FIG 1N₂

SUBSTITUTE SHEET (RULE 26)

20 / 38

Mus musculus PCSK9

Met	Gly	Thr	His	Cys	Ser	Ala	Trp	Leu	Arg	Trp	Pro	Leu	Leu	Pro	Leu
1				5				10					15		
Leu	Pro	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Cys	Pro	Thr	Gly	Ala	
			20					25				30			
Gly	Ala	Gln	Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Leu	Ala	Leu
		35					40				45				
Pro	Ser	Gln	Glu	Asp	Gly	Leu	Ala	Asp	Glu	Ala	Ala	His	Val	Ala	Thr
	50					55				60					
Ala	Thr	Phe	Arg	Arg	Cys	Ser	Lys	Glu	Ala	Trp	Arg	Leu	Pro	Gly	Thr
65					70				75					80	
Tyr	Ile	Val	Val	Leu	Met	Glu	Glu	Thr	Gln	Arg	Leu	Gln	Ile	Glu	Gln
				85					90				95		
Thr	Ala	His	Arg	Leu	Gln	Thr	Arg	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile
			100					105					110		
Lys	Val	Leu	His	Ile	Phe	Tyr	Asp	Leu	Phe	Pro	Gly	Phe	Leu	Val	Lys
		115					120				125				
Met	Ser	Ser	Asp	Leu	Leu	Gly	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Glu
	130					135					140				
Tyr	Ile	Glu	Glu	Asp	Ser	Phe	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn
145					150				155						160
Leu	Arg	Ile	Ile	Pro	Ala	Trp	His	Gln	Thr	Glu	Glu	Asp	Arg	Ser	Pro
				165					170					175	
Asp	Gly	Ser	Ser	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln
			180					185					190		
Gly	Ala	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Ile	Thr	Asp	Phe	Asn
		195					200				205				
Ser	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys
	210					215					220				
Cys	Asp	Ser	His	Gly	Thr	His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp
225					230				235						240
Ala	Gly	Val	Ala	Lys	Gly	Thr	Ser	Leu	His	Ser	Leu	Arg	Val	Leu	Asn
				245					250					255	
Cys	Gln	Gly	Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe
			260					265					270		
Ile	Arg	Lys	Ser	Gln	Leu	Ile	Gln	Pro	Ser	Pro	Leu	Val	Val	Leu	Pro
		275					280					285			
Leu	Ala	Gly	Gly	Tyr	Ser	Arg	Ile	Leu	Asn	Ala	Ala	Cys	Arg	His	Leu
	290					295					300				
Ala	Arg	Thr	Gly	Val	Val	Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp
305					310				315						320
Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val
				325					330					335	
Gly	Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly
			340					345					350		
Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile
		355					360					365			
Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Phe	Met	Ser	Gln	Ser	Gly
	370					375					380				
Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Val	Ala	Arg	Met	Leu
385					390					395					400

FIG 10₁

SUBSTITUTE SHEET (RULE 26)

21 / 38

Ser	Arg	Glu	Pro	Thr	Leu	Thr	Leu	Ala	Leu	Arg	Gln	Arg	Ile	His	Phe
				405					410					415	
Ser	Thr	Lys	Asp	Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Gln
			420					425					430		
Val	Leu	Thr	Pro	Asn	Leu	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	His	Glu
			435				440					445			
Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly
	450					455					460				
Pro	Thr	Arg	Thr	Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Glu	Glu	Glu
465					470					475					480
Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Arg	Arg	Arg	Gly	Asp
				485					490					495	
Arg	Ile	Glu	Ala	Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala
			500					505						510	
Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Val	Pro
		515					520					525			
His	Ala	Asn	Cys	Ser	Ile	His	Asn	Pro	Ala	Ala	Ala	Gly	Leu	Glu	Thr
	530					535					540				
His	Val	His	Cys	His	Gln	Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Phe
545					550					555					560
His	Trp	Glu	Val	Glu	Asp	Leu	Ser	Val	Arg	Arg	Gln	Pro	Ala	Leu	Arg
				565					570					575	
Ser	Arg	Arg	Gln	Pro	Gly	Gln	Cys	Val	Gly	His	Gln	Ala	Ala	Ser	Val
			580					585					590		
Tyr	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Ile	Lys	Glu
		595					600					605			
His	Gly	Ile	Ser	Gly	Ser	Ser	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Ala
	610					615					620				
Gly	Trp	Thr	Leu	Thr	Gly	Cys	Asn	Val	Leu	Pro	Gly	Ala	Ser	Leu	Thr
625					630					635					640
Leu	Gly	Ala	Tyr	Ser	Val	Asp	Asn	Leu	Cys	Val	Ala	Arg	Val	His	Asp
				645					650					655	
Thr	Ala	Arg	Ala	Asp	Arg	Thr	Gly	Glu	Thr	Val	Ala	Ala	Ala	Ile	Cys
			660					665					670		
Cys	Arg	Ser	Arg	Pro	Ser	Ala	Lys	Ala	Ser	Trp	Val	Gln			
		675					680					685			

SEQ ID NO: 27

FIG 10₂

SUBSTITUTE SHEET (RULE 26)

22 / 38

Macaca fascicularis PCSK9

Met 1	Gly	Thr	Val	Ser 5	Ser	Arg	Arg	Ser	Trp 10	Trp	Pro	Leu	Pro	Leu	Pro
Leu	Leu	Leu	Leu 20	Leu	Leu	Leu	Gly	Pro 25	Ala	Gly	Ala	Arg	Ala 30	Gln	Glu
Asp	Glu	Asp 35	Gly	Asp	Tyr	Glu	Glu 40	Leu	Val	Leu	Ala	Leu 45	Arg	Ser	Glu
Glu	Asp 50	Gly	Leu	Ala	Asp	Ala 55	Pro	Glu	His	Gly	Ala 60	Thr	Ala	Thr	Phe
His 65	Arg	Cys	Ala	Lys	Asp 70	Pro	Trp	Arg	Leu	Pro 75	Gly	Thr	Tyr	Val	Val 80
Val	Leu	Lys	Glu	Glu 85	Thr	His	Arg	Ser	Gln 90	Ser	Glu	Arg	Thr	Ala	Arg
Arg	Leu	Gln	Ala 100	Gln	Ala	Ala	Arg	Arg 105	Gly	Tyr	Leu	Thr	Lys 110	Ile	Leu
His	Val	Phe 115	His	His	Leu	Leu	Pro	Gly 120	Phe	Leu	Val	Lys 125	Met	Ser	Gly
Asp	Leu 130	Leu	Glu	Leu	Ala	Leu 135	Lys	Leu	Pro	His	Val 140	Asp	Tyr	Ile	Glu
Glu 145	Asp	Ser	Ser	Val	Phe 150	Ala	Gln	Ser	Ile	Pro 155	Trp	Asn	Glu	Arg	Ile 160
Thr	Pro	Ala	Arg	Tyr 165	Arg	Ala	Asp	Glu	Tyr 170	Gln	Pro	Pro	Lys	Gly 175	Gly
Ser	Leu	Val	Glu 180	Val	Tyr	Leu	Leu	Asp 185	Thr	Ser	Ile	Gln	Ser 190	Asp	His
Arg	Glu	Ile 195	Glu	Gly	Arg	Val	Met 200	Val	Thr	Asp	Phe	Glu 205	Ser	Val	Pro
Glu	Glu 210	Asp	Gly	Thr	Arg	Phe 215	His	Arg	Gln	Ala	Ser 220	Lys	Cys	Asp	Ser
His 225	Gly	Thr	His	Leu	Ala 230	Gly	Val	Val	Ser	Gly 235	Arg	Asp	Ala	Gly	Val 240
Ala	Lys	Gly	Ala	Gly 245	Leu	Arg	Ser	Leu	Arg 250	Val	Leu	Asn	Cys 255	Gln	Gly
Lys	Gly	Thr 260	Val	Ser	Gly	Thr	Leu 265	Ile	Gly	Leu	Glu	Phe 270	Ile	Arg	Lys
Ser	Gln	Leu 275	Val	Gln	Pro	Val	Pro 280	Leu	Val	Val	Leu	Pro 285	Leu	Ala	Gly
Gly	Tyr 290	Ser	Arg	Val	Phe	Asn 295	Ala	Ala	Cys	Gln	Arg 300	Leu	Ala	Arg	Ala
Gly 305	Val	Val	Leu	Val	Thr 310	Ala	Ala	Gly	Asn	Phe 315	Arg	Asp	Asp	Ala	Cys 320
Leu	Tyr	Ser	Pro	Ala 325	Ser	Ala	Pro	Glu	Val 330	Ile	Thr	Val	Gly	Ala 335	Thr
Asn	Ala	Gln 340	Asp	Gln	Pro	Val	Thr 345	Leu	Gly	Thr	Leu	Gly	Thr 350	Asn	Phe
Gly	Arg	Cys 355	Val	Asp	Leu	Phe	Ala 360	Pro	Gly	Glu	Asp	Ile 365	Ile	Gly	Ala
Ser	Ser 370	Asp	Cys	Ser	Thr	Cys 375	Phe	Val	Ser	Arg	Ser 380	Gly	Thr	Ser	Gln
Ala 385	Ala	Ala	His	Val	Ala 390	Gly	Ile	Ala	Ala	Met 395	Met	Leu	Ser	Ala	Glu 400

FIG 1P₁

SUBSTITUTE SHEET (RULE 26)

23 / 38

Pro	Glu	Leu	Thr	Leu	Ala	Leu	Arg	Gln	Leu	Ile	His	Phe	Ser	Ala	Lys
				405					410					415	
Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr
			420					425					430		
Pro	Asn	Leu	Val	Ala	Ala	Leu	Pro	Pro	Ser	Thr	His	Arg	Ala	Gly	Trp
		435					440					445			
Gln	Leu	Phe	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg
	450					455					460				
Met	Ala	Thr	Ala	Val	Ala	Arg	Cys	Ala	Gln	Asp	Glu	Glu	Leu	Leu	Ser
465					470					475					480
Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg	Gly	Glu	Arg	Ile	Glu
				485					490					495	
Ala	Gln	Gly	Gly	Lys	Arg	Val	Cys	Arg	Ala	His	Asn	Ala	Phe	Gly	Gly
			500					505						510	
Glu	Gly	Val	Tyr	Ala	Ile	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Gln	Val	Asn
		515					520						525		
Cys	Ser	Val	His	Thr	Pro	Pro	Gly	Ala	Ser	Met	Gly	Thr	Arg	Val	His
	530					535					540				
Cys	His	Gln	Gln	Gly	His	Val	Leu	Thr	Gly	Cys	Ser	Ser	His	Trp	Glu
545					550					555					560
Val	Glu	Asp	Leu	Gly	Thr	His	Lys	Pro	Pro	Val	Leu	Arg	Pro	Arg	Gly
				565					570					575	
Gln	Pro	Asn	Gln	Cys	Val	Gly	His	Arg	Glu	Ala	Ser	Ile	His	Ala	Ser
			580					585					590		
Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Val	Arg	Glu	His	Gly	Ile
		595					600					605			
Pro	Ala	Pro	Gln	Glu	Gln	Val	Ile	Val	Ala	Cys	Glu	Asp	Gly	Trp	Thr
	610					615						620			
Leu	Thr	Gly	Cys	Ser	Ala	Leu	Pro	Gly	Thr	Ser	His	Val	Leu	Gly	Ala
625					630					635					640
Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val	Arg	Ser	Arg	Asp	Val	Ser	Thr
				645					650					655	
Thr	Gly	Ser	Thr	Glu	Ala	Val	Ala	Ala	Val	Ala	Ile	Cys	Cys	Arg	Ser
			660					665					670		
Arg	His	Leu	Val	Gln	Ala	Ser	Gln	Glu	Leu	Gln					
		675					680								

SEQ ID NO: 28

FIG 1P₂

SUBSTITUTE SHEET (RULE 26)

24 / 38

Rattus norvegicus PCSK9

Met	Gly	Ile	Arg	Cys	Ser	Thr	Trp	Leu	Arg	Trp	Pro	Leu	Ser	Pro	Gln
1				5					10					15	
Leu	Leu	Leu	Leu	Leu	Leu	Leu	Cys	Pro	Thr	Gly	Ser	Arg	Ala	Gln	Asp
			20					25					30		
Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Leu	Ala	Leu	Pro	Ser	Gln	Glu
		35					40					45			
Asp	Ser	Leu	Val	Asp	Glu	Ala	Ser	His	Val	Ala	Thr	Ala	Thr	Phe	Arg
	50					55				60					
Arg	Cys	Ser	Lys	Glu	Ala	Trp	Arg	Leu	Pro	Gly	Thr	Tyr	Val	Val	Val
65					70					75					80
Leu	Met	Glu	Glu	Thr	Gln	Arg	Leu	Gln	Val	Glu	Gln	Thr	Ala	His	Arg
				85					90					95	
Leu	Gln	Thr	Trp	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile	Lys	Val	Leu	His
			100					105					110		
Val	Phe	Tyr	Asp	Leu	Phe	Pro	Gly	Phe	Leu	Val	Lys	Met	Ser	Ser	Asp
		115					120					125			
Leu	Leu	Gly	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Glu	Tyr	Ile	Glu	Glu
	130					135					140				
Asp	Ser	Leu	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Leu	Glu	Arg	Ile
145					150					155					160
Ile	Pro	Ala	Trp	Gln	Gln	Thr	Glu	Glu	Asp	Ser	Ser	Pro	Asp	Gly	Ser
				165					170					175	
Ser	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Gly	His
			180					185					190		
Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Ile	Thr	Asp	Phe	Asn	Ser	Val	Pro
	195						200					205			
Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser
	210					215						220			
His	Gly	Thr	His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val
225				230						235					240
Ala	Lys	Gly	Thr	Ser	Leu	His	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly
				245					250					255	
Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe	Ile	Arg	Lys
			260					265					270		
Ser	Gln	Leu	Ile	Gln	Pro	Ser	Gly	Pro	Leu	Val	Val	Leu	Leu	Pro	Leu
		275					280					285			
Ala	Gly	Gly	Tyr	Ser	Arg	Ile	Leu	Asn	Thr	Ala	Cys	Gln	Arg	Leu	Ala
	290					295					300				
Arg	Thr	Gly	Val	Val	Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp
305					310					315					320
Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly
				325					330					335	
Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr
			340					345					350		
Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile	Ile
		355					360					365			
Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Tyr	Met	Ser	Gln	Ser	Gly	Thr
	370					375					380				
Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Val	Ala	Met	Met	Leu	Asn
385					390					395					400

FIG 1Q₁

SUBSTITUTE SHEET (RULE 26)

25 / 38

Arg	Asp	Pro	Ala	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile	Leu
				405					410					415	
Phe	Ser	Thr	Lys	Asp	Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln
			420					425					430		
Arg	Val	Leu	Thr	Pro	Asn	Arg	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	Gln
		435					440					445			
Glu	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser
	450					455					460				
Gly	Pro	Thr	Arg	Thr	Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Glu	Glu
465					470					475					480
Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Arg	Arg	Arg	Gly
				485					490					495	
Asp	Arg	Ile	Glu	Ala	Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn
			500					505					510		
Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Leu
		515					520					525			
Pro	Arg	Val	Asn	Cys	Ser	Ile	His	Asn	Thr	Pro	Ala	Ala	Arg	Ala	Gly
		530				535					540				
Pro	Gln	Thr	Pro	Val	His	Cys	His	Gln	Lys	Asp	His	Val	Leu	Thr	Gly
545					550					555					560
Cys	Ser	Phe	His	Trp	Glu	Val	Glu	Asn	Leu	Arg	Ala	Gln	Gln	Gln	Pro
				565					570					575	
Leu	Leu	Arg	Ser	Arg	His	Gln	Pro	Gly	Gln	Cys	Val	Gly	His	Gln	Glu
			580					585					590		
Ala	Ser	Val	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys
		595				600						605			
Ile	Lys	Glu	His	Gly	Ile	Ala	Gly	Pro	Ala	Glu	Gln	Val	Thr	Val	Ala
	610				615						620				
Cys	Glu	Ala	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Asn	Val	Leu	Pro	Gly	Ala
625					630					635					640
Ser	Leu	Pro	Leu	Gly	Ala	Tyr	Ser	Val	Asp	Asn	Val	Cys	Val	Ala	Arg
				645					650					655	
Ile	Arg	Asp	Ala	Gly	Arg	Ala	Asp	Arg	Thr	Ser	Glu	Glu	Ala	Thr	Val
			660				665						670		
Ala	Ala	Ala	Ile	Cys	Cys	Arg	Ser	Arg	Pro	Ser	Ala	Lys	Ala	Ser	Trp
		675					680					685			
Val	His	Gln													
		690													

SEQ ID NO: 29

FIG 1Q₂

SUBSTITUTE SHEET (RULE 26)

26 / 38

Consensus sequence of PCSK9

Met	Gly	Thr	Xaa	Cys	Ser	Ala	Arg	Ser	Trp	Trp	Pro	Leu	Xaa	Xaa	Xaa
1				5					10				15		
Xaa	Xaa	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Pro	Ala	Gly	Ala	Ala
			20					25					30		
Ala	Ala	Gln	Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Leu	Ala	Leu
		35				40					45				
Pro	Ser	Gln	Glu	Asp	Gly	Leu	Ala	Asp	Glu	Ala	Glu	His	Val	Xaa	Xaa
	50				55					60					
Xaa	Ala	Thr	Ala	Thr	Phe	His	Arg	Cys	Ser	Lys	Asp	Ala	Trp	Arg	Leu
65				70					75					80	
Pro	Gly	Thr	Tyr	Val	Val	Leu	Lys	Glu	Glu	Thr	Gln	Arg	Leu	Gln	
			85					90				95			
Ser	Glu	Gln	Thr	Ala	His	Arg	Leu	Gln	Thr	Gln	Ala	Ala	Arg	Arg	Gly
			100					105				110			
Tyr	Val	Thr	Lys	Ile	Leu	His	Val	Phe	His	Asp	Leu	Leu	Pro	Gly	Phe
		115				120					125				
Leu	Val	Lys	Met	Ser	Ser	Asp	Leu	Leu	Asp	Leu	Ala	Leu	Lys	Leu	Pro
	130					135				140					
His	Val	Asp	Tyr	Ile	Glu	Glu	Asp	Ser	Ser	Val	Phe	Ala	Gln	Ser	Ile
145				150					155					160	
Pro	Trp	Asn	Leu	Glu	Arg	Ile	Ile	Pro	Ala	Arg	His	Gln	Ala	Asp	Glu
			165					170					175		
Tyr	Ser	Ser	Xaa	Xaa	Xaa	Xaa	Pro	Asp	Gly	Ser	Ser	Gln	Val	Glu	Val
			180					185				190			
Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Asp	His	Arg	Glu	Ile	Glu	Gly
	195					200					205				
Arg	Val	Thr	Val	Thr	Asp	Phe	Asn	Ser	Val	Pro	Glu	Glu	Asp	Gly	Thr
	210				215						220				
Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr	His	Leu
225				230					235					240	
Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly	Thr	Ser
			245					250				255			
Leu	Arg	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly	Lys	Gly	Thr	Val	Ser
		260					265					270			
Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe	Ile	Arg	Lys	Ser	Gln	Leu	Ile	Gln
	275					280						285			
Pro	Val	Gly	Pro	Leu	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Gly	Tyr	Ser
	290				295						300				
Arg	Val	Leu	Asn	Ala	Ala	Cys	Gln	Arg	Leu	Ala	Arg	Thr	Gly	Val	Val
305				310					315					320	
Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser
			325					330				335			
Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asn	Ala	Gln
		340					345					350			
Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly	Arg	Cys
	355				360						365				
Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp
	370				375						380				
Cys	Ser	Thr	Cys	Phe	Met	Ser	Gln	Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala
385					390				395						400

FIG 1R₁

SUBSTITUTE SHEET (RULE 26)

27 / 38

His	Val	Ala	Gly	Ile	Val	Ala	Met	Met	Leu	Ser	Ala	Glu	Pro	Glu	Leu
				405					410					415	
Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile	His	Phe	Ser	Thr	Lys	Asp
			420					425					430		
Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr	Pro
		435					440					445			
Asn	Leu	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	His	Gly	Thr	Gly	Gly	Gln
	450					455					460				
Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg	Thr
465					470					475					480
Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Asp	Glu	Glu	Leu	Leu	Ser	Cys
				485					490					495	
Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg	Gly	Asp	Arg	Ile	Glu	Ala
			500					505					510		
Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala	Phe	Gly	Gly	Glu
		515					520					525			
Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala	Asn	Cys
	530					535					540				
Ser	Ile	His	Thr	Thr	Pro	Ala	Ala	Arg	Ala	Ser	Met	Glu	Thr	Arg	Val
545					550					555					560
His	Cys	His	Gln	Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Ser	His	Trp
				565					570					575	
Glu	Val	Glu	Asp	Leu	Gly	Xaa	Xaa	Lys	Xaa	Pro	Val	Leu	Arg	Ser	Arg
			580					585					590		
Gly	Gln	Pro	Gly	Gln	Cys	Val	Gly	His	Arg	Glu	Ala	Ser	Val	His	Ala
		595					600					605			
Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Ile	Lys	Glu	His	Gly
	610					615					620				
Ile	Pro	Gly	Pro	Ala	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Ala	Gly	Trp
625					630					635					640
Thr	Leu	Thr	Gly	Cys	Ser	Val	Leu	Pro	Gly	Ala	Ser	Leu	Val	Leu	Gly
				645					650					655	
Ala	Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val	Arg	Ser	Arg	Asp	Val	Ser
			660					665					670		
Thr	Ala	Gly	Arg	Thr	Ser	Glu	Glu	Ala	Thr	Val	Ala	Ala	Ala	Ile	Cys
		675					680					685			
Cys	Arg	Ser	Arg	Pro	Ser	Ala	Gln	Ala	Ser	Trp	Val	Xaa	Gln		
	690					695					700				

SEQ ID NO: 30

Xaa = Any Amino Acid or No Amino Acid

FIG 1R₂

SUBSTITUTE SHEET (RULE 26)

28 / 38

Homo sapiens PCSK9

Met 1	Gly	Thr	Val	Ser 5	Ser	Arg	Arg	Ser	Trp 10	Trp	Pro	Leu	Pro	Leu 15	Leu
Leu	Leu	Leu	Leu 20	Leu	Leu	Leu	Gly	Pro 25	Ala	Gly	Ala	Arg	Ala 30	Gln	Glu
Asp	Glu	Asp 35	Gly	Asp	Tyr	Glu	Glu 40	Leu	Val	Leu	Ala	Leu 45	Arg	Ser	Glu
Glu	Asp 50	Gly	Leu	Ala	Glu	Ala 55	Pro	Glu	His	Gly	Thr 60	Thr	Ala	Thr	Phe
His 65	Arg	Cys	Ala	Lys 70	Asp	Pro	Trp	Arg	Leu	Pro 75	Gly	Thr	Tyr	Val 80	Val
Val	Leu	Lys	Glu	Glu 85	Thr	His	Leu	Ser	Gln 90	Ser	Glu	Arg	Thr	Ala 95	Arg
Arg	Leu	Gln	Ala 100	Gln	Ala	Ala	Arg	Arg 105	Gly	Tyr	Leu	Thr	Lys 110	Ile	Leu
His	Val	Phe 115	His	Leu	Leu	Pro	Gly 120	Phe	Leu	Val	Lys	Met 125	Ser	Gly	Asp
Leu 130	Leu	Glu	Leu	Ala	Leu	Lys 135	Leu	Pro	His	Val	Asp 140	Tyr	Ile	Glu	Glu
Asp 145	Ser	Ser	Val	Phe 150	Ala	Gln	Ser	Ile	Pro	Trp 155	Asn	Leu	Glu	Arg	Ile 160
Thr	Pro	Pro	Arg	Tyr 165	Arg	Ala	Asp	Glu	Tyr 170	Gln	Pro	Pro	Asp	Gly 175	Gly
Ser	Leu	Val	Glu 180	Val	Tyr	Leu	Leu	Asp 185	Thr	Ser	Ile	Gln	Ser 190	Asp	His
Arg	Glu	Ile 195	Glu	Gly	Arg	Val	Met 200	Val	Thr	Asp	Phe	Glu 205	Asn	Val	Pro
Glu	Glu 210	Asp	Gly	Thr	Arg	Phe 215	His	Arg	Gln	Ala	Ser 220	Lys	Cys	Asp	Ser
His 225	Gly	Thr	His	Leu	Ala 230	Gly	Val	Val	Ser	Gly 235	Arg	Asp	Ala	Gly	Val 240
Ala	Lys	Gly	Ala	Ser 245	Met	Arg	Ser	Leu	Arg 250	Val	Leu	Asn	Cys 255	Gln	Gly
Lys	Gly	Thr 260	Val	Ser	Gly	Thr	Leu 265	Ile	Gly	Leu	Glu	Phe 270	Ile	Arg	Lys
Ser	Gln 275	Leu	Val	Gln	Pro	Val	Pro 280	Leu	Val	Val	Leu	Leu 285	Pro	Leu	Ala
Gly 290	Gly	Tyr	Ser	Arg	Val	Leu 295	Asn	Ala	Ala	Cys	Gln 300	Arg	Leu	Ala	Arg
Ala 305	Gly	Val	Val	Leu	Val 310	Thr	Ala	Ala	Gly	Asn 315	Phe	Arg	Asp	Asp	Ala 320
Cys	Leu	Tyr	Ser	Pro 325	Ala	Ser	Ala	Pro	Glu 330	Val	Ile	Thr	Val	Gly 335	Ala
Thr	Asn	Ala 340	Gln	Asp	Gln	Pro	Val 345	Thr	Leu	Gly	Thr	Leu 350	Gly	Thr	Asn
Phe	Gly 355	Arg	Cys	Val	Asp	Leu	Phe 360	Ala	Pro	Gly	Glu	Asp 365	Ile	Ile	Gly
Ala	Ser 370	Ser	Asp	Cys	Ser	Thr 375	Cys	Phe	Val	Ser	Gln 380	Ser	Gly	Thr	Ser
Gln 385	Ala	Ala	Ala	His 390	Val	Ala	Gly	Ile	Ala	Ala 395	Met	Met	Leu	Ser	Ala 400

FIG 1S₁

SUBSTITUTE SHEET (RULE 26)

29 / 38

Glu	Pro	Glu	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Leu	Ile	His	Phe	Ser			
				405					410					415				
Ala	Lys	Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val			
			420					425					430					
Leu	Thr	Pro	Asn	Leu	Val	Ala	Ala	Leu	Pro	Pro	Ser	Thr	His	Gly	Ala			
		435					440					445						
Gly	Trp	Gln	Leu	Phe	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro			
	450					455					460							
Thr	Arg	Met	Ala	Thr	Ala	Ile	Ala	Arg	Cys	Ala	Pro	Asp	Glu	Glu	Leu			
465					470					475					480			
Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg	Gly	Glu	Arg			
				485					490					495				
Met	Glu	Ala	Gln	Gly	Gly	Lys	Leu	Val	Cys	Arg	Ala	His	Asn	Ala	Phe			
			500					505					510					
Gly	Gly	Glu	Gly	Val	Tyr	Ala	Ile	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Gln			
		515					520					525						
Ala	Asn	Cys	Ser	Val	His	Thr	Ala	Pro	Pro	Ala	Glu	Ala	Ser	Met	Gly			
	530					535					540							
Thr	Arg	Val	His	Cys	His	Gln	Gln	Gly	His	Val	Leu	Thr	Gly	Cys	Ser			
545				550					555						560			
Ser	His	Trp	Glu	Val	Glu	Asp	Leu	Gly	Thr	His	Lys	Pro	Pro	Val	Leu			
				565					570					575				
Arg	Pro	Arg	Gly	Gln	Pro	Asn	Gln	Cys	Val	Gly	His	Arg	Glu	Ala	Ser			
			580					585					590					
Ile	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Val	Lys			
		595				600						605						
Glu	His	Gly	Ile	Pro	Ala	Pro	Gln	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu			
	610					615					620							
Glu	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Ser	Ala	Leu	Pro	Gly	Thr	Ser	His			
625					630					635					640			
Val	Leu	Gly	Ala	Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val	Arg	Ser	Arg			
				645					650					655				
Asp	Val	Ser	Thr	Thr	Gly	Ser	Thr	Ser	Glu	Glu	Ala	Val	Thr	Ala	Val			
			660					665					670					
Ala	Ile	Cys	Cys	Arg	Ser	Arg	His	Leu	Ala	Gln	Ala	Ser	Gln	Glu	Leu			
		675					680						685					
Gln																		

SEQ ID NO: 31

FIG 1S₂

SUBSTITUTE SHEET (RULE 26)

30 / 38




FIG. 2

31 / 38





FIG. 3A

32 / 38






FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

38 / 38




FIG. 9

SEQUENCE_LISTING_APMOL_005VPC

SEQUENCE LISTING

<110> Jackson, Simon Mark
Piper, Derek E.

<120> NEUTRALIZING PROPROTEIN CONVERTASE
SUBTILISIN KEXIN TYPE 9 (PCSK9) VARIANTS AND USES THEREOF

<130> APMOL.005VPC

<150> 61/125304

<151> 2008-04-23

<160> 31

<170> Fast SEQ for Windows Version 4.0

<210> 1

<211> 662

<212> PRT

<213> Homo sapiens

<400> 1

```

G n G u A s p G u A s p G y A s p T y r G u G u L e u V a l L e u A l a L e u A r g
1      5      10      15
S e r G u G u A s p G y L e u A l a G u A l a P r o G u H i s G y T h r T h r A l a
20      25      30
T h r P h e H i s A r g C y s A l a L y s A s p P r o T r p A r g L e u P r o G y T h r T y r
35      40      45
V a l V a l V a l L e u L y s G u G u T h r H i s L e u S e r G n S e r G u A r g T h r
50      55      60
A l a A r g A r g L e u G n A l a G n A l a A l a A r g A r g G y T y r L e u T h r L y s
65      70      75      80
I l e L e u H i s V a l P h e H i s G y L e u L e u P r o G y P h e L e u V a l L y s M e t
85      90      95
S e r G y A s p L e u L e u G u L e u A l a L e u L y s L e u P r o H i s V a l A s p T y r
100     105     110
I l e G u G u A s p S e r S e r V a l P h e A l a G n S e r I l e P r o T r p A s n L e u
115     120     125
G u A r g I l e T h r P r o P r o A r g T y r A r g A l a A s p G u T y r G n P r o P r o
130     135     140
A s p G y G y S e r L e u V a l G u V a l T y r L e u L e u A s p T h r S e r I l e G n
145     150     155     160
S e r A s p H i s A r g G u I l e G u G y A r g V a l M e t V a l T h r A s p P h e G u
165     170     175
A s n V a l P r o G u A s p G y T h r A r g P h e H i s A r g G n A l a S e r L y s
180     185     190
C y s A s p S e r H i s G y T h r H i s L e u A l a G y V a l V a l S e r G y A r g A s p
195     200     205
A l a G y V a l A l a L y s G y A l a S e r M e t A r g S e r L e u A r g V a l L e u A s n
210     215     220
C y s G n G y L y s G y T h r V a l S e r G y T h r L e u I l e G y L e u G u P h e
225     230     235     240
I l e A r g L y s S e r G n L e u V a l G n P r o V a l G y P r o L e u V a l V a l L e u
245     250     255
L e u P r o L e u A l a G y G y T y r S e r A r g V a l L e u A s n A l a A l a C y s G n
260     265     270
A r g L e u A l a A r g A l a G y V a l V a l L e u V a l T h r A l a A l a G y A s n P h e
275     280     285
A r g A s p A s p A l a C y s L e u T y r S e r P r o A l a S e r A l a P r o G u V a l I l e
290     295     300
T h r V a l G y A l a T h r A s n A l a G n A s p G n P r o V a l T h r L e u G y T h r
305     310     315     320
L e u G y T h r A s n P h e G y A r g C y s V a l A s p L e u P h e A l a P r o G y G u
325     330     335

```


SEQUENCE LISTING_APMOL_005VPC

Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln
 340 345 350
 Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met
 355 360 365
 Met Leu Ser Ala Gu Pro Gu Leu Thr Leu Ala Gu Leu Arg Gln Arg
 370 375 380
 Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Gu Ala Trp Phe Pro
 385 390 395 400
 Gu Asp Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro
 405 410 415
 Ser Thr His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser
 420 425 430
 Ala His Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala
 435 440 445
 Pro Asp Gu Gu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys
 450 455 460
 Arg Arg Gly Gu Arg Met Gu Ala Gln Gly Gly Lys Leu Val Cys Arg
 465 470 475 480
 Ala His Asn Ala Phe Gly Gly Gu Gly Val Tyr Ala Ile Ala Arg Cys
 485 490 495
 Cys Leu Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala
 500 505 510
 Gu Ala Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val
 515 520 525
 Leu Thr Gly Cys Ser Ser His Trp Gu Val Gu Asp Leu Gly Thr His
 530 535 540
 Lys Pro Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly
 545 550 555 560
 His Arg Gu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu
 565 570 575
 Gu Cys Lys Val Lys Gu His Gly Ile Pro Ala Pro Gln Gly Gln Val
 580 585 590
 Thr Val Ala Cys Gu Gu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu
 595 600 605
 Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys
 610 615 620
 Val Val Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Gu Gu
 625 630 635 640
 Ala Val Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln
 645 650 655
 Ala Ser Gln Gu Leu Gln
 660

<210> 2

<211> 2076

<212> DNA

<213> Homo sapiens

<400> 2

at gggcaccg t cagct ccag gcggt cct gg t ggccgct gc cact gct gct gct gct g 60
 ct gct cct gg gt cccgcggg cgcccg gcg caggaggac aggcggcga ct acgaggag 120
 ct ggt gct ag cct t gcgct c cgaggaggac ggcct ggccg aagcaccga gcacggaacc 180
 acagccacct t ccaccgt g cgccaaggat ccgt ggaggt t gcct ggcac ct acgt ggt g 240
 gt gct gaagg aggagacca cct ct cgcag t cagagcgca ct gccgcgg cct gcaggcc 300
 caggct gccc gccggggat a cct caccaag at cct gcat g t ct t ccat gg cct t ct t cct 360
 ggct t cct gg t gaagat gag t ggcgacct g ct ggagct gg cct t gaagt t gccccat gt c 420
 gact acat cg aggaggact c ct ct gt ct t t gccagagca t cccgt ggaa cct ggagcgg 480
 at t acccct c cgcggt accg ggcggat gaa t accagcccc ccgacggagg cagcct ggt g 540
 gaggt gt at c t cct agacac cagcat acag agt gaccacc gggaaat cga gggcagggg c 600
 at ggt caccg act t cgagaa t gt gcccgag gaggacggga cccgt t cca cagacaggcc 660
 agcaagt gt g acagt cat gg caccacct g gcaggggt gg t cagcggccg ggat gccggc 720
 gt ggccaagg gt gccagcat gcgcagcct g cgcgt gct ca act gccaaagg gaagggcacg 780
 gt t agcggca ccct cat agg cct ggagt t t at t cggaataa gccagct ggt ccagcct gt g 840
 gggccact gg t ggt gct gct gccct ggcg ggt ggg aca gccgcgt cct caacgccgcc 900
 t gccagcgcc t ggcgagggc t ggggt cgt g ct ggt caccg ct gccggcaa ct t ccgggac 960
 gat gcct gcc t ct act cccc agcct cagct cccgaggt ca t cacagt t gg ggccaccaat 1020
 gcccaggacc agccggt gac cct ggggact t t ggggacca act t t ggccg ct gt gt ggac 1080

SEQUENCE_LI STI NG_APMOL_005VPC

```

ct ct t t gcc caggggagga cat cat t ggt gcct ccagcg act gcagcac ct gct t t gt g 1140
t cacagagt g ggacat caca ggct gct gcc cacgt ggct g gcat t gcagc cat gat gct g 1200
t ct gccgagc cggagct cac cct ggccgag t t gaggcaga gact gat cca ct t ct ct gcc 1260
aaagat gt ca t caat gaggc ct ggt t cctt gaggaccagc ggggt act gac ccccaacct g 1320
gt ggccgccc t gccccccag caccat ggg gcaggt t ggc agct gt t t t g caggact gt g 1380
t ggt cagcac act cggggcc t acacggat g gccacagcca t cgcccgt g cgccccagat 1440
gaggagct gc t gagct gct c cagt t t ct cc aggagt ggga agcggcgggg cgagcgc at g 1500
gaggcccaag ggggcaagct ggt ct gccgg gccacaacg ct t t t ggggg t gagggt gt c 1560
t acgccat t g ccaggt gct g cct gct accc caggccaact gcagcgt cca cacagct cca 1620
ccagct gagg ccagcat ggg gacccgt gt c cact gccacc aacagggcca cgt cct caca 1680
ggct gcagct cccact ggga ggt ggaggac ct t ggcaccc acaagccgcc t gt gct gagg 1740
ccacgaggt c agcccaacca gt gcgt gggc cacagggagg ccagcat cca cgct t cct gc 1800
t gccat gcc caggt ct gga at gcaaagt c aaggagcat g gaat cccggc ccct cagggg 1860
caggt gaccg t ggct gcga ggagggct gg accct gact g gct gcagcgc cct ccct ggg 1920
acct cccacg t cct gggggc ct acgccgt a gacaacacgt gt gt agt cag gagccgggac 1980
gt cagcact a caggcagcac cagcgaagag gccgt gacag ccgt t gccat ct gct gccgg 2040
agccggcacc t ggcgaggc ct cccaggag ct ccag 2076

```

<210> 3

<211> 692

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu
1      5      10      15
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
20     25     30
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35     40     45
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe
50     55     60
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65     70     75     80
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg
85     90     95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
100    105    110
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
115    120    125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
130    135    140
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145    150    155    160
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
165    170    175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180    185    190
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val
195    200    205
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
210    215    220
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225    230    235    240
Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln
245    250    255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260    265    270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275    280    285
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu
290    295    300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305    310    315    320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325    330    335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340    345    350

```

SEQUENCE LISTING_APMOL_005VPC

Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Glu	Asp	Ile
		355					360					365			
Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Phe	Val	Ser	Gln	Ser	Gly
	370					375					380				
Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Ala	Ala	Met	Met	Leu
385					390					395					400
Ser	Ala	Glu	Pro	Glu	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile
				405					410					415	
His	Phe	Ser	Ala	Lys	Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro	Glu	Asp
			420					425					430		
Gln	Arg	Val	Leu	Thr	Pro	Asn	Leu	Val	Ala	Ala	Leu	Pro	Pro	Ser	Thr
		435					440					445			
His	Gly	Ala	Gly	Trp	Gln	Leu	Phe	Cys	Arg	Thr	Val	Trp	Ser	Ala	His
	450					455					460				
Ser	Gly	Pro	Thr	Arg	Met	Ala	Thr	Ala	Ile	Ala	Arg	Cys	Ala	Pro	Asp
465					470					475					480
Glu	Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg
				485					490					495	
Gly	Glu	Arg	Met	Glu	Ala	Gln	Gly	Gly	Lys	Leu	Val	Cys	Arg	Ala	His
			500					505					510		
Asn	Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Ile	Ala	Arg	Cys	Cys	Leu
		515					520					525			
Leu	Pro	Gln	Ala	Asn	Cys	Ser	Val	His	Thr	Ala	Pro	Pro	Ala	Glu	Ala
	530					535					540				
Ser	Met	Gly	Thr	Arg	Val	His	Cys	His	Gln	Gln	Gly	His	Val	Leu	Thr
545					550					555					560
Gly	Cys	Ser	Ser	His	Trp	Glu	Val	Glu	Asp	Leu	Gly	Thr	His	Lys	Pro
				565					570					575	
Pro	Val	Leu	Arg	Pro	Arg	Gly	Gln	Pro	Asn	Gln	Cys	Val	Gly	His	Arg
			580					585					590		
Glu	Ala	Ser	Ile	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys
		595					600					605			
Lys	Val	Lys	Glu	His	Gly	Ile	Pro	Ala	Pro	Gln	Gly	Gln	Val	Thr	Val
	610				615						620				
Ala	Cys	Glu	Glu	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Ser	Ala	Leu	Pro	Gly
625					630					635					640
Thr	Ser	His	Val	Leu	Gly	Ala	Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val
			645						650					655	
Arg	Ser	Arg	Asp	Val	Ser	Thr	Thr	Gly	Ser	Thr	Ser	Glu	Glu	Ala	Val
			660					665					670		
Thr	Ala	Val	Ala	Ile	Cys	Cys	Arg	Ser	Arg	His	Leu	Ala	Gln	Ala	Ser
		675					680					685			
Gln	Glu	Leu	Gln												
	690														

<210> 4

<211> 692

<212> PRT

<213> Cavia porcellus

<400> 4

Met	Arg	Thr	Arg	Gly	Pro	Ala	Pro	Ala	Trp	Trp	Pro	Met	Leu	Leu	Leu
1				5					10				15		
Leu	Met	Leu	Gly	Pro	Ala	Pro	Ala	Gly	Ala	Gln	Ala	Arg	Asp	Ser	Glu
			20					25					30		
Asp	Gly	Asp	His	Glu	Gly	Leu	Ala	Phe	Ala	Phe	Pro	Pro	Glu	Glu	Asp
		35					40					45			
Gly	Pro	Ala	Glu	Ala	Ala	Pro	His	Val	Pro	Thr	Ala	Pro	Phe	His	Arg
	50					55					60				
Cys	Ser	Lys	Asp	Ala	Trp	Arg	Leu	Pro	Gly	Thr	Tyr	Leu	Val	Val	Leu
65					70					75					80
Lys	Glu	Gly	Thr	His	Arg	Gly	Gln	Thr	Lys	His	Thr	Ala	His	Arg	Leu
				85					90					95	
Gln	Ala	Lys	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Thr	Thr	Val	Leu	His	Leu
			100					105					110		
Phe	His	His	Leu	Val	Pro	Gly	Phe	Leu	Val	Arg	Met	Ser	Gly	Asp	Leu
		115					120					125			

SEQUENCE LISTING_APMOL_005VPC

Leu 130	Asp 130	Met	Ala	Leu 135	Arg 135	Leu 135	Pro	Leu 140	Val 140	Gln 140	Tyr 140	Ile 140	Glu 140	Glu 140	Asp 140
Ser 145	Ser 145	Val	Phe	Ala 150	Gln 150	Ser 150	Val	Pro	Trp 155	Asn 155	Leu 155	Glu 155	Arg 155	Ile 155	Leu 160
Pro 165	Val 165	Arg	His 165	Gln 165	Ala 165	Lys 165	Glu 165	Tyr 170	Ser 170	Ala 170	Pro 170	Ser 170	His 170	Pro 175	Val 175
Thr 180	Val 180	Tyr	Leu 180	Leu 180	Asp 180	Thr 180	Ser 180	Ile 185	Gln 185	Ser 185	Gly 185	His 185	Arg 185	Glu 185	Ile 185
Gln 190	Gly 190	Arg 195	Ile 195	Thr 195	Val 195	Thr 195	Asp 200	Phe 195	Glu 195	Ser 195	Val 195	Pro 205	Gln 205	Glu 205	Asp 205
Gly 210	Thr 210	Arg	Phe 210	His 210	Arg 210	Gln 215	Ala 215	Ser 215	Lys 215	Cys 215	Asp 220	Ser 220	His 220	Gly 220	Thr 220
His 225	Leu 225	Ala 225	Gly 225	Val 230	Val 230	Ser 230	Gly 230	Arg 230	Asp 235	Ala 235	Gly 235	Val 235	Ala 235	Lys 240	Gly 240
Ala 245	Gly 245	Leu 245	Arg 245	Ser 245	Leu 245	Arg 245	Val 245	Leu 250	Asn 250	Cys 250	Gln 250	Gly 250	Arg 250	Gly 255	Thr 255
Val 260	Ser 260	Ser 260	Thr 260	Leu 260	Arg 260	Gly 260	Leu 265	Glu 265	Phe 265	Ile 265	Arg 265	Lys 265	Ser 270	Gln 270	Leu 270
Ala 275	Gln 275	Pro 275	Val 275	Glu 275	Pro 275	Leu 275	Val 280	Val 280	Leu 280	Leu 280	Pro 280	Leu 285	Ala 285	Gly 285	Gly 285
Tyr 290	Ser 290	Arg 290	Thr 290	Leu 290	Asn 290	Ala 295	Ala 295	Cys 295	His 295	Leu 295	Leu 300	Ala 300	Arg 300	Ala 300	Gly 300
Val 305	Val 305	Leu 305	Val 305	Ala 310	Ala 310	Ala 310	Gly 310	Asn 310	Phe 310	Arg 315	Asp 315	Asp 315	Ala 315	Cys 315	Leu 320
Tyr 325	Ser 325	Pro 325	Ala 325	Ser 325	Ala 325	Pro 325	Glu 325	Val 330	Ile 330	Thr 330	Val 330	Gly 330	Ala 330	Thr 335	Asn 335
Ala 340	Gln 340	Asp 340	Gln 340	Pro 340	Val 340	Thr 340	Leu 345	Gly 345	Thr 345	Leu 345	Gly 345	Thr 345	Asn 350	Phe 350	Gly 350
Arg 355	Cys 355	Val 355	Asp 355	Leu 355	Phe 355	Ala 355	Pro 360	Gly 360	Glu 360	Asp 360	Ile 360	Ile 365	Gly 365	Ala 365	Ser 365
Ser 370	Asp 370	Cys 370	Ser 370	Thr 370	Cys 370	Phe 375	Val 375	Ser 375	Arg 375	Ser 375	Gly 380	Thr 380	Ser 380	Gln 380	Ala 380
Ala 385	Ala 385	His 385	Val 385	Ala 390	Gly 390	Ile 390	Val 390	Thr 390	Met 390	Met 395	Leu 395	Thr 395	Ala 395	Gln 395	Pro 400
Lys 405	Leu 405	Thr 405	Leu 405	Ala 405	Glu 405	Leu 405	Trp 405	Gln 405	Arg 410	Leu 410	Ile 410	His 410	Phe 410	Ala 415	Ala 415
Lys 420	Asp 420	Val 420	Ile 420	Asn 420	Glu 420	Ala 420	Trp 420	Phe 425	Pro 425	Glu 425	Asp 425	Gln 425	Arg 425	Val 430	Leu 430
Thr 435	Pro 435	Asn 435	Leu 435	Val 435	Ala 435	Thr 435	Leu 440	Pro 440	Pro 440	Ser 440	Thr 440	Arg 445	Gly 445	Ala 445	Gly 445
Gly 450	Arg 450	Leu 450	Leu 450	Cys 450	Arg 450	Thr 455	Val 455	Trp 455	Ser 455	Ala 455	Arg 460	Ser 460	Gly 460	Pro 460	Arg 460
His 465	Thr 465	Ala 465	Thr 465	Ala 470	Leu 470	Ala 470	His 470	Cys 470	Thr 470	Pro 475	Gly 475	Glu 475	Glu 475	Leu 475	Leu 480
Ser 485	Cys 485	Ser 485	Ser 485	Phe 485	Ser 485	Arg 485	Ser 485	Gly 485	Lys 490	Arg 490	Lys 490	Gly 490	Glu 490	Arg 495	Ile 495
Glu 500	Val 500	Leu 500	Arg 500	Gly 500	Arg 500	Arg 500	Val 500	Cys 505	Val 505	Ala 505	Tyr 505	Asn 505	Ala 510	Phe 510	Gly 510
Gly 515	Lys 515	Gly 515	Val 515	His 515	Ala 515	Val 515	Ala 520	Arg 515	Cys 515	Cys 515	Leu 515	Leu 525	Pro 525	Arg 525	Ala 525
Asn 530	Cys 530	Ser 530	Leu 530	His 530	Thr 530	Ala 535	Pro 535	Ala 535	Arg 535	Ala 535	Gly 535	Met 535	Glu 535	Pro 535	Arg 535
Val 545	His 545	Cys 545	His 545	Arg 545	Lys 545	Asp 545	Gln 545	Val 545	Leu 545	Thr 545	Gly 545	Cys 545	Ser 545	Ala 545	His 545
Trp 555	Glu 555	Ala 555	Glu 555	Asp 555	Phe 555	Arg 555	Ala 555	Arg 555	Gly 560	Trp 560	Pro 560	Met 560	Leu 560	Arg 560	Pro 560
Gly 570	Gly 570	Pro 570	Ser 570	Gln 570	Cys 570	Val 570	Gly 570	His 570	Ser 570	Lys 570	Ala 570	Ser 570	Val 570	His 570	Ala 570
Ser 580	Cys 580	Cys 580	Ser 580	Ala 580	Pro 580	Gly 580	Leu 580	Glu 580	Cys 580	Arg 580	Ile 580	Arg 580	Glu 580	His 580	Gly 580
Val 595	Pro 595	Trp 595	Pro 595	Ala 595	Glu 595	Gln 595	Val 595	Thr 595	Val 595	Ala 595	Cys 595	Glu 595	Asp 595	Gly 595	Trp 595
Thr 605	Leu 605	Thr 605	Gly 605	Cys 605	Ser 605	Thr 605	Leu 605	Pro 605	Gly 605	Ala 605	Ser 605	Ser 605	Val 605	Leu 605	Gly 605
Thr 625	Tyr 625	Ala 625	Val 625	Asp 625	Asp 625	Met 625	Cys 625	Val 625	Val 625	Arg 625	Ser 625	Arg 625	Asp 625	Val 625	Lys 625
Ala 640	Leu 640	Asp 640	Arg 640	Thr 640	Arg 640	Gly 640	Glu 640	Ala 640	Leu 640	Ala 640	Ala 640	Ile 640	Ala 640	Ile 640	Cys 640

SEQUENCE LISTING_APMOL_005VPC

Cys Arg Ser Gln Ala Ser Gln Gln Ala Ser Pro Gln Arg Gln His His
 675 680 685
 His His His
 690

<210> 5
 <211> 704
 <212> PRT
 <213> Mesocricetus auratus

<400> 5
 Met Gly Thr Ser Cys Ser Ala Arg Pro Arg Trp Leu Leu Ser Pro Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Leu Arg Tyr Met Gly Ala Ser Ala Gln Asp
 20 25 30
 Gln Asp Ala Gln Tyr Gln Gln Leu Met Leu Thr Leu Gln Ser Gln Asp
 35 40 45
 Asp Gly Leu Ala Asp Gln Thr Asp Gln Ala Pro Gln Gly Ala Thr Ala
 50 55 60
 Ala Phe His Arg Cys Pro Gln Gln Ala Trp Arg Val Pro Gly Thr Tyr
 65 70 75 80
 Ile Val Met Leu Ala Gln Gln Ala Gln Trp Val His Ile Gln Gln Thr
 85 90 95
 Met His Arg Leu Gln Thr Gln Ala Ala Arg Arg Gly Tyr Val Ile Lys
 100 105 110
 Ile Gln His Ile Phe Tyr Asp Phe Leu Pro Ala Phe Val Val Lys Met
 115 120 125
 Ser Ser Asp Leu Leu Asp Leu Ala Leu Lys Leu Pro His Val Lys Tyr
 130 135 140
 Ile Gln Gln Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Asn Leu
 145 150 155 160
 Asp Arg Ile Ile Pro Ala Gly Arg Gln Ala Gln Gln Tyr Ser Ser Ser
 165 170 175
 Arg Lys Val Pro Ser Gly Ser Gly Gln Val Gln Val Tyr Leu Leu Asp
 180 185 190
 Thr Ser Ile Gln Ser Asp His Arg Gln Ile Gln Gly Arg Val Thr Val
 195 200 205
 Thr Asp Phe Asn Ser Val Pro Gln Gln Asp Gly Thr Arg Phe His Arg
 210 215 220
 Gln Ala Ser Lys Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val
 225 230 235 240
 Ser Gly Arg Asp Ala Gly Val Ala Lys Gly Thr Ile Leu His Gly Leu
 245 250 255
 Arg Val Leu Asn Cys Gln Gly Lys Gly Ile Val Ser Gly Ile Leu Thr
 260 265 270
 Gly Leu Gln Phe Ile Trp Lys Ser Gln Leu Met Gln Pro Ser Gly Pro
 275 280 285
 Gln Val Val Leu Leu Pro Leu Ala Gly Arg Tyr Ser Arg Val Leu Asn
 290 295 300
 Thr Ala Cys Gln His Leu Ala Arg Thr Gly Val Val Leu Val Ala Ala
 305 310 315 320
 Ala Gly Asn Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala
 325 330 335
 Pro Gln Val Ile Thr Val Gly Ala Thr Asp Val Gln Asp Gln Pro Val
 340 345 350
 Thr Leu Gly Thr Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe
 355 360 365
 Ala Pro Gly Lys Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Ala Cys
 370 375 380
 Phe Met Ser Gln Ser Gly Thr Ser Gln Ala Ala His Val Ala Gly
 385 390 395 400
 Ile Val Ala Met Met Leu Thr Leu Gln Pro Gln Leu Thr Leu Thr Gln
 405 410 415
 Leu Arg Gln Arg Leu Ile His Phe Ser Thr Lys Asp Ala Ile Asn Met
 420 425 430
 Ala Trp Phe Pro Gln Asp Gln Arg Val Leu Thr Pro Asn Val Ala
 435 440 445

SEQUENCE LISTING_APMOL_005VPC

Thr	Leu	Pro	Pro	Ser	Thr	His	Gly	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg
450						455					460				
Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg	Ala	Ala	Thr	Ala	Thr
465					470					475					480
Ala	Arg	Cys	Ala	Pro	Gly	Glu	Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser
				485					490					495	
Arg	Ser	Gly	Arg	Arg	Arg	Gly	Asp	Arg	Ile	Glu	Ala	Ala	Gly	Thr	Gln
				500				505					510		
Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala
		515					520					525			
Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala	Asn	Cys	Ser	Ile	His	Thr
	530					535					540				
Thr	Pro	Ala	Ala	Arg	Thr	Ser	Leu	Glu	Thr	His	Ala	His	Cys	His	Gln
545					550					555					560
Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Leu	His	Trp	Glu	Val	Glu	Gly
				565					570					575	
Ile	Gly	Val	Gln	Pro	Leu	Ala	Val	Leu	Arg	Ser	Arg	His	Gln	Pro	Gly
			580					585					590		
Gln	Cys	Thr	Gly	His	Arg	Glu	Ala	Ser	Val	His	Ala	Ser	Cys	Cys	His
		595					600					605			
Ala	Pro	Gly	Leu	Glu	Cys	Lys	Ile	Lys	Glu	His	Gly	Ile	Ser	Gly	Pro
	610					615					620				
Ala	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Ala	Gly	Trp	Thr	Leu	Thr	Gly
625					630					635					640
Cys	Asn	Val	Leu	Pro	Gly	Ala	Phe	Ile	Thr	Leu	Gly	Ala	Tyr	Ala	Val
				645					650					655	
Asp	Asn	Thr	Cys	Val	Ala	Arg	Ser	Arg	Val	Thr	Asp	Thr	Ala	Gly	Arg
			660					665					670		
Thr	Gly	Glu	Glu	Ala	Thr	Val	Ala	Ala	Ala	Ile	Cys	Cys	Arg	Asn	Arg
		675					680					685			
Pro	Ser	Ala	Lys	Ala	Ser	Trp	Val	His	Gln	His	His	His	His	His	His
	690					695					700				

<210> 6

<211> 695

<212> PRT

<213> Mus musculus

<400> 6

Met	Gly	Thr	His	Cys	Ser	Ala	Trp	Leu	Arg	Trp	Pro	Leu	Leu	Pro	Leu
1				5					10					15	
Leu	Pro	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Cys	Pro	Thr	Gly	Ala	
			20					25				30			
Gly	Ala	Gln	Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Leu	Ala	Leu
		35					40					45			
Pro	Ser	Gln	Glu	Asp	Gly	Leu	Ala	Asp	Glu	Ala	Ala	His	Val	Ala	Thr
	50					55				60					
Ala	Thr	Phe	Arg	Arg	Cys	Ser	Lys	Glu	Ala	Trp	Arg	Leu	Pro	Gly	Thr
65					70					75					80
Tyr	Ile	Val	Val	Leu	Met	Glu	Glu	Thr	Gln	Arg	Leu	Gln	Ile	Glu	Gln
				85					90					95	
Thr	Ala	His	Arg	Leu	Gln	Thr	Arg	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile
			100					105					110		
Lys	Val	Leu	His	Ile	Phe	Tyr	Asp	Leu	Phe	Pro	Gly	Phe	Leu	Val	Lys
		115					120					125			
Met	Ser	Ser	Asp	Leu	Leu	Gly	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Glu
	130					135					140				
Tyr	Ile	Glu	Glu	Asp	Ser	Phe	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn
145					150					155					160
Leu	Arg	Ile	Ile	Pro	Ala	Trp	His	Gln	Thr	Glu	Glu	Asp	Arg	Ser	Pro
				165					170					175	
Asp	Gly	Ser	Ser	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln
			180					185					190		
Gly	Ala	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Ile	Thr	Asp	Phe	Asn
		195					200					205			
Ser	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys
	210					215					220				

SEQUENCE LISTING APMOL_005VPC

Cys 225	Asp	Ser	His	Gly	Thr 230	His	Leu	Ala	Gly	Val 235	Val	Ser	Gly	Arg	Asp 240
Ala	Gly	Val	Ala	Lys 245	Gly	Thr	Ser	Leu	His 250	Ser	Leu	Arg	Val	Leu 255	Asn
Cys	Gln	Gly	Lys 260	Gly	Thr	Val	Ser	Gly 265	Thr	Leu	Ile	Gly	Leu 270	Glu	Phe
Ile	Arg	Lys 275	Ser	Gln	Leu	Ile	Gln 280	Pro	Ser	Pro	Leu	Val 285	Val	Leu	Pro
Leu	Ala 290	Gly	Gly	Tyr	Ser	Arg 295	Ile	Leu	Asn	Ala	Ala 300	Cys	Arg	His	Leu
Ala 305	Arg	Thr	Gly	Val	Val 310	Leu	Val	Ala	Ala	Ala 315	Gly	Asn	Phe	Arg	Asp 320
Asp	Ala	Cys	Leu	Tyr 325	Ser	Pro	Ala	Ser	Ala 330	Pro	Glu	Val	Ile	Thr 335	Val
Gly	Ala	Thr	Asn 340	Ala	Gln	Asp	Gln 345	Pro	Val	Thr	Leu	Gly	Thr 350	Leu	Gly
Thr	Asn	Phe 355	Gly	Arg	Cys	Val	Asp 360	Leu	Phe	Ala	Pro	Gly 365	Lys	Asp	Ile
Ile	Gly 370	Ala	Ser	Ser	Asp	Cys 375	Ser	Thr	Cys	Phe	Met 380	Ser	Gln	Ser	Gly
Thr 385	Ser	Gln	Ala	Ala	Ala 390	His	Val	Ala	Gly	Ile 395	Val	Ala	Arg	Met	Leu 400
Ser	Arg	Glu	Pro	Thr 405	Leu	Thr	Leu	Ala	Leu 410	Arg	Gln	Arg	Ile	His 415	Phe
Ser	Thr	Lys	Asp 420	Val	Ile	Asn	Met	Ala 425	Trp	Phe	Pro	Glu	Asp 430	Gln	Gln
Val	Leu	Thr 435	Pro	Asn	Leu	Val	Ala 440	Thr	Leu	Pro	Pro	Ser 445	Thr	His	Glu
Thr	Gly 450	Gly	Gln	Leu	Leu	Cys 455	Arg	Thr	Val	Trp	Ser 460	Ala	His	Ser	Gly
Pro 465	Thr	Arg	Thr	Ala	Thr 470	Ala	Thr	Ala	Arg	Cys 475	Ala	Pro	Glu	Glu	Glu
Leu	Leu	Ser	Cys	Ser 485	Ser	Phe	Ser	Arg	Ser 490	Gly	Arg	Arg	Arg	Gly 495	Asp
Arg	Ile	Glu	Ala 500	Ile	Gly	Gly	Gln	Gln 505	Val	Cys	Lys	Ala	Leu 510	Asn	Ala
Phe	Gly 515	Glu	Gly	Val	Tyr	Ala 520	Val	Ala	Arg	Cys	Cys 525	Leu	Val	Pro	
His 530	Ala	Asn	Cys	Ser	Ile	His 535	Asn	Pro	Ala	Ala	Ala 540	Gly	Leu	Glu	Thr
His 545	Val	His	Cys	His 550	Gln	Lys	Asp	His	Val	Leu 555	Thr	Gly	Cys	Ser	Phe 560
His	Trp	Glu	Val	Glu 565	Asp	Leu	Ser	Val	Arg 570	Arg	Gln	Pro	Ala	Leu 575	Arg
Ser	Arg	Arg	Gln 580	Pro	Gly	Gln	Cys	Val 585	Gly	His	Gln	Ala	Ala 590	Ser	Val
Tyr	Ala	Ser 595	Cys	Cys	His	Ala	Pro 600	Gly	Leu	Glu	Cys	Lys 605	Ile	Lys	Glu
His 610	Gly	Ile	Ser	Gly	Ser	Ser 615	Glu	Gln	Val	Thr	Val 620	Ala	Cys	Glu	Ala
Gly 625	Trp	Thr	Leu	Thr	Gly 630	Cys	Asn	Val	Leu	Pro 635	Gly	Ala	Ser	Leu	Thr 640
Leu	Gly	Ala	Tyr	Ser 645	Val	Asp	Asn	Leu	Cys 650	Val	Ala	Arg	Val	His 655	Asp
Thr	Ala	Arg	Ala 660	Asp	Arg	Thr	Gly	Glu 665	Thr	Val	Ala	Ala	Ala 670	Ile	Cys
Cys	Arg	Ser 675	Arg	Pro	Ser	Ala	Lys 680	Ala	Ser	Trp	Val	Gln 685	Gly	Pro	His
His 690	His	His	His	His	His	His	His 695								

<210> 7

<211> 703

<212> PRT

<213> Macaca fascicularis

<400> 7

SEQUENCE LISTING_APMOL_005VPC

Met 1	Gly	Thr	Val	Ser 5	Ser	Arg	Arg	Ser	Trp 10	Trp	Pro	Leu	Pro	Leu 15	Pro
Leu	Leu	Leu	Leu 20	Leu	Leu	Leu	Gly	Pro 25	Ala	Gly	Ala	Arg	Ala 30	Gln	Glu
Asp	Glu	Asp 35	Gly	Asp	Tyr	Glu	Glu 40	Leu	Val	Leu	Ala	Leu 45	Arg	Ser	Glu
Glu	Asp 50	Gly	Leu	Ala	Asp	Ala 55	Pro	Glu	His	Gly	Ala 60	Thr	Ala	Thr	Phe
His 65	Arg	Cys	Ala	Lys	Asp 70	Pro	Trp	Arg	Leu	Pro 75	Gly	Thr	Tyr	Val	Val 80
Val	Leu	Lys	Glu 85	Glu	Thr	His	Arg	Ser	Gln 90	Ser	Glu	Arg	Thr	Ala 95	Arg
Arg	Leu	Gln	Ala 100	Gln	Ala	Ala	Arg	Arg 105	Gly	Tyr	Leu	Thr	Lys 110	Ile	Leu
His	Val	Phe 115	His	His	Leu	Leu	Pro 120	Gly	Phe	Leu	Val	Lys 125	Met	Ser	Gly
Asp	Leu 130	Leu	Glu	Leu	Ala	Leu 135	Lys	Leu	Pro	His	Val 140	Asp	Tyr	Ile	Glu
Glu 145	Asp	Ser	Ser	Val	Phe 150	Ala	Gln	Ser	Ile	Pro 155	Trp	Asn	Glu	Arg	Ile 160
Thr	Pro	Ala	Arg	Tyr 165	Arg	Ala	Asp	Glu	Tyr 170	Gln	Pro	Pro	Lys	Gly 175	Gly
Ser	Leu	Val	Glu 180	Val	Tyr	Leu	Leu	Asp 185	Thr	Ser	Ile	Gln	Ser 190	Asp	His
Arg	Glu	Ile 195	Glu	Gly	Arg	Val	Met 200	Val	Thr	Asp	Phe	Glu 205	Ser	Val	Pro
Glu	Glu 210	Asp	Gly	Thr	Arg	Phe 215	His	Arg	Gln	Ala	Ser 220	Lys	Cys	Asp	Ser
His 225	Gly	Thr	His	Leu	Ala 230	Gly	Val	Val	Ser	Gly 235	Arg	Asp	Ala	Gly	Val 240
Ala	Lys	Gly	Ala	Gly 245	Leu	Arg	Ser	Leu	Arg 250	Val	Leu	Asn	Cys	Gln 255	Gly
Lys	Gly	Thr	Val 260	Ser	Gly	Thr	Leu	Ile 265	Gly	Leu	Glu	Phe	Ile 270	Arg	Lys
Ser	Gln	Leu 275	Val	Gln	Pro	Val	Pro 280	Leu	Val	Val	Leu	Pro 285	Leu	Ala	Gly
Gly	Tyr 290	Ser	Arg	Val	Phe	Asn 295	Ala	Ala	Cys	Gln	Arg 300	Leu	Ala	Arg	Ala
Gly 305	Val	Val	Leu	Val	Thr 310	Ala	Ala	Gly	Asn	Phe 315	Arg	Asp	Asp	Ala	Cys 320
Leu	Tyr	Ser	Pro	Ala 325	Ser	Ala	Pro	Glu	Val 330	Ile	Thr	Val	Gly	Ala 335	Thr
Asn	Ala	Gln	Asp 340	Gln	Pro	Val	Thr	Leu 345	Gly	Thr	Leu	Gly	Thr 350	Asn	Phe
Gly	Arg	Cys 355	Val	Asp	Leu	Phe	Ala 360	Pro	Gly	Glu	Asp	Ile 365	Ile	Gly	Ala
Ser	Ser 370	Asp	Cys	Ser	Thr	Cys 375	Phe	Val	Ser	Arg	Ser 380	Gly	Thr	Ser	Gln
Ala 385	Ala	Ala	His	Val	Ala 390	Gly	Ile	Ala	Ala	Met 395	Met	Leu	Ser	Ala	Glu 400
Pro	Glu	Leu	Thr	Leu 405	Ala	Leu	Arg	Gln	Leu 410	Ile	His	Phe	Ser	Ala 415	Lys
Asp	Val	Ile	Asn 420	Glu	Ala	Trp	Phe	Pro 425	Glu	Asp	Gln	Arg	Val 430	Leu	Thr
Pro	Asn	Leu 435	Val	Ala	Ala	Leu	Pro 440	Pro	Ser	Thr	His	Arg 445	Ala	Gly	Trp
Gln	Leu	Phe	Cys	Arg	Thr	Val 455	Trp	Ser	Ala	His	Ser 460	Gly	Pro	Thr	Arg
Met 465	Ala	Thr	Ala	Val	Ala 470	Arg	Cys	Ala	Gln	Asp 475	Glu	Glu	Leu	Leu	Ser 480
Cys	Ser	Ser	Phe	Ser 485	Arg	Ser	Gly	Lys	Arg 490	Arg	Gly	Glu	Arg	Ile 495	Glu
Ala	Gln	Gly	Gly 500	Lys	Arg	Val	Cys	Arg 505	Ala	His	Asn	Ala	Phe 510	Gly	Gly
Glu	Gly	Val 515	Tyr	Ala	Ile	Ala	Arg 520	Cys	Cys	Leu	Leu	Pro 525	Gln	Val	Asn
Cys	Ser 530	Val	His	Thr	Pro	Pro 535	Gly	Ala	Ser	Met	Gly 540	Thr	Arg	Val	His

SEQUENCE LISTING_APMOL_005VPC

Cys 545	His 550	Gln 565	Gln 580	Gly 595	His 610	Val 625	Leu 630	Thr 645	Gly 660	Cys 675	Ser 690	Ser 555	His 575	Trp 590	Glu 560
Val 545	Glu 550	Asp 565	Leu 580	Gly 595	Thr 610	His 625	Lys 630	Pro 645	Pro 660	Val 675	Leu 690	Arg 555	Pro 575	Arg 590	Gly 560
Gln 545	Pro 550	Asn 565	Gln 580	Cys 595	Val 610	Gly 625	His 630	Arg 645	Glu 660	Ala 675	Ser 690	Ile 555	His 575	Ala 590	Ser 560
Cys 545	Cys 550	His 565	Ala 580	Pro 595	Gly 610	Leu 625	Glu 630	Lys 645	Val 660	Arg 675	Glu 690	His 555	Gly 575	Ile 590	Ile 560
Pro 545	Ala 550	Pro 565	Gln 580	Glu 595	Gln 610	Val 625	Ile 630	Val 645	Ala 660	Cys 675	Glu 690	Asp 555	Gly 575	Trp 590	Thr 560
Leu 545	Thr 550	Gly 565	Cys 580	Ser 595	Ala 610	Leu 625	Pro 630	Gly 645	Thr 660	Ser 675	His 690	Val 555	Leu 575	Gly 590	Ala 560
Tyr 545	Ala 550	Val 565	Asp 580	Asn 595	Thr 610	Cys 625	Val 630	Val 645	Arg 660	Ser 675	Arg 690	Asp 555	Val 575	Ser 590	Thr 560
Thr 545	Gly 550	Ser 565	Thr 580	Glu 595	Ala 610	Val 625	Ala 630	Ala 645	Val 660	Ile 675	Cys 690	Cys 555	Arg 575	Ser 590	Ser 560
Arg 545	His 550	Leu 565	Val 580	Gln 595	Ala 610	Ser 625	Gln 630	Glu 645	Leu 660	Gln 675	Gly 690	Lys 555	Pro 575	Ile 590	Pro 560
Asn 545	Pro 550	Leu 565	Leu 580	Gly 595	Leu 610	Asp 625	Ser 630	Thr 645	His 660	His 675	His 690	His 555	His 575	His 590	His 560

<210> 8

<211> 699

<212> PRT

<213> Rattus norvegicus

<400> 8

Met 1	Gly 5	Ile 20	Arg 35	Cys 50	Ser 65	Thr 80	Trp 95	Leu 110	Arg 125	Trp 140	Pro 155	Leu 170	Ser 185	Pro 200	Gln 215
Leu 1	Leu 5	Leu 20	Leu 35	Leu 50	Leu 65	Leu 80	Cys 95	Pro 110	Thr 125	Gly 140	Ser 155	Arg 170	Ala 185	Leu 200	Asp 215
Glu 1	Asp 5	Gly 20	Asp 35	Tyr 50	Glu 65	Glu 80	Leu 95	Met 110	Leu 125	Ala 140	Leu 155	Pro 170	Ser 185	Gln 200	Glu 215
Asp 1	Ser 5	Leu 20	Val 35	Asp 50	Glu 65	Ala 80	Ser 95	His 110	Val 125	Ala 140	Thr 155	Ala 170	Thr 185	Phe 200	Arg 215
Arg 1	Cys 5	Ser 20	Lys 35	Glu 50	Ala 65	Trp 80	Arg 95	Leu 110	Pro 125	Gly 140	Thr 155	Tyr 170	Val 185	Val 200	Val 215
Leu 1	Met 5	Glu 20	Glu 35	Thr 50	Gln 65	Arg 80	Leu 95	Gln 110	Val 125	Glu 140	Gln 155	Thr 170	Ala 185	His 200	Arg 215
Leu 1	Gln 5	Thr 20	Trp 35	Ala 50	Ala 65	Arg 80	Arg 95	Gly 110	Tyr 125	Val 140	Ile 155	Lys 170	Val 185	Leu 200	His 215
Val 1	Phe 5	Tyr 20	Asp 35	Leu 50	Phe 65	Pro 80	Gly 95	Phe 110	Leu 125	Val 140	Lys 155	Met 170	Ser 185	Ser 200	Asp 215
Leu 1	Leu 5	Gly 20	Leu 35	Ala 50	Leu 65	Lys 80	Leu 95	Pro 110	His 125	Val 140	Glu 155	Tyr 170	Ile 185	Glu 200	Glu 215
Asp 1	Ser 5	Leu 20	Val 35	Phe 50	Ala 65	Gln 80	Ser 95	Ile 110	Pro 125	Trp 140	Asn 155	Leu 170	Glu 185	Arg 200	Ile 215
Ile 1	Pro 5	Ala 20	Trp 35	Gln 50	Gln 65	Thr 80	Glu 95	Glu 110	Asp 125	Ser 140	Ser 155	Pro 170	Asp 185	Gly 200	Ser 215
Ser 1	Gln 5	Val 20	Glu 35	Val 50	Tyr 65	Leu 80	Leu 95	Asp 110	Thr 125	Ser 140	Ile 155	Gln 170	Ser 185	Gly 200	His 215
Arg 1	Glu 5	Ile 20	Glu 35	Gly 50	Arg 65	Val 80	Thr 95	Ile 110	Thr 125	Asp 140	Phe 155	Asn 170	Ser 185	Val 200	Pro 215
Glu 1	Glu 5	Asp 20	Gly 35	Thr 50	Arg 65	Phe 80	His 95	Arg 110	Gln 125	Ala 140	Ser 155	Lys 170	Cys 185	Asp 200	Ser 215
His 1	Gly 5	Thr 20	His 35	Leu 50	Ala 65	Gly 80	Val 95	Ser 110	Gly 125	Arg 140	Asp 155	Ala 170	Gly 185	Val 200	Val 215
Ala 1	Lys 5	Gly 20	Thr 35	Ser 50	Leu 65	His 80	Ser 95	Leu 110	Arg 125	Val 140	Leu 155	Asn 170	Cys 185	Gln 200	Gly 215
Lys 1	Gly 5	Thr 20	Val 35	Ser 50	Gly 65	Thr 80	Leu 95	Ile 110	Gly 125	Leu 140	Glu 155	Phe 170	Ile 185	Arg 200	Lys 215
Ser 1	Gln 5	Leu 20	Ile 35	Gln 50	Pro 65	Ser 80	Gly 95	Pro 110	Leu 125	Val 140	Val 155	Leu 170	Leu 185	Pro 200	Leu 215
Ala 1	Gly 5	Gly 20	Tyr 35	Ser 50	Arg 65	Ile 80	Leu 95	Asn 110	Thr 125	Ala 140	Cys 155	Gln 170	Arg 185	Leu 200	Ala 215
Arg 1	Thr 5	Gly 20	Val 35	Val 50	Leu 65	Val 80	Ala 95	Ala 110	Gly 125	Asn 140	Phe 155	Arg 170	Asp 185	Asp 200	Asp 215

SEQUENCE LISTING_APMOL_005VPC

Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly
				325					330					335	
Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr
			340					345					350		
Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile	Ile
		355					360					365			
Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Tyr	Met	Ser	Gln	Ser	Gly	Thr
	370					375					380				
Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Val	Ala	Met	Met	Leu	Asn
385					390					395					400
Arg	Asp	Pro	Ala	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile	Leu
				405					410					415	
Phe	Ser	Thr	Lys	Asp	Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln
			420					425					430		
Arg	Val	Leu	Thr	Pro	Asn	Arg	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	Gln
		435					440					445			
Glu	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser
	450					455					460				
Gly	Pro	Thr	Arg	Thr	Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Glu	Glu
465					470					475					480
Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Arg	Arg	Arg	Gly
			485						490					495	
Asp	Arg	Ile	Glu	Ala	Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn
			500					505					510		
Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Leu
		515					520					525			
Pro	Arg	Val	Asn	Cys	Ser	Ile	His	Asn	Thr	Pro	Ala	Ala	Arg	Ala	Gly
	530					535					540				
Pro	Gln	Thr	Pro	Val	His	Cys	His	Gln	Lys	Asp	His	Val	Leu	Thr	Gly
545					550					555					560
Cys	Ser	Phe	His	Trp	Glu	Val	Glu	Asn	Leu	Arg	Ala	Gln	Gln	Gln	Pro
			565						570					575	
Leu	Leu	Arg	Ser	Arg	His	Gln	Pro	Gly	Gln	Cys	Val	Gly	His	Gln	Glu
			580					585					590		
Ala	Ser	Val	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys
		595					600					605			
Ile	Lys	Glu	His	Gly	Ile	Ala	Gly	Pro	Ala	Glu	Gln	Val	Thr	Val	Ala
	610					615					620				
Cys	Glu	Ala	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Asn	Val	Leu	Pro	Gly	Ala
625					630					635					640
Ser	Leu	Pro	Leu	Gly	Ala	Tyr	Ser	Val	Asp	Asn	Val	Cys	Val	Ala	Arg
			645						650					655	
Ile	Arg	Asp	Ala	Gly	Arg	Ala	Asp	Arg	Thr	Ser	Glu	Glu	Ala	Thr	Val
			660					665					670		
Ala	Ala	Ala	Ile	Cys	Cys	Arg	Ser	Arg	Pro	Ser	Ala	Lys	Ala	Ser	Trp
		675					680					685			
Val	His	Gln	His	His	His	His	His	His	His	His					
	690					695									

<210> 9

<211> 722

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence

<220>

<221> VARI ANT

<222> 4, 14, 15, 16, 17, 18, 63, 64, 65, 180, 181, 182, 183, 583, 584, 586, 701, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714

<223> Xaa = Any Amino Acid or No Amino Acid

<400> 9

Met	Gly	Thr	Xaa	Cys	Ser	Ala	Arg	Ser	Trp	Trp	Pro	Leu	Xaa	Xaa	Xaa
1				5					10				15		

SEQUENCE LISTING_APMOL_005VPC

Xaa	Xaa	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Pro	Ala	Gly	Ala	Ala
Ala	Ala	Gln	Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Ala	Leu
Pro	Ser	Gln	Glu	Asp	Gly	Leu	Ala	Asp	Glu	Ala	Glu	His	Val	Xaa
Xaa	Ala	Thr	Ala	Thr	Phe	His	Arg	Cys	Ser	Lys	Asp	Ala	Trp	Arg
65					70					75				80
Pro	Gly	Thr	Tyr	Val	Val	Val	Leu	Lys	Glu	Glu	Thr	Gln	Arg	Leu
				85					90					95
Ser	Glu	Gln	Thr	Ala	His	Arg	Leu	Gln	Thr	Gln	Ala	Ala	Arg	Gly
			100					105					110	
Tyr	Val	Thr	Lys	Ile	Leu	His	Val	Phe	His	Asp	Leu	Leu	Pro	Gly
			115					120					125	
Leu	Val	Lys	Met	Ser	Ser	Asp	Leu	Leu	Asp	Leu	Ala	Leu	Lys	Leu
	130					135					140			Pro
His	Val	Asp	Tyr	Ile	Glu	Glu	Asp	Ser	Ser	Val	Phe	Ala	Gln	Ser
145					150					155				160
Pro	Trp	Asn	Leu	Glu	Arg	Ile	Ile	Pro	Ala	Arg	His	Gln	Ala	Asp
			165						170					175
Tyr	Ser	Ser	Xaa	Xaa	Xaa	Xaa	Pro	Asp	Gly	Ser	Ser	Gln	Val	Glu
			180					185					190	Val
Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Asp	His	Arg	Glu	Ile	Glu
			195				200					205		Gly
Arg	Val	Thr	Val	Thr	Asp	Phe	Asn	Ser	Val	Pro	Glu	Glu	Asp	Gly
	210					215					220			Thr
Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr	His
225					230					235				240
Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly	Thr
				245					250					255
Leu	Arg	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly	Lys	Gly	Thr	Ser
			260					265					270	
Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe	Ile	Arg	Lys	Ser	Gln	Leu	Ile
		275					280					285		Gln
Pro	Val	Gly	Pro	Leu	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Gly	Tyr
	290					295					300			Ser
Arg	Val	Leu	Asn	Ala	Ala	Cys	Gln	Arg	Leu	Ala	Arg	Thr	Gly	Val
305					310					315				320
Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu	Tyr
				325					330					335
Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asn	Ala
			340					345					350	Gln
Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly	Arg
		355					360					365		Cys
Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile	Ile	Gly	Ala	Ser	Ser
	370					375					380			Asp
Cys	Ser	Thr	Cys	Phe	Met	Ser	Gln	Ser	Gly	Thr	Ser	Gln	Ala	Ala
385					390					395				400
His	Val	Ala	Gly	Ile	Val	Ala	Met	Met	Leu	Ser	Ala	Glu	Pro	Glu
				405					410					415
Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile	His	Phe	Ser	Thr	Lys
			420					425					430	Asp
Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr
		435					440					445		Pro
Asn	Leu	Val	Ala	Thr	Leu	Pro	Ser	Thr	His	Gly	Thr	Gly	Gly	Gln
	450					455				460				
Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg
465					470					475				480
Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Asp	Glu	Glu	Leu	Leu	Ser
				485					490					495
Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg	Gly	Asp	Arg	Ile	Ala
			500					505					510	
Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala	Phe	Gly	Gly
		515					520					525		Glu
Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala	Asn
	530					535					540			Cys
Ser	Ile	His	Thr	Thr	Pro	Ala	Ala	Arg	Ala	Ser	Met	Glu	Thr	Val
545					550					555				560

SEQUENCE LISTING_APMOL_005VPC

His Cys His Gln Lys Asp His Val Leu Thr Gly Cys Ser Ser His Trp
 565 570 575
 Glu Val Glu Asp Leu Gly Xaa Xaa Lys Xaa Pro Val Leu Arg Ser Arg
 580 585 590
 Gly Gln Pro Gly Gln Cys Val Gly His Arg Glu Ala Ser Val His Ala
 595 600
 Ser Cys Cys His Ala Pro Gly Leu Glu Cys Lys Ile Lys Glu His Gly
 610 620
 Ile Pro Gly Pro Ala Glu Gln Val Thr Val Ala Cys Glu Ala Gly Trp
 625 630 635 640
 Thr Leu Thr Gly Cys Ser Val Leu Pro Gly Ala Ser Leu Val Leu Gly
 645 650 655
 Ala Tyr Ala Val Asp Asn Thr Cys Val Val Arg Ser Arg Asp Val Ser
 660 665 670
 Thr Ala Gly Arg Thr Ser Glu Glu Ala Thr Val Ala Ala Ile Cys
 675 680 685
 Cys Arg Ser Arg Pro Ser Ala Gln Ala Ser Trp Val Xaa Gln Xaa Xaa
 690 700
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His His His His His
 705 710 715 720
 His His

<210> 10
 <211> 293
 <212> PRT
 <213> Homo sapiens

<400> 10
 Ser Ile Pro Trp Asn Leu Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala
 1 5 10 15
 Asp Glu Tyr Gln Pro Pro Asp Gly Gly Ser Leu Val Glu Val Tyr Leu
 20 25 30
 Leu Asp Thr Ser Ile Gln Ser Asp His Arg Glu Ile Glu Gly Arg Val
 35 40 45
 Met Val Thr Asp Phe Glu Asn Val Pro Glu Glu Asp Gly Thr Arg Phe
 50 55 60
 His Arg Gln Ala Ser Lys Cys Asp Ser His Gly Thr His Leu Ala Gly
 65 70 75 80
 Val Val Ser Gly Arg Asp Ala Gly Val Ala Lys Gly Ala Ser Met Arg
 85 90 95
 Ser Leu Arg Val Leu Asn Cys Gln Gly Lys Gly Thr Val Ser Gly Thr
 100 105 110
 Leu Ile Gly Leu Glu Phe Ile Arg Lys Ser Gln Leu Val Gln Pro Val
 115 120 125
 Gly Pro Leu Val Val Leu Leu Pro Leu Ala Gly Gly Tyr Ser Arg Val
 130 135 140
 Leu Asn Ala Ala Cys Gln Arg Leu Ala Arg Ala Gly Val Val Leu Val
 145 150 155 160
 Thr Ala Ala Gly Asn Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala
 165 170 175
 Ser Ala Pro Glu Val Ile Thr Val Gly Ala Thr Asn Ala Gln Asp Gln
 180 185 190
 Pro Val Thr Leu Gly Thr Leu Gly Thr Asn Phe Gly Arg Cys Val Asp
 195 200 205
 Leu Phe Ala Pro Gly Glu Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser
 210 215 220
 Thr Cys Phe Val Ser Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val
 225 230 235 240
 Ala Gly Ile Ala Ala Met Met Leu Ser Ala Glu Pro Glu Leu Thr Leu
 245 250 255
 Ala Glu Leu Arg Gln Arg Leu Ile His Phe Ser Ala Lys Asp Val Ile
 260 265 270
 Asn Glu Ala Trp Phe Pro Glu Asp Gln Arg Val Leu Thr Pro Asn Leu
 275 280 285
 Val Ala Ala Leu Pro
 290

SEQUENCE_LISTING_APMOL_005VPC

<210> 11
 <211> 293
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Consensus sequence

<220>
 <221> VARI ANT
 <222> 7, 10, 11, 12, 13, 14, 16, 17, 20, 23, 24, 26, 27, 37, 40,
 47, 49, 51, 55, 58, 62, 63, 66, 72, 78, 82, 91, 92, 94,
 95, 98, 113, 114, 121, 122, 128, 129, 132, 137, 141, 144,
 150, 151, 153, 155, 157, 158, 159, 160, 161, 166, 172, 178
 <223> Xaa = Any Amino Acid or No Amino Acid

<220>
 <221> VARI ANT
 <222> 194, 195, 198, 224, 228, 245, 247, 249, 253, 256, 257, 268,
 270, 271, 283, 291
 <223> Xaa = Any Amino Acid or No Amino Acid

<400> 11
 Ser Ile Pro Trp Asn Leu Xaa Arg Ile Xaa Xaa Xaa Xaa Xaa Arg Xaa
 1 5 10 15
 Xaa Glu Tyr Xaa Pro Pro Xaa Xaa Gly Xaa Xaa Val Glu Val Tyr Leu
 20 25 30
 Leu Asp Thr Ser Xaa Gn Ser Xaa His Arg Glu Ile Glu Gly Xaa Val
 35 40 45
 Xaa Val Xaa Asp Phe Glu Xaa Val Pro Xaa Glu Asp Gly Xaa Xaa Phe
 50 55 60
 His Xaa Gn Ala Ser Lys Cys Xaa Ser His Gly Thr His Xaa Ala Gly
 65 70 75 80
 Val Xaa Ser Gly Arg Asp Ala Gly Val Ala Xaa Xaa Ala Xaa Xaa Arg
 85 90 95
 Ser Xaa Arg Val Leu Asn Cys Gn Gly Lys Gly Thr Val Ser Gly Thr
 100 105 110
 Xaa Xaa Gly Leu Glu Phe Ile Arg Xaa Xaa Gn Leu Val Gn Pro Xaa
 115 120 125
 Xaa Pro Leu Xaa Val Leu Leu Pro Xaa Ala Gly Gly Xaa Ser Arg Xaa
 130 135 140
 Leu Asn Ala Ala Cys Xaa Xaa Leu Xaa Arg Xaa Gly Xaa Xaa Xaa Xaa
 145 150 155 160
 Xaa Ala Ala Gly Asn Xaa Arg Asp Asp Ala Cys Xaa Tyr Ser Pro Ala
 165 170 175
 Ser Xaa Pro Glu Val Ile Thr Val Gly Ala Thr Asn Ala Gn Asp Gn
 180 185 190
 Pro Xaa Xaa Leu Gly Xaa Leu Gly Thr Asn Phe Gly Arg Cys Val Asp
 195 200 205
 Leu Phe Ala Pro Gly Gu Asp Ile Ile Gly Ala Ser Ser Asp Cys Xaa
 210 215 220
 Thr Cys Phe Xaa Ser Gn Ser Gly Thr Ser Gn Ala Ala Ala His Val
 225 230 235 240
 Ala Gly Ile Ala Xaa Met Xaa Leu Xaa Ala Glu Pro Xaa Leu Thr Xaa
 245 250 255
 Xaa Glu Leu Arg Gn Arg Leu Ile His Phe Ser Xaa Lys Xaa Xaa Ile
 260 265 270
 Asn Glu Ala Trp Phe Pro Gu Asp Gn Arg Xaa Leu Thr Pro Asn Leu
 275 280 285
 Val Ala Xaa Leu Pro
 290

<210> 12
 <211> 293
 <212> PRT

SEQUENCE_LISTING_APMOL_005VPC

<213> Monodelphis domestica

<400> 12

```

Ser Ile Pro Trp Asn Leu Asp Arg Ile Val Leu Ala Pro Ser Arg Ser
 1      5      10      15
Glu Glu Tyr Ser Pro Pro Asn Lys Gly Asp Gln Val Glu Val Tyr Leu
 20      25      30
Leu Asp Thr Ser Leu Gln Ser Gly His Arg Glu Ile Glu Gly Lys Val
 35      40      45
Thr Val Ala Asp Phe Glu Asp Val Pro Asp Glu Asp Gly Ala Gln Phe
 50      55      60
His Ser Gln Ala Ser Lys Cys Glu Ser His Gly Thr His Val Ala Gly
 65      70      75      80
Val Leu Ser Gly Arg Asp Ala Gly Val Ala Arg Ala Ala Val Arg
 85      90      95
Ser Val Arg Val Leu Asn Cys Gln Gly Lys Gly Thr Val Ser Gly Thr
 100      105      110
Ala Arg Gly Leu Glu Phe Ile Arg Arg Thr Gln Leu Val Gln Pro Tyr
 115      120      125
Ser Pro Leu Ile Val Leu Leu Pro Phe Ala Gly Gly His Ser Arg Thr
 130      135      140
Leu Asn Ala Ala Cys Arg Leu Leu Val Arg Ser Gly Ala Ala Val Ile
 145      150      155      160
Ala Ala Ala Gly Asn Tyr Arg Asp Asp Ala Cys Ser Tyr Ser Pro Ala
 165      170      175
Ser Glu Pro Glu Val Ile Thr Val Gly Ala Thr Asn Ala Gln Asp Gln
 180      185      190
Pro Ala Ala Leu Gly Ala Leu Gly Thr Asn Phe Gly Arg Cys Val Asp
 195      200      205
Leu Phe Ala Pro Gly Glu Asp Ile Ile Gly Ala Ser Ser Asp Cys Gly
 210      215      220
Thr Cys Phe Thr Ser Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val
 225      230      235      240
Ala Gly Ile Ala Ser Met Leu Leu Asn Ala Glu Pro Ser Leu Thr Val
 245      250      255
Pro Glu Leu Arg Gln Arg Leu Ile His Phe Ser Val Lys Asn Ala Ile
 260      265      270
Asn Glu Ala Trp Phe Pro Glu Asp Gln Arg Leu Leu Thr Pro Asn Leu
 275      280      285
Val Ala Arg Leu Pro
 290

```

<210> 13

<211> 293

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence

<220>

<221> VARI ANT

<222> 2, 7, 10, 12, 13, 14, 15, 17, 18, 19, 20, 23, 24, 26, 27,
40, 47, 49, 54, 72, 78, 83, 93, 94, 95, 112, 114, 122, 123,
124, 125, 128, 129, 132, 134, 135, 137, 138, 144, 149, 150,
151, 153, 154, 155, 158, 159, 160, 161, 166, 167, 178

<223> Xaa = Any Amino Acid or No Amino Acid

<220>

<221> VARI ANT

<222> 184, 189, 194, 196, 198, 203, 205, 207, 214, 228, 230, 247,
249, 250, 251, 253, 255, 256, 257, 265, 268, 270, 275, 283,
284, 288, 291

<223> Xaa = Any Amino Acid or No Amino Acid

<400> 13

```

Ser Xaa Pro Trp Asn Leu Xaa Arg Ile Xaa Pro Xaa Xaa Xaa Xaa Ala

```

SEQUENCE_LI STI NG_APMOL_005VPC

1	Xaa	Xaa	Xaa	5	Pro	Pro	Xaa	Xaa	10	Xaa	Xaa	Val	Gl u	Val	15	Tyr	Leu
			20						25					30			
Leu	Asp	Thr	Ser	I le	G n	Ser	Xaa	Hi s	Arg	Gl u	I le	Gl u	Gl y	Xaa	Val		
		35					40					45					
Xaa	Val	Thr	Asp	Phe	Xaa	Asn	Val	Pro	Gl u	Gl u	Asp	Gl y	Thr	Arg	Phe		
	50					55					60						
Hi s	Arg	G n	Al a	Ser	Lys	Oys	Xaa	Ser	Hi s	Gl y	Thr	Hi s	Xaa	Al a	Gl y		
65					70					75					80		
Val	Val	Xaa	Gl y	Arg	Asp	Al a	Gl y	Val	Al a	Lys	Gl y	Xaa	Xaa	Xaa	Arg		
				85					90					95			
Ser	Leu	Arg	Val	Leu	Asn	Oys	G n	Gl y	Lys	Gl y	Thr	Val	Ser	Gl y	Xaa		
			100					105					110				
Leu	Xaa	Gl y	Leu	Gl u	Phe	I le	Arg	Lys	Xaa	Xaa	Xaa	Xaa	G n	Pro	Xaa		
		115					120						125				
Xaa	Pro	Leu	Xaa	Val	Xaa	Xaa	Pro	Xaa	Xaa	Gl y	Gl y	Tyr	Ser	Arg	Xaa		
	130					135					140						
Leu	Asn	Al a	Al a	Xaa	Xaa	Xaa	Leu	Xaa	Xaa	Xaa	Gl y	Val	Xaa	Xaa	Xaa		
145					150					155					160		
Xaa	Al a	Al a	Gl y	Asn	Xaa	Xaa	Asp	Asp	Al a	Oys	Leu	Tyr	Ser	Pro	Al a		
				165					170					175			
Ser	Xaa	Pro	Gl u	Val	I le	Thr	Xaa	Gl y	Al a	Thr	Asn	Xaa	G n	Asp	G n		
		180						185					190				
Pro	Xaa	Thr	Xaa	Gl y	Xaa	Leu	Gl y	Thr	Asn	Xaa	Gl y	Xaa	Oys	Xaa	Asp		
		195					200					205					
Leu	Phe	Al a	Pro	Gl y	Xaa	Asp	I le	I le	Gl y	Al a	Ser	Asp	Oys	Ser			
	210					215					220						
Thr	Oys	Phe	Xaa	Ser	Xaa	Ser	Gl y	Thr	Ser	G n	Al a	Al a	Al a	Hi s	Val		
225					230					235					240		
Al a	Gl y	I le	Al a	Al a	Met	Xaa	Leu	Xaa	Xaa	Xaa	Pro	Xaa	Leu	Xaa	Xaa		
				245						250				255			
Xaa	Gl u	Leu	Arg	G n	Arg	Leu	I le	Xaa	Phe	Ser	Xaa	Lys	Xaa	Val	I le		
			260					265					270				
Asn	Gl u	Xaa	Trp	Phe	Pro	Gl u	Asp	G n	Arg	Xaa	Xaa	Thr	Pro	Asn	Xaa		
		275					280					285					
Val	Al a	Xaa	Leu	Pro													
	290																

<210> 14
 <211> 293
 <212> PRT
 <213> Xenopus laevis

<400> 14	Ser	Val	Pro	Trp	Asn	Leu	Asp	Arg	I le	Val	Pro	Al a	G n	G n	Met	Al a	
	1				5					10					15		
Ser	G n	Phe	Ser	Pro	Pro	Asn	Thr	Gl y	Asp	Ser	Val	Gl u	Val	Tyr	Leu		
			20					25					30				
Leu	Asp	Thr	Ser	I le	G n	Ser	Asn	Hi s	Arg	Gl u	I le	Gl u	Gl y	Lys	Val		
		35					40					45					
Phe	Val	Thr	Asp	Phe	G n	Asn	Val	Pro	Gl u	Gl u	Asp	Gl y	Thr	Arg	Phe		
	50					55					60						
Hi s	Arg	G n	Al a	Ser	Lys	Oys	Gl u	Ser	Hi s	Gl y	Thr	Hi s	Met	Al a	Gl y		
65					70					75					80		
Val	Val	Asn	Gl y	Arg	Asp	Al a	Gl y	Val	Al a	Lys	Gl y	Val	Asn	Val	Arg		
				85					90				95				
Ser	Leu	Arg	Val	Leu	Asn	Oys	G n	Gl y	Lys	Gl y	Thr	Val	Ser	Gl y	Ser		
			100					105					110				
Leu	Thr	Gl y	Leu	Gl u	Phe	I le	Arg	Lys	Thr	Leu	I le	Gl u	G n	Pro	Tyr		
		115					120					125					
Asn	Pro	Leu	I le	Val	I le	I le	Pro	Phe	Val	Gl y	Gl y	Tyr	Ser	Arg	I le		
	130					135					140						
Leu	Asn	Al a	Al a	Ser	Arg	Al a	Leu	Val	Asn	Thr	Gl y	Val	I le	I le	I le		
145					150					155					160		
Al a	Al a	Al a	Gl y	Asn	Tyr	Lys	Asp	Asp	Al a	Oys	Leu	Tyr	Ser	Pro	Al a		
				165					170					175			
Ser	Gl u	Pro	Gl u	Val	I le	Thr	I le	Gl y	Al a	Thr	Asn	Tyr	G n	Asp	G n		

SEQUENCE LISTING_APMOL_005VPC

Pro	Ala	Thr	180	Gly	Val	Leu	Gly	185	Thr	Asn	Tyr	Gly	Asn	190	Cys	Ile	Asp
		195	Met					200						205			
Leu	Phe	Ala	Pro	Gly	Asp	Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser		
	210					215						220					
Thr	Cys	Phe	Thr	Ser	Lys	Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala	His	Val		
225					230					235					240		
Ala	Gly	Ile	Ala	Ala	Met	Ile	Leu	Asn	Asp	Lys	Pro	Asp	Leu	Ser	Val		
				245					250					255			
Ser	Glu	Leu	Arg	Gln	Arg	Leu	Ile	Gln	Phe	Ser	Thr	Lys	Lys	Val	Ile		
			260					265						270			
Asn	Glu	Val	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Leu	Ile	Thr	Pro	Asn	Arg		
		275					280						285				
Val	Ala	Gly	Leu	Pro													
	290																

<210> 15

<211> 323

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence

<220>

<221> VARIANT

<222> 3, 6, 12, 18, 21, 26, 30, 35, 38, 41, 44, 50, 61, 62, 66, 68, 78, 80, 83, 92, 100, 104, 110, 131, 135, 145, 152, 173, 176, 177, 180, 184, 185, 188, 189, 191, 192, 193, 194, 195, 198

<223> Xaa = Any Amino Acid or No Amino Acid

<400> 15

Pro	Trp	Xaa	Leu	Xaa	Arg	Xaa	Xaa	Xaa	Pro	Arg	Xaa	Arg	Xaa	Xaa	Xaa		
1				5					10					15			
Xaa	Xaa	Xaa	Pro	Xaa	Xaa	Gly	Xaa	Xaa	Val	Glu	Val	Tyr	Leu	Xaa	Asp		
			20					25					30				
Xaa	Ser	Xaa	Xaa	Ser	Xaa	His	Arg	Glu	Xaa	Xaa	Gly	Arg	Val	Xaa	Val		
	35						40					45					
Thr	Asp	Phe	Xaa	Xaa	Val	Pro	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	His	Arg		
	50					55						60					
Xaa	Ala	Ser	Xaa	Cys	Xaa	His	Gly	Thr	His	Xaa	Ala	Xaa	Val	Val			
65				70					75					80			
Xaa	Gly	Xaa	Asp	Xaa	Gly	Val	Ala	Xaa	Gly	Ala	Xaa	Xaa	Xaa	Xaa	Xaa		
			85					90					95				
Arg	Val	Leu	Xaa	Cys	Xaa	Gly	Lys	Gly	Thr	Val	Ser	Gly	Xaa	Leu	Xaa		
			100					105					110				
Gly	Xaa	Glu	Xaa	Ile	Arg	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Pro	Xaa	Gly	Xaa		
		115					120					125					
Xaa	Val	Val	Leu	Leu	Pro	Xaa	Xaa	Gly	Xaa	Xaa	Ser	Arg	Xaa	Leu	Asn		
	130					135					140						
Ala	Ala	Cys	Xaa	Xaa	Leu	Xaa	Xaa	Xaa	Gly	Xaa	Val	Xaa	Val	Xaa	Ala		
145					150				155					160			
Ala	Gly	Asn	Xaa	Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Xaa		
			165					170					175				
Pro	Glu	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa		
			180					185					190				
Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa		
		195						200				205					
Xaa	Val	Ile	Thr	Val	Gly	Ala	Xaa	Asn	Xaa	Xaa	Asp	Gln	Xaa	Val	Xaa		
	210					215					220						
Xaa	Gly	Xaa	Xaa	Gly	Thr	Asn	Xaa	Gly	Arg	Cys	Val	Asp	Xaa	Phe	Ala		
225				230						235				240			
Pro	Gly	Xaa	Asp	Ile	Xaa	Xaa	Ala	Ser	Ser	Asp	Cys	Xaa	Thr	Cys	Phe		
			245					250					255				
Xaa	Ser	Xaa	Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala	His	Xaa	Ala	Gly	Xaa		
			260					265					270				

SEQUENCE LISTING_APMOL_005VPC

Ala Ala Xaa Xaa Leu Ser Xaa Xaa Pro Xaa Leu Thr Xaa Xaa Xaa Xaa
 275 280 285
 Xaa Gln Xaa Leu Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 290 295 300
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Pro Xaa Leu Val Ala Ala
 305 310 315 320
 Leu Pro Pro

<210> 16
 <211> 312
 <212> PRT
 <213> Tetraodon nigroviridis

<400> 16
 Pro Trp Ser Leu Arg Arg Leu Pro Arg Pro Arg Gly Arg Pro Gly Asp
 1 5 10 15
 Gly Ala Ala Val Glu Val Tyr Leu Met Asp Gly Ser Val Leu Ser Ser
 20 25 30
 His Arg Glu Leu Gly Gly Arg Val Leu Val Thr Asp Phe His Ser Val
 35 40 45
 Pro Val Gly Glu Ala Gly Gly His Arg Glu Ala Ser Arg Cys Lys Gly
 50 55 60
 His Gly Thr His Val Ala Ala Val Val Met Gly Ser Asp Thr Gly Val
 65 70 75 80
 Ala Pro Gly Ala Arg Val Asn Leu Val Arg Val Leu Asp Cys Arg Gly
 85 90 95
 Lys Gly Thr Val Ser Gly Ala Leu Ala Gly Val Glu Tyr Ile Arg Ala
 100 105 110
 Ala Leu Arg Ala His Pro Pro Gly Ala Ala Val Val Leu Leu Pro Phe
 115 120 125
 Thr Gly Ala Phe Ser Arg Ser Leu Asn Ala Ala Cys Arg Asp Leu Val
 130 135 140
 Asn Thr Gly Ala Val Val Val Ala Ala Ala Gly Asn Tyr Arg Asp Asp
 145 150 155 160
 Ala Cys Leu Tyr Ser Pro Ala Ser Glu Pro Glu Val Cys Thr Gly Gly
 165 170 175
 Ser Ala Arg Ser His Thr His Thr His Thr His Thr His Thr His Leu
 180 185 190
 Leu Gln Ala Val Leu Cys Val Cys Val Gln Val Ile Thr Val Gly Ala
 195 200 205
 Val Asn Ser Ala Asp Gln Leu Val Ser Gln Gly Pro Gly Gly Thr Asn
 210 215 220
 Val Gly Arg Cys Val Asp Val Phe Ala Pro Gly Gly Asp Ile Val Ser
 225 230 235 240
 Ala Ser Ser Asp Cys Asp Thr Cys Phe Ala Ser Gly Ser Gly Thr Ser
 245 250 255
 Gln Ala Ala Ala His Ala Ala Gly Met Ala Ala Val Leu Leu Ser Ser
 260 265 270
 Ser Pro Ser Leu Thr Pro Val Gln Val Leu Gln Thr Leu Leu Arg Tyr
 275 280 285
 Ser Val Ser Leu Pro Ser Val Ser Gly Arg Arg Gly Leu Val Thr Pro
 290 295 300
 Ser Leu Val Ala Ala Leu Pro Pro
 305 310

<210> 17
 <211> 292
 <212> PRT
 <213> Homo sapiens

<400> 17
 Pro Trp Asn Leu Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu
 1 5 10 15
 Tyr Gln Pro Pro Asp Gly Gly Ser Leu Val Glu Val Tyr Leu Leu Asp
 20 25 30

SEQUENCE LISTING_APMOL_005VPC

Thr	Ser	Ile	Gln	Ser	Asp	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Met	Val
	35						40					45			
Thr	Asp	Phe	Glu	Asn	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg
	50					55					60				
Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr	His	Leu	Ala	Gly	Val	Val
65					70					75					80
Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly	Ala	Ser	Met	Arg	Ser	Leu
				85					90					95	
Arg	Val	Leu	Asn	Cys	Gln	Gly	Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile
			100					105					110		
Gly	Leu	Glu	Phe	Ile	Arg	Lys	Ser	Gln	Leu	Val	Gln	Pro	Val	Gly	Pro
		115					120					125			
Leu	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Gly	Tyr	Ser	Arg	Val	Leu	Asn
		130				135					140				
Ala	Ala	Cys	Gln	Arg	Leu	Ala	Arg	Ala	Gly	Val	Val	Leu	Val	Thr	Ala
145					150					155					160
Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala
				165					170					175	
Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val
			180					185					190		
Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe
		195					200					205			
Ala	Pro	Gly	Glu	Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys
	210				215						220				
Phe	Val	Ser	Gln	Ser	Gly	Thr	Ser	Gln	Ala	Ala	His	Val	Ala	Gly	
225					230					235				240	
Ile	Ala	Ala	Met	Met	Leu	Ser	Ala	Glu	Pro	Glu	Leu	Thr	Leu	Ala	Glu
				245					250					255	
Leu	Arg	Gln	Arg	Leu	Ile	His	Phe	Ser	Ala	Lys	Asp	Val	Ile	Asn	Glu
			260					265					270		
Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr	Pro	Asn	Leu	Val	Ala
		275					280					285			
Ala	Leu	Pro	Pro												
	290														

<210> 18
 <211> 860
 <212> PRT
 <213> Homo sapiens

Met	Gly	Pro	Trp	Gly	Trp	Lys	Leu	Arg	Trp	Thr	Val	Ala	Leu	Leu	Leu
1				5					10				15		
Ala	Ala	Ala	Gly	Thr	Ala	Val	Gly	Asp	Arg	Cys	Glu	Arg	Asn	Glu	Phe
			20					25					30		
Gln	Cys	Gln	Asp	Gly	Lys	Cys	Ile	Ser	Tyr	Lys	Trp	Val	Cys	Asp	Gly
			35				40					45			
Ser	Ala	Glu	Cys	Gln	Asp	Gly	Ser	Asp	Glu	Ser	Gln	Glu	Thr	Cys	Leu
	50					55					60				
Ser	Val	Thr	Cys	Lys	Ser	Gly	Asp	Phe	Ser	Cys	Gly	Gly	Arg	Val	Asn
65					70					75					80
Arg	Cys	Ile	Pro	Gln	Phe	Trp	Arg	Cys	Asp	Gly	Gln	Val	Asp	Cys	Asp
				85					90					95	
Asn	Gly	Ser	Asp	Glu	Gln	Gly	Cys	Pro	Pro	Lys	Thr	Cys	Ser	Gln	Asp
			100					105					110		
Glu	Phe	Arg	Cys	His	Asp	Gly	Lys	Cys	Ile	Ser	Arg	Gln	Phe	Val	Cys
		115					120					125			
Asp	Ser	Asp	Arg	Asp	Cys	Leu	Asp	Gly	Ser	Asp	Glu	Ala	Ser	Cys	Pro
	130					135					140				
Val	Leu	Thr	Cys	Gly	Pro	Ala	Ser	Phe	Gln	Cys	Asn	Ser	Ser	Thr	Cys
145					150					155					160
Ile	Pro	Gln	Leu	Trp	Ala	Cys	Asp	Asn	Asp	Pro	Asp	Cys	Glu	Asp	Gly
				165					170					175	
Ser	Asp	Glu	Trp	Pro	Gln	Arg	Cys	Arg	Gly	Leu	Tyr	Val	Phe	Gln	Gly
			180					185					190		
Asp	Ser	Ser	Pro	Cys	Ser	Ala	Phe	Glu	Phe	His	Cys	Leu	Ser	Gly	Glu
		195					200					205			

SEQUENCE LISTING_APMOL_005VPC

Cys 210	Ile	His	Ser	Ser	Trp	Arg 215	Cys	Asp	Gly	Gly	Pro 220	Asp	Cys	Lys	Asp
Lys 225	Ser	Asp	Glu	Glu	Asn 230	Cys	Ala	Val	Ala	Thr 235	Cys	Arg	Pro	Asp	Glu 240
Phe	Gln	Cys	Ser	Asp 245	Gly	Asn	Cys	Ile	His 250	Gly	Ser	Arg	Gln	Cys 255	Asp
Arg	Glu	Tyr	Asp 260	Cys	Lys	Asp	Met	Ser 265	Asp	Glu	Val	Gly	Cys 270	Val	Asn
Val	Thr	Leu 275	Cys	Glu	Gly	Pro	Asn 280	Lys	Phe	Lys	Cys	His 285	Ser	Gly	Glu
Cys 290	Ile	Thr	Leu	Asp	Lys	Val 295	Cys	Asn	Met	Ala	Arg 300	Asp	Cys	Arg	Asp
Trp 305	Ser	Asp	Glu	Pro	Ile 310	Lys	Glu	Cys	Gly	Thr 315	Asn	Glu	Cys	Leu	Asp 320
Asn	Asn	Gly	Gly	Cys 325	Ser	His	Val	Cys	Asn 330	Asp	Leu	Lys	Ile	Gly 335	Tyr
Glu	Cys	Leu	Cys 340	Pro	Asp	Gly	Phe	Gln	Leu	Val	Ala	Gln	Arg 350	Arg	Cys
Glu	Asp	Ile 355	Asp	Glu	Cys	Gln	Asp 360	Pro	Asp	Thr	Cys	Ser 365	Gln	Leu	Cys
Val	Asn 370	Leu	Glu	Gly	Gly	Tyr 375	Lys	Cys	Gln	Cys	Glu 380	Glu	Gly	Phe	Gln
Leu 385	Asp	Pro	His	Thr	Lys 390	Ala	Cys	Lys	Ala	Val 395	Gly	Ser	Ile	Ala	Tyr 400
Leu	Phe	Phe	Thr	Asn 405	Arg	His	Glu	Val	Arg 410	Lys	Met	Thr	Leu	Asp 415	Arg
Ser	Glu	Tyr	Thr 420	Ser	Leu	Ile	Pro	Asn 425	Leu	Arg	Asn	Val 430	Val	Ala	Leu
Asp	Thr	Glu 435	Val	Ala	Ser	Asn	Arg 440	Ile	Tyr	Trp	Ser	Asp 445	Leu	Ser	Gln
Arg	Met 450	Ile	Cys	Ser	Thr	Gln 455	Leu	Asp	Arg	Ala	His 460	Gly	Val	Ser	Ser
Tyr 465	Asp	Thr	Val	Ile	Ser 470	Arg	Asp	Ile	Gln	Ala 475	Pro	Asp	Gly	Leu	Ala 480
Val	Asp	Trp	Ile	His 485	Ser	Asn	Ile	Tyr	Trp 490	Thr	Asp	Ser	Val	Leu 495	Gly
Thr	Val	Ser	Val 500	Ala	Asp	Thr	Lys	Gly 505	Val	Lys	Arg	Lys	Thr 510	Leu	Phe
Arg	Glu	Asn 515	Gly	Ser	Lys	Pro	Arg 520	Ala	Ile	Val	Val	Asp 525	Pro	Val	His
Gly	Phe 530	Met	Tyr	Trp	Thr	Asp 535	Trp	Gly	Thr	Pro	Ala 540	Lys	Ile	Lys	Lys
Gly 545	Gly	Leu	Asn	Gly	Val 550	Asp	Ile	Tyr	Ser	Leu 555	Val	Thr	Glu	Asn	Ile 560
Gln	Trp	Pro	Asn 565	Gly	Ile	Thr	Leu	Asp	Leu 570	Leu	Ser	Gly	Arg	Leu 575	Tyr
Trp	Val	Asp	Ser 580	Lys	Leu	His	Ser	Ile 585	Ser	Ser	Ile	Asp	Val 590	Asn	Gly
Gly	Asn 595	Arg	Lys	Thr	Ile	Leu	Glu 600	Asp	Glu	Lys	Arg	Leu 605	Ala	His	Pro
Phe	Ser 610	Leu	Ala	Val	Phe	Glu 615	Asp	Lys	Val	Phe	Trp 620	Thr	Asp	Ile	Ile
Asn 625	Glu	Ala	Ile	Phe	Ser 630	Ala	Asn	Arg	Leu	Thr 635	Gly	Ser	Asp	Val	Asn 640
Leu	Leu	Ala	Glu	Asn 645	Leu	Leu	Ser	Pro	Glu 650	Asp	Met	Val	Leu	Phe 655	His
Asn	Leu	Thr	Gln 660	Pro	Arg	Gly	Val	Asn 665	Trp	Cys	Glu	Arg	Thr 670	Thr	Leu
Ser	Asn 675	Gly	Gly	Cys	Gln	Tyr	Leu 680	Cys	Leu	Pro	Ala	Pro 685	Gln	Ile	Asn
Pro	His 690	Ser	Pro	Lys	Phe	Thr 695	Cys	Ala	Cys	Pro	Asp 700	Gly	Met	Leu	Leu
Ala 705	Arg	Asp	Met	Arg	Ser 710	Oys	Leu	Thr	Glu	Ala 715	Glu	Ala	Ala	Val	Ala 720
Thr	Gln	Glu	Thr	Ser 725	Thr	Val	Arg	Leu	Lys 730	Val	Ser	Ser	Thr	Ala 735	Val
Arg	Thr	Gln 740	His	Thr	Thr	Thr	Arg	Pro 745	Val	Pro	Asp	Thr	Ser 750	Arg	Leu

SEQUENCE LISTING_APMOL_005VPC

Pro	Gly	Ala	Thr	Pro	Gly	Leu	Thr	Thr	Val	Glu	Ile	Val	Thr	Met	Ser
		755				760						765			
His	Gln	Ala	Leu	Gly	Asp	Val	Ala	Gly	Arg	Gly	Asn	Glu	Lys	Lys	Pro
	770					775					780				
Ser	Ser	Val	Arg	Ala	Leu	Ser	Ile	Val	Leu	Pro	Ile	Val	Leu	Leu	Val
785					790					795					800
Phe	Leu	Cys	Leu	Gly	Val	Phe	Leu	Leu	Trp	Lys	Asn	Trp	Arg	Leu	Lys
				805					810					815	
Asn	Ile	Asn	Ser	Ile	Asn	Phe	Asp	Asn	Pro	Val	Tyr	Gln	Lys	Thr	Thr
			820					825					830		
Glu	Asp	Glu	Val	His	Ile	Cys	His	Asn	Gln	Asp	Gly	Tyr	Ser	Tyr	Pro
		835					840					845			
Ser	Arg	Gln	Met	Val	Ser	Leu	Glu	Asp	Asp	Val	Ala				
	850					855					860				

<210> 19

<211> 860

<212> PRT

<213> Macaca fascicularis

<400> 19

Met	Glu	Pro	Trp	Gly	Trp	Lys	Leu	Arg	Trp	Thr	Val	Ala	Phe	Leu	Leu
1				5					10					15	
Ala	Ala	Ala	Glu	Ala	Ala	Val	Gly	Asp	Arg	Cys	Glu	Arg	Asn	Glu	Phe
			20					25					30		
Gln	Cys	Glu	Asp	Gly	Lys	Cys	Ile	Ser	Tyr	Lys	Trp	Val	Cys	Asp	Gly
		35					40					45			
Thr	Ala	Glu	Cys	Gln	Asp	Gly	Ser	Asp	Glu	Ser	Gln	Glu	Thr	Cys	Leu
	50					55					60				
Ser	Val	Thr	Cys	Lys	Ser	Gly	Asp	Phe	Ser	Cys	Gly	Gly	Arg	Val	Asn
65					70					75					80
Arg	Cys	Ile	Pro	Gln	Phe	Trp	Arg	Cys	Asp	Gly	Glu	Val	Asp	Cys	Glu
				85					90					95	
Asn	Gly	Ser	Asp	Glu	Gln	Asp	Cys	Pro	Pro	Lys	Thr	Cys	Ser	Gln	Asp
			100					105					110		
Glu	Phe	Arg	Cys	His	Asp	Gly	Lys	Cys	Ile	Tyr	Arg	Gln	Phe	Val	Cys
		115					120					125			
Asp	Ser	Asp	Arg	Asp	Cys	Leu	Asp	Gly	Ser	Asp	Glu	Ala	Ser	Cys	Pro
	130					135					140				
Val	Leu	Thr	Cys	Gly	Pro	Ala	Ser	Phe	Gln	Cys	Asn	Ser	Ser	Thr	Cys
145					150					155					160
Ile	Pro	Gln	Leu	Trp	Ala	Cys	Asp	Asn	Asp	Pro	Asp	Cys	Glu	Asp	Gly
			165						170					175	
Ser	Asp	Glu	Trp	Pro	Gln	His	Cys	Gln	Gly	Leu	Glu	Val	Pro	Lys	Arg
		180						185					190		
Asp	Ser	Ser	Pro	Cys	Ser	Ala	Phe	Glu	Phe	His	Cys	Gln	Ser	Gly	Glu
		195					200					205			
Cys	Ile	His	Ser	Gly	Trp	Arg	Cys	Asp	Gly	Gly	Pro	Asp	Cys	Lys	Asp
	210					215					220				
Lys	Ser	Asp	Glu	Glu	Asn	Cys	Pro	Val	Ala	Thr	Cys	Arg	Pro	Asp	Glu
225					230					235					240
Phe	Gln	Cys	Ser	Asp	Gly	Thr	Cys	Ile	His	Gly	Ser	Arg	Gln	Cys	Asp
				245					250					255	
Arg	Glu	Tyr	Asp	Cys	Lys	Asp	Met	Ser	Asp	Glu	Val	Gly	Cys	Ile	Asn
			260					265					270		
Val	Thr	Leu	Cys	Glu	Gly	Pro	Asn	Lys	Phe	Lys	Cys	His	Ser	Gly	Glu
		275					280					285			
Cys	Ile	Ser	Leu	Asp	Lys	Val	Cys	Asn	Met	Ala	Arg	Asp	Cys	Arg	Asp
	290					295					300				
Trp	Ser	Asp	Glu	Pro	Ile	Lys	Glu	Cys	Gly	Thr	Asn	Glu	Cys	Leu	Asp
305					310					315					320
Asn	Asn	Gly	Gly	Cys	Ser	His	Ile	Cys	Asn	Asp	Leu	Lys	Ile	Gly	Tyr
				325					330					335	
Glu	Cys	Leu	Cys	Pro	Asp	Gly	Phe	Gln	Leu	Val	Ala	Gln	Arg	Arg	Cys
			340					345					350		
Glu	Asp	Ile	Asp	Glu	Cys	Gln	Asp	Pro	Asp	Thr	Cys	Ser	Gln	Leu	Cys
		355					360					365			

SEQUENCE LISTING_APMOL_005VPC

Val	Asn	Leu	Glu	Gly	Ser	Tyr	Lys	Cys	Gln	Cys	Glu	Glu	Gly	Phe	Gln
370	370					375					380				
Leu	Asp	Pro	His	Thr	Lys	Ala	Cys	Lys	Ala	Val	Gly	Ser	Ile	Ala	Tyr
385					390					395					400
Leu	Ile	Phe	Thr	Asn	Arg	His	Glu	Val	Arg	Lys	Met	Thr	Leu	Asp	Arg
				405					410					415	
Ser	Glu	Tyr	Thr	Ser	Leu	Ile	Pro	Asn	Leu	Arg	Asn	Val	Val	Ala	Leu
				420				425					430		
Asp	Thr	Glu	Val	Ala	Ser	Asn	Arg	Ile	Tyr	Trp	Ser	Asp	Leu	Ser	Gln
		435					440					445			
Arg	Met	Ile	Tyr	Ser	Thr	Gln	Leu	Asp	Arg	Ala	His	Ser	Val	Ser	Ser
	450					455					460				
Tyr	Asp	Thr	Val	Ile	Ser	Arg	Asp	Leu	Gln	Ala	Pro	Asp	Gly	Leu	Ala
465					470					475					480
Val	Asp	Trp	Ile	His	Ser	Asn	Ile	Tyr	Trp	Thr	Asp	Ser	Val	Leu	Gly
				485					490					495	
Thr	Val	Ser	Val	Ala	Asp	Thr	Lys	Gly	Val	Lys	Arg	Lys	Thr	Leu	Phe
			500					505					510		
Arg	Glu	Asn	Gly	Ser	Lys	Pro	Arg	Ala	Ile	Val	Val	Asp	Pro	Val	His
		515					520					525			
Gly	Phe	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Thr	Pro	Ala	Lys	Ile	Lys	Lys
	530					535					540				
Gly	Gly	Leu	Asn	Gly	Val	Asp	Ile	Tyr	Ser	Leu	Val	Thr	Glu	Asn	Ile
545					550					555					560
Glu	Trp	Pro	Asn	Gly	Ile	Thr	Leu	Asp	Phe	Pro	Ser	Gly	Arg	Leu	Tyr
				565					570					575	
Trp	Val	Asp	Ser	Lys	Leu	His	Ser	Ile	Ser	Ser	Ile	Asp	Val	Asn	Gly
			580					585					590		
Gly	Asn	Arg	Lys	Thr	Val	Leu	Glu	Asp	Glu	Glu	Arg	Leu	Ala	His	Pro
		595					600					605			
Phe	Ser	Leu	Ala	Ile	Phe	Glu	Asp	Lys	Val	Phe	Trp	Thr	Asp	Ile	Ile
	610					615					620				
Asn	Glu	Ala	Ile	Phe	Ser	Ala	Asn	Arg	Leu	Thr	Gly	Ser	Asp	Ile	Asn
625					630					635					640
Leu	Leu	Ala	Glu	Asn	Leu	Leu	Ser	Pro	Glu	Asp	Met	Val	Leu	Phe	His
				645					650					655	
Asn	Leu	Thr	Gln	Pro	Arg	Gly	Val	Asn	Trp	Cys	Glu	Arg	Thr	Thr	Leu
			660					665					670		
Ser	Asn	Gly	Gly	Cys	Gln	Tyr	Leu	Cys	Leu	Pro	Ala	Pro	Gln	Ile	Asn
		675					680					685			
Pro	Gln	Ser	Pro	Lys	Phe	Thr	Cys	Thr	Cys	Pro	Asp	Gly	Met	Leu	Leu
	690					695					700				
Ala	Lys	Asp	Met	Arg	Ser	Cys	Leu	Thr	Glu	Ala	Glu	Ala	Ala	Val	Ala
705					710					715					720
Thr	Gln	Glu	Thr	Ser	Thr	Val	Arg	Leu	Met	Val	Ser	Ser	Lys	Ala	Val
				725					730					735	
Ala	Thr	Gln	His	Thr	Thr	Thr	Arg	Pro	Val	Pro	Asn	Thr	Ser	Gln	Leu
			740					745					750		
Pro	Gly	Ala	Thr	Pro	Gly	Leu	Thr	Thr	Ala	Glu	Thr	Val	Thr	Met	Ser
		755					760					765			
His	Gln	Ala	Leu	Gly	Asp	Val	Ala	Gly	Arg	Gly	Asn	Glu	Lys	Lys	Pro
	770					775					780				
Lys	Ser	Val	Gly	Ala	Leu	Ser	Ile	Val	Leu	Pro	Thr	Val	Leu	Leu	Val
785					790					795					800
Phe	Leu	Cys	Leu	Gly	Ala	Phe	Leu	Leu	Trp	Lys	Asn	Trp	Arg	Leu	Lys
				805					810					815	
Ser	Ile	Asn	Ser	Ile	Asn	Phe	Asp	Asn	Pro	Val	Tyr	Gln	Lys	Thr	Thr
			820					825					830		
Glu	Asp	Glu	Val	His	Ile	Cys	Arg	Asn	Gln	Asp	Gly	Tyr	Ser	Tyr	Pro
		835					840					845			
Ser	Arg	Gln	Met	Val	Ser	Leu	Glu	Asp	Asp	Val	Ala				
	850					855					860				

<210> 20
 <211> 862
 <212> PRT
 <213> Mus musculus

SEQUENCE_LISTING_APMOL_005VPC

<400> 20

Met 1	Ser	Thr	Ala	Asp 5	Leu	Met	Arg	Arg	Trp 10	Val	Ile	Ala	Leu	Leu 15	Leu
Ala	Ala	Ala	Gly 20	Val	Ala	Ala	Glu	Asp 25	Ser	Cys	Ser	Arg	Asn 30	Glu	Phe
Gln	Cys	Arg 35	Asp	Gly	Lys	Cys	Ile 40	Ala	Ser	Lys	Trp 45	Val	Cys	Asp	Gly
Ser	Pro 50	Glu	Cys	Pro	Asp	Gly 55	Ser	Asp	Glu	Ser	Pro 60	Glu	Thr	Cys	Met
Ser 65	Val	Thr	Cys	Gln	Ser 70	Asn	Gln	Phe	Ser	Cys 75	Gly	Gly	Arg	Val	Ser 80
Arg	Cys	Ile	Pro	Asp 85	Ser	Trp	Arg	Cys	Asp 90	Gly	Gln	Val	Asp	Cys 95	Glu
Asn	Asp	Ser	Asp 100	Glu	Gln	Gly	Cys	Pro 105	Pro	Lys	Thr	Cys	Ser 110	Gln	Asp
Asp	Phe	Arg 115	Cys	Gln	Asp	Gly	Lys 120	Cys	Ile	Ser	Pro	Gln	Phe	Val	Cys
Asp	Gly 130	Asp	Arg	Asp	Cys	Leu 135	Asp	Gly	Ser	Asp	Glu 140	Ala	His	Cys	Gln
Ala 145	Thr	Thr	Cys	Gly	Pro 150	Ala	His	Phe	Arg	Cys 155	Asn	Ser	Ser	Ile	Cys 160
Ile	Pro	Ser	Leu	Trp 165	Ala	Cys	Asp	Gly	Asp 170	Val	Asp	Cys	Val	Asp 175	Gly
Ser	Asp	Glu	Trp 180	Pro	Gln	Asn	Cys	Gln 185	Gly	Arg	Asp	Thr	Ala 190	Ser	Lys
Gly	Val	Ser 195	Ser	Pro	Cys	Ser	Ser 200	Leu	Glu	Phe	His 205	Cys	Gly	Ser	Ser
Glu	Cys 210	Ile	His	Arg	Ser	Trp 215	Val	Cys	Asp	Gly	Glu 220	Ala	Asp	Cys	Lys
Asp 225	Lys	Ser	Asp	Glu	Glu 230	His	Cys	Ala	Val	Ala 235	Thr	Cys	Arg	Pro	Asp 240
Glu	Phe	Gln	Cys	Ala 245	Asp	Gly	Ser	Cys	Ile 250	His	Gly	Ser	Arg	Gln	Cys 255
Asp	Arg	Glu	His 260	Asp	Cys	Lys	Asp	Met 265	Ser	Asp	Glu	Leu	Gly 270	Cys	Val
Asn	Val	Thr 275	Gln	Cys	Asp	Gly	Pro 280	Asn	Lys	Phe	Lys	Cys 285	His	Ser	Gly
Glu	Cys 290	Ile	Ser	Leu	Asp	Lys 295	Val	Cys	Asp	Ser	Ala 300	Arg	Asp	Cys	Gln
Asp 305	Trp	Ser	Asp	Glu	Pro 310	Ile	Lys	Glu	Cys	Lys 315	Thr	Asn	Glu	Cys	Leu 320
Asp	Asn	Asn	Gly 325	Cys	Ser	His	Ile	Cys 330	Lys	Asp	Leu	Lys	Ile 335	Gly	
Ser	Glu	Cys	Leu 340	Cys	Pro	Ser	Gly	Phe 345	Arg	Leu	Val	Asp	Leu 350	His	Arg
Cys	Glu	Asp 355	Ile	Asp	Glu	Cys	Gln 360	Glu	Pro	Asp	Thr	Cys 365	Ser	Gln	Leu
Cys	Val 370	Asn	Leu	Glu	Gly	Ser 375	Tyr	Lys	Cys	Glu	Cys 380	Gln	Ala	Gly	Phe
His 385	Met	Asp	Pro	His	Thr 390	Arg	Val	Cys	Lys	Ala 395	Val	Gly	Ser	Ile	Gly 400
Tyr	Leu	Leu	Phe	Thr 405	Asn	Arg	His	Glu	Val 410	Arg	Lys	Met	Thr	Leu	Asp 415
Arg	Ser	Glu	Tyr 420	Thr	Ser	Leu	Leu	Pro 425	Asn	Leu	Lys	Asn	Val 430	Val	Ala
Leu	Asp	Thr 435	Glu	Val	Thr	Asn	Asn 440	Arg	Ile	Tyr	Trp	Ser 445	Asp	Leu	Ser
Gln	Lys 450	Lys	Ile	Tyr	Ser	Ala 455	Leu	Met	Asp	Gln	Ala 460	Pro	Asn	Leu	Ser
Tyr 465	Asp	Thr	Ile	Ile	Ser 470	Glu	Asp	Leu	His	Ala 475	Pro	Asp	Gly	Leu	Ala 480
Val	Asp	Trp	Ile	His 485	Arg	Asn	Ile	Tyr	Trp 490	Thr	Asp	Ser	Val	Pro 495	Gly
Ser	Val	Ser	Val 500	Ala	Asp	Thr	Lys	Gly 505	Val	Lys	Arg	Arg	Thr 510	Leu	Phe
Gln	Glu	Ala 515	Gly	Ser	Arg	Pro	Arg 520	Ala	Ile	Val	Val	Asp 525	Pro	Val	His

SEQUENCE LISTING_APMOL_005VPC

Gly Phe Met Tyr Trp Thr Asp Trp Gly Thr Pro Ala Lys Ile Lys Lys
530 535 540
Gly Gly Leu Asn Gly Val Asp Ile His Ser Leu Thr Glu Asn Ile
545 550 555 560
Gln Trp Pro Asn Gly Ile Thr Leu Asp Leu Ser Ser Gly Arg Leu Tyr
565 570 575
Trp Val Asp Ser Lys Leu His Ser Ile Ser Ser Ile Asp Val Asn Gly
580 585 590
Gly Asn Arg Lys Thr Ile Leu Glu Asp Glu Asn Arg Leu Ala His Pro
595 600 605
Phe Ser Leu Ala Ile Tyr Glu Asp Lys Val Tyr Trp Thr Asp Val Ile
610 615 620
Asn Glu Ala Ile Phe Ser Ala Asn Arg Leu Thr Gly Ser Asp Val Asn
625 630 635 640
Leu Val Ala Glu Asn Leu Leu Ser Pro Glu Asp Ile Val Leu Phe His
645 650 655
Lys Val Thr Gln Pro Arg Gly Val Asn Trp Cys Glu Thr Thr Ala Leu
660 665 670
Leu Pro Asn Gly Gly Cys Gln Tyr Leu Cys Leu Pro Ala Pro Gln Ile
675 680 685
Gly Pro His Ser Pro Lys Phe Thr Cys Ala Cys Pro Asp Gly Met Leu
690 695 700
Leu Ala Lys Asp Met Arg Ser Cys Leu Thr Glu Val Asp Thr Val Leu
705 710 715 720
Thr Thr Gln Gly Thr Ser Ala Val Arg Pro Val Val Thr Ala Ser Ala
725 730 735
Thr Arg Pro Pro Lys His Ser Glu Asp Leu Ser Ala Pro Ser Thr Pro
740 745 750
Arg Gln Pro Val Asp Thr Pro Gly Leu Ser Thr Val Ala Ser Val Thr
755 760 765
Val Ser His Gln Val Gln Gly Asp Met Ala Gly Arg Gly Asn Glu Glu
770 775 780
Gln Pro His Gly Met Arg Phe Leu Ser Ile Phe Phe Pro Ile Ala Leu
785 790 795 800
Val Ala Leu Leu Val Leu Gly Ala Val Leu Leu Trp Arg Asn Trp Arg
805 810 815
Leu Lys Asn Ile Asn Ser Ile Asn Phe Asp Asn Pro Val Tyr Gln Lys
820 825 830
Thr Thr Glu Asp Glu Leu His Ile Cys Arg Ser Gln Asp Gly Tyr Thr
835 840 845
Tyr Pro Ser Arg Gln Met Val Ser Leu Glu Asp Asp Val Ala
850 855 860

<210> 21

<211> 865

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus Sequence

<220>

<221> VARI ANT

<222> 2, 3, 4, 5, 6, 7, 8, 11, 21, 24, 26, 27, 28, 35, 42, 50,
53, 60, 61, 69, 71, 72, 80, 85, 86, 98, 117, 124, 130, 142,
145, 146, 152, 154, 156, 159, 163, 169, 171, 174, 178, 183,
185, 187, 188, 189, 190, 191, 192, 194, 201, 206, 208

<223> Xaa = Any Ami no Aci d or No Ami no Aci d

<220>

<221> VARI ANT

<222> 213, 216, 220, 221, 231, 248, 276, 298, 299, 304, 315, 331,
337, 343, 346, 349, 350, 351, 375, 379, 381, 382, 385, 392,
403, 438, 439, 451, 453, 455, 456, 459, 461, 462, 465, 472,
475, 487, 496, 514, 516, 572, 604, 658, 670, 672, 674

<223> Xaa = Any Ami no Aci d or No Ami no Aci d

SEQUENCE_LI STI NG_APMOL_005VPC

<220>

<221> VARI ANT

<222> 675, 690, 717, 719, 720, 722, 725, 728, 731, 732, 738, 740, 741, 742, 745, 746, 747, 748, 749, 751, 753, 755, 757, 758, 766, 767, 774, 775, 785, 786, 788, 789, 792, 796, 797, 800, 803, 804, 806, 809, 810, 821, 822, 845, 846

<223> Xaa = Any Ami no Aci d or No Ami no Aci d

<400> 21

Met	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Arg	Trp	Xaa	Ile	Ala	Leu	Leu	Leu
1				5					10				15		
Ala	Ala	Ala	Gly	Xaa	Ala	Val	Xaa	Asp	Xaa	Xaa	Xaa	Arg	Asn	Glu	Phe
			20					25					30		
Gln	Cys	Xaa	Asp	Gly	Lys	Cys	Ile	Ala	Xaa	Lys	Trp	Val	Cys	Asp	Gly
		35					40					45			
Ser	Xaa	Glu	Cys	Xaa	Asp	Gly	Ser	Asp	Glu	Ser	Xaa	Xaa	Thr	Cys	Leu
	50				55						60				
Ser	Val	Thr	Cys	Xaa	Ser	Xaa	Xaa	Phe	Ser	Cys	Gly	Gly	Arg	Val	Xaa
65					70					75					80
Arg	Cys	Ile	Pro	Xaa	Xaa	Trp	Arg	Cys	Asp	Gly	Gln	Val	Asp	Cys	Asp
				85					90					95	
Asn	Xaa	Ser	Asp	Glu	Gln	Gly	Cys	Pro	Pro	Lys	Thr	Cys	Ser	Gln	Asp
			100					105					110		
Asp	Phe	Arg	Cys	Xaa	Asp	Gly	Lys	Cys	Ile	Ser	Xaa	Gln	Phe	Val	Cys
		115					120					125			
Asp	Xaa	Asp	Arg	Asp	Cys	Leu	Asp	Gly	Ser	Asp	Glu	Ala	Xaa	Cys	Pro
	130					135					140				
Xaa	Xaa	Thr	Cys	Gly	Pro	Ala	Xaa	Phe	Xaa	Cys	Xaa	Ser	Ser	Xaa	Cys
145					150					155					160
Ile	Pro	Xaa	Leu	Trp	Ala	Cys	Asp	Xaa	Asp	Xaa	Asp	Cys	Xaa	Asp	Gly
				165					170					175	
Ser	Xaa	Glu	Trp	Pro	Gln	Xaa	Cys	Xaa	Ala	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa
		180						185					190		
Gly	Xaa	Ser	Ser	Pro	Cys	Ser	Ala	Xaa	Glu	Phe	His	Cys	Xaa	Ser	Xaa
		195					200					205			
Glu	Cys	Ile	His	Xaa	Ser	Trp	Xaa	Cys	Asp	Gly	Xaa	Xaa	Asp	Cys	Lys
	210					215					220				
Asp	Lys	Ser	Asp	Glu	Glu	Xaa	Cys	Ala	Val	Ala	Thr	Cys	Arg	Pro	Asp
225				230						235				240	
Glu	Phe	Gln	Cys	Ala	Asp	Gly	Xaa	Cys	Ile	His	Gly	Ser	Arg	Gln	Cys
				245						250				255	
Asp	Arg	Glu	His	Asp	Cys	Lys	Asp	Met	Ser	Asp	Glu	Leu	Gly	Cys	Val
			260					265					270		
Asn	Val	Thr	Xaa	Cys	Asp	Gly	Pro	Asn	Lys	Phe	Lys	Cys	His	Ser	Gly
		275					280					285			
Glu	Cys	Ile	Ser	Leu	Asp	Lys	Val	Cys	Xaa	Xaa	Ala	Arg	Asp	Cys	Xaa
	290					295					300				
Asp	Trp	Ser	Asp	Glu	Pro	Ile	Lys	Glu	Cys	Xaa	Thr	Asn	Glu	Cys	Leu
305					310					315					320
Asp	Asn	Asn	Gly	Gly	Cys	Ser	His	Ile	Cys	Xaa	Asp	Leu	Lys	Ile	Gly
				325					330					335	
Xaa	Glu	Cys	Leu	Cys	Pro	Xaa	Gly	Phe	Xaa	Leu	Val	Xaa	Xaa	Xaa	Arg
			340					345					350		
Cys	Glu	Asp	Ile	Asp	Glu	Cys	Gln	Asp	Pro	Asp	Thr	Cys	Ser	Gln	Leu
		355					360					365			
Cys	Val	Asn	Leu	Glu	Gly	Xaa	Tyr	Lys	Cys	Xaa	Cys	Xaa	Xaa	Gly	Phe
	370					375					380				
Xaa	Leu	Asp	Pro	His	Thr	Lys	Xaa	Cys	Lys	Ala	Val	Gly	Ser	Ile	Ala
385					390					395					400
Tyr	Leu	Xaa	Phe	Thr	Asn	Arg	His	Glu	Val	Arg	Lys	Met	Thr	Leu	Asp
				405						410				415	
Arg	Ser	Glu	Tyr	Thr	Ser	Leu	Ile	Pro	Asn	Leu	Lys	Asn	Val	Val	Ala
			420					425					430		
Leu	Asp	Thr	Glu	Val	Xaa	Xaa	Asn	Arg	Ile	Tyr	Trp	Ser	Asp	Leu	Ser
		435					440					445			
Gln	Lys	Xaa	Ile	Xaa	Ser	Xaa	Xaa	Leu	Asp	Xaa	Ala	Xaa	Xaa	Leu	Ser
	450					455					460				
Xaa	Tyr	Asp	Thr	Ile	Ile	Ser	Xaa	Asp	Ile	Xaa	Ala	Pro	Asp	Gly	Leu

SEQUENCE_LISTING_APMOL_005VPC

465	Ala	Val	Asp	Trp	Ile	470	Xaa	Asn	Ile	Tyr	475	Trp	Thr	Asp	Ser	Val	480	Xaa
					485						490						495	
	Gly	Ser	Val	Ser	Val	Ala	Asp	Thr	Lys	Gly	Val	Lys	Arg	Lys	Thr	Leu		
				500						505					510			
	Phe	Xaa	Glu	Xaa	Gly	Ser	Lys	Pro	Arg	Ala	Ile	Val	Val	Asp	Pro	Val		
			515						520					525				
	His	Gly	Phe	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Thr	Pro	Ala	Lys	Ile	Lys		
		530						535					540					
	Lys	Gly	Gly	Leu	Asn	Gly	Val	Asp	Ile	His	Ser	Leu	Val	Thr	Glu	Asn		
545						550					555					560		
	Ile	Gln	Trp	Pro	Asn	Gly	Ile	Thr	Leu	Asp	Leu	Xaa	Ser	Gly	Arg	Leu		
					565					570					575			
	Tyr	Trp	Val	Asp	Ser	Lys	Leu	His	Ser	Ile	Ser	Ser	Ile	Asp	Val	Asn		
				580					585					590				
	Gly	Gly	Asn	Arg	Lys	Thr	Ile	Leu	Glu	Asp	Glu	Xaa	Arg	Leu	Ala	His		
			595					600					605					
	Pro	Phe	Ser	Leu	Ala	Ile	Phe	Glu	Asp	Lys	Val	Phe	Trp	Thr	Asp	Ile		
		610					615					620						
	Ile	Asn	Glu	Ala	Ile	Phe	Ser	Ala	Asn	Arg	Leu	Thr	Gly	Ser	Asp	Val		
625						630					635					640		
	Asn	Leu	Leu	Ala	Glu	Asn	Leu	Leu	Ser	Pro	Glu	Asp	Ile	Val	Leu	Phe		
				645						650					655			
	His	Xaa	Leu	Thr	Gln	Pro	Arg	Gly	Val	Asn	Trp	Cys	Glu	Xaa	Thr	Xaa		
				660					665					670				
	Leu	Xaa	Xaa	Asn	Gly	Gly	Cys	Gln	Tyr	Leu	Cys	Leu	Pro	Ala	Pro	Gln		
			675					680					685					
	Ile	Xaa	Pro	His	Ser	Pro	Lys	Phe	Thr	Cys	Ala	Cys	Pro	Asp	Gly	Met		
		690					695					700						
	Leu	Leu	Ala	Lys	Asp	Met	Arg	Ser	Cys	Leu	Thr	Glu	Xaa	Asp	Xaa	Xaa		
705						710					715					720		
	Leu	Xaa	Thr	Gln	Xaa	Thr	Ser	Xaa	Val	Arg	Xaa	Xaa	Val	Ser	Ala	Ser		
				725						730					735			
	Ala	Xaa	Arg	Xaa	Xaa	Xaa	His	Ser	Xaa	Xaa	Xaa	Xaa	Xaa	Pro	Xaa	Thr		
				740					745					750				
	Xaa	Arg	Xaa	Pro	Xaa	Xaa	Thr	Pro	Gly	Leu	Ser	Thr	Val	Xaa	Xaa	Val		
			755					760					765					
	Thr	Met	Ser	His	Gln	Xaa	Xaa	Gly	Asp	Met	Ala	Gly	Arg	Gly	Asn	Glu		
		770					775					780						
	Xaa	Xaa	Pro	Xaa	Xaa	Met	Arg	Xaa	Leu	Ser	Ile	Xaa	Xaa	Pro	Ile	Xaa		
785						790					795					800		
	Leu	Leu	Xaa	Xaa	Leu	Xaa	Leu	Gly	Xaa	Xaa	Leu	Leu	Trp	Lys	Asn	Trp		
				805						810					815			
	Arg	Leu	Lys	Asn	Xaa	Xaa	Ile	Asn	Ser	Ile	Asn	Phe	Asp	Asn	Pro	Val		
			820						825					830				
	Tyr	Gln	Lys	Thr	Thr	Glu	Asp	Glu	Leu	His	Ile	Cys	Xaa	Xaa	Gln	Asp		
			835					840					845					
	Gly	Tyr	Ser	Tyr	Pro	Ser	Arg	Gln	Met	Val	Ser	Leu	Glu	Asp	Asp	Val		
		850					855					860						

<210> 22
 <211> 860
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Consensus Sequence

<220>
 <221> VARIANT
 <222> 2, 14, 20, 21, 35, 92, 103, 123, 183, 185, 188, 190, 191,
 192, 205, 213, 232, 247, 374, 402, 452, 461, 561, 570, 571,
 603, 690, 697, 730, 734, 737, 748, 751, 762, 764, 785, 788,
 796, 806, 817, 840
 <223> Xaa = Any Amino Acid or No Amino Acid

SEQUENCE_LISTING_APMOL_005VPC

<400> 22

Met 1	Xaa	Pro	Trp	Gly 5	Trp	Lys	Leu	Arg	Trp 10	Thr	Val	Ala	Xaa	Leu 15	Leu
Ala	Ala	Ala	Xaa 20	Xaa	Ala	Val	Gly	Asp 25	Arg	Cys	Glu	Arg	Asn 30	Glu	Phe
Gln	Cys	Xaa 35	Asp	Gly	Lys	Cys	Ile 40	Ser	Tyr	Lys	Trp 45	Val	Cys	Asp	Gly
Ser	Ala 50	Glu	Cys	Gln	Asp	Gly 55	Ser	Asp	Glu	Ser	Gln 60	Glu	Thr	Cys	Leu
Ser 65	Val	Thr	Cys	Lys	Ser 70	Gly	Asp	Phe	Ser	Cys 75	Gly	Gly	Arg	Val	Asn 80
Arg	Cys	Ile	Pro	Gln 85	Phe	Trp	Arg	Cys	Asp 90	Gly	Xaa	Val	Asp	Cys 95	Asp
Asn	Gly	Ser	Asp 100	Glu	Gln	Xaa	Cys	Pro 105	Pro	Lys	Thr	Cys	Ser 110	Gln	Asp
Glu	Phe	Arg 115	Cys	His	Asp	Gly	Lys 120	Cys	Ile	Xaa	Arg	Gln 125	Phe	Val	Cys
Asp	Ser 130	Asp	Arg	Asp	Cys	Leu 135	Asp	Gly	Ser	Asp	Glu 140	Ala	Ser	Cys	Pro
Val 145	Leu	Thr	Cys	Gly	Pro 150	Ala	Ser	Phe	Gln	Cys 155	Asn	Ser	Ser	Thr	Cys 160
Ile	Pro	Gln	Leu	Trp 165	Ala	Cys	Asp	Asn	Asp 170	Pro	Asp	Cys	Glu	Asp 175	Gly
Ser	Asp	Glu	Trp 180	Pro	Gln	Xaa	Cys	Xaa 185	Gly	Leu	Xaa	Val	Xaa 190	Xaa	Xaa
Asp	Ser 195	Ser	Pro	Cys	Ser	Ala	Phe 200	Glu	Phe	His	Cys	Xaa 205	Ser	Gly	Glu
Cys	Ile 210	His	Ser	Xaa	Trp	Arg 215	Cys	Asp	Gly	Gly	Pro 220	Asp	Cys	Lys	Asp
Lys 225	Ser	Asp	Glu	Glu	Asn 230	Cys	Xaa	Val	Ala	Thr 235	Cys	Arg	Pro	Asp	Glu 240
Phe	Gln	Cys	Ser	Asp 245	Gly	Xaa	Cys	Ile	His 250	Gly	Ser	Arg	Gln	Cys 255	Asp
Arg	Glu	Tyr	Asp 260	Cys	Lys	Asp	Met	Ser 265	Asp	Glu	Val	Gly	Cys 270	Ile	Asn
Val	Thr 275	Leu	Cys	Glu	Gly	Pro	Asn 280	Lys	Phe	Lys	Cys	His 285	Ser	Gly	Glu
Cys	Ile 290	Ser	Leu	Asp	Lys	Val 295	Cys	Asn	Met	Ala	Arg 300	Asp	Cys	Arg	Asp
Trp 305	Ser	Asp	Glu	Pro	Ile 310	Lys	Glu	Cys	Gly	Thr 315	Asn	Glu	Cys	Leu	Asp 320
Asn	Asn	Gly	Gly	Cys 325	Ser	His	Ile	Cys	Asn 330	Asp	Leu	Lys	Ile	Gly 335	Tyr
Glu	Cys	Leu	Cys 340	Pro	Asp	Gly	Phe	Gln 345	Leu	Val	Ala	Gln	Arg 350	Arg	Cys
Glu	Asp	Ile 355	Asp	Glu	Cys	Gln	Asp 360	Pro	Asp	Thr	Cys	Ser 365	Gln	Leu	Cys
Val	Asn 370	Leu	Glu	Gly	Xaa	Tyr 375	Lys	Cys	Gln	Cys	Glu 380	Glu	Gly	Phe	Gln
Leu 385	Asp	Pro	His	Thr	Lys 390	Ala	Cys	Lys	Ala	Val 395	Gly	Ser	Ile	Ala	Tyr 400
Leu	Xaa	Phe	Thr	Asn 405	Arg	His	Glu	Val	Arg 410	Lys	Met	Thr	Leu	Asp 415	Arg
Ser	Glu	Tyr	Thr 420	Ser	Leu	Ile	Pro	Asn 425	Leu	Arg	Asn	Val	Val 430	Ala	Leu
Asp	Thr 435	Glu	Val	Ala	Ser	Asn	Arg 440	Ile	Tyr	Trp	Ser	Asp 445	Leu	Ser	Gln
Arg	Met 450	Ile	Xaa	Ser	Thr	Gln 455	Leu	Asp	Arg	Ala	His 460	Xaa	Val	Ser	Ser
Tyr 465	Asp	Thr	Val	Ile	Ser 470	Arg	Asp	Ile	Gln	Ala 475	Pro	Asp	Gly	Leu	Ala 480
Val	Asp	Trp	Ile	His 485	Ser	Asn	Ile	Tyr	Trp 490	Thr	Asp	Ser	Val	Leu 495	Gly
Thr	Val	Ser	Val 500	Ala	Asp	Thr	Lys	Gly 505	Val	Lys	Arg	Lys	Thr 510	Leu	Phe
Arg	Glu	Asn 515	Gly	Ser	Lys	Pro	Arg 520	Ala	Ile	Val	Val	Asp 525	Pro	Val	His

SEQUENCE LISTING_APMOL_005VPC

Gly	Phe	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Thr	Pro	Ala	Lys	Ile	Lys	Lys
530						535					540				
Gly	Gly	Leu	Asn	Gly	Val	Asp	Ile	Tyr	Ser	Leu	Val	Thr	Glu	Asn	Ile
545					550					555					560
Xaa	Trp	Pro	Asn	Gly	Ile	Thr	Leu	Asp	Xaa	Xaa	Ser	Gly	Arg	Leu	Tyr
				565					570					575	
Trp	Val	Asp	Ser	Lys	Leu	His	Ser	Ile	Ser	Ser	Ile	Asp	Val	Asn	Gly
			580					585					590		
Gly	Asn	Arg	Lys	Thr	Ile	Leu	Glu	Asp	Glu	Xaa	Arg	Leu	Ala	His	Pro
		595					600					605			
Phe	Ser	Leu	Ala	Ile	Phe	Glu	Asp	Lys	Val	Phe	Trp	Thr	Asp	Ile	Ile
610						615					620				
Asn	Glu	Ala	Ile	Phe	Ser	Ala	Asn	Arg	Leu	Thr	Gly	Ser	Asp	Ile	Asn
625					630					635					640
Leu	Leu	Ala	Glu	Asn	Leu	Leu	Ser	Pro	Glu	Asp	Met	Val	Leu	Phe	His
				645					650					655	
Asn	Leu	Thr	Gln	Pro	Arg	Gly	Val	Asn	Trp	Cys	Glu	Arg	Thr	Thr	Leu
			660					665					670		
Ser	Asn	Gly	Gly	Cys	Gln	Tyr	Leu	Cys	Leu	Pro	Ala	Pro	Gln	Ile	Asn
		675					680					685			
Pro	Xaa	Ser	Pro	Lys	Phe	Thr	Cys	Xaa	Cys	Pro	Asp	Gly	Met	Leu	Leu
	690					695					700				
Ala	Lys	Asp	Met	Arg	Ser	Cys	Leu	Thr	Glu	Ala	Glu	Ala	Ala	Val	Ala
705					710					715					720
Thr	Gln	Glu	Thr	Ser	Thr	Val	Arg	Leu	Xaa	Val	Ser	Ser	Xaa	Ala	Val
				725					730					735	
Xaa	Thr	Gln	His	Thr	Thr	Thr	Arg	Pro	Val	Pro	Xaa	Thr	Ser	Xaa	Leu
			740					745					750		
Pro	Gly	Ala	Thr	Pro	Gly	Leu	Thr	Thr	Xaa	Glu	Xaa	Val	Thr	Met	Ser
		755				760						765			
His	Gln	Ala	Leu	Gly	Asp	Val	Ala	Gly	Arg	Gly	Asn	Glu	Lys	Lys	Pro
	770					775					780				
Xaa	Ser	Val	Xaa	Ala	Leu	Ser	Ile	Val	Leu	Pro	Xaa	Val	Leu	Leu	Val
785					790					795					800
Phe	Leu	Cys	Leu	Gly	Xaa	Phe	Leu	Leu	Trp	Lys	Asn	Trp	Arg	Leu	Lys
				805					810					815	
Xaa	Ile	Asn	Ser	Ile	Asn	Phe	Asp	Asn	Pro	Val	Tyr	Gln	Lys	Thr	Thr
		820						825					830		
Glu	Asp	Glu	Val	His	Ile	Cys	Xaa	Asn	Gln	Asp	Gly	Tyr	Ser	Tyr	Pro
		835					840					845			
Ser	Arg	Gln	Met	Val	Ser	Leu	Glu	Asp	Asp	Val	Ala				
	850					855					860				

<210> 23
 <211> 672
 <212> PRT
 <213> Homo sapiens

<400> 23

Gln	Glu	Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Val	Leu	Ala	Leu	Arg
1				5				10						15	
Ser	Glu	Glu	Asp	Gly	Leu	Ala	Glu	Ala	Pro	Glu	His	Gly	Thr	Thr	Ala
			20					25					30		
Thr	Phe	His	Arg	Cys	Ala	Lys	Asp	Pro	Trp	Arg	Leu	Pro	Gly	Thr	Tyr
		35					40					45			
Val	Val	Val	Leu	Lys	Glu	Glu	Thr	His	Leu	Ser	Gln	Ser	Glu	Arg	Thr
		50				55					60				
Ala	Arg	Arg	Leu	Gln	Ala	Gln	Ala	Ala	Arg	Arg	Gly	Tyr	Leu	Thr	Lys
65					70				75						80
Ile	Leu	His	Val	Phe	His	Gly	Leu	Leu	Pro	Gly	Phe	Leu	Val	Lys	Met
				85					90					95	
Ser	Gly	Asp	Leu	Leu	Glu	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Asp	Tyr
			100					105					110		
Ile	Glu	Glu	Asp	Ser	Ser	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Leu
		115					120					125			
Glu	Arg	Ile	Thr	Pro	Pro	Arg	Tyr	Arg	Ala	Asp	Glu	Tyr	Gln	Pro	Pro
	130					135					140				

SEQUENCE LISTING_APMOL_005VPC

Asp 145	Gly	Gly	Ser	Leu	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln
Ser	Asp	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Met	Val	Thr	Asp	Phe	Glu
Asn	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys
Cys	Asp	Ser	His	Gly	Thr	His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp
Ala	Gly	Val	Ala	Lys	Gly	Ala	Ser	Met	Arg	Ser	Leu	Arg	Val	Leu	Asn
Cys	Gln	Gly	Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe
Ile	Arg	Lys	Ser	Gln	Leu	Val	Gln	Pro	Val	Gly	Pro	Leu	Val	Val	Leu
Leu	Pro	Leu	Ala	Gly	Gly	Tyr	Ser	Arg	Val	Leu	Asn	Ala	Ala	Cys	Gln
Arg	Leu	Ala	Arg	Ala	Gly	Val	Val	Leu	Val	Thr	Ala	Ala	Gly	Asn	Phe
Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile
Thr	Val	Gly	Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr
Leu	Gly	Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Glu
Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Phe	Val	Ser	Gln
Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Ala	Ala	Met
Met	Leu	Ser	Ala	Glu	Pro	Glu	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg
Leu	Ile	His	Phe	Ser	Ala	Lys	Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro
Glu	Asp	Gln	Arg	Val	Leu	Thr	Pro	Asn	Leu	Val	Ala	Ala	Leu	Pro	Pro
Ser	Thr	His	Gly	Ala	Gly	Trp	Gln	Leu	Phe	Cys	Arg	Thr	Val	Trp	Ser
Ala	His	Ser	Gly	Pro	Thr	Arg	Met	Ala	Thr	Ala	Ile	Ala	Arg	Cys	Ala
Pro	Asp	Glu	Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys
Arg	Arg	Gly	Glu	Arg	Met	Glu	Ala	Gln	Gly	Gly	Lys	Leu	Val	Cys	Arg
Ala	His	Asn	Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Ile	Ala	Arg	Cys
Cys	Leu	Leu	Pro	Gln	Ala	Asn	Cys	Ser	Val	His	Thr	Ala	Pro	Pro	Ala
Glu	Ala	Ser	Met	Gly	Thr	Arg	Val	His	Cys	His	Gln	Gln	Gly	His	Val
Leu	Thr	Gly	Cys	Ser	Ser	His	Trp	Glu	Val	Glu	Asp	Leu	Gly	Thr	His
Lys	Pro	Pro	Val	Leu	Arg	Pro	Arg	Gly	Gln	Pro	Asn	Gln	Cys	Val	Gly
His	Arg	Glu	Ala	Ser	Ile	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu
Glu	Cys	Lys	Val	Lys	Glu	His	Gly	Ile	Pro	Ala	Pro	Gln	Gly	Gln	Val
Thr	Val	Ala	Cys	Glu	Glu	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Ser	Ala	Leu
Pro	Gly	Thr	Ser	His	Val	Leu	Gly	Ala	Tyr	Ala	Val	Asp	Asn	Thr	Cys
Val	Val	Arg	Ser	Arg	Asp	Val	Ser	Thr	Thr	Gly	Ser	Thr	Ser	Glu	Glu
Ala	Val	Thr	Ala	Val	Ala	Ile	Cys	Cys	Arg	Ser	Arg	His	Leu	Ala	Gln
Ala	Ser	Gln	Glu	Leu	Gln	Gly	Pro	His	His	His	His	His	His	His	His

SEQUENCE_LI STI NG_APMOL_005VPC

<210> 24
 <211> 699
 <212> PRT
 <213> Homo sapiens

<400> 24
 Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Gu
 20 25 30
 Asp Gu Asp Gly Asp Tyr Gu Gu Leu Val Leu Ala Leu Arg Ser Gu
 35 40 45
 Gu Asp Gly Leu Ala Gu Ala Pro Gu His Gly Thr Thr Ala Thr Phe
 50 55 60
 His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
 65 70 75 80
 Val Leu Lys Gu Gu Thr His Leu Ser Gln Ser Gu Arg Thr Ala Arg
 85 90 95
 Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
 100 105 110
 His Val Phe His Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly Asp
 115 120 125
 Leu Leu Gu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Gu Gu
 130 135 140
 Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Gu Arg Ile
 145 150 155 160
 Thr Pro Pro Arg Tyr Arg Ala Asp Gu Tyr Gln Pro Pro Asp Gly Gly
 165 170 175
 Ser Leu Val Gu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp His
 180 185 190
 Arg Gu Ile Gu Gly Arg Val Met Val Thr Asp Phe Gu Asn Val Pro
 195 200 205
 Gu Gu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp Ser
 210 215 220
 His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val
 225 230 235 240
 Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln Gly
 245 250 255
 Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Gu Phe Ile Arg Lys
 260 265 270
 Ser Gln Leu Val Gln Pro Val Pro Leu Val Val Leu Leu Pro Leu Ala
 275 280 285
 Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu Ala Arg
 290 295 300
 Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp Asp Ala
 305 310 315 320
 Cys Leu Tyr Ser Pro Ala Ser Ala Pro Gu Val Ile Thr Val Gly Ala
 325 330 335
 Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly Thr Asn
 340 345 350
 Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Gu Asp Ile Ile Gly
 355 360 365
 Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly Thr Ser
 370 375 380
 Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu Ser Ala
 385 390 395 400
 Gu Pro Gu Leu Thr Leu Ala Gu Leu Arg Gln Leu Ile His Phe Ser
 405 410 415
 Ala Lys Asp Val Ile Asn Gu Ala Trp Phe Pro Gu Asp Gln Arg Val
 420 425 430
 Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr His Gly Ala
 435 440 445
 Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His Ser Gly Pro
 450 455 460
 Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro Asp Gu Gu Leu
 465 470 475 480
 Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg Gly Gu Arg
 485 490 495

SEQUENCE LISTING_APMOL_005VPC

Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His Asn Ala Phe
500 505
Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu Pro Gln
515 520
Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala Ser Met Gly
530 535 540
Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr Gly Cys Ser
545 550 555
Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro Pro Val Leu
565 570 575
Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg Glu Ala Ser
580 585 590
Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys Lys Val Lys
595 600 605
Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val Ala Cys Glu
610 615 620
Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly Thr Ser His
625 630 635 640
Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val Arg Ser Arg
645 650 655
Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val Thr Ala Val
660 665 670
Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser Gln Glu Leu
675 680 685
Gln Gly Pro His His His His His His His
690 695

<210> 25

<211> 686

<212> PRT

<213> Cavia porcellus

<400> 25

Met Arg Thr Arg Gly Pro Ala Pro Ala Trp Trp Pro Met Leu Leu Leu
1 5 10 15
Leu Met Leu Gly Pro Ala Pro Ala Gly Ala Gln Ala Arg Asp Ser Glu
20 25 30
Asp Gly Asp His Glu Gly Leu Ala Phe Ala Phe Pro Pro Glu Glu Asp
35 40 45
Gly Pro Ala Glu Ala Ala Pro His Val Pro Thr Ala Pro Phe His Arg
50 55 60
Cys Ser Lys Asp Ala Trp Arg Leu Pro Gly Thr Tyr Leu Val Val Leu
65 70 75 80
Lys Glu Gly Thr His Arg Gly Gln Thr Lys His Thr Ala His Arg Leu
85 90 95
Gln Ala Lys Ala Ala Arg Arg Gly Tyr Val Thr Thr Val Leu His Leu
100 105 110
Phe His His Leu Val Pro Gly Phe Leu Val Arg Met Ser Gly Asp Leu
115 120 125
Leu Asp Met Ala Leu Arg Leu Pro Leu Val Gln Tyr Ile Glu Glu Asp
130 135 140
Ser Ser Val Phe Ala Gln Ser Val Pro Trp Asn Leu Glu Arg Ile Leu
145 150 155 160
Pro Val Arg His Gln Ala Lys Glu Tyr Ser Ala Pro Ser His Pro Val
165 170 175
Thr Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Gly His Arg Glu Ile
180 185 190
Gln Gly Arg Ile Thr Val Thr Asp Phe Glu Ser Val Pro Gln Glu Asp
195 200 205
Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp Ser His Gly Thr
210 215 220
His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val Ala Lys Gly
225 230 235 240
Ala Gly Leu Arg Ser Leu Arg Val Leu Asn Cys Gln Gly Arg Gly Thr
245 250 255
Val Ser Ser Thr Leu Arg Gly Leu Glu Phe Ile Arg Lys Ser Gln Leu
260 265 270

SEQUENCE LISTING_APMOL_005VPC

Ala Gln Pro Val Gu Pro Leu Val Val Leu Leu Pro Leu Ala Gly Gly
 275 280 285
 Tyr Ser Arg Thr Leu Asn Ala Cys His Leu Leu Ala Arg Ala Gly
 290 295 300
 Val Val Leu Val Ala Ala Ala Gly Asn Phe Arg Asp Asp Ala Cys Leu
 305 310 315 320
 Tyr Ser Pro Ala Ser Ala Pro Gu Val Ile Thr Val Gly Ala Thr Asn
 325 330 335
 Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly Thr Asn Phe Gly
 340 345 350
 Arg Cys Val Asp Leu Phe Ala Pro Gly Gu Asp Ile Ile Gly Ala Ser
 355 360 365
 Ser Asp Cys Ser Thr Cys Phe Val Ser Arg Ser Gly Thr Ser Gln Ala
 370 375 380
 Ala Ala His Val Ala Gly Ile Val Thr Met Met Leu Thr Ala Gln Pro
 385 390 395 400
 Lys Leu Thr Leu Ala Gu Leu Trp Gln Arg Leu Ile His Phe Ala Ala
 405 410 415
 Lys Asp Val Ile Asn Gu Ala Trp Phe Pro Gu Asp Gln Arg Val Leu
 420 425 430
 Thr Pro Asn Leu Val Ala Thr Leu Pro Pro Ser Thr Arg Gly Ala Gly
 435 440 445
 Gly Arg Leu Leu Cys Arg Thr Val Trp Ser Ala Arg Ser Gly Pro Arg
 450 455 460
 His Thr Ala Thr Ala Leu Ala His Cys Thr Pro Gly Gu Gu Leu Leu
 465 470 475 480
 Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Lys Gly Gu Arg Ile
 485 490 495
 Gu Val Leu Arg Gly Arg Arg Val Cys Val Ala Tyr Asn Ala Phe Gly
 500 505 510
 Gly Lys Gly Val His Ala Val Ala Arg Cys Cys Leu Leu Pro Arg Ala
 515 520 525
 Asn Cys Ser Leu His Thr Ala Pro Ala Arg Ala Gly Met Gu Pro Arg
 530 535 540
 Val His Cys His Arg Lys Asp Gln Val Leu Thr Gly Cys Ser Ala His
 545 550 555 560
 Trp Gu Ala Gu Asp Phe Arg Ala Arg Gly Trp Pro Met Leu Arg Pro
 565 570 575
 Gly Gly Pro Ser Gln Cys Val Gly His Ser Lys Ala Ser Val His Ala
 580 585 590
 Ser Cys Cys Ser Ala Pro Gly Leu Gu Cys Arg Ile Arg Gu His Gly
 595 600 605
 Val Pro Trp Pro Ala Gu Gln Val Thr Val Ala Cys Gu Asp Gly Trp
 610 615 620
 Thr Leu Thr Gly Cys Ser Thr Leu Pro Gly Ala Ser Ser Val Leu Gly
 625 630 635 640
 Thr Tyr Ala Val Asp Asp Met Cys Val Val Arg Ser Arg Asp Val Lys
 645 650 655
 Ala Leu Asp Arg Thr Arg Gly Gu Ala Leu Ala Ala Ile Ala Ile Cys
 660 665 670
 Cys Arg Ser Gln Ala Ser Gu Gln Ala Ser Pro Gu Arg Gln
 675 680 685

<210> 26

<211> 698

<212> PRT

<213> Mesocricetus auratus

<400> 26

Met Gly Thr Ser Cys Ser Ala Arg Pro Arg Trp Leu Leu Ser Pro Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Leu Arg Tyr Met Gly Ala Ser Ala Gln Asp
 20 25 30
 Gu Asp Ala Gu Tyr Gu Gu Leu Met Leu Thr Leu Gln Ser Gln Asp
 35 40 45
 Asp Gly Leu Ala Asp Gu Thr Asp Gu Ala Pro Gln Gly Ala Thr Ala
 50 55 60

SEQUENCE LISTING_APMOL_005VPC

Ala	Phe	His	Arg	Cys	Pro	Glu	Glu	Ala	Trp	Arg	Val	Pro	Gly	Thr	Tyr
65					70					75					80
Ile	Val	Met	Leu	Ala	Glu	Glu	Ala	Gln	Trp	Val	His	Ile	Glu	Gln	Thr
				85					90					95	
Met	His	Arg	Leu	Gln	Thr	Gln	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile	Lys
			100					105					110		
Ile	Gln	His	Ile	Phe	Tyr	Asp	Phe	Leu	Pro	Ala	Phe	Val	Val	Lys	Met
		115					120					125			
Ser	Ser	Asp	Leu	Leu	Asp	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Lys	Tyr
	130					135					140				
Ile	Glu	Glu	Asp	Ser	Leu	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Leu
145					150					155					160
Asp	Arg	Ile	Ile	Pro	Ala	Gly	Arg	Gln	Ala	Gln	Glu	Tyr	Ser	Ser	Ser
				165					170					175	
Arg	Lys	Val	Pro	Ser	Gly	Ser	Gly	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp
			180					185					190		
Thr	Ser	Ile	Gln	Ser	Asp	His	Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Val
		195					200					205			
Thr	Asp	Phe	Asn	Ser	Val	Pro	Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg
	210					215					220				
Gln	Ala	Ser	Lys	Cys	Asp	Ser	His	Gly	Thr	His	Leu	Ala	Gly	Val	Val
225				230						235					240
Ser	Gly	Arg	Asp	Ala	Gly	Val	Ala	Lys	Gly	Thr	Ile	Leu	His	Gly	Leu
				245					250					255	
Arg	Val	Leu	Asn	Cys	Gln	Gly	Lys	Gly	Ile	Val	Ser	Gly	Ile	Leu	Thr
			260					265					270		
Gly	Leu	Glu	Phe	Ile	Trp	Lys	Ser	Gln	Leu	Met	Gln	Pro	Ser	Gly	Pro
		275					280					285			
Gln	Val	Val	Leu	Leu	Pro	Leu	Ala	Gly	Arg	Tyr	Ser	Arg	Val	Leu	Asn
	290					295					300				
Thr	Ala	Cys	Gln	His	Leu	Ala	Arg	Thr	Gly	Val	Val	Leu	Val	Ala	Ala
305					310					315					320
Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala
				325					330					335	
Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr	Asp	Val	Gln	Asp	Gln	Pro	Val
			340					345					350		
Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe
		355					360					365			
Ala	Pro	Gly	Lys	Asp	Ile	Ile	Gly	Ala	Ser	Ser	Asp	Cys	Ser	Ala	Cys
	370					375					380				
Phe	Met	Ser	Gln	Ser	Gly	Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly
385					390					395					400
Ile	Val	Ala	Met	Met	Leu	Thr	Leu	Glu	Pro	Glu	Leu	Thr	Leu	Thr	Glu
				405					410					415	
Leu	Arg	Gln	Arg	Leu	Ile	His	Phe	Ser	Thr	Lys	Asp	Ala	Ile	Asn	Met
			420					425					430		
Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr	Pro	Asn	Leu	Val	Ala
		435					440					445			
Thr	Leu	Pro	Pro	Ser	Thr	His	Gly	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg
	450					455					460				
Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg	Ala	Ala	Thr	Ala	Thr
465					470					475					480
Ala	Arg	Cys	Ala	Pro	Gly	Glu	Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser
				485					490					495	
Arg	Ser	Gly	Arg	Arg	Gly	Asp	Arg	Ile	Glu	Ala	Ala	Gly	Val	Thr	Gln
			500				505						510		
Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala	Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala
		515					520					525			
Val	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Arg	Ala	Asn	Cys	Ser	Ile	His	Thr
	530					535					540				
Thr	Pro	Ala	Ala	Arg	Thr	Ser	Leu	Glu	Thr	His	Ala	His	Cys	His	Gln
545					550					555					560
Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Leu	His	Trp	Glu	Val	Glu	Gly
				565					570					575	
Ile	Gly	Val	Gln	Pro	Leu	Ala	Val	Leu	Arg	Ser	Arg	His	Gln	Pro	Gly
			580					585					590		
Gln	Cys	Thr	Gly	His	Arg	Glu	Ala	Ser	Val	His	Ala	Ser	Cys	Cys	His
		595					600					605			

SEQUENCE LISTING APMOL_005VPC

Ala Pro Gly Leu Gu Cys Lys Ile Lys Gu His Gly Ile Ser Gly Pro
610 615 620
Ala Gu Gn Val Thr Val Ala Cys Gu Ala Gly Trp Thr Leu Thr Gly
625 630 635 640
Cys Asn Val Leu Pro Gly Ala Phe Ile Thr Leu Gly Ala Tyr Ala Val
645 650 655
Asp Asn Thr Cys Val Ala Arg Ser Arg Val Thr Asp Thr Ala Gly Arg
660 665 670
Thr Gly Gu Gu Ala Thr Val Ala Ala Ile Cys Cys Arg Asn Arg
675 680 685
Pro Ser Ala Lys Ala Ser Trp Val His Gn
690 695

<210> 27
<211> 685
<212> PRT
<213> Mus musculus

<400> 27
Met Gly Thr His Cys Ser Ala Trp Leu Arg Trp Pro Leu Leu Pro Leu
1 5 10 15
Leu Pro Pro Leu Leu Leu Leu Leu Leu Cys Pro Thr Gly Ala
20 25 30
Gly Ala Gn Asp Gu Asp Gly Asp Tyr Gu Gu Leu Met Leu Ala Leu
35 40 45
Pro Ser Gn Gu Asp Gly Leu Ala Asp Gu Ala Ala His Val Ala Thr
50 55 60
Ala Thr Phe Arg Arg Cys Ser Lys Gu Ala Trp Arg Leu Pro Gly Thr
65 70 75 80
Tyr Ile Val Val Leu Met Gu Gu Thr Gn Arg Leu Gn Ile Gu Gn
85 90 95
Thr Ala His Arg Leu Gn Thr Arg Ala Ala Arg Arg Gly Tyr Val Ile
100 105 110
Lys Val Leu His Ile Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys
115 120 125
Met Ser Ser Asp Leu Leu Gly Leu Ala Leu Lys Leu Pro His Val Gu
130 135 140
Tyr Ile Gu Gu Asp Ser Phe Val Phe Ala Gn Ser Ile Pro Trp Asn
145 150 155 160
Leu Arg Ile Ile Pro Ala Trp His Gn Thr Gu Gu Asp Arg Ser Pro
165 170 175
Asp Gly Ser Ser Gn Val Gu Val Tyr Leu Leu Asp Thr Ser Ile Gn
180 185 190
Gly Ala His Arg Gu Ile Gu Gly Arg Val Thr Ile Thr Asp Phe Asn
195 200 205
Ser Val Pro Gu Gu Asp Gly Thr Arg Phe His Arg Gn Ala Ser Lys
210 215 220
Cys Asp Ser His Gly Thr His Leu Ala Gly Val Ser Gly Arg Asp
225 230 235 240
Ala Gly Val Ala Lys Gly Thr Ser Leu His Ser Leu Arg Val Leu Asn
245 250 255
Cys Gn Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Gu Phe
260 265 270
Ile Arg Lys Ser Gn Leu Ile Gn Pro Ser Pro Leu Val Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Ile Leu Asn Ala Ala Cys Arg His Leu
290 295 300
Ala Arg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Gu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gn Asp Gn Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Lys Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Met Ser Gn Ser Gly
370 375 380

SEQUENCE LISTING_APMOL_005VPC

Thr	Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Val	Ala	Arg	Met	Leu
385					390					395					400
Ser	Arg	Glu	Pro	Thr	Leu	Thr	Leu	Ala	Leu	Arg	Gln	Arg	Ile	His	Phe
				405					410					415	
Ser	Thr	Lys	Asp	Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Gln
			420					425					430		
Val	Leu	Thr	Pro	Asn	Leu	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	His	Glu
			435					440				445			
Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly
	450					455					460				
Pro	Thr	Arg	Thr	Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Glu	Glu	Glu
465				470						475					480
Leu	Leu	Ser	Cys	Ser	Phe	Ser	Arg	Ser	Gly	Arg	Arg	Arg	Gly	Asp	
				485				490						495	
Arg	Ile	Glu	Ala	Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn	Ala
			500					505					510		
Phe	Gly	Gly	Glu	Gly	Val	Tyr	Ala	Val	Ala	Arg	Cys	Cys	Leu	Val	Pro
	515						520					525			
His	Ala	Asn	Cys	Ser	Ile	His	Asn	Pro	Ala	Ala	Ala	Gly	Leu	Glu	Thr
	530					535					540				
His	Val	His	Cys	His	Gln	Lys	Asp	His	Val	Leu	Thr	Gly	Cys	Ser	Phe
545				550						555					560
His	Trp	Glu	Val	Glu	Asp	Leu	Ser	Val	Arg	Arg	Gln	Pro	Ala	Leu	Arg
			565					570						575	
Ser	Arg	Arg	Gln	Pro	Gly	Gln	Cys	Val	Gly	His	Gln	Ala	Ala	Ser	Val
			580					585					590		
Tyr	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Ile	Lys	Glu
	595						600					605			
His	Gly	Ile	Ser	Gly	Ser	Ser	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu	Ala
	610					615					620				
Gly	Trp	Thr	Leu	Thr	Gly	Cys	Asn	Val	Leu	Pro	Gly	Ala	Ser	Leu	Thr
625				630						635					640
Leu	Gly	Ala	Tyr	Ser	Val	Asp	Asn	Leu	Cys	Val	Ala	Arg	Val	His	Asp
			645					650						655	
Thr	Ala	Arg	Ala	Asp	Arg	Thr	Gly	Glu	Thr	Val	Ala	Ala	Ala	Ile	Cys
			660					665					670		
Cys	Arg	Ser	Arg	Pro	Ser	Ala	Lys	Ala	Ser	Trp	Val	Gln			
		675					680					685			

<210> 28

<211> 683

<212> PRT

<213> Macaca fascicularis

<400> 28

Met	Gly	Thr	Val	Ser	Ser	Arg	Arg	Ser	Trp	Trp	Pro	Leu	Pro	Leu	Pro
1				5					10					15	
Leu	Leu	Leu	Leu	Leu	Leu	Leu	Gly	Pro	Ala	Gly	Ala	Arg	Ala	Gln	Glu
			20					25					30		
Asp	Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Val	Leu	Ala	Leu	Arg	Ser	Glu
		35				40						45			
Glu	Asp	Gly	Leu	Ala	Asp	Ala	Pro	Glu	His	Gly	Ala	Thr	Ala	Thr	Phe
	50					55					60				
His	Arg	Cys	Ala	Lys	Asp	Pro	Trp	Arg	Leu	Pro	Gly	Thr	Tyr	Val	Val
65				70						75					80
Val	Leu	Lys	Glu	Glu	Thr	His	Arg	Ser	Gln	Ser	Glu	Arg	Thr	Ala	Arg
			85						90					95	
Arg	Leu	Gln	Ala	Gln	Ala	Ala	Arg	Arg	Gly	Tyr	Leu	Thr	Lys	Ile	Leu
			100					105					110		
His	Val	Phe	His	His	Leu	Leu	Pro	Gly	Phe	Leu	Val	Lys	Met	Ser	Gly
		115					120					125			
Asp	Leu	Leu	Glu	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Asp	Tyr	Ile	Glu
	130					135					140				
Glu	Asp	Ser	Ser	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Glu	Arg	Ile
145				150						155					160
Thr	Pro	Ala	Arg	Tyr	Arg	Ala	Asp	Glu	Tyr	Gln	Pro	Pro	Lys	Gly	Gly
				165					170					175	

SEQUENCE LISTING_APMOL_005VPC

Ser	Leu	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Asp	His
Arg	Glu	Ile	Glu	Gly	Arg	Val	Met	Val	Thr	Asp	Phe	Glu	Ser	Val	Pro
Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser
His	Gly	Thr	His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val
Ala	Lys	Gly	Ala	Gly	Leu	Arg	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly
Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe	Ile	Arg	Lys
Ser	Gln	Leu	Val	Gln	Pro	Val	Pro	Leu	Val	Val	Leu	Pro	Leu	Ala	Gly
Gly	Tyr	Ser	Arg	Val	Phe	Asn	Ala	Ala	Cys	Gln	Arg	Leu	Ala	Arg	Ala
Gly	Val	Val	Leu	Val	Thr	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp	Ala	Cys
Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly	Ala	Thr
Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr	Asn	Phe
Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Glu	Asp	Ile	Ile	Gly	Ala
Ser	Ser	Asp	Cys	Ser	Thr	Cys	Phe	Val	Ser	Arg	Ser	Gly	Thr	Ser	Gln
Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Ala	Ala	Met	Met	Leu	Ser	Ala	Glu
Pro	Glu	Leu	Thr	Leu	Ala	Leu	Arg	Gln	Leu	Ile	His	Phe	Ser	Ala	Lys
Asp	Val	Ile	Asn	Glu	Ala	Trp	Phe	Pro	Glu	Asp	Gln	Arg	Val	Leu	Thr
Pro	Asn	Leu	Val	Ala	Ala	Leu	Pro	Pro	Ser	Thr	His	Arg	Ala	Gly	Trp
Gln	Leu	Phe	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser	Gly	Pro	Thr	Arg
Met	Ala	Thr	Ala	Val	Ala	Arg	Cys	Ala	Gln	Asp	Glu	Glu	Leu	Leu	Ser
Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Lys	Arg	Arg	Gly	Glu	Arg	Ile	Glu
Ala	Gln	Gly	Gly	Lys	Arg	Val	Cys	Arg	Ala	His	Asn	Ala	Phe	Gly	Gly
Glu	Gly	Val	Tyr	Ala	Ile	Ala	Arg	Cys	Cys	Leu	Leu	Pro	Gln	Val	Asn
Cys	Ser	Val	His	Thr	Pro	Pro	Gly	Ala	Ser	Met	Gly	Thr	Arg	Val	His
Cys	His	Gln	Gln	Gly	His	Val	Leu	Thr	Gly	Cys	Ser	Ser	His	Trp	Glu
Val	Glu	Asp	Leu	Gly	Thr	His	Lys	Pro	Pro	Val	Leu	Arg	Pro	Arg	Gly
Gln	Pro	Asn	Gln	Cys	Val	Gly	His	Arg	Glu	Ala	Ser	Ile	His	Ala	Ser
Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Val	Arg	Glu	His	Gly	Ile
Pro	Ala	Pro	Gln	Glu	Gln	Val	Ile	Val	Ala	Cys	Glu	Asp	Gly	Trp	Thr
Leu	Thr	Gly	Cys	Ser	Ala	Leu	Pro	Gly	Thr	Ser	His	Val	Leu	Gly	Ala
Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val	Arg	Ser	Arg	Asp	Val	Ser	Thr
Thr	Gly	Ser	Thr	Glu	Ala	Val	Ala	Ala	Val	Ala	Ile	Cys	Cys	Arg	Ser
Arg	His	Leu	Val	Gln	Ala	Ser	Gln	Glu	Leu	Gln					

<210> 29
<211> 691

SEQUENCE_LI STI NG_APMOL_005VPC

<212> PRT

<213> Ratt us nor vegi cus

<400> 29

Met	Gly	Ile	Arg	Cys	Ser	Thr	Trp	Leu	Arg	Trp	Pro	Leu	Ser	Pro	Gln
1				5					10					15	
Leu	Leu	Leu	Leu	Leu	Leu	Leu	Cys	Pro	Thr	Gly	Ser	Arg	Ala	Gln	Asp
			20					25					30		
Glu	Asp	Gly	Asp	Tyr	Glu	Glu	Leu	Met	Leu	Ala	Leu	Pro	Ser	Gln	Glu
		35					40					45			
Asp	Ser	Leu	Val	Asp	Glu	Ala	Ser	His	Val	Ala	Thr	Ala	Thr	Phe	Arg
	50					55					60				
Arg	Cys	Ser	Lys	Glu	Ala	Trp	Arg	Leu	Pro	Gly	Thr	Tyr	Val	Val	Val
65					70					75					80
Leu	Met	Glu	Glu	Thr	Gln	Arg	Leu	Gln	Val	Glu	Gln	Thr	Ala	His	Arg
				85					90					95	
Leu	Gln	Thr	Trp	Ala	Ala	Arg	Arg	Gly	Tyr	Val	Ile	Lys	Val	Leu	His
			100					105					110		
Val	Phe	Tyr	Asp	Leu	Phe	Pro	Gly	Phe	Leu	Val	Lys	Met	Ser	Ser	Asp
		115					120					125			
Leu	Leu	Gly	Leu	Ala	Leu	Lys	Leu	Pro	His	Val	Glu	Tyr	Ile	Glu	Glu
	130					135					140				
Asp	Ser	Leu	Val	Phe	Ala	Gln	Ser	Ile	Pro	Trp	Asn	Leu	Glu	Arg	Ile
145					150					155					160
Ile	Pro	Ala	Trp	Gln	Gln	Thr	Glu	Glu	Asp	Ser	Ser	Pro	Asp	Gly	Ser
				165					170					175	
Ser	Gln	Val	Glu	Val	Tyr	Leu	Leu	Asp	Thr	Ser	Ile	Gln	Ser	Gly	His
			180					185					190		
Arg	Glu	Ile	Glu	Gly	Arg	Val	Thr	Ile	Thr	Asp	Phe	Asn	Ser	Val	Pro
		195					200					205			
Glu	Glu	Asp	Gly	Thr	Arg	Phe	His	Arg	Gln	Ala	Ser	Lys	Cys	Asp	Ser
	210					215					220				
His	Gly	Thr	His	Leu	Ala	Gly	Val	Val	Ser	Gly	Arg	Asp	Ala	Gly	Val
225					230					235					240
Ala	Lys	Gly	Thr	Ser	Leu	His	Ser	Leu	Arg	Val	Leu	Asn	Cys	Gln	Gly
				245					250					255	
Lys	Gly	Thr	Val	Ser	Gly	Thr	Leu	Ile	Gly	Leu	Glu	Phe	Ile	Arg	Lys
			260					265					270		
Ser	Gln	Leu	Ile	Gln	Pro	Ser	Gly	Pro	Leu	Val	Val	Leu	Leu	Pro	Leu
		275					280					285			
Ala	Gly	Gly	Tyr	Ser	Arg	Ile	Leu	Asn	Thr	Ala	Cys	Gln	Arg	Leu	Ala
	290					295					300				
Arg	Thr	Gly	Val	Val	Leu	Val	Ala	Ala	Ala	Gly	Asn	Phe	Arg	Asp	Asp
305					310					315					320
Ala	Cys	Leu	Tyr	Ser	Pro	Ala	Ser	Ala	Pro	Glu	Val	Ile	Thr	Val	Gly
				325					330					335	
Ala	Thr	Asn	Ala	Gln	Asp	Gln	Pro	Val	Thr	Leu	Gly	Thr	Leu	Gly	Thr
			340					345					350		
Asn	Phe	Gly	Arg	Cys	Val	Asp	Leu	Phe	Ala	Pro	Gly	Lys	Asp	Ile	Ile
		355					360					365			
Gly	Ala	Ser	Ser	Asp	Cys	Ser	Thr	Cys	Tyr	Met	Ser	Gln	Ser	Gly	Thr
	370					375					380				
Ser	Gln	Ala	Ala	Ala	His	Val	Ala	Gly	Ile	Val	Ala	Met	Met	Leu	Asn
385					390					395					400
Arg	Asp	Pro	Ala	Leu	Thr	Leu	Ala	Glu	Leu	Arg	Gln	Arg	Leu	Ile	Leu
				405					410					415	
Phe	Ser	Thr	Lys	Asp	Val	Ile	Asn	Met	Ala	Trp	Phe	Pro	Glu	Asp	Gln
			420					425					430		
Arg	Val	Leu	Thr	Pro	Asn	Arg	Val	Ala	Thr	Leu	Pro	Pro	Ser	Thr	Gln
		435					440					445			
Glu	Thr	Gly	Gly	Gln	Leu	Leu	Cys	Arg	Thr	Val	Trp	Ser	Ala	His	Ser
	450					455					460				
Gly	Pro	Thr	Arg	Thr	Ala	Thr	Ala	Thr	Ala	Arg	Cys	Ala	Pro	Glu	Glu
465					470					475					480
Glu	Leu	Leu	Ser	Cys	Ser	Ser	Phe	Ser	Arg	Ser	Gly	Arg	Arg	Arg	Gly
				485					490					495	
Asp	Arg	Ile	Glu	Ala	Ile	Gly	Gly	Gln	Gln	Val	Cys	Lys	Ala	Leu	Asn
			500					505					510		

SEQUENCE LISTING_APMOL_005VPC

Ala Phe Gly Gly Gu Gly Val Tyr Ala Val Ala Arg Cys Cys Leu Leu
515 520 525
Pro Arg Val Asn Cys Ser Ile His Asn Thr Pro Ala Ala Arg Ala Gly
530 535 540
Pro Gln Thr Pro Val His Cys His Gln Lys Asp His Val Leu Thr Gly
545 550 555 560
Cys Ser Phe His Trp Gu Val Gu Asn Leu Arg Ala Gln Gln Gln Pro
565 570 575
Leu Leu Arg Ser Arg His Gln Pro Gly Gln Cys Val Gly His Gln Gu
580 585 590
Ala Ser Val His Ala Ser Cys Cys His Ala Pro Gly Leu Gu Cys Lys
595 600 605
Ile Lys Gu His Gly Ile Ala Gly Pro Ala Gu Gln Val Thr Val Ala
610 615 620
Cys Gu Ala Gly Trp Thr Leu Thr Gly Cys Asn Val Leu Pro Gly Ala
625 630 635 640
Ser Leu Pro Leu Gly Ala Tyr Ser Val Asp Asn Val Cys Val Ala Arg
645 650 655
Ile Arg Asp Ala Gly Arg Ala Asp Arg Thr Ser Gu Gu Ala Thr Val
660 665 670
Ala Ala Ala Ile Cys Cys Arg Ser Arg Pro Ser Ala Lys Ala Ser Trp
675 685
Val His Gln
690

<210> 30

<211> 702

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence

<220>

<221> VARI ANT

<222> 4, 14, 15, 16, 17, 18, 63, 64, 65, 180, 181, 182, 183, 583, 584, 586, 701

<223> Xaa = Any Amino Acid or No Amino Acid

<400> 30

Met Gly Thr Xaa Cys Ser Ala Arg Ser Trp Trp Pro Leu Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Pro Leu Leu Leu Leu Leu Leu Leu Leu Pro Ala Gly Ala Ala
20 25 30
Ala Ala Gln Asp Gu Asp Gly Asp Tyr Gu Gu Leu Met Leu Ala Leu
35 40 45
Pro Ser Gln Gu Asp Gly Leu Ala Asp Gu Ala Gu His Val Xaa Xaa
50 55 60
Xaa Ala Thr Ala Thr Phe His Arg Cys Ser Lys Asp Ala Trp Arg Leu
65 70 75 80
Pro Gly Thr Tyr Val Val Val Leu Lys Gu Gu Thr Gln Arg Leu Gln
85 90 95
Ser Gu Gln Thr Ala His Arg Leu Gln Thr Gln Ala Ala Arg Arg Gly
100 105 110
Tyr Val Thr Lys Ile Leu His Val Phe His Asp Leu Leu Pro Gly Phe
115 120 125
Leu Val Lys Met Ser Ser Asp Leu Leu Asp Leu Ala Leu Lys Leu Pro
130 135 140
His Val Asp Tyr Ile Gu Asp Ser Ser Val Phe Ala Gln Ser Ile
145 150 155 160
Pro Trp Asn Leu Gu Arg Ile Ile Pro Ala Arg His Gln Ala Asp Gu
165 170 175
Tyr Ser Ser Xaa Xaa Xaa Xaa Pro Asp Gly Ser Ser Gln Val Gu Val
180 185 190
Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp His Arg Gu Ile Gu Gly
195 200 205
Arg Val Thr Val Thr Asp Phe Asn Ser Val Pro Gu Gu Asp Gly Thr

SEQUENCE_LISTING_APMOL_005VPC

210	Arg	Phe	His	Arg	Gln	Ala	215	Ser	Lys	Cys	Asp	Ser	220	His	Gly	Thr	His	Leu
225	Ala	Gly	Val	Val	Ser	Gly	230	Arg	Asp	Ala	Gly	Val	235	Ala	Lys	Gly	Thr	Ser
	Leu	Arg	Ser	Leu	Arg	Val	245	Leu	Asn	Cys	Gln	Gly	250	Lys	Gly	Thr	Val	Ser
	Gly	Thr	Leu	Ile	Gly	Leu	260	Glu	Phe	Ile	Arg	Lys	265	Ser	Gln	Leu	Ile	Gln
	Pro	Val	Gly	Pro	Leu	Val	275	Val	Leu	Leu	Pro	Leu	280	Ala	Gly	Gly	Tyr	Ser
	Arg	Val	Leu	Asn	Ala	Ala	290	Cys	Gln	Arg	Leu	Ala	295	Arg	Thr	Gly	Val	Val
305	Leu	Val	Ala	Ala	Ala	Gly	310	Asn	Phe	Arg	Asp	Ala	315	Ala	Cys	Leu	Tyr	Ser
	Pro	Ala	Ser	Ala	Pro	Glu	325	Val	Ile	Thr	Val	Gly	330	Ala	Thr	Asn	Ala	Gln
	Asp	Gln	Pro	Val	Thr	Leu	340	Gly	Thr	Leu	Gly	Thr	345	Asn	Phe	Gly	Arg	Cys
	Val	Asp	Leu	Phe	Ala	Pro	355	Gly	Lys	Asp	Ile	Ile	360	Gly	Ala	Ser	Ser	Asp
	Cys	Ser	Thr	Cys	Phe	Met	370	Ser	Gln	Ser	Gly	Thr	375	Ser	Gln	Ala	Ala	Ala
385	His	Val	Ala	Gly	Ile	Val	385	Ala	Met	Met	Leu	Ser	390	Ala	Glu	Pro	Glu	Leu
	Thr	Leu	Ala	Glu	Leu	Arg	405	Gln	Arg	Leu	Ile	His	410	Phe	Ser	Thr	Lys	Asp
	Val	Ile	Asn	Met	Ala	Trp	420	Phe	Pro	Glu	Asp	Gln	425	Val	Leu	Thr	Pro	
	Asn	Leu	Val	Ala	Thr	Leu	435	Pro	Pro	Ser	Thr	His	440	Gly	Thr	Gly	Gln	
	Leu	Leu	Cys	Arg	Thr	Val	445	Trp	Ser	Ala	His	Ser	450	Gly	Pro	Thr	Arg	Thr
465	Ala	Thr	Ala	Thr	Ala	Arg	465	Cys	Ala	Pro	Asp	Glu	470	Glu	Leu	Leu	Ser	Cys
	Ser	Ser	Phe	Ser	Arg	Ser	485	Gly	Lys	Arg	Arg	Gly	490	Asp	Arg	Ile	Glu	Ala
	Ile	Gly	Gly	Gln	Gln	Val	500	Cys	Lys	Ala	Leu	Asn	505	Ala	Phe	Gly	Gly	Glu
	Gly	Val	Tyr	Ala	Val	Ala	515	Arg	Cys	Cys	Leu	Leu	520	Pro	Arg	Ala	Asn	Cys
	Ser	Ile	His	Thr	Thr	Pro	535	Ala	Ala	Arg	Ala	Ser	540	Met	Glu	Thr	Arg	Val
545	His	Cys	His	Gln	Lys	Asp	545	His	Val	Leu	Thr	Gly	550	Cys	Ser	Ser	His	Trp
	Glu	Val	Glu	Asp	Leu	Gly	565	Xaa	Xaa	Lys	Xaa	Pro	570	Val	Leu	Arg	Ser	Arg
	Gly	Gln	Pro	Gly	Gln	Cys	580	Val	Gly	His	Arg	Glu	585	Ala	Ser	Val	His	Ala
	Ser	Cys	Cys	His	Ala	Pro	595	Gly	Leu	Glu	Cys	Lys	600	Ile	Lys	Glu	His	Gly
	Ile	Pro	Gly	Pro	Ala	Glu	610	Gln	Val	Thr	Val	Ala	615	Cys	Glu	Ala	Gly	Trp
625	Thr	Leu	Thr	Gly	Cys	Ser	625	Val	Leu	Pro	Gly	Ala	630	Ser	Leu	Val	Leu	Gly
	Ala	Tyr	Ala	Val	Asp	Asn	645	Thr	Cys	Val	Val	Arg	650	Ser	Arg	Asp	Val	Ser
	Thr	Ala	Gly	Arg	Thr	Ser	660	Glu	Glu	Ala	Thr	Val	665	Ala	Ala	Ala	Ile	Cys
	Cys	Arg	Ser	Arg	Pro	Ser	675	Gln	Ala	Ser	Trp	Val	680	Xaa	Gln			
							690						700					

<210> 31
 <211> 689
 <212> PRT
 <213> Homo sapiens

SEQUENCE_LISTING_APMOL_005VPC

<400> 31

Met 1	Gly	Thr	Val	Ser 5	Ser	Arg	Arg	Ser	Trp 10	Trp	Pro	Leu	Pro	Leu 15	Leu
Leu	Leu	Leu	Leu 20	Leu	Leu	Leu	Gly	Pro 25	Ala	Gly	Ala	Arg	Ala 30	Gln	Glu
Asp	Glu	Asp 35	Gly	Asp	Tyr	Glu	Glu 40	Leu	Val	Leu	Ala	Leu 45	Arg	Ser	Glu
Glu	Asp 50	Gly	Leu	Ala	Glu	Ala 55	Pro	Glu	His	Gly	Thr 60	Thr	Ala	Thr	Phe
His 65	Arg	Cys	Ala	Lys	Asp 70	Pro	Trp	Arg	Leu	Pro 75	Gly	Thr	Tyr	Val 80	Val
Val	Leu	Lys	Glu	Glu 85	Thr	His	Leu	Ser	Gln 90	Ser	Glu	Arg	Thr	Ala 95	Arg
Arg	Leu	Gln	Ala 100	Gln	Ala	Ala	Arg	Arg 105	Gly	Tyr	Leu	Thr	Lys 110	Ile	Leu
His	Val	Phe 115	His	Leu	Leu	Pro	Gly 120	Phe	Leu	Val	Lys	Met 125	Ser	Gly	Asp
Leu	Leu 130	Glu	Leu	Ala	Leu	Lys 135	Leu	Pro	His	Val	Asp 140	Tyr	Ile	Glu	Glu
Asp 145	Ser	Ser	Val	Phe	Ala 150	Gln	Ser	Ile	Pro	Trp 155	Asn	Leu	Glu	Arg	Ile
Thr	Pro	Pro	Arg	Tyr 165	Arg	Ala	Asp	Glu	Tyr 170	Gln	Pro	Pro	Asp	Gly 175	Gly
Ser	Leu	Val	Glu 180	Val	Tyr	Leu	Leu	Asp 185	Thr	Ser	Ile	Gln	Ser 190	Asp	His
Arg	Glu	Ile 195	Glu	Gly	Arg	Val	Met 200	Val	Thr	Asp	Phe	Glu 205	Asn	Val	Pro
Glu	Glu 210	Asp	Gly	Thr	Arg	Phe 215	His	Arg	Gln	Ala	Ser 220	Lys	Cys	Asp	Ser
His 225	Gly	Thr	His	Leu	Ala 230	Gly	Val	Val	Ser	Gly 235	Arg	Asp	Ala	Gly	Val
Ala	Lys	Gly	Ala	Ser 245	Met	Arg	Ser	Leu	Arg 250	Val	Leu	Asn	Cys	Gln 255	Gly
Lys	Gly	Thr	Val 260	Ser	Gly	Thr	Leu	Ile 265	Gly	Leu	Glu	Phe	Ile 270	Arg	Lys
Ser	Gln	Leu 275	Val	Gln	Pro	Val	Pro 280	Leu	Val	Val	Leu	Leu 285	Pro	Leu	Ala
Gly	Gly 290	Tyr	Ser	Arg	Val	Leu 295	Asn	Ala	Ala	Cys	Gln 300	Arg	Leu	Ala	Arg
Ala 305	Gly	Val	Val	Leu	Val 310	Thr	Ala	Ala	Gly	Asn 315	Phe	Arg	Asp	Asp	Ala
Cys	Leu	Tyr	Ser	Pro 325	Ala	Ser	Ala	Pro	Glu 330	Val	Ile	Thr	Val	Gly 335	Ala
Thr	Asn	Ala	Gln 340	Asp	Gln	Pro	Val	Thr 345	Leu	Gly	Thr	Leu	Gly 350	Thr	Asn
Phe	Gly	Arg 355	Cys	Val	Asp	Leu	Phe 360	Ala	Pro	Gly	Glu	Asp 365	Ile	Ile	Gly
Ala	Ser 370	Ser	Asp	Cys	Ser	Thr 375	Cys	Phe	Val	Ser	Gln 380	Ser	Gly	Thr	Ser
Gln 385	Ala	Ala	Ala	His 390	Val	Ala	Gly	Ile	Ala	Ala 395	Met	Met	Leu	Ser	Ala
Glu	Pro	Glu	Leu	Thr 405	Leu	Ala	Glu	Leu	Arg 410	Gln	Leu	Ile	His	Phe 415	Ser
Ala	Lys	Asp	Val 420	Ile	Asn	Glu	Ala	Trp 425	Phe	Pro	Glu	Asp	Gln 430	Arg	Val
Leu	Thr	Pro 435	Asn	Leu	Val	Ala	Ala 440	Leu	Pro	Pro	Ser	Thr 445	His	Gly	Ala
Gly	Trp 450	Gln	Leu	Phe	Cys	Arg 455	Thr	Val	Trp	Ser	Ala 460	His	Ser	Gly	Pro
Thr 465	Arg	Met	Ala	Thr	Ala 470	Ile	Ala	Arg	Cys	Ala 475	Pro	Asp	Glu	Glu	Leu
Leu	Ser	Cys	Ser	Ser 485	Phe	Ser	Arg	Ser	Gly 490	Lys	Arg	Arg	Gly	Glu 495	Arg
Met	Glu	Ala	Gln 500	Gly	Gly	Lys	Leu	Val 505	Cys	Arg	Ala	His	Asn 510	Ala	Phe
Gly	Gly	Glu 515	Gly	Val	Tyr	Ala	Ile 520	Ala	Arg	Cys	Cys	Leu 525	Leu	Pro	Gln
Ala	Asn	Cys	Ser	Val	His	Thr	Ala	Pro	Pro	Ala	Glu	Ala	Ser	Met	Gly

SEQUENCE_LISTING_APMOL_005VPC

530	Thr	Arg	Val	His	Cys	His	Gln	Gln	Gly	His	Val	Leu	Thr	Gly	Cys	Ser
545	Ser	His	Trp	Glu	Val	Glu	Asp	Leu	Gly	Thr	His	Lys	Pro	Pro	Val	Leu
	Arg	Pro	Arg	Gly	Gln	Pro	Asn	Gln	Cys	Val	Gly	His	Arg	Glu	Ala	Ser
	Ile	His	Ala	Ser	Cys	Cys	His	Ala	Pro	Gly	Leu	Glu	Cys	Lys	Val	Lys
	Glu	His	Gly	Ile	Pro	Ala	Pro	Gln	Glu	Gln	Val	Thr	Val	Ala	Cys	Glu
	Glu	Gly	Trp	Thr	Leu	Thr	Gly	Cys	Ser	Ala	Leu	Pro	Gly	Thr	Ser	His
625	Val	Leu	Gly	Ala	Tyr	Ala	Val	Asp	Asn	Thr	Cys	Val	Val	Arg	Ser	Arg
	Asp	Val	Ser	Thr	Thr	Gly	Ser	Thr	Ser	Glu	Glu	Ala	Val	Thr	Ala	Val
	Ala	Ile	Cys	Cys	Arg	Ser	Arg	His	Leu	Ala	Gln	Ala	Ser	Gln	Glu	Leu
	Gln															